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Abstract 
 
Systemic infections by encapsulated bacteria are a major aetiological agent of 
neonatal mortality. Neonatal meningitic Escherichia coli (NMEC) are isolated in a 
significant proportion of these infections. 80-85% of NMEC isolates express the K1 
polysaccharide capsular antigen, a homopolymer of α-2,8-linked polysialic acid (PSA) 
which mimics the PSA modulator of neuronal plasticity in mammalian hosts and 
enables these strains to evade components of the innate and adaptive neonatal immune 
system. Systemic E. coli K1 infection is age-dependent. The basis of age-dependency is 
the capacity of the pathogen to translocate from the gastrointestinal (GI) tract into the 
systemic circulation. This initial step in pathogenesis is poorly characterized and the 
mechanistic basis of age-dependency is unknown. Post-partum development of the GI 
microbial population (microbiota) and host tissue may modulate susceptibility to E. coli 
K1.  
Age-dependency was characterized in the neonatal rat model of infection. Two-
day old (P2) neonates were highly susceptible to infection after oral dosing with E. coli 
K1 strain A192PP, whereas P9 neonates were highly refractive. This variation was not 
caused by the capacity of the pathogen to colonize the GI tract. The P2-P9 GI 
microbiota was assessed using culture-independent methods. Quantitative and 
qualitative analysis of the microbiota revealed that the P2-P9 microbiota was 
significantly different to that of the adult, but that very little variation occurred between 
the neonatal groups examined. Suppression of the P9 microbiota using combined 
antibiotic treatment did not increase the susceptibility of this group to E. coli K1. The 
P2-P9 development of the GI tissues and the response of P2 and P9 tissues to E. coli K1 
colonization were assessed at the transcriptional level. A substantial degree of 
developmental expression was observed over P2-P9, including the up-regulation of 
putative components of the small intestinal (α-defensin peptides Defa24 and Defa-rs1) 
and colonic (trefoil factor peptide Tff2) mucus barrier. Colonization with E. coli K1 
modulated expression of these peptides: The developmental expression of Tff2 was 
dysregulated in P2 tissues, likely due to IL-1β and NFκB signalling, and was 
accompanied by a decrease in the gel-forming mucin Muc2. Conversely, α-defensin 
expression was up-regulated in P9 tissues.  
These results indicated that the intestinal barrier function of the P9 GI tract is 
more developed than the P2 equivalent. Furthermore, E. coli K1 colonization may 
compromise the development of the colonic mucus barrier in P2 neonates. This supports 
the hypothesis that the developmental state of the GI tissue, but not the microbiota, 
modulates susceptibility to systemic E. coli K1 infection. In addition, these results 
imply that supplementation of the neonatal GI with recombinant α-defensins or Tff2 
represent potential strategies for the prophylaxis of neonatal E. coli K1 infection.  
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1.1 Infant mortality in the 21
st
 century 
 
1.1.1 Overview 
 In 2001 delegates gathered at the United Nations (UN) in New York for what 
was, at the time, the single largest meeting of world leaders in history. The purpose of 
the Millennium Summit was to discuss the role of the UN. in the new century and 
beyond, and resulted in the eight chapter Millennium Declaration, from which were 
derived the 8 Millennium Development Goals (MDGs) providing eight clear and 
achievable  targets for global development to be met by 2015. The fourth MDG was 
targeted specifically at child health, with the goal of reducing by two thirds the 
mortality rates of infants (children under the age of five) compared to the 20% reduction 
observed over the previous decade (Figure 1.1).  
 
 
Figure 1.1: Infant (children under 5 years old) mortality rates (A) and total deaths (B) 
recorded in the years 1990 and 2000. Data sourced from WHO Global Health 
Observatory Data Repository (http://apps.who.int/ghodata). 
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Figure 1.2: Global causes of death for all infants under the age of five (A) and total 
deaths by cause of all neonates under the age of one month (B) in 2008. All percentages 
reflect proportion of total infant deaths (8.79 million) recorded in 2008. Data sourced 
from Black et al., 2010. 
 
The total number of infant deaths per year at the turn of the millennium was over 
9.5 million, the equivalent of 26,000 deaths per day, or a nation with a population the 
size of Sweden, with the highest mortality rates and the vast majority of deaths 
occurring in the developing nations of the African and South East Asian regions. 
Infant mortality has been attributed to multiple causes including fatal injuries, 
congenital defects, other non-communicable diseases and both preterm and intrapartum 
complications (Figure 1.2). However, as of 2008, the vast majority (64%) of infant 
deaths were directly attributable to infectious disease, with combined pneumonia, 
diarrhoeal disease, malaria and sepsis accounting for 77% of fatal infections. The 
available data also conclusively demonstrates that risk substantially decreases with age, 
with 77% of total infant mortality occurring in the first year of life and the most at-risk 
age group being the neonatal cohort, defined as infants less than one month old, which 
alone account for 41% (3.57 million in 2008) of all infant deaths (Black et al., 2010). 
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1.1.2 The Increasing Importance of Neonatal Mortality 
Figure 1.3: Infant mortality rates from for each WHO region (A) and average global 
infant mortality rates (B) from 1990-2010 for all deaths occurring under the age of 5 
years (Total) and under the age of one month 1 month (Neonates). Percentage neonatal 
mortality of total infant mortality for 1990 and 2010 are indicated in B. Infant mortality 
rate data sourced from WHO Global Health Observatory Data Repository 
(http://apps.who.int/ghodata), and neonatal mortality rate data sourced from 
Oestergaard et al., 2011. 
 
The relative importance, in terms of infant mortality, of the neonatal cohort has 
increased substantially in comparison to older infants since the initiation of the MDG 
program (Figure 1.3). According to the Inter-agency Group for Child Mortality 
Estimation (IGME) report “Levels & Trends in Child Mortality” published in 2011, the 
primary reason for this increase is that, although global infant mortality rates have 
declined by approximately 35% over the 1990-2010 period, with notable decreases in 
certain African and Asian regions, neonatal mortality has only declined by 28% over the 
same period. This equates to 1.7% per year, a significantly slower rate than the 2.2% per 
year decrease observed in the total infant mortality rate. This disparity in reduction rates 
has resulted in neonatal mortality accounting for up to 42% of the total infant mortality 
rate, a relative increase of over 10% from the 37% observed in 1990. The report also 
notes that the vast majority of neonatal mortality occurs in geographically restricted 
regions, with Sub-Saharan Africa and the Indian subcontinent combined accounting for 
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approximately two-thirds of all neonatal deaths worldwide. The disparity between 
neonates and older infants is due to the varying degrees of success encountered in 
reducing cause-specific mortality in the infant population (Figure 1.4). Comparison of 
data from studies conducted in 2003 (Bryce et al., 2005) and 2008 (Black et al., 2010) 
show that in the older cohort significant reductions have been achieved in deaths caused 
by pneumonia (38.9%; 0.78 million fewer deaths per year), diarrhoea (31.7%; 0.57 
million fewer deaths per year), and autoimmune deficiency syndrome (44.8%; 0.14 
million fewer deaths per year). A comprehensive WHO drive to improve global 
vaccination against the Measles virus in Egypt and Bangladesh, as part of an MDG 
orientated program, has also seen global immunization coverage expand from 74% in 
2003 to 82% in 2008, resulting in an almost 80% decline in 2008 compared to 2003, the 
equivalent to 0.34 million fewer deaths per year.   
 
Figure 1.4: Global total deaths, subdivided by cause, of infants from different age 
groups in 2003 (10.6 million deaths) and 2008 (8.79 million deaths). Data for different 
years sourced from Bryce et al., 2005 and Black et al., 2010 respectively. 
Although almost all of the primary causes of death in the neonatal cohort show 
reductions in deaths per year over this period, none of the causes which account for the 
majority of neonatal mortality (preterm and intrapartum complications, sepsis and 
pneumonia) decreased by more than 17%. An exception to this trend is that some 
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success has been achieved in the neonatal cohort by both maternal and neonatal 
immunization against the toxin produced by Clostridium tetani, the aetiological agent of 
tetanus, utilizing expanded distribution of the tetanus toxoid vaccine, with notable 
successes in Vietnam and other South-East Asia region nations. Overall this has resulted 
in a 68% decrease in neonatal tetanus deaths in 2008 compared to 2003, the equivalent 
0.19 million fewer deaths per year. 
 
1.1.3 Aetiology of Neonatal Mortality 
The causes that result in neonatal mortality are partially distinct from those 
afflicting older infants. Some causes, by their nature, are clearly only applicable to 
either the neonatal or older infant cohorts, for example preterm and intrapartum 
complications (birth asphyxia) are major contributors to mortality and can only affect 
the neonatal cohort. Conversely neonates are much less susceptible to mortality induced 
by microorganisms which require over 30 days of incubation time prior to the 
development of lethal symptoms. Illustrative examples are the replication cycle of the 
malarial parasite Plasmodium falciparum in liver hepatocytes, prior to the infection of 
erythrocytes leading to the hemorrhagic complications associated with malarial 
mortality (reviewed by Miller et al.,1994) and the progression of perinatally acquired 
Human Immunodeficiency Virus (HIV) infection (Scott et al., 1989) which involves 
degradation of the systemic CD4
+
 T-cell population prior to the onset of the potentially 
lethal secondary infections associated with autoimmune deficiency syndrome (reviewed 
by Hel et al., 2006). It should be noted however that mortality induced by HIV/AIDS is 
almost certainly acquired at the neonatal stage by maternal vertical transmission, 
emphasising the importance of the neonatal stage in the mortality of older infants. 
Broadly speaking, neonatal mortality can be subdivided into two aetiological groups, 
mortality induced by either non-infectious or infectious disease.  
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1.1.3.1 Non-infectious disease  
Non-infectious diseases (NIDs) are responsible for a significant fraction of 
neonatal mortality with intrapartum complications, preterm complications and 
congenital defects attributed to 58% of neonatal deaths in 2008 (Black et al., 2010). 
NID‟s are defined as conditions that are not directly caused by a pathogenic agent and 
hence cannot be transmitted from one individual to another. NIDs may account for a 
larger share of neonatal mortality than their infectious counterparts; however, there are 
microbial elements to the aetiology of all the major non-infectious causes of neonatal 
mortality. Both perinatal hypoxia (birth asphyxia) and the induction of preterm labour 
are strongly associated with intra-uterine infections (reviewed by Romero et al., 2007; 
Goldenberg et al., 2000) and maternal bacterial vaginosis also appears to be a 
significant risk factor in the development of pre-term labour (Hillier et al., 1995), 
although whether or not this is simply as a marker of intra-uterine infection rather than a 
primary cause itself remains to be determined.  
What is known is that one of the possible major complications of pre-term 
neonates, necrotizing enterocolitis (NEC), is mediated by microbial colonization of the 
neonatal intestines (reviewed by Morowitz et al., 2010), with colonization by members 
of the Gram-negative Enterobacteriaceae family believed to be of direct significance in 
the development of the condition (Hoy et al., 2000). Congenital infection of the foetus 
can also have a direct impact on the subsequent development of congenital defects 
(Epps et al., 1995).  
The microbes that can mediate these clinical outcomes are not restricted to a 
specific taxonomic grouping and contain representatives from the protozoan, bacterial 
and viral lineages (summarized in Figure 1.5). This serves as persuasive evidence that 
that the action of microbes, both directly and indirectly, plays a significant role in the 
aetiology of NID-related mortality, and should therefore be considered as potentially 
involved in all aspects of neonatal mortality and not solely in infectious disease.         
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Figure 1.5: Summary of microbial species and groups implicated in intra-uterine 
infection (purple), bacterial vaginosis (green), congenital infection (blue), bacterial 
colonization (orange) and the clinical outcomes associated with each grouping (bold). 
Image adapted from Wikimedia Commons file (Placenta.svg).   
 
1.1.3.2 Infectious Disease 
 Infectious diseases are aetiologically accountable for the remainder of neonatal 
mortality that is not covered by the aforementioned NIDs, and are thus responsible for 
approximately 42% of neonatal mortality. Infectious diseases differ from NIDs 
inasmuch as they are illnesses caused by infection with either a primary or opportunistic 
pathogenic agent (or agents), the pathogenesis of which directly mediates the clinical 
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symptoms of the disease. Although a range of infectious diseases can afflict the neonate, 
over 70% of deaths are due to four specific conditions, namely pneumonia, sepsis, 
diarrhoea and tetanus. Despite the greater overall burden of pneumonia as an infectious 
aetiological agent of mortality, in relation to neonates the single most prolific killer is 
sepsis, accounting for the bulk (35%) of all neonatal deaths with an infectious aetiology. 
This represents 15% of total infant deaths, the equivalent of over 527,000 deaths in 
2008 (Black et al., 2010). 
 
1.1.3.2.1 Sepsis 
 Despite its prominence sepsis is problematic to universally define, with signs 
and symptoms varying between patients to such a degree that describing a „typical‟ 
sepsis case remains a challenge (reviewed by Martinot et al., 1997). However it is 
generally agreed that sepsis is the combination of two physiological events. Firstly 
infection itself, defined as the presence of microorganisms in normally sterile host 
tissues or fluids, and secondly the development of systemic inflammatory response 
syndrome (SIRS), defined as a combination of abnormal temperature, heart rate, 
respiratory rate and leukocyte blood cell count. Bacterial sepsis, the most common 
form, occurs when infecting viable bacteria penetrate the circulatory system and 
disseminate to systemic tissues haematogenously (bacteraemia). The infection can 
subsequently remain diffuse (septicaemia) or localize to multiple or individual organs 
leading to multi-organ dysfunction (MODS), pneumonia or meningitis. 
 Bacteraemia and the subsequent development of sepsis can occur at any age and 
carry a significant risk of mortality, especially in elderly patients with underlying 
medical conditions (Martin et al., 2006). In relation to paediatric sepsis, the neonatal 
period presents the highest risk with mortality rates significantly higher than older 
children and survival directly related to the gestational age of infection, resulting in the 
status of preterm birth as a major mortality risk factor. A US-based multi-centre study 
of sepsis in children from 0-18 years of age found the highest rates (5.16 per 1000 live 
births) of sepsis in infants less than one year of age, and reported an overall case-
mortality rate of 10.6% in this cohort (Watson et al., 2003). Of these cases, 70% 
occurred in the neonatal period, and 60% of neonatal cases were preterm. Data from the 
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developing world is harder to assess but a review of community-based studies 
conducted in South Asian and African nations describes very high rates of neonatal 
sepsis ranging from 49-170 per 1000 live births, and case-mortality rates of up to 17% 
(Thaver & Zaidi, 2009). Both these measures are considered underestimates due to the 
lack of effective health system coverage in the developing regions in question.   
In similar fashion to neonatal pneumonia, the microbial aetiology of neonatal 
sepsis is complex, with multiple bacterial species and groups represented. The 
microorganisms which are isolated from approximately 80% of sepsis patients are listed 
in Table 1.1.  It is useful to distinguish two aetiological groups based on the timing of 
infection; early onset neonatal sepsis (EONS) is sepsis occurring in the first 72h post-
partum and late onset neonatal sepsis (LONS) is sepsis which occurs after 72h but 
within the neonatal period of 30 days. Multi-centre studies of neonatal sepsis indicate 
that systemic infection with Gram-positive pathogens is responsible for the majority of 
both EONS (62%) and LONS (70%) cases in the US, with Streptococcus agalactiae 
dominating EONS  and coagulase-negative staphylococci most frequently isolated in 
LONS cases (Stoll et al., 2011/2002a). Interestingly, a meta-analysis of studies 
conducted in developing regions indicates that this does not hold true in global regions 
which account for the bulk of sepsis cases (Zaidi et al., 2009). Gram-negative pathogens 
were isolated in 58% of EONS whereas LONS cases were evenly split between the two 
groups, with Klebsiella species and Escherichia coli accounting for almost 40% of 
EONS infections. Although Gram-positive pathogens appear to dominate sepsis in 
industrialized nations such as the USA, this is not reflected in the neonatal mortality 
rate. Gram-negative infection resulted in 36% mortality in LONS cases compared to 
11% for Gram-positive infection (Stoll et al., 2002a). The two pathogens which rank 
highest for EONS cases, Gram-positive S. agalactiae and Gram-negative Escherichia 
coli, also have highly divergent mortality rates at 9% and 33% respectively (Stoll et al., 
2011). This pattern is repeated in developing countries, compounded by higher rates of 
Gram-negative infection which significantly add to the burden of neonatal deaths in 
these regions (reviewed by Vergnano et al., 2005).            
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Region Bacterial pathogen EONS LONS 
    
Industrialized Coagulase-negative staph. 0.8% 47.9% 
(USA) Streptococcus agalactiae 43% 2.3% 
 Escherichia coli 29% 4.9% 
 Staphylococcus aureus 2% 7.8% 
 Enterococcus spp. 3% 3.3% 
 Streptococcus viridans 5%  
 Klebsiella spp.  4.0% 
 Haemophilus spp 3%  
 Pseudomonas spp.  2.7% 
 Enterobacter spp.  2.5% 
 Serratia spp.  2.2% 
 Streptococcus pyogenes 2%  
Total  370 (89%) 1313 (78%) 
    
Developing  Klebsiella spp. 26.4% 5.6% 
 Staphylococcus aureus 17.3% 13.7% 
 Streptococcus agalactiae 13.1% 11.5% 
 Escherichia coli 12.6% 9.3% 
 Salmonella spp 0.7% 13.3% 
 Streptococcus pneumoniae 1.1% 12.3% 
 Streptococcus pyogenes 0.4% 9.7% 
 Pseudomonas spp. 5.9% 1.8% 
 Enterococcus spp. 5.3% 0.8% 
 Enterobacter spp. 3.6% 1.2% 
 Haemophilus spp. 0.1% 2.0% 
 Listeria monocytogenes 0.5%  
 Streptococcus viridans 0.4% 0.1% 
Total  834 (86%) 835 (81%) 
 
Table 1.1: Bacterial pathogens isolated from cases of early onset neonatal sepsis 
(EONS) and late onset neonatal sepsis (LONS) in industrialized and developing 
regions. Values represent % of total isolates. Totals represent number of sepsis cases 
examined and % coverage by the pathogens listed. EONS and LONS data for the 
industrialized regions sourced from Stoll et al., 2011/2002a respectively. Data for the 
developing regions sourced from Zaidi et al., 2009.        
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Much as the signs and symptoms of sepsis are hard to define the characterization 
of its pathogenesis is complex. This is due to the multiple interrelated variables that 
interact to produce the ultimate bacteraemic state which typifies sepsis. The first 
variable to consider is the source of the pathogen. EONS pathogens are common 
constituents of the vaginal and gastrointestinal microbiota and are thus considered to be 
intrapartally acquired from the maternal microbiota. Conversely LONS pathogens are 
ubiquitous environmental organisms and constituents of the skin microbiota, and are 
thus thought to be nosocomially- or community-acquired. The second and third 
variables are the site of pathogen colonization and the invasive steps required to 
penetrate the host tissues and access the blood compartment, both of which are highly 
dependent on the specific pathogen encountered. The mucosal epithelial surfaces of the 
gastrointestinal and urogenital tracts, respiratory system, and oronasopharynx are 
colonized by a diverse range of commensal microorganisms, and are also common sites 
of initial pathogen colonization. Alternatively, physical disruption of the skin barrier 
function by injury or an indwelling catheter may provide direct access to the blood 
compartment for environmental pathogens. Persistent colonization of mucosal surfaces 
and the initial steps in epithelial translocation are mediated in part by bacterial 
adherence factors; examples include multimeric pilus structures such as type I pili (Fim 
proteins) from E. coli (reviewed by Schilling et al., 2001) and RlrA from Streptococcus 
pneumoniae (Barocchi et al., 2006), anchorless extracellular matrix-binding adhesins 
such as streptococcal PavA (reviewed by Chhatwal, 2002) and the multiple cell surface 
adhesins (IsdA, ClfB, SdrC/D) of Staphylococcus aureus (Corrigan et al., 2009).  
Post-colonization, sepsis-causing pathogens have to translocate across the tissue 
epithelium in order to access the bloodstream. Multiple factors contribute to this 
invasive process; one example is the glycosaminoglycan-binding Hek protein which is 
thought to contribute to epithelial cell invasion in sepsis-causing E. coli pathotypes 
(Fagan & Smith, 2007). S. agalactiae is believed to penetrate tissues by secretion of 
toxins such as β-haemolysin/cytolysin (βh/c) which mediate cytolytic damage to 
epithelial cells, disrupting barrier function and opening the epithelial gateway to the 
blood compartment and systemic circulation (Hensler et al., 2005).  
The fourth variable in the pathogenesis of sepsis is the mechanism employed by 
the pathogen to allow it to multiply in the host circulatory system whilst evading host 
immune responses. Again, multiple mechanisms have been identified; Staphylococcus 
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aureus coats itself with host antibodies by using protein A to bind the Fc fragment of 
IgG which inhibits recognition of the pathogen by Fc-receptors on host phagocytes, one 
of several mechanisms the organism possesses that inhibit immune function (reviewed 
by Foster, 2005). A prevalent mechanism of immune evasion is the elaboration of a 
polysaccharide capsule by the pathogen. Such capsules can be produced by streptococci, 
Staphylococcus aureus, Haemophilus influenzae and Escherichia coli and exploit the 
relatively poor immunological response of the neonatal immune system to 
polysaccharide antigens (reviewed by Klouwenberg & Bont, 2008). Furthermore some 
pathogens, if phagocytosed, have evolved to survive and replicate inside phagocytic 
leukocytes (Sukumaran et al., 2003). 
The ultimate cause of sepsis-induced mortality can be considered as the final 
variable in its pathogenesis. The systemic dissemination of pathogenic bacteria and the 
accompanying host inflammatory responses can result in both localized and 
systemically defined clinical outcomes. Induction of SIRS can result in MODS; a failure 
in the regulation of host homeostasis that results in the sequential failure of multiple 
organs. Although a full understanding of the mechanisms which drive MODS has not 
yet been achieved, it has been known for some time that pro-inflammatory cytokines IL-
1β and TNFα are involved, as well as cellular components of the immune response 
(reviewed by Brown et al., 2006; Abraham & Singer, 2007). Pneumonia can be both a 
prelude to and an outcome of sepsis. Pathogens may penetrate the blood compartment 
via the lungs or disseminate to them after invasion at an alternative site, both of which 
may result in eventual respiratory failure.  A further, potentially deadly localized 
complication of sepsis is bacterial meningitis, an inflammation of the meningeal 
membranes that protect the brain and spinal cord which occurs when blood-borne 
pathogens penetrate the CNS, and which is detailed in the next section. 
Sepsis is a devastating disease with a complex pathogenesis, derived from the 
multiple pathogens which act as its aetiological agents and the systemic nature of the 
infection and it can readily result in the development of fatal complications if left 
untreated. The treatment recommended by the WHO for suspected sepsis is immediate 
application of a dual intravenous antibiotic therapy targeting both Gram-positive and 
Gram-negative pathogens with a combination of aminoglycoside and expanded-
spectrum β-lactam antibiotics. However the trend towards increasing resistance to front-
line antibiotics in neonatal pathogens in both the developed and developing world 
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(Hyde et al., 2002; Alarcon et al., 2004; Thaver et al., 2009) means that this strategy 
will become less effective over time and in the long-term may fail to provide any 
therapeutic benefit. This trend necessitates alternative treatment and prevention 
strategies, and a significant volume of research has been conducted in this area. This is 
typified by attempts at immunomodulation by transfusion of granulocytes, granulocyte 
growth factors and immunoglobulins in an endeavour to boost deficiencies in neonatal 
immune function that are thought to underpin the susceptibility of this age-group to 
sepsis. However, the results of multiple trials utilizing these techniques have so far 
failed to yield a significant decline in sepsis mortality (reviewed by Wynn et al., 2009), 
but there is hope that a greater understanding of the early stages of sepsis pathogenesis 
and the maturation processes which govern the neonatal immune system may result in 
more positive results in the future.  
 
1.1.3.2.2 Bacterial Meningitis 
 The WHO epidemiological neonatal mortality data published for 2003 and 2008 
(Bryce et al., 2005; Black et al., 2010) does not list bacterial meningitis as a specific 
aetiology of neonatal mortality, with deaths from meningitis grouped with sepsis; 
however, this should not detract from the impact of this acute condition. The symptoms 
of meningitis in the neonate, unlike pneumonia, are indistinguishable from non-focal 
neonatal sepsis, and accurate diagnosis of meningitis is entirely dependent upon analysis 
of cerebrospinal fluid (CSF) sampled by a lumbar puncture procedure in order to detect 
any microbial pathogens which may have penetrated the CNS (Garges et al., 2006). 
Although a relatively simple procedure, lumbar punctures are often not performed on 
preterm neonates due to the perceived risks of doing so, despite the fact that this 
neonatal group is at an elevated risk of meningitis, with the consequence that the 
condition is believed to be significantly underdiagnosed (Stoll et al., 2004). Neonatal 
meningitis is diagnosed in a fraction of neonatal sepsis cases, with studies indicating 
that somewhere between 10-25% of reported sepsis cases progress to meningitis 
(Greenberg et al., 1997; Sáez-Llorens & McCracken, 2003; Thaver & Zaidi, 2009). If 
concerns regarding the diagnosis of meningitis are correct, this proportion may be an 
underestimate. What is clear, however, is that the mortality rate of this condition is 
particularly high, especially in the developing world. Mortality rates in the developed 
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world have declined from 50% in the mid-20
th
 century to approximately 10% at present 
(Puopolo et al., 2005), however, despite this improvement the rate of morbidity has not 
declined to the same extent, with almost 20% of meningitis survivors afflicted with 
permanent severe or moderate neurological disabilities (Bedford et al., 2001). Mortality 
rates in the developing world are poorly reported, however, a systematic review of 22 
studies reported a median mortality rate of 40% (Furyk et al., 2011). 
 Meningitis is a potentially lethal acute inflammatory condition which affects the 
meninges, the three membranes which envelop and protect the CNS. In order to 
understand meningitis it is first necessary to comprehend the structure and function of 
these membranes, and associated anatomical features, which are illustrated in Figure 
1.6. The outermost meningeal membrane is the dura mater, the thickest and most 
structurally robust of the meninges, which is composed of fibroblast-like cells, a dense 
web of extracellular collagen fibres which provide its strength and elements of the 
cranial vasculature (reviewed by Adeeb et al., 2012). The peripheral side of the dura 
mater is connected to the skull. The central meningeal membrane is the arachnoid, a 
multilayered but very thin epithelium with intercellular tight junctions and extracellular 
connections to both the dura mater and the innermost membrane, the pia mater. The pia 
mater is also extremely thin, intimately connected to the cerebral cortex by the 
extrusions of astrocytes and contains the cerebral vasculature which feeds blood into the 
cerebral cortex (Nakazawa & Ishikawa, 1998). The pia mater has several functions, 
including the formation of a perivascular space between the brain parenchyma and 
penetrating blood vessels, providing the organ with a form of lymphatic system (Zhang 
& Weller, 1990). The cavities between each meningeal membrane are the subdural and 
subarachnoid spaces which are filled with CSF, a vital component of the CNS which 
cushions the brain against concussive physical impacts and washes over the cerebral 
parenchyma, via the perivascular space, transporting nutrients to neurons and flushing 
metabolic waste back towards the circulatory system (reviewed by Cutler & Spertell, 
1982). The CSF is produced in the four choroid plexi, specialized structures of the brain 
ventricles containing capillaries with fenestrated endothelia and the specialised 
ependymal cells of the choroid plexus epithelium which possess a range of apical ion 
cotransporters which actively transport Na
+
, K
+
, and Cl
2-
 into the CSF-containing 
ventricular lumen (reviewed by Wolburg & Paulus, 2010). This builds up a strong 
osmotic gradient between the blood and the CSF which precipitates water flux from the 
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circulation into the ventricles via a transcellular transport process across the epithelial 
cells mediated by the water channel protein AQP1 (Praetorius & Nielson, 2006).  
 
 
Figure 1.6: Anatomy of (A) the meninges and associated neural, skeletal and vascular 
cranial structures; (B) the choroid plexus and surrounding tissues. The three meningeal 
membranes are underlined. Images adapted from Wikimedia Commons files 
(Gray769.png; Gray708.svg). 
 
Meningitis frequently occurs as a sequela of bacteraemia and sepsis with 
bacterial pathogens gaining access by various mechanisms and potential routes to the 
CSF compartments via the circulatory system. Bacteria subsequently propagate 
throughout the CSF, spreading through the subarachnoid and subdural spaces. Despite 
the fact that a significant fraction of meningitis-causing bacteria are encapsulated, 
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inhibiting recognition by elements of the immune system, bacterial replication and lysis 
releases prokaryotic cellular components into the CSF. Components that have been 
implicated in the pathophysiology of meningitis include classical stimulators of the 
inflammatory response such as the Gram-positive cell wall constituents peptidoglycan 
(PPG) and lipoteichoic acid (LTA) and the Gram-negative outer membrane-bound LPS-
containing endotoxin complex (Tuomanen et al., 1985; Syrogiannopoulos et al., 1988). 
The fact that bacterial debris modulates the inflammatory response in the CNS is 
evidenced by the fact that bactericidal antibiotic treatment of meningeal infections 
results in increased release of these products and a correlating increase in inflammation 
(Mertsola et al., 1989; Arditi et al., 1989).  
Until relatively recently the CNS was regarded as an „immunologically 
privileged‟ site with a relatively immunoincompetent leukocyte population composed of 
microglia cells and hidden from the adaptive lymphocyte-driven immune response by 
its isolation behind the endothelial blood-brain barrier (BBB). This view has been 
challenged by studies demonstrating that, although both innate and adaptive immune 
responses are differentially regulated in the CNS, they do interact with the peripheral 
immune system. The BBB is permeable to leukocytes and lymphocytes and the 
peripheral microenvironments of the CNS, namely the meninges and sub-meningeal 
spaces, have populations of highly immunocompetent macrophage and dendritic cells 
capable of stimulating robust innate and adaptive immune responses (reviewed by 
Carson et al., 2006).  
Innate immune response pathways are stimulated in these leukocytes by the 
aforementioned prokaryotic cellular components, which are pathogen-associated 
molecular patterns (PAMPs). For example, LPS is complexed by extracellular LPS-
binding protein (LBP) which is then recognized by the pattern-recognition receptor 
(PRR) proteins CD14 and TLR4 (Poltorak et al., 1998; Muta & Takeshige, 2001). PPG 
and LTA are recognized by a heterodimer of two Toll-like receptors, namely TLR2 and 
TLR6 (Takeuchi et al., 1999; Ozinsky et al., 2000). Binding to, and activation of, these 
PRRs results in activation of primary transcription factors such as NFκB (reviewed by 
Gilmore, 2006), leading to the production of pro-inflammatory cytokines that include 
TNFα, IL-1β, IL-6, IL-8, and platelet-activating factor (PAF), which are commonly 
detected in increased quantities in CSF samples from clinical meningitis cases (Ramilo 
et al., 1990; reviewed by Sáez-Llorens et al., 1990). 
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Secretion of pro-inflammatory cytokines by meningeal monocyte-derived 
leukocytes induces expression of cellular adhesion molecules ICAM1 and VCAM1 in 
brain vascular endothelial cells. The cytokine chemotactic gradient attracts circulating 
innate-effector leukocytes such as neutrophils which bind to the aforementioned 
adhesion molecules and translocate into the sub-meningeal spaces (Henninger et al., 
1997; Bohatschek et al., 2001). The migration of circulatory leukocytes into the inter-
meningeal spaces represents the inflammatory process that is the critical step in the 
pathophysiology of meningitis. As with other inflammatory conditions, such as 
pneumonia, the vasogenic influx of leukocytes stimulated by macrophage and dendritic 
cells is vital in both limiting and combating infection in the meninges (Polfliet et al., 
2001). However the deleterious cytotoxic effects of inflammation, such as the 
production of reactive oxygen species and nitric oxide, and increased permeability of 
the BBB during vasogenic influx can have significant consequences, potentiating the 
development of lethal sequelae. These include oedema, hypertension, and decreased 
blood flow to the brain parenchyma (Tauber, 1989; Koedel et al., 1995), leading to 
hypoxia, neuronal apoptosis and eventual death. 
As a potential consequence of sepsis, the aetiology of neonatal bacterial 
meningitis is represented by a restricted cohort of the pathogens that comprise the 
aetiological agents of EONS and LONS. As with these conditions, there are some 
regional variations with respect to the pathogens isolated in developed and developing 
nations. A multi-centre study of neonatal sepsis and meningitis in the US reported an 
equal number of Gram-positive and Gram-negative meningitis cases, with E. coli 
accounting for 44% and S. agalactiae 19% of total meningeal infections (Stoll et al., 
2011). As expected, data from developing nations is much harder to evaluate; however, 
a recent systematic review of 22 reports with representative studies from most 
geographical regions of the developing world appears to indicate that E. coli, S. 
agalactiae, Klebsiella spp. and S. pneumoniae are the four most frequently isolated 
pathogens (Furyk et al., 2011). All of these pathogens, and thus the bulk of meningitis 
isolates, express capsular polysaccharide. 
The polysaccharide capsule is an essential virulence factor in relation to both 
Gram-positive and Gram-negative bacterial neonatal pathogens with regard to their 
capacity to cause meningitis. The molecular composition of the polysaccharide can be 
that of a homopolymer, consisting of a single repeated monosaccharide, or a 
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heteropolymer comprised of repeating units of 2-6 different sugar monomers. The 
primary function of the capsule is defensive, with the long polysaccharide chains 
masking the bacterial cell from potentially hostile determinants, including cellular and 
humoral elements of the neonatal immune system (Kolb-Maurer et al., 2001; reviewed 
by Moxon & Kroll, 1990). The neonatal humoral immune system performs particularly 
poorly in the recognition of foreign polysaccharide, as it constitutes a thymus-
independent type 2 antigen (reviewed by Weintraub, 2003; Klouwenberg & Bont, 
2008). Antigens can be broadly classified as thymus-dependent (TD) or thymus-
independent type 1 or 2 (TI-1 or TI-2) based on whether the immunological response 
requires the involvement of thymus-derived CD4
+
 T-cells or can be directly mediated 
by B-cells without T-cell involvement. Most proteins are TD antigens; LPS is an 
example of a TI-1 antigen and most polysaccharides, as indicated, are TI-2 antigens. TI-
2 antigens were first differentiated from TI-1 antigens by the lack of response of 
neonatal B-cells to certain molecules, including polysaccharide (Mosier et al., 1977), 
and it was later shown that responsiveness to TI-2 antigens in humans does not develop 
until 2 years of age, due to immature B-cell receptor deficiencies (reviewed by Rijkers 
et al., 1998). This developmental deficiency is a key determinant in the susceptibility of 
neonates to infection by encapsulated pathogens; however, some meningitis-causing 
bacteria employ an extra layer of subterfuge in that their capsules mimic the molecular 
structure of a host antigen. A prime example of this capsule class is a homopolymer of 
α-2,8 linked N-acetyl neuraminic acid (NeuNAc), also termed polysialic acid (PSA), 
which is elaborated by E. coli capsular serotype K1 (E. coli K1) and Neisseria 
meningitidis capsular serotype B (Group B meningococcus). This structure mimics a 
host-derived PSA glycoconjugate, which functions as a key regulator of neuronal 
plasticity during neonatal cerebral development through its interactions with neural cell 
adhesion molecules (NCAM; reviewed by Rutishauser, 1996; Troy, 1992). This 
structure is extremely poorly immunogenic (Keller et al., 1980; Jennings & Lugowski, 
1981) and only appears to elicit an IgG-mediated immunological response in hosts with 
autoimmune hyper-reactivity (Frosch et al., 1985). 
Many clinically significant bacteria can produce capsular polysaccharide, with 
sub-strains of the same species capable of producing a diverse range of biochemically 
distinct structures, giving rise to multiple capsular serotypes. The number of capsular 
serotypes that have been identified for a given bacterial species is variable; however, the 
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species that are most frequently isolated in cases of neonatal meningitis tend to be 
among the most prolific in terms of capsular diversity with, over 80 different serotypes 
identified in E. coli, Klebsiella species and S. pneumoniae (reviewed by Weintraub, 
2003; Whitfield, 2006; Ørskov & Ørskov 1984; Podschun & Ullmann, 1998). The 
exception is S. agalactiae, which has relatively few capsular serotypes, with only 9 
identified at present (Ryc et al., 1988; Slotved et al., 2007). Although all capsules serve 
a defensive function, only a relatively restricted cohort are associated with neonatal 
invasive disease and meningitis. These include E. coli capsular serotypes K1, K2 and 
K5 (Korhonen et al., 1985); Klebsiella capsular serotypes K1, K2, K4 and K5 (reviewed 
by Podschun & Ullmann, 1998); S. pneumoniae capsular serogroups 1, 19, 6, 5 and 14 
(Hausdorff et al., 2000) and S. agalactiae capsular serotype III (reviewed by Schuchat, 
1998). The underlying cause of this association can be traced in part to additional 
factors relating to polysaccharide structure, such as molecular mimicry of host antigens 
(Troy, 1992; Vann et al., 1981) and intrinsic resistance to specific innate immune 
mechanisms (Kabha et al., 1995); however the basis of a good deal of specific capsular 
serotype-virulence relationships remains to be fully described. 
 As with its parent condition, sepsis, bacterial meningitis is clearly an 
aetiologically complex and potentially fatal complication of the neonate which requires 
prompt treatment in order to elude its associated morbidities and high mortality rate. 
The recommended treatment of meningitis mirrors that of sepsis, namely an aggressive 
antimicrobial chemotherapeutic strategy targeting both Gram-positive and Gram-
negative bacteria, with the additional requirement that the agent in question be able to 
transverse the BBB into the CNS. However, as described in the previous section, 
antimicrobial resistance in neonatal pathogens is on the rise. A recent study of neonatal 
pathogen resistance patterns in the developing world has shown that the resistance of 
the two predominant Gram-negative aetiological agents of neonatal meningitis, 
Klebsiella and E. coli, to Ceftriaxone, a 3
rd
 generation cephalosporin class β-lactam that 
is commonly used to treat meningitis, has risen from 33% to 66% and 0% to 19% 
respectively over the previous decade (Thaver et al., 2009). This factor, combined with 
the high morbidity rates observed even after effective antimicrobial treatment, strongly 
indicates that new alternative treatments and prophylactic strategies should be employed 
in combating this disease. 
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1.1.4 Reducing Neonatal Mortality 
 The UN 2010 MDG report indicated that infant mortality significantly declined 
over the previous 2 decades, but did not fall fast enough to achieve the 4
th
 MDG target 
of a global two-thirds reduction by 2015. Significant gains have been made in reducing 
mortality in infants, with dramatic decreases in mortality due to diarrhoea and 
pneumonia observed in infants outside the neonatal cohort. This success has been 
primarily due to the use of effective condition-specific management strategies such as 
oral rehydration therapy (ORT) in the case of diarrhoea and the WHO prescribed case-
management approach in relation to pneumonia (Victoria et al., 2000; Sazawal et al., 
2003; Theodoratou et al., 2010a). These core strategies can be expected to continue to 
reduce infant mortality as their coverage expands further. Additionally, data suggests 
that supplemental reductions in mortality may well be achieved by expansion of   
vaccination programmes against the common viral and bacterial aetiological agents of 
these diseases (Jiang et al., 2010; Simonsen et al., 2011; Theodoratou et al., 2010b). It 
appears that progress in these areas, whilst by no means complete at this stage, may 
feasibly result in these two global killers losing their pole position in terms of infant 
mortality in the not too distant future. 
 Unfortunately, these developments are not as advantageous to the neonatal 
cohort, where diarrhoea and pneumonia only accounted for 12% of neonatal mortality in 
2008 (Black et al., 2010). In order to have any hope of achieving drastic reductions in 
infant mortality, the afflictions of the neonatal cohort must be addressed as a matter of 
urgency. Over the course of the previous few sections, I have reviewed the aetiological 
basis of neonatal mortality and, from this, several themes have emerged. Firstly, 
although the two foremost afflictions of the neonate, preterm birth and intrapartum 
complications, are classed as NIDs the direct or indirect role of microorganisms in the 
development of these afflictions should not be understated. From the pathophysiology 
of preterm complications such as NEC and the intrauterine infections implicated in 
driving both preterm birth and perinatal hypoxia, as well as the more direct involvement 
of the pathogens isolated in infectious neonatal disease, it is clear that the focus of any 
strategy to reduce neonatal deaths must derive from a greater understanding of the 
relevant microorganisms and the pathogenic mechanisms that drive the aetiological 
motors of mortality.  
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Other themes to emerge are the role of immunological responses in the 
progression of neonatal disease and the role that inflammation plays in mediating 
mortality. The development of the various elements of the neonatal immune system is a 
rich area of research and not without controversy. Whilst some research indicates that 
adaptive immune pro-inflammatory responses are dulled in the neonate compared to the 
adult (reviewed by Levy, 2007) others, have reported over-production of inflammatory 
mediators in response to innate immune stimuli (Tatad et al., 2007; Zhao et al., 2008). 
Whether or not elements of the neonatal immune system are in some way impaired or 
hyper-responsive, prolonged and/or excessive inflammatory responses appear to inflict 
the bulk of the damage responsible for the mortality observed in sepsis, pneumonia and 
meningitis. Thus, a greater understanding of neonatal developmental immunology will 
allow the refinement or development of therapeutic and prophylactic strategies designed 
to compensate for immunodeficiencies in the developing neonate.  
The third major theme is the conservation of specific microorganisms across the 
spectrum of neonatal disease. Several species recur in the microbial aetiology of 
neonatal disease, although E. coli and S. agalactiae are among the most consistently 
prominent, with both pathogens implicated in intra-uterine infections that can prompt 
preterm birth and perinatal hypoxia, as well as sepsis, pneumonia, meningitis, and, in 
the case of E. coli, diarrhoea. The fact that these microbes are constituents of the 
maternal gastrointestinal or vaginal microbiota explains why these pathogens dominate 
intra-uterine and early-onset forms of disease, as they are frequently among the first 
microorganisms encountered by the neonate.  
S. agalactiae, commonly referred to as the group B streptococcus (GBS), was 
recognized as a prominent agent of neonatal mortality in industrialized countries in the 
1970s and, as a result, the use of intrapartum antibiotic chemoprophylaxis was trialed 
and found to be effective in reducing the incidence of neonatal GBS infections and 
associated mortality (Boyer et al., 1986). Developments throughout the 1990s led to 
recommendations for standardized culture-based GBS screening of pregnant women 
and antibiotic treatment (Halsey et al., 1997), with the result that GBS disease has 
significantly declined in the neonatal population since their implementation  (Brooks et 
al., 2006). The use of intrapartum antibiotics has not reduced rates of neonatal E. coli 
infection (Schrag et al., 2006) and has been accompanied by reports of an increasing 
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incidence of neonatal disease caused by this pathogen, especially in the preterm 
population (Stoll et al., 2002b; Cordero et al., 2004; Bizzarro et al., 2008). 
 Although GBS screening is mostly confined to industrialized nations, the 
benefits of this prophylactic measure make it likely this procedure will be implemented 
in developing nations in the near future. Should the pattern of increased neonatal 
Escherichia coli infection observed in industrialized nations be observed in developing 
nations, this will increase the burden of disease caused by this pathogen in regions 
which already account for the majority of neonatal infectious disease mortality, and 
which already suffer from increased rates of Gram-negative bacterial infections and 
associated elevated mortality rate. Increased infections in industrialized nations, the 
relatively high rates of infection in developing nations and the potential for increases in 
these rates mean that effective treatment strategies for the management or prophylaxis 
of neonatal Escherichia coli infection are essential in order to reduce neonatal mortality. 
Although the resistance of GBS to frontline antibiotics does not appear to have 
significantly increased since the introduction of intrapartum chemoprophylaxis (Heelan 
et al., 2004; Chohan et al., 2006), the same does not hold true for E. coli, with isolates 
showing significant increases in resistance to multiple antibiotic classes (Hyde et al., 
2002; Thaver et al., 2009). This strongly indicates that antibiotic therapy cannot alone 
reduce infections by this pathogen and efforts should be made to understand its 
pathogenesis, allowing specific steps on the path to mortality and morbidity to be 
therapeutically targeted.    
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1.2 Escherichia coli  
 
1.2.1 Natural History 
 E coli belongs to the Enterobacteriaceae and was originally isolated in 1886  by 
the German paediatric bacteriologist Theodor Escherich following his investigations 
into bacteria that inhabited the infant colon. The bacterium is a Gram-negative rod-
shaped non-sporulating facultative anaerobe approximately 2 µm long and 0.5 µm wide. 
E. coli is the most thoroughly characterized organism, with the best known strain being 
K-12, an isolate which has been grown in the laboratory for almost a century and from 
which a large number of mutant strains have been derived (Bachmann, 1972). Due to 
the relative ease and safety with which it is cultured and the numerous techniques that 
have been developed for its manipulation at the molecular level, this strain has long 
served as a model organism for a range of microbiological disciplines, including 
genetics, metabolism, proteomics and evolution and it was one of the first organisms to 
be genome sequenced (Blattner et al., 1997). Some strains, such as protease-defective 
BL21, are widely used in the biotechnology industry as a recombinant microbiological 
system for the large scale production of prokaryotic and eukaryotic heterologous 
proteins (reviewed by Baneyx, 1999).   
Outside of the laboratory, Escherichia coli is a principal component of the 
intestinal microbiota of infants (Penders et al., 2005) and is also present to a lesser 
extent in the adult intestine, in which facultative anaerobes make up a much smaller 
proportion of the bacterial population (Eckburg et al., 2005). The gastrointestinal (GI) 
tract of endothermic organisms is considered to be the natural habitat of E. coli and the 
bacterium has been used as a biological marker of faecal contamination as it was 
considered to be unable to survive for long outside the GI tract. However, several 
studies have demonstrated that under certain conditions E. coli can colonize and 
replicate in environments external to the host GI tract (Desmarais et al., 2002; Ishii et 
al., 2006; Liang et al., 2011), demonstrating a surprising environmental versatility. 
The ecological adaptability of E. coli may be explained by its versatility in key 
biological arenas, especially with regard to its metabolic capabilities. It is able to utilize 
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a wide range of carbon-containing compounds as sole source of carbon and for 
generation of adenosine tri-phosphate (ATP). The catabolic pathways that E. coli are 
capable of utilizing to form ATP from these sources are highly varied. As a facultative 
anaerobe, E. coli has the biochemical means to utilize both oxygen (aerobic) and 
fumarate or nitrate (anaerobic) as terminal electron acceptors in its respiratory ATP-
generating chain (reviewed by Ingledew & Poole, 1984). Switching between these two 
respiratory pathways is regulated by the oxygen sensitive FNR global transcriptional 
regulator and its associated regulon (Constantinidou et al., 2006). Additionally, in the 
absence of these electron acceptors and the presence of a suitable substrate, E. coli 
continues to produce ATP by mixed-acid fermentation (reviewed by Clark, 1989) 
although this, and the alternate forms of anaerobic respiration, are significantly less 
efficient in producing ATP than aerobic respiration. 
E. coli are a Gram-negative species and have a cell wall structure typical for this 
group of bacteria (Figure 1.7). The cytoplasmic membrane (CM), a hydrophobic 
phospholipid bilayer containing an array of membrane associated proteins many of 
which function in an influx/efflux transporter capacity (Daley et al., 2005) and mediate 
electron transport for the various ATP-generating pathways, retains vital metabolic 
components and nucleic acids within the cytoplasm. External to the CM is the periplasm 
which contains the sugar/amino acid heteropolymer peptidoglycan (PPG) and another 
phospholipid bilayer, the outer membrane (OM). The periplasm contains a continuous 
mesh of PPG which forms the sacculus, a cell-encompassing macromolecule which is 
synthesised in the CM (Bupp & van Heijenoort, 1992) and may be regulated by 
complexes of the cytoplasmic actin homologue MreB and membrane-bound RodZ (van 
den Ent et al., 2010), although the exact role of these proteins has yet to be determined 
(Swulius et al., 2011). The PPG sacculus is anchored to the OM by a murein lipoprotein 
(Braun & Sieglin, 1970) and provides rigidity and structure to the cell wall.  
Beside the Braun murein lipoprotein, the OM proteins (OMPs) include iron 
receptors (FhuE, FhuA), porins (OmpC, OmpF) and the porin-like multifunctional high-
copy β-barrel OmpA (Molloy et al., 2000). Biogenesis of the OM is mediated by a 
complex of OMPs, including YeaT (Omp84), which is essential for the proper folding 
of other OMP proteins (Wu et al., 2005). The OM bilayer has an outer leaflet composed 
of LPS (Kamio & Nikaido, 1976). The structure of LPS is illustrated in  Figure 1.8  and  
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Figure 1.7: The cell wall of an encapsulated Escherichia coli cell illustrating the 
membrane structure and external surface O-antigen (LPS) and K-antigen (capsule). H-
antigen (flagellum) is not illustrated.  
 
 
Figure 1.8: Representation of lipopolysaccharide (LPS) components. Lipid A (blue), 
core oligosaccharide (inner: yellow; outer: green) and the O- Antigen serotype-specific 
polysaccharide (purple) are indicated. 
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consists of the proximal membrane-anchored constituent lipid A, the inner and outer 
core oligosaccharide linked to lipid A and the distal O-Antigen polysaccharide. Lipid A 
is the endotoxin component of the molecule, which is recognised by the innate 
LBP/CD14/TLR4 receptor pathway, stimulating a strong immune response (Poltorak et 
al., 1998; Muta & Takeshige, 2001) but which is also structurally essential to the E. coli 
cell (Galloway & Raetz, 1990). The inner core oligosaccharide is generally conserved 
within species but the outer core is more variable, with 5 different variants currently 
known of in E. coli (reviewed by Heinrichs et al., 1998). The core does not appear to be 
vital to E. coli cellular viability but does appear to influence the stability of the outer 
membrane by the formation of intermolecular cationic bonds between core domains 
(reviewed by Vaara, 1992), as well as providing a linkage site for the O-antigen 
polysaccharide. The repeating oligosaccharide units that constitute the O-antigen 
polysaccharide are of great epidemiological significance to Escherichia coli as they are 
serologically heterogeneous, with over 170 different serotypes thus far identified within 
the species (reviewed by Raetz & Whitfield, 2002). If the strain is non-capsulated, the 
O-antigen is the peripheral component of the cell and has a protective function. The 
polysaccharide prevents the bactericidal and/or lytic actions of both the serum 
complement cascade and neutrophil-secreted BPI protein in a length-dependent fashion 
(Burns & Hull 1998; Weiss et al., 1986). Both the toxic effect of lipid A and the innate 
immune-evasion function of the O-antigen mean that this component of the E. coli cell 
wall is generally considered to be a virulence factor in pathogenic strains of the 
organism. 
 If the E. coli strain is encapsulated, the capsular polysaccharide, or K-antigen, 
constitutes the outermost component of the cell. In similar fashion to the O-antigens, 
capsules are highly heterogeneous, with approximately 80 different serotypes thus far 
identified (reviewed by Weintraub, 2003; Whitfield, 2006). Serotyping of E. coli has 
been utilized since the 1940‟s, with serological characteristics and thermostability 
initially used to classify the K-antigens into 3 groups. The currently used system of 
Whitfield and Roberts breaks the different K-antigens down further into 4 groups based 
on genetic and biosynthetic criteria rather than structure (Whitfield & Roberts, 1999). 
Group 1  (e.g. K30) and 4 (e.g. K40) capsules are closely related to the O-antigen 
polysaccharide, with each K-antigen expressed as two distinct forms on the cell surface, 
one linked to the LPS lipid A-core (KLPS) and the other which is not (MacLachlan et al., 
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1993; Amor & Whitfield, 1997). In genetic terms, the cps gene clusters required for 
capsular expression for both groups are located near the his locus (Drummelsmith et al., 
1997; Amor & Whitfield, 1997) and in biosynthetic terms depend on the integral 
membrane machinery mediated by the Wza (translocation), Wzx (translocation), Wzc 
(polymerization/translocation) and Wzy (polymerase) proteins (Drummelsmith & 
Whitfield, 1999). Differences between group 1 and 2 capsules lie in the length of the 
KLPS chain (Dodgson et al., 1996) and the polysaccharide composition, with 
polysaccharides of the less diverse group 1 typically containing uronic acids and the 
more diverse group 2 containing acetamido sugars (reviewed by Whitfield, 2006).  
The chemical composition of group 2 (e.g. K1, K5) and 3 (e.g. K10) capsular 
structures are highly variable but possess several homologous characteristics. Both are 
expressed in a single form with no link to the LPS lipid A and most have a phosphatidic 
acid or 3-Deoxy-D-manno-oct-2-ulosonic acid (KDO) residue at the reducing terminus 
of the polysaccharide, thought to mediate attachment to the cell surface (reviewed by 
Roberts, 1996). However, there are exceptions, notably the PSA-based K1 capsule 
(detailed in previous sections) which does not appear to interact with the cell surface in 
this fashion. Instead, it has been proposed that the K1 capsule is anchored to the cell 
surface by ionic interactions with the negative charges on phosphate groups of the LPS 
core oligosaccharide (Jiménez et al., 2012). The genes that encode the biosynthetic and 
export machinery of group 2 and 3 capsules are the kps cluster, a relatively well 
conserved set of genes that are organized into 3 regions. Regions 1 and 3 encode export 
and translocation proteins, including an ATP-binding-cassette (ABC) transporter 
(KpsMT), and a serotype-specific set of region 2 genes such as the neu cluster of K1-
polysaccharide, located near the serA chromosomal locus (Silver et al., 1981; reviewed 
by Whitfield, 2006). There are differences in the organisation of the group 2 and 3 kps 
clusters which account for a major difference between the 2 groups, namely that, in 
contrast to group 3, group 2 capsule expression is thermoregulated with maximal 
expression of the capsular genes at 37°C and significantly less expression at lower 
temperatures (Rowe et al., 2000). 
A number of functions have been proposed for capsular polysaccharides. These 
include prevention of dessication (Ophir & Gutnick 1994) and modulation of biofilm 
formation (Valle et al., 2006). However, their most well-established function is to 
provide protection against immune and environmental insults. Although the various K-
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antigens do not possess the toxic characteristics of LPS lipid A, they are key virulence 
factors and contribute to the pathogenicity of E. coli. In similar fashion to O-antigens, 
K-antigen polysaccharides provide resistance to innate host immune processes such as 
the serum complement cascade and complement–mediated opsinophagocytosis 
(Howard & Glynn, 1971). Some capsular types provide protection from adaptive 
immune responses by molecular mimicry of host glycoconjugates; for example, the K1 
and K5 group 2 capsular antigens (Troy, 1992; Vann et al., 1981), enable pathogenic 
strains of E. coli to evade immune surveillance mechanisms by capitalizing on the host-
age-dependent immune response to TI-2 antigens (Mosier et al., 1977; reviewed by 
Rijkers et al., 1998). 
E. coli strains frequently possess other surface structures of physiological 
importance. These include peritrichous flagellae (the H-antigens), which are highly 
complex whip-like structures driven by rotary transmembrane proton-powered motors 
to provide directional motility (reviewed by Macnab, 1992). Other common structural 
features are pili (or fimbrae); these are thin protein tubes which protrude from the CM 
to decorate the bacterial surface where they mediate adhesion to host surfaces (Krogfelt 
et al., 1990). Although there are a number of pilus types, one specific type serves to 
illustrate a factor of importance in the natural history of E. coli. The F-pilus mediates 
plasmid-driven conjugation, the transfer of DNA from one cell to another through the 
tubular F-pilus (reviewed by Ippenihler, 1986), constituting a critical element of 
horizontal gene transfer (HGT). 
Tatum and Lederberg were the first to document the capacity of E.coli to 
directly exchange genetic material (Tatum & Lederberg, 1947), and since this discovery 
the study of HGT in this species has become a rich area of research. The acquisition of 
genetic material in HGT can be driven by several mechanisms that include conjugation 
(transfer of DNA by direct cell-cell contact), transformation (uptake of DNA from the 
environment) and transduction (introduction of DNA by infection of the bacterium with 
lysogenic phage; reviewed by Ochman et al., 2000). Codon-bias and G/C base content 
analysis of the genome of Escherichia coli K-12 shortly after publication in 1997 
revealed that approximately 18% of chromosomal open reading frames (ORFs) were of 
foreign origin, with a significant fraction physically associated with mobile genetic 
elements such as transposon and prophage. It has been estimated that Escherichia coli 
has acquired approximately 16 kb of DNA for each million years since speciation from 
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its phylogenetic ancestor, Salmonella enterica, about 100 million years ago (Lawrence 
& Ochman, 1998). 
Colonization of the GI tract by the majority of Escherichia coli strains is 
commensular in nature, with the GI environmental niche providing the organism with a 
steady supply of nutrients and a relatively stable, if competitive, environmental medium 
where E. coli may exploit its ability to utilize gluconate as a carbon source more 
efficiently than other components of the microbiota (Sweeney et al., 1996). The 
presence of E. coli in the GI tract may even provide some mutualistic benefits to the 
host in terms of resistance to colonization by pathogens (Hudault et al., 2001; 
Schamberger et al., 2004). However, many strains of Escherichia coli are pathogenic, 
which can be traced to pathogenesis-related determinants, or virulence factors (VFs). 
These include structures such as the O/K/H antigens and a variety of exotoxins. Many 
of these VFs can themselves be traced to HGT events which have occurred during the 
evolutionary history of the microbe. The expanding number of fully sequenced E. coli 
genomes has allowed the comparison of commensals and pathogenic isolates causing 
different types of infections (also known as different pathovars). It is surprising that the 
E. coli genome has a highly mosaic structure, with only 39% of genes conserved 
between strains. The large majority of VF genes are either associated with chromosomal 
pathogenicity islands (PAIs) flanked by mobile genetic elements or associated with 
plasmids; both provide well-recognised evidence of HGT (Welch et al., 2002). 
Although the impact on the host of virulence factors, especially those associated with 
potentially lethal systemic infection, with concomitant dysregulation of the E. coli 
habitat, may at first sight appear to provide little or no benefit in evolutionary terms 
there must be significant selective pressure in addition to maintenance of microbe-host 
homeostasis that drives their retention in the E. coli population. There is growing 
evidence that VFs play a significant role in augmenting the ability of E. coli to colonize 
the GI tract (Wold et al., 1992; Nowrouzian et al., 2006) and survive micro-predation 
(Alsam et al., 2006; Steinberg & Levin, 2007). Both may represent selective pressure 
for maintainance of beneficial HGT events, with the result that multiple E. coli 
pathovars persist in the environment and continue to cause disease in humans.  
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1.2.2 One Species, Multiple Pathovars 
 Although designated as members of a single species, E. coli strains are 
genetically heterogeneous, with pathogenic strains causing infections with 
mechanistically diverse modes of pathogenesis. Strains that utilize distinct pathogenic 
mechanisms are grouped together as pathovars; although many elements of 
pathogenesis are shared, each pathovar has its own unique profile. At present, eight 
pathovars have been identified and subjected to extensive investigations. They are 
designated enteropathogenic (EPEC), enterohaemorrhagic (EHEC), enterotoxigenic 
(ETEC), enteroinvasive (EIEC; classified as the separate genus Shigella), 
enteroaggregative (EAEC), diffusely adherent (DAEC), uropathogenic (UPEC) and 
neonatal meningitic (NMEC). They can be further classified into two groups on the 
basis of site of infection, namely the intestinal and extra-intestinal pathovars (reviewed 
by Kaper et al., 2004; Croxen & Finlay, 2010).   
 
1.2.2.1 Intestinal Pathovars 
Pathovars which exert their pathogenic effects in the intestine are common 
mediators of diarrhoeagenic disease in humans and animals as a consequence of 
disruption of the intestinal epithelium, leading to fluid loss and watery diarrhoea. As 
noted, the mechanistic basis of disease can vary significantly between pathovars. The 
diversity in pathogenic mechanisms employed is matched by their diversity with respect 
to epidemiology, disease associations and mortality in infants, including neonates.  
EPEC has an extremely strong association with diarrhoeagenic disease and 
mortality in neonates and infants younger than 2 months of age in the developing world 
(reviewed by Levine & Edelman, 1984). EPEC pathogenesis involves the formation of 
attaching and effacing (A/E) lesions on host intestinal epithelial cells. The bacterium 
adheres to the cell membrane and induces effacement of the cell microvilli and 
formation of a pedestal like structure upon which the bacterial cell sits (Moon et al., 
1983). The genes involved in A/E lesion formation are clustered in a PAI designated the 
locus of enterocyte effacement (LEE; McDaniel et al., 1995). The proteins encoded by 
this locus include the components of a type III secretion system (T3SS) and multiple 
T3SS-delivered effector proteins. These effectors have a multitude of intracellular 
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functions. For example, Tir (translocated intimin receptor) protein localizes to the 
enterocyte apical membrane, binds the bacterial outer membrane protein intimin and 
promotes close association between the pathogen and host cell (Kenny et al., 1997). Tir 
subsequently activates host N-WASP and the ARP2/3 complex that mediate the actin 
cytoskeletal rearrangements which drive A/E lesion and pedestal formation (Kalman et 
al., 1999). Other effectors include Map, EspF, Nle1 and Cif which inhibit mitochondrial 
function, disrupt intercellular tight junctions, inhibit solute transport and can induce 
enterocyte apoptosis (Guttman et al., 2006; Thanabalasuriar et al., 2010; Samba-Louaka 
et al., 2009). 
EHEC is capable of causing severe haemorrhagic diarrhoea in all age-groups. 
However, subsequent development of potentially fatal haemolytic uremic syndrome 
(HUS) is significantly more common in young infants, including neonates, and the 
elderly (Bell et al., 1997). EHEC pathogenesis is similar to EPEC as this pathovar also 
possesses the LEE PAI and thus forms similar A/E lesions (McDaniel et al., 1995). 
However, EHEC strains possess additional VF‟s which mediate greater damage to the 
intestinal lining and can also cause systemic tissue damage. The characteristic VF of 
EHEC is the Shiga cytotoxin (Stx; otherwise known as Verotoxin). This multimeric 
protein binds to Gb3 receptors present on Paneth cells and kidney epithelial cells via its 
pentameric B subunit (Schuller et al., 2007; Boyd & Lingwood, 1989). This allows 
intracellular trafficking of the enzymatic A subunit, an N-glycosidase which inhibits 
protein synthesis (reviewed by Nataro & Kaper, 1998). Interestingly, Stx is not secreted 
by EHEC but is instead released upon lysis of the bacterial cell. This is due to the fact 
that the cytotoxin is encoded by a lysogenic phage which enters the lytic cycle in 
response to any DNA damage suffered by its host (Toshima et al., 2007). The intestinal 
tissue damage mediated by Stx and the other EHEC VF‟s can result in the systemic 
dissemination of Stx which can then go on to mediate damage to the kidneys.  
The ETEC pathovar is characterized by the production of enterotoxins and  has a 
strong association with mortality in young infants and neonates compared to older 
children. This may be due to the fact that specific enterotoxin receptors are much more 
prevalent in the infant intestine compared to adults (Cohen et al., 1988). ETEC 
enterotoxins are classed as LT (heat-labile) or ST (heat-stable) and any given strain of 
ETEC may secrete either one or both types. LT‟s are multimeric proteins with an 
enzymatic A subunit and a pentameric B subunit which enter host cells via B subunit 
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binding to the ubiquitous host ganglioside GM1 (Fukuta et al., 1988). Holotoxin 
internalization and processing releases the A subunit leading to disruption of 
intracellular cAMP (cyclic adenosine monophosphate) regulation and consequent 
activation of apical chloride channels. ST‟s are single peptides which are thought to 
bind to and activate multiple receptors including guanylatecyclase C (Cohen et al., 
1993). ST binding results in increased intracellular cGMP (cyclic guanosine 
monophosphate) and a similar activation of chloride channels (Forte et al., 1992). 
Transport of Cl
-
 into the intestinal lumen results in the osmotic diarrhoea associated 
with ETEC (reviewed by Sears & Kaper, 1996).  
EIEC/Shigella strains have a very low infectious dose and infection can be 
severe in older infants, resulting in fever and inflammatory bloody diarrhoea 
(dysentery). However, neonatal infection is very rare and characteristically mild 
(reviewed by Tarlow, 1994). EIEC strains invade the intestinal epithelium by 
transcytosis of specialized enteric microfold cells (Jensen et al., 1998). The bacterium is  
phagocytosed by resident macrophages where they induce apoptosis and the release of 
pro-inflammatory cytokines IL-1β and IL-18. This triggers the inflammatory response 
that characterizes dysentery (Zychlinsky et al., 1992; Sansonetti et al., 2000). Release 
from apoptotic macrophage cells allows EIEC to invade the basolateral membranes of 
enterocytes. This process is facilitated by delivery of intracellular effectors secreted via 
a T3SS. The internalized bacterium subverts cytoskeletal signalling mechanisms and 
induces the polymerization of F-actin in a uni-directional fashion (Sansonetti et al., 
1986). This actin „tail‟ propels the pathogen into adjacent enterocytes. The execution of 
this complex invasive process is mediated by an array of VF‟s many of which are 
encoded on the pINV plasmid which encodes the T3SS and 25 secreted effector proteins 
(reviewed by Schroeder & Hilbi, 2008). 
A growing body of evidence indicates that EAEC strains are commonly 
associated with persistent diarrhoea and are frequently isolated in infants from 
developing countries, but do not appear to be associated with high mortality rates 
(reviewed by Nataro & Kaper, 1998). DAEC strains are associated with infections in 
older infants but, critically, are rare neonatal pathogens and not associated with neonatal 
mortality (Levine et al., 1993). The pathogenesis of these pathovars is not well 
understood due to their heterogeneous nature and lack of well-developed animal models 
to study infection. 
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Although it is clear that some intestinal pathovars, especially EPEC, ETEC and 
to a lesser extent EHEC, are associated with diarrhoeagenic disease and mortality in 
neonates, this should be viewed in the context of the relatively low number of neonatal 
deaths attributable to diarrhoea, the majority of which are due to rotavirus infection 
(Tate et al., 2012). The strongest association of Escherichia coli with neonatal disease 
and mortality lies with the extra-intestinal pathovars. 
 
1.2.2.2 Extra-Intestinal Pathovars 
 The extra-intestinal pathovars of E. coli comprise strains which are non-
diarrhoeagenic but cause infections in extra-intestinal tissues. It has been proposed that 
these pathovars should be grouped under the single designation ExPEC (Russo & 
Johnson, 2000). However, two groups, UPEC and NMEC, are currently recognised on 
the basis of extra-intestinal tissue tropisms displayed by each disease-causing isolate. 
Both UPEC and NMEC affect different tissues, are aetiological agents of distinct 
diseases and utilize distinct repertoires of pathogenic mechanisms.  
Colonization of the normally sterile urinary tract and infection of associated 
tissues are mediated by UPEC strains, which account for approximately 80% of all 
urinary tract infections (UTIs) in humans (Foxman, 2003). Under normal circumstances, 
UPEC strains are components of the intestinal microbiota, where they coexist with the 
host without causing overt symptoms of disease. However the close proximity of rectum 
and urinary tract may permit transmission from the gut to the genitourinary tract (Russo 
et al., 1995). UTIs can occur at any age and UPEC strains cause disease in all age-
groups, including infants and neonates (Winberg et al., 1973; Foxman, 2003). Even in 
neonates UTIs are not associated with high mortality rates, although in a small 
proportion of cases the infection may progress from local to systemic, with the 
consequence of bacteraemia and sepsis (Biyikli et al., 2004).  
 Members of the NMEC pathovar may penetrate the CNS of vulnerable neonates 
to cause meningitis, a potentially lethal inflammatory condition. As previously 
highlighted, NMEC strains are frequently isolated in such cases. The symptoms of 
neonatal meningitis and sepsis are essentially identical and strains isolated from cases of 
neonatal sepsis (termed ExPEC isolates) are generally indistinguishable from E. coli 
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meningitis isolates. As a consequence, non-UPEC ExPEC isolates are grouped within 
the NMEC pathovar. As the pathophysiology and epidemiology of neonatal bacterial 
meningitis have been examined previously, the following sections will focus on the 
molecular epidemiology and pathogenesis of NMEC strains.   
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1.3 NMEC 
 
1.3.1 The molecular epidemiology of NMEC 
 Although E. coli is a heterogeneous species, with over 170 somatic O-antigens 
and 80 capsular K-antigens thus far described (reviewed by Raetz & Whitfield, 2002; 
Whitfield, 2006), the NMEC pathovar is restricted to a very small group of specific 
serotype combinations. Studies conducted over 35 years ago demonstrated that the most 
striking and significant element of this group is the K1 capsule. The K1 antigen is a 
homopolymer of α-2,8-linked N-acetyl neuraminic acid (NeuNAc), polysialic acid 
(PSA), which mimics host PSA (reviewed by Rutishauser, 1996; Troy, 1992); its 
structure is shown in Figure 1.9. Over 80% of NMEC neonatal meningitis and sepsis 
isolates express this K-antigen (Robbins et al., 1974; Sarff et al., 1975). Although 
alternate K-antigens can be found in other NMEC strains, mortality and neurological 
morbidity rates are significantly higher in K1-expressing isolates (McCracken et al., 
1974). 
 
Figure 1.9: The chemical structure of α-2, 8 linked polysialic acid; one NeuNAc 
monomer is highlighted. 
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NMEC isolates expressing the K1-antigen belong to a restricted number of O- 
and H-antigen serotypes, with O1, O7, O16 and O18 accounting for almost all NMEC 
O-serotypes and H6 and H7 flagellar antigens for almost all H-serotypes from human 
disease isolates (Robbins et al., 1974; Achtman et al., 1983). O1, O7 and O18 NMEC 
strains are isolated in an approximately equal proportion (~30%) of neonatal sepsis 
cases; however, O18 serotype strains are found in almost 50% of neonatal meningitis 
cases and are responsible for a high proportion of lethal events in neonates and 
experimentally induced animal infections (Pluschke et al., 1983). The serological 
epidemiology of NMEC indicates that the dominant clonal serotype, with respect to 
frequency of isolation and severity of disease, is O18:K1:H7, although studies have 
noted the emergence of virulent O83- and O45-bearing clones in Europe (Bonacorsi et 
al., 2003; Mulder et al., 1984). 
Multi-locus enzyme electrophoresis (MLEE) has been frequently used to 
phylogenetically differentiate E. coli clonal lineages; isolates have been assigned to one 
of four phylogenetic groups, designated A, B1, B2, and D (Whittam et al., 1983). 
Analysis of UPEC and NMEC strains has shown that the majority of ExPEC isolates are 
members of the B2 lineage (Johnson et al., 2001). Further, ribotyping of NMEC strains 
has revealed that they form a distinct but related sub-group within the B2 lineage, 
referred to as B21, indicating that the NMEC pathovar and other ExPEC strains are 
descended from a common ancestor which acquired the VFs necessary for survival and 
pathogensis in the extra-intestinal environment (Bonacorsi et al., 2003).   
The K- and O-antigens are major VFs of NMEC; however, other genetic loci are 
also common to many NMEC isolates and are frequently associated with highly virulent 
serotypes, such as O18:K1:H7 strains. These include loci encoding the type-1, P- and S-
pili (fimH, papG, sfa), α-haemolysin (hylA), cytotoxic necrotizing factor 1 (cnf1), Hek 
adhesin/invasin protein (hek), Ibe invasin proteins (ibeA/B/C), TraJ protein (traJ), OM 
protein A (ompA), arylsulfatase-like A (aslA) and the siderophore receptors for 
salmochelin, yersiniabactin and aerobactin (iroN, fyuA, iucA/C), as well as 
uncharacterized NMEC-specific PAIs (Moulin-Schouleur et al., 2006; Watt et al., 2003; 
reviewed by Xie et al., 2004; Bonacorsi & Bingen, 2005). In many NMEC strains, the 
siderophores and other VFs can be localized to a large 134 kb mobile plasmid, pS88, 
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which plays a role in virulence, in particular survival in the host‟s blood compartment 
(Peigne et al., 2009). 
Based on serology, phylogenetics and distribution of VFs in NMEC isolates, the 
molecular epidemiology of NMEC strains clearly indicates that meningitis and sepsis 
isolates of E. coli belong to a closely related sub-group of the species. These pathogens 
have usually been identified from the presence of their most conserved and possibly 
most important VF, the K1 capsule, and are designated E. coli K1.             
 
1.3.2 Pathogenesis of E. coli K1 infection 
 The pathogenesis of E. coli K1, from gastrointestinal colonization to penetration 
of the CNS, is a multi-step process involving attachment to, and invasion of, multiple 
host cell types, transcytosis across two formidable biological barriers and survival in an 
extremely hostile environment. Although the major E. coli K1 VF, the capsular 
polysaccharide, plays an indispensible role in neonatal pathogenesis, an array of other 
VFs are implicated in the translocation of the bacterium from the intestinal lumen to the 
CSF. The major steps towards CSF penetration and disease causation, as well as the 
roles of the bacterial factors involved, are summarized in Figure 1.10. 
 To cause systemic infection, pathogens must first gain access to the blood 
compartment. In the absence of direct entry due to a breach in the skin-barrier, this 
necessitates colonization of host mucosal surfaces. With E. coli K1, this is generally 
presumed to be the colon and distal small intestine (Sarff et al., 1975; Pluschke et al., 
1983). This is a reasonable assumption given that these sites are heavily colonized by 
the pathogen in animal models (Glode et al., 1977; Plushke et al., 1983) and the bacteria 
are well-adapted to niches within the GI tract. Genetic analysis of E. coli K1 mutants 
unable to colonize the GI tract has revealed several proteins which are vital to the 
capacity of the pathogen to survive in this niche (Martindale et al., 2000). These include 
the type-1 pilus adhesin FimH, proteins involved in adaptation to anaerobic respiration 
and a bile salt efflux pump; all are clearly necessary for survival in the GI tract. 
Interestingly, this work highlighted the importance of four proteins of unknown 
function, termed DgcA-D. All have homologues in strains belonging to other E. coli 
pathovars, with the exception of DgcD which appears unique to E. coli K1.  
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Figure 1.10: The pathogenesis of neonatal E. coli K1 infection and induction of 
meningitis is a multi-step, multifactorial process. 1; E. coli K1 colonizes the intestines 
and penetrates the intestinal mucous layer. 2; the bacterium adheres to and 
subsequently invades enterocytes of the intestinal epithelium, a process mediated by the 
binding of bacterial Hek to enterocyte glycosaminoglycan (GAG) and possibly involving 
the PapG pilus adhesin. 3; transcytosed bacteria penetrate the blood compartment 
where the K1 capsule inhibits complement deposition and innate/adaptive opsonisation 
and secreted siderophores scavenge free iron. 4; the bacterium invades circulating 
leukocytes by binding to the CD64 receptor on macrophages or gp96 on neutrophils 
through outer membrane protein A (OmpA), which also promotes intracellular survival 
and replication by inhibition of leukocyte apoptosis and the release of cytokines and 
reactive oxygen species (ROS). 5; circulating bacteria replicate to a CNS-invasion 
threshold level of >10
3
 CFU/mL of blood. 6; bacterial adherence to and invasion of 
endothelial cells of the blood/CSF barrier is mediated by binding of FimH, OmpA and 
IbeA bacterial surface proteins to cellular CD48, Ecgp96 and vimentin (Vim) 
respectively. Secreted cytotoxic necrotizing factor 1 (CNF1) and Hcp1 effector secreted 
by a type VI secretion system (T6SS) are also involved in the invasive process. 7; 
bacteria transcytose into the cerebrospinal fluid (CSF) where the K1 capsule is no 
longer expressed by the pathogen, exposing immunogenic LPS. The lipid A moiety of 
LPS is detected by CD14 receptor of meningeal leukocytes resulting in secretion of pro-
inflammatory cytokines. 8; Cytokine secretion stimulates expression of adhesion 
molecules ICAM1 and VCAM1 on endothelial cells, which mediate extravasation of 
polymorphonuclear leukocytes (PMN) into the CSF, resulting in meningeal 
inflammation. Host receptors binding bacterial ligands are displayed in receptor/ligand 
colour-coded format. 
 
Stable colonization is the first step in the pathogenic process, followed by 
adhesion, to, and invasion of, GI epithelial enterocytes, mediated in part by the P-pilus 
adhesin PapG and the Hek protein. The role of pilus-based adhesins in adhesion to the 
GI epithelium is unsurprising when one considers their role in binding urinary tract 
epithelia in UPEC strains (Bahrani-Mougeot et al., 2002; Korhonen et al., 1986). 
However the precise role of each pilus type in E. coli K1 enterocyte adherence is less 
clear. Although type-1 pili are essential for colonization, they do not appear to play a 
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significant role in enterocyte adhesion, whereas the P-pilus, which was originally 
associated with kidney cell adherence, does appear to bind enterocyte membranes and 
therefore may play a role in the adhesion of E. coli K1 (Tullus et al., 1992; Wold et al., 
1992; Goetz et al., 1999). Studies in bladder epithelial cells and polarized enterocyte 
epithelial cell lines have revealed that E. coli K1 can invade and transcytose these cells 
in vitro (Burns et al., 2001) and that invasion involves manipulation of the enterocyte 
cytoskeleton (Meier et al., 1996). The only factor directly implicated in epithelial cell 
invasion is the Hek protein, an OM protein which confers an invasive phenotype in 
recombinant non-invasive E. coli strains (Fagan & Smith, 2007). This protein has a 
putative β-barrel structure with adhesion and invasion dependent on a 25-amino-acid 
loop which mediates binding to the glycosaminoglycan moieties of host cell surface 
proteoglycans (Fagan et al., 2008). As yet, however, the invasive mechanism mediated 
by Hek is unclear and its relevance to pathogenesis has not been confirmed in vivo.  
 If E. coli K1 traverses the intestinal epithelium, how does it gain access to the 
epithelial cells? The intestinal epithelium is coated by a layer of gel-forming mucins 
(for example, Muc2 in the colon), which forms a bilayered structure, with the inner 
stratified mucin layer functioning as an exclusion barrier, physically separating the 
bacteria of the intestinal microbiota from the enterocyte cell surface (Johansson et al., 
2008). Although pathogenic bacteria can penetrate this layer (Bergstrom et al., 2010), 
the enabling processes have not been characterized in any intestinal E. coli pathovars. 
This lack of understanding, coupled with incomplete knowledge of adhesion and 
invasion mechanisms permitting transcytosis of the intestinal epithelium in vivo, 
illustrates that E. coli K1 translocation of the intestinal mucosa is the least well 
characterized step in the pathogenic process.  
 The survival and replication of the pathogen in the vascular compartment is 
comparatively well characterized. The K1 capsular antigen is the critical determinant of 
the capacity of E. coli K1 to survive in the bloodstream (Kim et al., 1992), in part due to 
the molecular mimicry of endogenous host PSA. K1-antigen inhibits adaptive immune 
responses to the bacterium by inhibition of immunoglobulin-mediated opsonisation and 
its capacity to contribute to serum resistance through inhibitory modulation of the 
alternative complement pathway (Leying et al., 1990; Mushtaq et al., 2004). The O-
antigen polysaccharide acts synergistically with the K-antigen with respect to 
complement inhibition by disrupting activation of the classical pathway (Burns & Hull, 
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1998). Interference with complement activation is also mediated by OmpA which 
sequesters C4b-binding protein (C4bp), an inhibitory component of the complement 
cascade which promotes the degradation of C4b and C3b, essential components of the 
activated complement cascade (Wooster et al., 2006).  
The availability of free iron is a factor limiting bacterial growth and survival in 
vivo. Bacteria generally require a cytoplasmic concentration in the 10
-5
-10
-7
 M range 
(reviewed by Andrews, 2003) but only 10
-24 
M is present in human serum (reviewed by 
Fischbach et al., 2006). Bacteria secrete iron-chelating siderophores which compete for 
free iron and are recognized by high affinity receptors at the bacterial surface to 
facilitate transport back into the cell. E. coli K1 strains produce a range of siderophores 
and associated receptors; however, bloodstream survival is dependent on the 
siderophore salmochelin and its receptor IroN (Nègre et al., 2004; Peigne et al., 2009). 
 Factors other than resistance to complement and iron acquisition contribute 
towards the capacity of E. coli K1 to survive in the blood compartment. The bacteria are 
able to invade circulating leukocytes and replicate within them, utilizing these key 
immune cells as a reservoir for systemic growth. E. coli K1 binds to and invades 
macrophages in an opsonisation-independent manner (Sukumaran et al., 2003). This 
process is mediated by binding of bacterial OmpA to the α-chain of the macrophage 
receptor CD64 (Fcγ receptor Ia). Uptake of the bacterium is effected by manipulation of 
the macrophage cytoskeleton and the bacterium is sequestered in a vacuole within the 
cytoplasm, where it is able to replicate and avoid phagosome-lysosome fusion. 
Depletion of the macrophage population renders neonatal mice resistant to systemic E. 
coli K1 infection (Mittal et al., 2010). Internalized E. coli K1 not only replicate in the 
macrophage but also ensure preservation of this replicative niche by activating the host 
anti-apoptotic mediator BclXL (Sukumaran et al., 2004). Furthermore intracellular E. 
coli K1 inhibits the phosphorylation and degradation of IκB, the negative regulator of 
NFκB activation, thus preventing the production of pro-inflammatory cytokines; 
Selvaraj et al., 2005).  
E. coli K1 is able to utilize neutrophils in a similar fashion (Mittal et al., 2011). 
Again, OmpA is the critical determinant of this process through its capacity to bind to 
gp96 neutrophil receptors prior to internalization. Neutrophil-internalized E. coli K1 
reduces the expression of NADPH oxidase complex proteins, preventing the generation 
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of reactive oxygen species (ROS) and crippling the oxidative burst process used by the 
neutrophil to degrade phagocytosed bacteria. Interestingly, this study also demonstrated 
that depletion of the neutrophil population rendered neonatal mice resistant to systemic 
E. coli K1 infection, indicating that replication in both macrophages and neutrophils is 
critical to E. coli K1 survival in the bloodstream. Initially, neutrophils are colonized; 
macrophages subsequently also provide a replicative niche. This sequence may reflect 
the relatively short lifespan of neutrophils in comparison to the more long-lived 
macrophage population.    
Intracellular replication in circulating leukocytes and E. coli K1‟s significant 
resistance to serum-mediated clearance results in the bacterial load of the pathogen 
increasing in the host‟s bloodstream until a critical threshold, empirically determined to 
be approximately 10
3
 CFU/mL, is reached which precipitates invasion of the CNS 
(Dietzman et al., 1974). This requires transversal of an endothelial barrier which has 
evolved, even more so than the gastrointestinal barrier, to isolate the tissues which it 
protects; the blood-brain barrier (BBB).  
Although a significant proportion of E. coli K1 research has been dedicated to 
the biomechanics of CNS invasion, the site of translocation into the CNS remains 
controversial. The BBB comprises two interfaces between the CNS and the vasculature. 
The larger interface is formed by the microvascular endothelial cells of the capillaries 
which penetrate the CNS, henceforth referred to as the endothelial barrier. The smaller 
is the blood-CSF barrier (BCSFB) formed by the fenestrated endothelium of the 
capillaries surrounded by epithelial cells of the choroid plexus (reviewed by Abbott et 
al., 2010). Whilst some research has indicated that E. coli K1 is associated with the 
endothelial barrier and not the BCSFB (Kim et al., 1992), others have indicated that the 
BCSFB is the more likely site of pathogen-CNS association (Parkkinen et al., 1988; 
Zelmer et al., 2008). Evidence obtained from investigations of the capacity of other 
pathogens to access the CNS indicates that both translocation sites can be exploited by 
neuropathogens. Thus, the site of translocation varies between species, with the BCSFB 
implicated in H. influenzae,  N. meningitidis (which can also transverse the endothelial 
barrier) and Streptococcus suis infections (Daum et al., 1978; Pron et al., 1997; 
Tenenbaum et al., 2009) and the endothelial barrier in S. pneumoniae infections 
(Zwijnenburg et al., 2001; Fillon et al., 2006). The capacity to cross the endothelial 
barrier implies a pathogen must access the neuropil (the neuron-containing brain 
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parenchyma), as the capillaries of the cerebral vasculature form a network throughout 
the brain and, in contrast to the postcapillary venules from which the capillaries branch, 
are not surrounded by a perivascular space containing CSF (reviewed by Bechmann et 
al., 2007). E. coli K1 has been observed in the perivascular space and it was therefore 
proposed that translocation occurred at the endothelial barrier (Kim et al., 1992). 
However, E.coli K1 has not been observed in the neuropil (Kim et al., 1992; Zelmer et 
al., 2008). This contrasts with invasion by S. pneumoniae, which is widely distributed in 
brain tissue (Fillon et al., 2006). This represents compelling evidence that the pathogen 
utilizes the BCSFB as the site of entry to the CNS, rather than the endothelial barrier. 
The vascular endothelial barrier and the epithelial BCSFB are comprised of cells 
that are intimately connected by intercellular tight junctions and adherens junctions 
(reviewed by Abbott et al., 2010). These junctions provide the barrier function of the 
BBB interfaces, severely inhibiting the paracellular movement of molecules. Invading 
pathogens must either disrupt these junctions or utilize the transcellular pathway in 
order to gain access to the CNS. E. coli K1 is believed to use the transcellular route to 
migrate across this barrier and a significant volume of research has focused on the 
mechanics of this process. The bulk of this work has focused on in vitro interactions of 
human brain microvascular endothelial cells (BMEC) and E. coli K1 and may not be 
representative of interactions in vivo if the pathogen does not invade the CNS through 
the vascular endothelium. However this does not mean that the factors and mechanisms 
identified by this work are irrelevant, as in vitro studies have been complemented in 
vivo using single locus isogenic E. coli K1 mutants that indicate their importance to the 
penetration process. 
Adhesion to BMEC cells is mediated by multiple factors, some of which are 
involved in intracellular invasion. One is the FimH adhesin of the type-1 pilus, which 
binds mannosylated glycoconjugate receptor CD48 on the cell surface (Khan et al., 
2007). OmpA is involved in adhesion through binding to Ecgp96, a homologue of the 
gp96 receptor employed by the bacterium to adhere to neutrophils (Pascal et al., 2010). 
S-pilus adhesin (Sfa) binding to sialoglycoprotein receptors has not been considered 
critical for BMEC adhesion, although it does occur (Prasadarao et al., 1997). However, 
this view does not take into account the fact that S-pili have a much stronger affinity for 
the choroid epithelial cells of the BCSFB than for BMEC cells (Parkkinen et al., 1988).  
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The invasion and transcytosis of endothelial cells is a multifactorial process. 
CNF1, a Rho GTPase activating secreted bacterial toxin (reviewed by Lemonnier et al., 
2007) contributes to E. coli K1 invasion in similar fashion to its role in UPEC (Khan et 
al., 2003). The toxin binds cellular the 37 kDa laminin receptor precursor (37LRP) on 
the endothelial cell surface, activating RhoA and mediating actin filament formation at 
the site of bacterial entry (Khan et al., 2002). FimH binding also triggers RhoA 
activation (Khan et al., 2007). This mechanism is complemented by OmpA which, after 
binding to Ecgp96, activates cellular PI3K (phosphatidylinositol 3-kinase), resulting in 
actin condensation (Prasadarao et al., 1999; Khan et al., 2003). Another critical factor in 
E. coli K1 invasion is IbeA, which initially binds to the receptor vimentin, an 
intermediate filament protein of the cellular cytoskeleton (Zou et al., 2006). IbeA and 
OmpA binding to their cognate receptors induce the activation of STAT3 (signal 
transducer and activator of transcription 3) which activates the Rho GTPase Rac1, 
mediating further cytoskeletal rearrangements (Maruvada & Kim, 2012). A recent 
addition to the mechanisms utilized by the pathogen to invade BMEC cells is a type VI 
secretion system (T6SS). These complexes are thought to deliver effector proteins to 
host cells by a mechanism that mimics the tail spike of the T4 bacteriophage (Pukatzki 
et al., 2009). The T6SS-secreted effector Hcp1 has been implicated in interactions 
leading to E. coli K1 invasion (Zhou et al., 2012). The cumulative actions of these 
invasion factors lead to the internalization of E. coli K1 within a vacuole. The pathogen 
does not replicate within the vacuole but survives transit through the cell; survival is 
dependent on the presence of the K1-capsule (Hoffman et al., 1999). Intracellular 
vacuoles containing K1-encapsulated E. coli are not targeted for lysosomal fusion by 
cellular endosomal maturation mechanisms; the role of the capsule in this process is 
presently unclear (Kim et al., 2003). 
Transcytosis of the BBB allows access of E. coli K1 to the CSF, where bacterial 
cell division invariably takes place. As described earlier, bacterial growth in the CSF 
stimulates the production of pro-inflammatory mediators by CNS leukocytes, leading to 
infiltration of polymorphonuclear leukocytes (PMNs) as part of an inflammatory 
response that is the primary mediator of cerebral damage associated with meningitis. 
Massively increased expression and production of chemokines and other cytokine 
inflammatory mediators have been documented in experimental E. coli K1 infection 
(Zelmer et al., 2010). However, there is another intriguing aspect to this final step in E. 
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coli K1 pathogenesis. Once the bacterium has penetrated the CSF and colonized the 
meninges, there appears to be a marked reduction in detectable K1-antigen at the 
surface of the bacterial cell (Zelmer et al., 2008). Removal of the protective capsule in 
this environment has clear implications with respect to the inflammatory response 
within the CNS, as it would expose highly immunogenic LPS to resident leukocytes, 
prompting a rapid inflammatory reaction mediated by LBP/CD14 interactions with 
TLR4, facilitating opsonisation and phagocytosis of the pathogen by leukocytes. Such 
rapid-onset inflammatory events induced by exposure to pro-inflammatory mediators 
may contribute to the severe mortality and morbidity of E. coli K1 meningitis (Stoll et 
al., 2002ab; Harvey et al., 1999). The mechanistic basis of capsule reduction has not yet 
been determined. It is possible that exposure to host factors in the CNS induces removal 
of the capsular structure; this could involve the recently-identified sialidase Neu4, 
which hydrolyzes α2, 8 linked PSA and is used by the host to regulate NCAM adhesion 
(Takahashi et al., 2012).      
 Thus, the pathogenic processes associated with neuroinvasive E. coli K1 form a 
complex multi-step process that has evolved to circumvent an array of host 
mechanisms. The pathogen has the capacity to survive and subvert these mechanisms 
using a palette of VFs, which together allow the bacterium to colonize the inhospitable 
environment of the GI tract and cause potentially fatal disease in neonates. However, in 
this regard a key pathogenesis-related question remains unanswered; in light of the clear 
pathogenic potential of this microorganism, why is E. coli K1-mediated disease 
prevalent in the neonatal population but not in adults? An answer to this question would 
provide a clearer understanding of E. coli K1-mediated neonatal disease and may 
provide clues as to how to prevent it.     
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1.4 The age-dependency of E. coli K1 infection 
 
1.4.1 The basis of age-dependency 
 Sepsis and meningitis due to E. coli K1 is strongly dependent on the age of the 
host. The pathogen is isolated in over 80% of cases of neonatal meningitis where E. coli 
is determined to be the aetiological agent (Robbins et al., 1974; Sarff et al., 1975); the 
organism only very rarely causes systemic infection in older infants and adults (Pitt, 
1978; Sarff et al., 1975). Age dependency is especially interesting in the context of E. 
coli K1 carriage in different age groups of the general population, as shown by Sarff and 
colleagues in 1975 (Figure 1.11).  
 
Figure 1.11: (A). Proportion of E. coli meningitis and bacteraemia isolates expressing 
K1 antigen in neonatal and non-neonatal infections; (B) rate of carriage of E. coli K1 
in different age-groups, as determined by rectal swab culture. Data from Sarff et al., 
1975.      
 
Neonates
Non-neonates
A B
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The rate of carriage does not positively correlate with incidence of E. coli K1 
disease, the „at risk‟ population (the neonates) displays a lower incidence of carriage 
than older infants and adults, both of whom have higher overall rates of carriage but a 
much lower incidence of disease. This data indicates that, although E. coli K1 acts as a 
pathogen in the neonatal population, it has a commensular lifestyle in older infants and 
adults. The age dependency of systemic infection has been confirmed in rodent models 
of E. coli K1 infection, showing that age dependency is not restricted to human 
infections (Glode et al., 1977; Bortolussi et al., 1978; Pluschke & Pelkonen, 1988).  
This raises the question as to which factors influence this change from susceptibility to 
resistance to infection and at what stage in the pathogenic process of E. coli K1 disease 
do they act? In other words, which elements of the host mediate the development of 
resistance to systemic infection? 
 Few studies have addressed these important questions and none provide 
definitive evidence for specific resistance mechanisms, but they do provide some 
indication as to which host factors are not involved in the determination of age 
dependency. For example, it has been shown that type 1- and S-pilus-mediated adhesion 
of E. coli K1 to host cells is an age-independent process (Schroten et al., 1992; Clegg et 
al., 1984). The capacity of the pathogen to invade BMEC cells harvested from humans 
and animals of different age groups is also age independent (Stins et al., 1999). E. coli 
K1 survival in the blood circulation and penetration of the CNS after systemic 
administration to animals of differing ages has also been examined. Although a higher 
dose of E. coli K1 is required to induce meningitis in older animals (not unexpected 
given the size differences between neonatal and adult rodents), the pathogen survives in 
the adult bloodstream and penetrates the CNS (Bortolussi et al., 1978; Pelkonen & 
Pluschke, 1989; Kim et al., 1992). Studies of GI tract colonization by E. coli K1 in 
relation to susceptibility to systemic infection suggest that age dependency may be 
determined, at least in part, by the capacity of the bacterium to translocate from the gut 
to the blood circulation. Although E. coli K1 may colonize the GI tract of rats at any 
age, younger neonates were found to be susceptible to systemic infection following 
colonization of the GI tract, whereas older neonatal rats were not, although colonization 
rates were lower in the older cohort (Glode et al., 1977). In a more recent study, 
Mushtaq and colleagues also demonstrated lower rates of bacteraemia in older neonatal 
rats despite comparable rates of intestinal colonization (Mushtaq et al., 2005). These 
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studies demonstrate a very close correlation between bacteraemia and mortality, 
suggesting that systemic dissemination is not age related once the bacteria have entered 
the bloodstream, again implicating penetration of the intestinal barrier as the source of 
variability. Despite these observations, the relationship between the age of the infected 
individual and intestinal translocation of E. coli K1 has not been interrogated. In 
considering this issue, the host tissue and the microbial population which comprises the 
intestinal microbiota must be taken into account.  
 
1.4.2 The intestinal microbiota 
With an estimated 4-6 nonillion (10
30
) prokaryotic cells comprising 350-550 
billion metric tonnes of carbon and representing tens of billions of genes, the bacterial 
superkingdom outstrips all other forms of life on the Earth in terms of biomass and 
biodiversity, as well as in importance to the global biosphere (reviewed by Whitman et 
al., 1998). A small proportion of this vast global micro-ecology inhabits the external 
environ and internal mucosal surfaces of multi-cellular organisms of the animal 
kingdom. Mammals, including humans, are densely colonised by microorganisms. 
Diverse, yet specialised communities of organisms inhabit the skin, urogenital tract, 
nasal and oral cavities and GI tract, with the number of bacteria estimated to be between 
ten and one hundred times greater than the combined total of somatic and germ cells of 
the colonized host (reviewed by Berg, 1996). 
Of all the colonized regions of the mammalian organism, the GI tract, in 
particular the large intestine that comprises the various colonic elements, is most 
heavily populated by microorganisms. The large majority of these are bacteria and a 
small proportion belong to the Archaea and Eukarya (Eckburg et al., 2003). The typical 
adult human intestine contains 100 trillion microbes (10
14
), with 10
11
-10
12
 microbes per 
millilitre of colonic luminal content (Ley et al., 2006). At the species and genus levels, 
this population varies significantly between individuals; however, metagenomic 
analyses have shown the phyla Firmicutes, Bacteriodetes and Proteobacteria are the 
dominant organisms within this niche (Gill et al., 2006; Palmer et al., 2007). The GI 
tract microbiota possesses in excess of 100 times as many genes as the mammalian 
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nuclear genome (Gill et al., 2006), constituting a microbiome that has co-evolved with 
the human genome and which impacts significantly on human metabolism and health.  
For example, the capacity of the gut to absorb fibrous components and long 
chain polysaccharides such as cellulose is due to prior digestion by the microbiome 
(Flint et al., 2007). Members of the microbiota have been implicated in the regulation of 
host fat storage (Bäckhed et al., 2004). The gut microbiota is intimately involved in 
vitamin biosynthesis and lipid and mineral metabolism (reviewed by Resta, 2009). 
These and other bacterial influences on the gastrointestinal contents provide the 
mammalian gut with enhanced metabolism in terms of both efficiency and capability.  
The microbiota plays a key role in the orderly development of gut tissues and the 
immune response and in protection of the host from enteric disease. It must also 
concomitantly compete with opportunistic and obligate pathogens for resources. It plays 
an important role in the regulation of angiogenesis (Stappenbeck et al., 2002) and the 
development of humoral and cellular mucosal immune processes through interactions 
with gut-associated lymphoid tissues (GALT; reviewed by Cebra, 1999; Round & 
Mazmanian, 2009). Intestinal colonization by bacterial species such as Bacteroides 
thetaiotaomicron and the segmented filamentous bacteria induce the gut to secrete 
antimicrobial peptides (AMPs) such as angiogenins and REG3γ (Keilbaugh et al., 2005) 
In terms of pathogen-protection, probiotic organisms such as the lactobacilli stimulate 
mucin production by intestinal epithelial cells, compromising adhesion of pathogenic E. 
coli (Mack et al., 1999). This protective mechanism is part of a group of related 
processes termed colonization-resistance, affording protection of the host from 
opportunistic and obligate pathogens by the competitive dynamics of the endogenous 
commensal/mutualistic bacterial population, considered a primary beneficial function of 
the microbiota (Endt et al., 2010; reviewed by Vollaard & Clasener, 1994). The 
influence of the microbiota on health is, however, not solely beneficial. Specific groups 
of organisms have been implicated in the development of gastric cancer (Blaser et al., 
1995), inflammatory bowel disease (Ott et al., 2004) and NEC (Hoy et al., 2000; De La 
Cochetière, 2004). 
The temporal development of the human intestinal microbiota varies between 
individuals; however, general trends are evident due to the application of metagenomic 
techniques and DNA sequencing technology (Figure 1.12). It has long been thought that  
65 
 
   
 
 Figure 1.12: Changes in the relative proportions of facultative (blue) and obligate 
(orange) anaerobes in the neonatal intestinal microbiota.   
 
during the gestation period in the absence of in utero complications, the foetal 
gastrointestinal tract remained sterile. Post-partum, the neonate is rapidly colonised by 
microorganisms in successive waves which, over time, cumulate into a climax 
community representing an adult-like microbiota (Favier et al., 2002). The early 
colonisation period tends to be dominated by single taxonomic groups, usually 
facultative anaerobes such as Enterobacteriaceae, Streptococcus and Staphylococcus 
spp. These reduce the oxygen tension within the intestines and facilitate later 
colonisation and domination by obligate anaerobes such as Eubacteria and Clostridia 
(Palmer et al., 2007). Acquisition of these colonizers is dependent on environmental 
factors and vertical transmission from the cutaneous, vaginal and colonic maternal 
microbiota (Bettelheim et al., 1974, Schwiertz et al., 2003). 
 The GI tract is a complex environment comprising microbe-host interactions in 
conjunction with interactions between members of the microbiota. This system is finely 
balanced and dependent on a multitude of factors. In the neonate, the microbiota is a 
dynamic entity, with significant micro-ecological shifts as the host develops. These 
alterations may increase the colonization-resistance of the intestine and impact on the 
capacity of E. coli K1 to access and translocate across the enterocyte epithelium. 
Interactions between members of the microbiota inhibit the adhesion and toxin secretion 
of EHEC strains (Mack et al., 1999; de Sablet et al., 2009) and compromise the 
pathogenesis of other enteric pathogens (Pultz et al., 2005; Endt et al., 2010). In 
addition, the microbiota stimulate development of the GALT (reviewed by Cebra, 1999; 
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Round & Mazmanian, 2009); such maturation of host tissues may ensure that the GI 
tract becomes refractory to bacterial translocation across the intestinal epithelium. 
 
1.4.3 The intestinal tissues 
 The internal surface area of the adult human intestinal tissues is approximately 
two million cm
2
. The GI tract undergoes significant morphological and cytological 
differentiation in the postnatal period. This period comprises Phase IV in the ontogeny 
of mammalian intestinal development and is defined by the changes that occur in 
response to stimulation through exposure to enteral nutrition (i.e. maternal milk) and a 
glut of novel antigenic material to which the neonate must develop an effective 
tolerance in order to survive in the extra-uterine environment (reviewed by Wagner et 
al., 2008). The developmental process is highly complex and controlled by a swathe of 
highly conserved genes, such as the hedgehog, Notch, SOX, and WNT pathway 
mediators (reviewed by Barbara et al., 2003). Despite its complexity there are several 
key features of the development process which may be relevant in the context of 
susceptibility to E. coli K1 colonization and infection.    
 The neonatal proteome is altered in age dependent fashion during postnatal 
development of the intestine (Hansson et al., 2011). Changes in the biochemical 
physiology of the tissues affect their digestive and absorptive properties as they mature 
towards the adult phenotype (reviewed by Henning, 1979). It has been established that 
the neonatal intestine is permeable to macromolecules such as intact proteins and sugars 
(Weaver et al., 1984) due to macropinocytosis, a form of endocytosis similar to 
phagocytosis (reviewed by Swanson & Watts, 1995). The neonatal intestine utilizes this 
process to acquire macromolecules prior to the development of a more mature digestive 
capacity; it also mediates the maternal-neonatal transfer of passive immunity by 
absorption of secretory IgA molecules present in breast milk (reviewed by Wagner et 
al., 2008). Cessation of macromolecular uptake, or gut closure, occurs at different times 
post-partum in different mammalian species (Lecce et al., 1973). In humans, it may 
occur as early as three days post-partum (Vukavic, 1984). It is possible to speculate that 
the increased permeability of the neonatal intestine plays a role in E. coli K1 epithelial 
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translocation, although this would be dependent on the time of gut closure and its 
correlation with the epidemiology of E. coli K1 infection. 
     At the anatomical level the intestines are fully formed pre-partum but at the 
cellular level a significant degree of differentiation occurs post-partum, a process which 
is driven by the intestinal epithelial cells. The intestinal epithelium of the late foetus 
already possesses long protruding villous structures in the small intestine, but the 
perinatal epithelial development of both large and small intestinal compartments is 
characterized by the formation of tubular invaginations, or crypts. At the base of crypts 
lie the pluripotent stem cells, the motors of cellular differentiation, and from which the 
various cellular subpopulations of the intestine arise (reviewed by van der Flier & 
Clevers, 2009; Barbara et al., 2003). Intestinal cellular differentiation gives rise to four 
primary intestinal cell lineages. The most prevalent is the enterocyte, which constitutes 
~80% of epithelial cells in the adult intestine. These are the absorptive workhorses of 
the intestine and are highly polarized, with apical membrane microvilli serving to 
massively increase the absorptive surface area of the gut.  The second is the 
enteroendocrine cell, which account for only 1% of the intestinal epithelium yet 
comprises the largest population of hormone-secreting cells in the body and has a 
critical regulatory role in intestinal function (reviewed by Schonhoff et al., 2004). The 
remaining two cellular lineages are goblet cells and Paneth cells, both of which 
contribute in different ways to the defence of the intestine; thus, the developmental 
regulation of their differentiation may impact on E. coli K1 infection. 
 Paneth cells, named after the Austrian physician Joseph Paneth who first 
described them in 1888, are highly granulated cells with densely packed rough 
endoplasmic reticuli that are spatially restricted to the bottom of the small intestinal 
crypts. Unlike other enteric epithelial lineages, they do not migrate along the villi as 
they mature. In humans, there are usually between 5-15 cells per crypt; they are present 
in most, but not all, mammalian species. Although they may play a role in digestion and 
regulation of crypt development, their primary function is the production and secretion 
of a range of antimicrobial peptides (AMPs) which modulate the microbiota and 
maintain intestinal homeostasis (reviewed by Porter et al., 2002; Bevins & Salzman, 
2011). Paneth cells produce a range of AMPs, including the constitutively expressed α-
defensins, defensin-related peptides, lysozyme C, phospholipase A2 and the inducible 
REG3 C-type lectins and angiogenins, all of which have broad-spectrum or Gram-type 
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specific antibacterial activities (Ericksen et al., 2005; Hornef et al., 2004; Pellegrini et 
al., 1992; Harwig et al., 1995; Vaishnava et al., 2011; Hooper et al., 2003). Although 
Paneth cells first appear during prenatal gestation, their numbers and AMP secretion 
increase post-partum (Mallow et al., 1996; Bry et al., 1994). The expression of some 
AMPs is constitutive whereas others are dependent on colonization by the microbiota 
(Putsep et al., 2000; Hooper et al., 2003). This age-dependent augmentation of innate 
immunity in the neonatal intestine may be critical with respect to E. coli K1 infection. 
Experimental ablation of Paneth cells with the dye dithizone renders neonatal rats 
susceptible to intestinal overgrowth of the pathogen and dithizone-treated neonates have 
higher mortality rates than their untreated counterparts (Sherman et al, 2005). 
 The final major lineage of enteric epithelial cells is the goblet cell. These cells 
are present throughout the intestines but increase in number from the proximal duodenal 
compartment, where they comprise approximately 4% of the epithelium, to the distal 
colonic compartments, where they form around 16% of total epithelial cells (reviewed 
by van der Flier & Clevers, 2009). Goblet cells are secretory cells; they produce and 
maintain a fundamental component of the innate intestinal defensive mechanism: the 
intestinal mucus layer. The mucus layer has a well-established cytoprotective role in the 
gut and it has recently been demonstrated that, in addition to its capacity to inhibit 
bacterial adhesion to the epithelium, it forms a deep, stratified exclusion barrier which 
maintains the microbiota at a safe distance from the epithelial surface (Johansson et al., 
2008). The stratified layer is composed of gel-forming mucin proteins, such as Muc2, 
which are large linear glycoproteins polymerized in goblet cells by disulphide-bonded 
C-terminal dimerization and N-terminal trimerization, then secreted into the intestinal 
lumen where they form dimers with adjacent mucins through internal CysD domains 
(Ambort et al., 2011; reviewed by Perez-Vilar & Hill, 1999). These interactions allow 
gel-forming mucins to produce the stratified exclusion barrier of the inner mucous layer. 
External to this layer and resting upon it is a much looser outer layer of mucus derived 
from the inner layer and colonized by the microbiota. The mucus layer is thinner in the 
small intestine and does not form an exclusion barrier, but serves as a repository for 
Paneth cell-derived AMPs (Vaishnava et al., 2011; reviewed by Johansson & Hansson, 
2011). Goblet cells also secrete trefoil factor peptides (Podolsky et al., 1993); these are 
small proteins that bind to mucins and alter their viscoelastic properties. They appear to 
stabilize and maintain the function of the mucus exclusion barrier (Thim et al., 2002, 
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Kindon et al., 1995). Goblet cells and their secreted mucins appear in the intestine at an 
early stage of prenatal gestation, are not fully developed at birth and continue to 
proliferate postnatally (Chambers et al., 1994; Fanca-Berthon et al., 2009). The 
ontogeny of the colonic mucin exclusion barrier has not been investigated so it is not 
known when the barrier is formed. Interestingly, the secretion of the trefoil factor Tff3 
occurs late in gestation and increases postnatally (Lin et al., 1999, Mashimo et al., 
1995), indicating that the mucin-barrier function of the neonate may not be fully 
developed at birth, so it may influence susceptibility to pathogens such as E. coli K1. 
 The intestine contains a large amount of foreign antigenic material which, if 
allowed to come into contact with extra-intestinal tissues, would trigger a strong an 
immediate inflammatory response mediated by the systemic leukocyte populations. The 
adult intestine is the largest reservoir of macrophages in the mammalian body (Lee et 
al., 1985) but displays a dulled pro-inflammatory cytokine production upon antigenic 
stimulation. This is due in part to the lack of expression of innate response receptors 
such as CD14 by intestinal macrophages, even though these macrophages maintain their 
capacity to phagocytose and eliminate invading bacteria (Smythies et al., 2005). This 
inflammatory anergy has evolved to enable intestinal tissues to tolerate the antigenic 
load whilst undertaking vital absorptive functions in the absence of deleterious 
inflammatory reactions. Critically, this tolerance does not develop until the perinatal 
period (Maheshwari et al., 2011) and has been shown to be developmentally regulated 
by exposure to foreign antigens such as LPS immediately post-partum (Lotz et al., 
2006). The macrophages and intestinal epithelial cells of very young and preterm 
neonates do not possess the non-inflammatory phenotype of older neonates. This may 
play a role in the development of NEC (Maheshwari et al., 2011) and indicates that the 
immature bowel is susceptible to inflammatory damage, a factor which may be relevant 
to the intestinal translocation of E. coli K1 and other neonatal bacterial pathogens. 
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1.5 Aims & Objectives 
 
 The endogenous host tissues and the exogenous microbiota are in a state of 
developmental flux in the neonatal intestine and are likely to play a role in the 
determination of susceptibility of the neonate to at least some infections, in all 
likelihood including E. coli K1. Colonization of the intestine by E. coli K1 is age-
independent. However, translocation across the GI epithelium and subsequent 
development of systemic disease is an age-dependent process. Insights into the 
influences of the developing microbiota and host tissues influences on the capacity of E. 
coli K1 to cause systemic disease in the neonate will shed light on the pathogenic 
mechanisms which drive the development of neonatal sepsis and meningitis. Moreover, 
a deeper understanding of these mechanisms may provide a rationale for the 
development of prophylactic strategies to control these often devastating infections and 
further the global campaign to reduce infant mortality in the 21
st
 Century. 
The primary aim of this project is to determine the influence of the developing 
intestinal microbiota and maturing intestinal tissues on the capacity of E. coli K1 to 
translocate from the neonatal intestine into the systemic circulation using a neonatal rat 
model of infection. Such work will contribute to the understanding of E. coli K1 
pathogenesis, provide insights into the processes that drive the progression of the 
infection and may facilitate prophylactic interventions through abrogation of the 
capacity of the pathogen to egress from the GI lumen. 
 The initial objectives will be to develop the animal model and the methods 
required to fulfil to specific aims of the project. These include defining the age-
dependency of E. coli K1 infection in the neonatal rat, thereby delineating susceptible 
and refractive neonatal populations for later analysis. The potential of the natural 
maternal-neonatal route to establish infection will be investigated, as will the design and 
optimization of an assay for the quantification of E. coli K1 in the intestinal microbiota.  
 The second objective will examine, using quantitative and qualitative analytical 
methods, the intestinal microbiota of neonates that are innately susceptible or refractive 
to systemic E. coli K1 infection. The dynamics of E. coli K1 intestinal colonization will 
be investigated in susceptible and resistant neonates. Any protective effect of the 
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microbiota will be determined by antimicrobial suppression of the natural microbiota of 
refractive neonates and by assessment of the impact of suppression on susceptibility to 
E. coli K1. 
 The final objective will examine the role of host intestinal tissues in the 
determination of susceptibility to E. coli K1 infection. Host tissue responses to E. coli 
K1 colonization will be determined at the transcriptomic level and the responses of 
susceptible and refractive neonatal tissues compared. Differentially expressed host 
factors of interest will be examined in greater depth, in terms of normal developmental 
expression and differential expression in response to E. coli K1 colonization. If 
appropriate and feasible, the mechanistic basis of differential expression will be 
explored. 
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CHAPTER 2 
MODEL & METHOD DEVELOPMENT 
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2.1 Introduction 
 The use of animal models of infection remains a key element for the 
investigation of microbial pathogenesis and the development of new agents and 
modalities for the prophylaxis and treatment of infectious disease. In many cases, 
advances in in vitro technologies such as developments in organ culture, have not 
obviated the need for modelling infections in suitable animal hosts. Although the ability 
to grow different types of cell and even whole tissues in the laboratory environment has 
proven to be extremely useful in the study of host-pathogen interactions, these in vitro 
models can provide only preliminary evidence of the mechanics of in vivo interactions 
and hypotheses based on in vitro data must be validated in vivo. The rationale for this is 
clear; the different cell types and tissues of the multicellular organism are never found 
in isolation in vivo and are subject to modulation by endocrine, paracrine and nervous 
signalling which can have profound effects on the phenotype of a specific tissue, or of 
individual cells within that tissue. Furthermore, many systems, such as the digestive 
system and the GALT, are intrinsically interwoven with the lymphatic system. Thus, 
host-pathogen interactions are a complex interplay of factors, with specific interactions 
between the pathogen and host tissues that trigger systemic responses that cannot 
currently be thoroughly replicated in vitro. 
 Animal models for the study E. coli K1 infection generally employ rodent 
species, most frequently the laboratory rat Rattus norvegicus (Glode et al., 1977; 
Bortolussi et al., 1978; Kim et al., 1992; Sukumaran et al., 2003; Zelmer et al., 2008) 
and the laboratory mouse Mus musculus (Pluschke & Pelkonen, 1988; Mittal et al., 
2010; Mittal & Prasadarao, 2011). Both species have a proven track record in 
replicating many features of infections in humans. Murine models present the 
investigator with a significant advantage that derives from the extensive genetic 
database that has been accumulated, together with the huge range of gene knockout 
(KO) strains that are available. However, the small size of the neonatal mouse 
sometimes presents a challenge; modelling E. coli K1 systemic infection may involve 
administration by the oral route and this can be problematical in this species. 
Conversely, although the rat lacks the powerful genetic capacity of the mouse, the 
relative size of the neonate allows for easier infection via the „natural‟ oral route. There 
are also some differences in the innate immunity, specifically the expression of 
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defensins of both species compared to humans which may impact on their suitability as 
models for E. coli K1 infection. Firstly, the α-defensin repertoire of mice is much larger 
(20) than the rat (13) or human (9) and rat defensins are in the main more closely related 
to humans that the murine equivalents (Patil et al., 2004). Secondly, murine neutrophils 
do not express defensin peptides, whereas both rat and human neutrophils do 
(Eisenhauer et al., 1992), which may be of importance considering the likely role of 
these cells in E. coli K1 pathogenesis (Mittal & Prasadarao, 2011). These differences 
indicate that the rat is almost certianly more suitable in terms of modelling human 
infections than the mouse.  
The anatomical configuration of the GI tract of humans and rats is similar but 
there are some key structural differences between this organ in these two species 
(reviewed by Kararli, 1995). The caecum of the rat is enlarged in comparison to that of 
humans and rats lack a gallbladder. The rat secretes bile salts directly into the small 
intestine from the liver via the hepatic bile duct but in most mammals, including 
humans, bile salts are concentrated in the gallbladder prior to secretion. However, key 
elements of the biochemistry of the GI tract, such as pH and bile salt concentration and 
composition, are comparable. Diseases of the GI tract that afflict humans and are 
considered to possess a major microbial aetiological component, such as NEC, can be 
reproduced experimentally in the rat and the symptoms displayed often closely mirror 
those of the human condition (Caplan et al., 2001), Rotavirus (Ciarlet et al., 2002) and 
Salmonella infections (Naughton et al., 1996) provide good examples. GI tract 
colonization of susceptible neonatal rats after oral administration of E. coli K1 produces 
an infection which closely mimics the course of human sepsis and meningitis; the 
bacteria disseminate into the blood compartment, gain access to systemic tissues and 
can induce lethal inflammatory responses in the CNS (Glode et al., 1977; Zelmer et al., 
2008; 2010). This evidence strong suggests that the neonatal rat is an appropriate model 
animal for the study of E. coli K1 age dependent pathogenesis. 
The majority of laboratory rats currently in use are derived from the outbred 
Wistar strain developed for use as a general model organism in the early 20
th
 century. 
These animals were selectively bred to maintain traits useful to researchers such as 
docility and the ability to thrive in a laboratory environment. Many strains have been 
derived from the Wistar rat for use in different research areas. Examples include Long 
Evans and Zucker rats (obesity), Sprague Dawley rats (general research, toxicology and 
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oncology) as well as Athymic Nude and Fischer 344 rats (immunology). Previous 
studies which have employed a rat model of E. coli K1 infection have used the general 
research Wistar and Sprague Dawley rat strains. In our laboratory the Wistar strain has 
previously been successfully used to study different aspects of E. coli K1 infection 
including experimental chemotherapy (Mushtaq et al., 2004; 2005; Zelmer et al., 2010) 
and pathogenesis (Zelmer et al., 2008). This model was therefore employed in this 
investigation.     
The epidemiology of E. coli K1 infection persuasively infers that acquisition of 
the pathogen by the neonate generally occurs by vertical transmission from the maternal 
intestinal and/or vaginal microbiota during the perinatal period, although secondary 
non-maternal acquisition from the environment does occur (Sarff et al., 1975; Glode et 
al., 1977). However, there have been few, if any, attempts to replicate vertical 
transmission in animals. Oral challenge models of infection employ bacterial innocula 
of 10
5
-10
8
 CFU E. coli K1 (Glode et al., 1977; Mushtaq et al., 2005; Zelmer et al., 
2008; 2010), probably a much larger than that encountered in the natural infection. 
Further, this mode of experimental infection does not take into account any phenotypic 
variation between laboratory-cultured bacteria and those of the maternal GI tract. 
 Quantification of bacteria in experimental infections presents a number of 
challenges, particularly in a heavily contaminated environment such the GI tract, which 
possesses a large resident bacterial population. Many intestinal bacteria are difficult to 
grow on laboratory media and traditional culture methods are limited in their capacity to 
discriminate between members of the microbiota and the bacterial innoculum. Selective 
media containing antibiotics or other inhibitors may be used to aid discrimination, as 
will the inclusion of a pH indicator that responds to specific bacterial metabolites. For 
differentiation of E. coli from other, related bacteria, MacConkey agar, containing 
inhibitory bile salts and toluene red as a pH indicator, is frequently employed for the 
detection of E. coli within complex bacterial populations. Further differentiation of E. 
coli K1 from other E. coli clones can be achieved using K1-specific lytic bacteriophage 
(Gross et al., 1977; Cross et al., 1984).  
An E. coli K1-specific quantitative polymerase chain reaction (qPCR) would 
provide a viable alternative to culture and phage-typing methods. PCR is widely used as 
a molecular diagnostic tool for the detection of a wide range of pathogens (reviewed by 
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Malorny et al., 2002); qPCR was developed to achieve real-time monitoring using 
DNA-binding fluorophores and permits quantification of the copy number of target 
DNA sequences by comparison of the PCR amplification curves from DNA sample 
amplification with those from amplification of known quantities of target DNA (for 
example Palmer et al., 2007; Furet et al., 2004; Gueimonde et al., 2004). It may provide 
a valuable tool for assessing colonization of the GI tract by E. coli K1. 
   Here I describe the development of the neonatal rat model of systemic E. coli 
K1 infection and introduce analytical methods for the investigation of intestinal 
colonization by E. coli K1.  
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2.2 Materials & Methods 
 
Unless otherwise indicated, media for bacterial cultivation were purchased from 
Oxoid Ltd, chemicals, reagents and enzymes were purchased from Sigma-Aldrich and 
oligonucleotides were synthesised by, and purchased from, Eurofins MWG Operon.  
  
2.2.1 Bacteria: strains, growth conditions and stock maintenance 
 The bacterial strains used throughout this work are shown in Table 2.1. E. coli 
K1 strain A192PP is a derivative of strain A192 (also designated DSM 10719 in the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen [DSMZ] collection), a 
neonatal septicaemia isolate from the Netherlands and described by Achtman et al. 
(1983). The virulence of A192 was enhanced by serial passage in the neonatal rat by 
 
Strain Description O:K serotype Source 
A192PP Enhanced virulence; septicaemia isolate O18:K1 Mushtaq et al., 2004 
C14 UTI isolate O?:K1 In-house collection 
DSM 10723 Meningitis isolate O18:K1 DSMZ 
LP1674 UTI isolate O7:K1 In-house collection 
EV36 K-12/K1 hybrid O?:K1 Vimr & Troy, 1985 
LP1395 UTI isolate O18:K? In-house collection 
DSM 10797 UTI isolate O18:K5 DSMZ 
DSM 10794 UTI isolate O18:K5 DSMZ 
CGSC 5073 K-12 strain N/A CGSC 
Klspp10 Klebsiella pneumoniae isolate N/A In-house collection 
Citro14 Citrobacter freundii isolate N/A In-house collection 
Prmirab42 Proteus mirabilis isolate N/A In-house collection 
 
Table 2.1: Bacteria used in this study. Strain designations, descriptions and O-/K-
antigenic serotypes are provided where applicable. Strains were obtained from an in-
house collection at the UCL School of Pharmacy or purchased from either the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ) or the Coli Genetic Stock 
Centre (CGSC). All strains are E. coli unless indicated.  
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Mushtaq et al., (2004); a single colony from the blood culture of an infected rat after 
second passage was designated A192PP. This strain efficiently colonizes the GI tract 
and causes systemic infections in 100% of susceptible neonatal rats. It was used in this 
study for all oral challenges with E. coli K1. Strain EV36 is an E. coli K-12 strain 
carrying the E. coli K1 RS1085 kps locus on an Hfr plasmid; this locus encodes the 
genes for K1 capsule biosynthesis (Vimr & Troy, 1985). Bacteria were grown in 
Mueller-Hinton (MH) broth in an orbital incubator (200 orbits/min) and on MH or 
MacConkey agar; cultures were incubated overnight (~24 h) at 37 °C. Optical density of 
liquid cultures was measured at a wavelength of 600 nm (OD600) using a Lambda 25 
spectrophotometer (Perkin-Elmer). Stocks of each strain were prepared by mixing 
aliquots of liquid cultures with sterile glycerol to a final glycerol concentration of 20% 
(v/v) and stored at -80 °C.  
       
2.2.2 Animals 
 Pregnant, non-pregnant and lactating adult Wistar rats with neonatal pups were 
purchased from Harlan Olac UK. All adult rats were 9-11-week-old females and were 
housed in individual cages with associated neonates. Neonates were of mixed gender 
and either provided with their natural mothers or littered in-house, in the case of 
pregnant animals. Pregnant animals were supplied at 12-14 days gestation. All animals 
were kept in rooms at 19-21 °C with 45-55% humidity, 15-20 air changes/h, and a 12 h 
light/dark cycle. They were provided with a 5LF5 basic maintenance diet and water ab 
libitum. Adults were killed by CO2 euthanasia and neonates by decapitation. All 
procedures conformed to National and European legislation and were approved by the 
institutional Ethics Committee and the UK Home Office.      
    
2.2.3 Bacteriophage K1E propagation, purification and titration 
E. coli K1-specific lytic bacteriophage K1E was isolated by Gross et al. (1977), 
has been further characterized by Tomlinson & Taylor (1985) and Leiman et al. (2007) 
and was provided by Tom Cheasty (Health Protection Agency, UK). Methods for 
bacteriophage propagation precipitation were based on those described by Tomlinson & 
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Taylor (1985). Five hundred mL cultures of A192PP were grown to OD600 0.8, K1E 
bacteriophage added at a multiplicity of infection (MOI) of 0.25 and the mixture 
incubated for a further 30 min at 37 °C. Cultures were cooled to room temperature, 
DNase I and RNase added to 1 µg/mL and left to stand for 30 min. NaCl was added to 
give a final concentration of 1 M and the culture placed on ice for 1 h. PEG 8000 was 
added to give a final concentration in solution of 10% (w/v). Cultures were maintained 
in ice water for 1 h. Precipitated phage particles were recovered by centrifugation at 
11000 x g for 10 min and the pellet suspended in SM buffer (100 mM NaCl, 8 mM 
MgSO4•7H2O, 50 mM pH 7.5 Tris-HCl). PEG and cellular debris were extracted by 
addition of an equal volume of chloroform followed by gentle mixing and centrifugation 
at 3000 x g for 15 min to recover the aqueous phase containing phage. The phage 
suspension was filtered (0.22 µm MILLEX GP filter; Millipore) and the filtrate stored at 
4 °C. Phage was titrated using ten-fold serial dilutions of the filtrate and each diluted 
suspension incubated for 5 min with mid-exponential-phase (OD600 0.5) A192PP in 3 
mL of molten overlay agar (0.5% [w/v] Bacteriological agar in MH broth). Overlay agar 
was spread onto MH agar base and incubated overnight at 37 °C. Plaques were 
enumerated and expressed as plaque forming units per mL (PFU/mL). 
 
2.2.4 Oral inoculation of neonates and adults 
 The inoculation of neonatal rats by the oral route was based on a method 
developed by Glode et al. (1977) and refined by Pluschke et al. (1983). E. coli strains 
were grown in liquid culture to mid-exponential-phase (OD600 0.5; 0.5 x 10
9
 CFU/mL); 
2-9 day old (P2-P9) neonatal rats were removed from their cages and fed 20 µL of a 
bacterial suspension (10
7
 CFU) using a micropipette fitted with sterile tips pre-warmed 
to 37 °C. Controls received sterile MH broth. Animals were returned as soon as possible 
to their cages. Pregnant and non-pregnant adult rats were given larger amounts of mid-
exponential-phase bacteria (10
8
-10
10
 CFU) by gastric lavage.  
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2.2.5 Processing of tissue & stool samples 
 Neonatal tissue and adult stool samples were collected for downstream analysis. 
For collection of adult stool samples, rats were removed from their cages and placed in 
a clean cage without bedding. Fresh stools were obtained immediately post-defaecation 
and placed in pre-weighed collection tubes containing 4 mL ice-cold phosphate buffered 
saline (PBS) and kept on ice. Neonatal whole intestinal (duodenum-rectum) tissues were 
collected by dissection of animals immediately post-mortem. Tissue removal was 
performed under sterile conditions in a class II biological safety cabinet (C2BSC) with 
sterile instruments. These were soaked in 70% ethanol and washed with sterile PBS 
between samples. Tissues for bacterial enumeration and DNA extraction were placed in 
pre-weighed collection tubes containing 2 mL ice-cold PBS and kept on ice. After 
collection, all samples were immediately weighed and homogenized on ice using an 
Ultra-Turrax T-10 homogenizer (IKA-Werke). The homogenizer blade was washed 
before homogenization of each sample with 70% ethanol followed by three washes in 
sterile PBS. Tissue and stool homogenates were examined immediately or stored at -80 
°C. 
 
2.2.6 Detection of E. coli K1 colonization and bacteraemia  
 Inoculated neonatal rats were examined for intestinal colonization by E. coli K1 
and the presence of bacteria in blood. Intestinal colonization was determined after peri-
anal swabbing. Sterile swabs were moistened in sterile PBS and used to swab the 
neonatal peri-anal area; swab tips were placed in Eppendorf tubes containing 300 µL 
sterile PBS, the tube contents mixed by vortex for 30 s and 100 µL spread-plated onto 
MacConkey agar and incubated overnight at 37 °C. Blood (10 µL) was taken from the 
foot pad with a 26G BD microlance and blood mixed with 90 µL PBS containing 
heparin at a concentration of 2 units/mL. The mixture was plated onto MacConkey agar; 
after overnight incubation at 37 °C, plates were examined for coliform lac
+
 (pink) 
colonies. Pink colonies were examined for susceptibility to E. coli K1-specific phage. 
Colonies were picked with a sterile loop, placed in 200 µL sterile PBS, mixed and 
streaked onto MH agar plates. Streaks were left to dry and 10 µL of 10
9
 PFU/mL K1E 
phage suspension dropped onto the mid-point of each streak; plates were incubated 
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overnight at 37 °C. After incubation, bacterial streaks were examined for phage lysis to 
determine the presence or absence of K1 capsule (Figure 2.1). Phage-sensitive (K1
+
) 
bacteria were assumed to be E. coli K1. 
 
2.2.7 E. coli K1 quantification 
 E. coli K1 from neonatal tissue and adult stool samples were quantified in 
similar fashion to the method to that described in 2.2.6 (Figure 2.2). Serial tenfold 
dilutions (100 µL) of tissue and stool homogenates were spread-plated on MacConkey 
agar and incubated overnight at 37 °C. Coliform colonies were sub-cultured on MH 
agar and their sensitivity to K1E phage determined. After enumeration, the data was 
normalized to sample mass to give CFU/g tissue or stool. 
 
2.2.8 DNA extraction 
 Bacterial DNA was extracted for non-quantitative PCR and for use as genomic 
standards in qPCR. Strains were streaked onto MH agar from glycerol stocks and 
incubated overnight at 37 °C. Isolated colonies were used to inoculate 10 mL MH broth 
and grown to OD600 0.5 and bacteria recovered by centrifugation at 5000 x g for 10 min. 
A192PP provided qPCR genomic standards: serial dilutions were plated in triplicate 
onto MH agar, incubated overnight at 37 °C and enumerated by colony plate count. 
Total DNA was extracted from bacterial pellets using QIAamp DNA Mini kits (Qiagen) 
according to the manufacturer‟s instructions. The composition of extraction buffers is 
proprietary information unless otherwise stated. Pellets were suspended in 180 µL of 
lysis buffer ATL supplemented with 20 µL proteinase K (20 mg/mL) and incubated at 
56 °C for 1 h. RNA was selectively degraded by addition of 4 µL RNase A (100 
mg/mL) and incubated at room temperature for 2 min; 200 µL lysis buffer AL was 
added to the DNA extraction mixture, mixed by vortex for 15 s and incubated at 70 °C 
for 10 min. Ethanol (100% [v/v]; 200 µL) was added, the tube contents mixed by vortex 
for 15 s and applied to a QIAamp Mini spin-column. The column was centrifuged at 
6000 x g for 1 min. The filtrate was discarded and the column washed with 500 µL each 
of the wash buffers AW1 and AW2. Elution buffer AE (10 mM pH 9 Tris-HCl, 0.5 mM 
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Figure 2.1: Identification of K1 capsule by K1E bacteriophage-mediated lysis (K1
+
) of 
coliform bacteria. Red circles indicate area covered by phage droplet.  
 
 
Figure 2.2: E. coli K1 quantification by culture and phage-typing. Tenfold dilutions, 
MacConkey agar (red), Mueller-Hinton agar (light green), confluent bacterial growth 
(orange), lac
-
 colonies (yellow), lac
+
 colonies (pink) and sub-cultured bacterial streaks 
(green) are illustrated. 
K1-
K1+
Direction of streak
10-1 10-2 10-3
10-4 10-5
83 
 
EDTA; 200 µL) was applied to the column and the DNA eluted by centrifugation at 
6000 x g for 1 min. This procedure was repeated using a further 200 µL of buffer AE to 
ensure full recovery of the DNA. The concentration and purity of DNA were 
determined with a NanoDrop spectrophotometer (Thermo Scientific). The genome copy 
number (gDNA/µL) was calculated using plate counts. DNA samples were stored at -20 
°C.         
 
2.2.9 DNA extraction of GI tissues and stool samples  
 DNA was extracted from neonatal GI tract tissues, with contents, and adult stool 
samples for downstream PCR. Tissue and stool extractions were undertaken using 
QIAamp DNA Stool Mini kits (Qiagen) according to the manufacturer‟s instructions. 
The composition of buffers or tablets was proprietary information unless otherwise 
indicated. Initially, 200 µL of tissue or stool homogenate was mixed with 1.4 mL of 
lysis buffer ASL, mixed by vortex and incubated at 95 °C for 5 min. Extraction 
mixtures were again mixed by vortex for 15 s and centrifuged at 20000 x g for 1 min to 
pellet tissue debris or stool particles. An InhibitEx tablet was then added to 1.2 mL of 
the recovered supernatant and mixed by vortex until the tablet was completely 
suspended. The tablet was pelleted by centrifugation at 20000 x g for 3 min. 200 µL of 
the supernatant was collected and again centrifuged to remove any further suspended 
tablet material. Proteinase K (20 mg/mL; 15 µL) was added to the 200 µL extraction 
mixture followed by 200 µL of the lysis buffer AL; after mixing by vortex for 15 s, the 
mixture was incubated at 70 °C for 10 min. Ethanol (100% [v/v]; 200 µL) was added to 
the lysate and the mixture applied to a QIAamp spin-column. The columns were 
centrifuged at 20000 x g for 1 min. The filtrate was discarded, the columns washed 
sequentially with 500 µL of wash buffers AW1 and AW2 and dried by centrifugation at 
20000 x g for 1 min. Elution buffer AE (10 mM pH 9 Tris-HCl, 0.5 mM EDTA; 200 
µL) was applied to the column and DNA eluted at room temperature as described 
above. The concentration and purity of DNA were determined with a NanoDrop 
spectrophotometer (Thermo Scientific).  
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2.2.10 neuS PCR and amplicon agarose gel electrophoresis 
 The E. coli K1-specific gene neuS encodes poly-α-2, 8 sialosyl sialyltransferase 
and was selected the development of a PCR assay for the identification and 
quantification of E. coli K1 in mixed bacterial populations. The oligonucleotide primer 
pair NeuSF3 (5‟-CCAA AGAAGATGATGTTAATCCAATTAAG-3‟) and NeuSR3 
(5‟-ATCATCAACCAGAATAGATAATGTTATCC-3‟) was designed to amplify a 332 
bp fragment within the neuS gene. The primer pair was designed using v.9 Clone 
Manager Suite software (Scientific & Educational Software) utilizing the neuS gene 
sequence from the O7:K1 serotype NMEC strain CE10 complete genome sequence 
(NCBI accession number: NC_017646) as a design template. Primer specificity for E. 
coli K1 strains was examined using Primer-BLAST (www.ncbi.nlm.nih.gov 
/tools/primer-blast) with primer pair specificity checking parameters set to all deposited 
bacterial and Rattus norvegicus sequences in all DNA sequence repository databases. 
PCR reactions (50 µL) were prepared by mixing 25 µL of GoTaq Green Master Mix 
(Promega) with 10 µL nuclease-free water, 5 µL each of 2.5 µM NeuSF3 and NeuSR3 
primers (final primer concentration 625 nM) and 5 µL of 40 ng/µL bacterial DNA 
(200ng in total). PCR reactions were performed in a Techne Thermocycler (Bibby 
Scientific). The thermocycling program comprised an initial DNA denaturation step of 
95 °C for 5 min followed by 35 cycles of denaturation at 95 °C for 30 s, primer 
annealing at 61 °C for 30 s and amplicon extension at 72 °C for 30 s and a final 
extension cycle at 72 °C for 5 min. Amplified DNA was resolved by loading 10 µL of 
PCR reaction mixture onto a 1% (w/v) agarose gel containing 0.5 µg/mL ethidium 
bromide and electrophoresis at 80 V in Tris-acetate-EDTA buffer (TAE; 40 mM Tris-
acetate, 1mM EDTA, pH8) for 30 min or until the dye front reached the end of the gel. 
Ethidium bromide-intercalated DNA within the gel was visualized by scanning with a 
Molecular Imager FX system (Bio-Rad) set to detect UV fluorescence.  
 
2.2.11 Amplicon cleanup and DNA sequencing 
 PCR products amplified with GoTaq Green Master Mix were cleaned using 
Wizard SV Gel and PCR Cleanup kit (Promega) according to the manufacturer‟s 
instructions prior to DNA sequencing. PCR reaction mixture (20 µL) was mixed with 
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20 µL of Membrane Binding Solution (4.5 M guanidine isothiocyante, 0.5 M potassium 
acetate, pH 5.0). The mixture was then transferred to a cleanup kit spin column and 
incubated at room temperature for 1 min to allow binding to the membrane. The column 
was centrifuged at 16000 x g for 1 min and the filtrate discarded. The membrane was 
washed with 700 μL followed by 500 µL of Wash Solution (10 mM potassium acetate 
pH 5.0, 80% ethanol, 16.7 μM EDTA, pH 8.0), with centrifugation at 16000 x g for 1 
min after each wash. The wash filtrate was discarded and the membrane dried by 
centrifugation of the column at 16000 x g for 5 min. Nuclease-free water (50 µL) was 
applied to the column membrane and DNA eluted by incubation at room temperature 
for 1 min followed by centrifugation at 16000 x g for 1 min. Cleaned DNA was assayed 
for concentration and purity using a NanoDrop spectrophotometer (Thermo Scientific) 
and stored at -20 °C. DNA for sequencing was prepared in Eppendorf tubes in 15 µL 
volume containing 5 ng/µL cleaned DNA and the primer NeuSF3 at a final 
concentration of 15 pM. DNA sequencing was undertaken by Eurofins MWG Operon; 
sequences were aligned with the neuS sequence using ClustalW 
(www.ebi.ac.uk/Tools/msa/clustalw2) to verify sequence identity.   
 
2.2.12 E. coli K1 quantification by neuS qPCR 
 A qPCR assay of the neuS gene was used to quantify E. coli K1 in tissue or stool 
samples by DNA analysis. Genomic standard DNA was prepared by 10-fold serial 
dilution of A192PP DNA using previously calculated gDNA/µL values (see section 
2.2.8). Standards used in qPCR typically ranged from 2-2000 gDNA/µL. qPCR 
reactions (15 µL) were established by combining, in order and on ice, 2.7 µL of 
nuclease-free water, 10 µL of Brilliant III Ultra-Fast SYBR Green QPCR Master Mix 
(Agilent Technologies), 1 µL each of 12.5 µM NeuSF3 and NeuSR3 primers (see 
section 2.2.10; final concentration per primer of 625 nM) and 0.3 µL of 600 nM ROX 
reference dye (final concentration 30 nM). qPCR reactions were prepared in light-
protected tubes and in large batches, depending on the number of reactions required for 
each experiment and to ensure reaction mixture homogeneity. Preparation of qPCR 
reactions was also carried out in a C2BSC to reduce the risk of DNA contamination. 
Batch-made qPCR reaction mixtures were divided into individual 15 µL reactions by 
pipetting into 96-well PCR plates. 5 µL of genomic standard DNA, tissue or stool 
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sample DNA extracts, or nuclease free water (acting as a no-template control) were 
added to each qPCR reaction mixture to a final volume of 20 µL. Wells were sealed 
with optically clear strip caps. qPCR reactions were carried out using an Mx3000P 
system and v.2 software (Stratagene) set to detect SYBR1 and ROX fluorescence. The 
thermal cycling programme comprised an initial DNA denaturation step at 95 °C for 3 
min, 40 cycles of denaturation at 95 °C for 20 s and anneal/extend at 61 °C for 20 s. 
Fluorescence was measured at the anneal/extend step of each amplification cycle and 
amplification curves recorded. DNA melt-curves to determine the number of DNA 
products produced during amplification were constructed by cooling reaction mixtures 
to 55 °C and incrementally increasing to 95 °C over 30 min; fluorescence was measured 
at 20 s intervals. SYBR1 fluorescence was normalized to ROX fluorescence to enable 
the software to generate a cycle-threshold (Ct) of SYBR1 fluorescence utilizing 
adaptive baseline and amplification-based threshold algorithm enhancements. Ct values 
of genomic standard DNA amplifications were used to generate standard curves for 
analysis of test DNA samples, enabling determination of sample concentration 
(gDNA/µL) and calculation of E. coli K1 CFU/g sample. Standard gDNA extracted 
from 3 separate A192PP cultures was used for each qPCR reaction plate and standards, 
samples and control reactions were duplicated on each plate. All assays were duplicated 
on a separate occasion and data for each sample averaged across the 4 replicate values.  
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2.3 Results 
 
2.3.1 Characterization of the neonatal rat model of E. coli K1 infection 
  
2.3.1.1 Age-dependency 
 The impact of age on susceptibility to lethal infection of was examined by 
feeding E. coli A192PP cultures to neonates 2-9 days post-partum (P2-P9). Sterile MH 
broth was used as a control. Experimental and control groups comprised two litters, 
each of twelve neonates, for each age-group. Survival of colonized neonates was 
monitored for two weeks after inoculation but no deaths were recorded after 7 days had 
elapsed; survival over this period was recorded and used to construct Kaplan-Meier 
survival curves (Figure 2.3). Animals manifesting symptoms of systemic disease, such 
as lack of responsiveness and pallor, were immediately culled and blood and brain 
tissue obtained in order to determine the presence of E. coli K1. The data demonstrates 
a strong correlation between the age of inoculation and survival in response to oral 
inoculation with A192PP. Analysis of the survival curves produced in this experiment 
indicated the presence of three distinct groups. P2-3 neonates were extremely 
susceptible to A192PP and had very low survival rates. P4-6 neonates were moderately 
susceptible to A192PP and had intermediate survival rates. P8-9 neonates were mostly 
refractive to A192PP and had high survival rates. No mortality was observed in any of 
the control litters and E. coli K1 was found in blood and brain samples from culled sick 
animals (n=7) using culture and K1E phage-typing methods, strongly indicating that 
A192PP was the aetiological agent of mortality. 
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Figure 2.3: Age-dependent survival of neonatal rats in response to oral inoculation 
with E. coli K1. P2-P9 (n=24 per group) neonates were orally inoculated with 10
7
 CFU 
of strain A192PP and survival monitored for seven days. Significant differences in 
survival as determined by Logrank test are indicated (* p<0.05, ** p<0.01, *** 
p<0.001). 
 
2.3.1.2 Relationship between colonization, bacteraemia and mortality 
 The susceptibility of P2, P5 and P9 neonatal rats to E. coli K1 was examined 
together with an assessment of intestinal colonization and translocation into the blood 
compartment. Litters of 12 neonates for each age group were inoculated with mid-
exponential-phase liquid cultures of A192PP and monitored for survival over seven 
days. Each neonate was assessed daily during this period for intestinal colonization and 
bacteraemia by selective culture and K1E phage typing to determine the presence of E. 
coli K1. Deaths, colonization and bacteraemia were  recorded for  each  age  group, with  
*
*
***
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Figure 2.4: Colonization, bacteraemia and deaths in neonatal rats orally inoculated 
with E. coli A192PP at P2 (A), P5 (B) and P9 (C). Litters of twelve neonatal rats were 
inoculated with 10
7 
CFU and colonization and bacteraemia detected by culture and 
K1E phage-typing of peri-anal swabs and blood samples. Data are from two or more 
experiments.     
 
dead animals scored as colonized and bacteraemic (Figure 2.4).  E.coli A192PP   
colonized neonates inoculated at P2, P5 and P9, although there was a small but 
noticeable lag in E. coli K1 detection in P9 and, to a lesser extent, P5-inoculated 
neonates. Mortality rates of the three age groups were comparable to those in Figure 2.3 
and there was a strong correlation between bacteraemia and death, with a 94.4% 
incidence of mortality in animals with E. coli K1 bacteraemia. Although all rats 
inoculated at P9 were colonized 72 h after inoculation, no bacteraemia was detected in 
any of these animals. The lack of detectable bacteraemia in the refractive P9 neonatal 
group and the strong correlation between bacteraemia and mortality in the more 
susceptible P2 and P5 cohorts is a strong indication that the capacity of E. coli K1 to 
translocate from the intestines is the determining factor of the age-dependency of 
systemic infection.    
A B C
Days post-inoculation
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2.3.1.3 Onset of systemic infection 
 The onset of systemic E. coli K1 infection in susceptible neonates was 
investigated using phage K1E to selectively reduce the E. coli K1 intestinal population 
at various time-points after inoculation with E. coli K1 (Figure 2.5). Litters of twelve P2 
neonates were inoculated with 10
7
 CFU of strain A192PP and intestinal colonization, 
bacteraemia and deaths recorded; animals which died were scored as colonized and 
bacteraemic. Neonates with each litter were orally inoculated with 10
9
 PFU phage K1E 
at P3, P4 and P5, that is one, two, and three days after A192PP inoculation. Inoculation 
with K1E at all time points resulted in a significant decrease in the proportion of rats 
from which E. coli K1 intestinal colonization could be detected by peri-anal swabbing 
(Figure 2.5 A-C). The development of bacteraemia and subsequent mortality was 
significantly reduced in experimental groups which received the phage inoculum at P3 
and P4 (Figure 2.5 A/B). However, neither were reduced in neonates that received the 
K1E inoculation at P5 (Figure 2.5 C) and this group suffered comparable rates of 
bacteraemia and mortality to SM buffer-inoculated controls (Figure 2.5 D). Although a 
small degree of mortality was observed in neonates inoculated at P4, this was 
attributable to neonates which were bacteraemic prior to K1E inoculation. The inability 
of phage to prevent mortality in colonized neonates inoculated with K1E at P5 strongly 
suggests that the onset of bacteraemia occurred prior to this time-point. As the 
proportion of bacteraemic rats in this group continued to rise after K1E administration, 
it is very likely that these animals were already bacteraemic but bacterial numbers in the 
blood were below the detection threshold. 
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Figure 2.5: Colonization, bacteraemia and deaths in P2 neonates colonized by E. coli 
K1 and inoculated with phage K1E. Neonates were fed 10
9
 PFU of K1E (▼) at P3 (A), 
P4 (B) and P5 (C) or were treated with sterile SM buffer at P3 (D). Data are from two 
or more experiments.  
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2.3.2 The maternal-neonatal route of infection 
 The vertical transmission of the E. coli A192PP from the pregnant mother to the 
neonate during the peri-natal period was investigated to determine the viability of this 
route of infection for further studies. 
 
2.3.2.1 Colonization of adults rats with E. coli K1 
 Induction of stable colonization of the adult rat intestinal tract with E. coli 
A192PP was investigated by gastric lavage of non-pregnant adult rats. Rats were 
inoculated with 10
8
, 10
9
 or 10
10
 CFU or with sterile MH broth as a control.  
 
 
Figure 2.6: Intestinal colonization of non-pregnant adult rats by E. coli A192PP. Rats 
were inoculated with 10
8
, 10
9
 or 10
10
 CFU by gastric lavage. Error bars represent the 
SEM of CFU/g quantified from n=3 rats. The limit of detection (LOD) is indicated.
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Each test group comprised three adults; two rats were employed for each control 
group. Two stool samples were collected from each animal over a fourteen day period 
after colonization and the presence of E. coli K1 determined (Figure 2.6). An inoculum 
of 10
10 
CFU A192PP was required to induce stable and prolonged E. coli K1 
colonization of the adult intestine. Inoculation with 10
9 
CFU produced a transient 
colonization with E. coli K1 no longer detectable after five days. No E. coli K1 could be 
detected in the stool of animals inoculated with 10
8
 CFU or in control animals. The 
mean mass of stool samples (n=330) was 0.32 g and a sample dilution factor of 10
-4
 was 
required to culture individual lac
+
 colonies for phage typing. The limit of detection 
(LOD) based on selective culture and phage typing was determined to be approximately 
1.24 x 10
6
 CFU/g of stool.     
 
2.3.2.2 Colonization of pregnant rats with E. coli K1 
 The method of induction of stable colonization in non-pregnant adult rats was 
applied to pregnant adults in order to investigate the feasibility of establishing neonatal 
colonization through maternal-neonatal vertical transmission. Four pregnant rats were 
inoculated with 10
10 
CFU A192PP and two with sterile MH broth as a control. Stools 
were collected and processed to determine E. coli K1 CFU/g of stool as described in the 
previous section and the survival of live offspring monitored post-partum (Figure 2.7). 
Pregnant rats were inoculated at thirteen days of gestation (E13) and the extent of E. 
coli K1 colonization was similar to that found with non-pregnant rats at 10
7
-10
8
 CFU/g 
of stool. Gestation of the two control animals continued normally with live births of 
eleven neonates each at E20 and E21. No neonatal mortality within and beyond the 
seven day post-partum period was found. Two of A192PP-colonized animals gave birth 
to live offspring, one littering five and the other eight neonates. There was a rapid onset 
of mortality of these neonates with no survival at P3. E. coli K1 was found in the blood 
compartment and brain tissues of these animals. Differences in mortality between the 
offspring of colonized and control animals illustrated vertical transmission of the 
pathogen and neonatal systemic infection. Interestingly, two colonized adults did not 
produce live offspring and suffered blood loss at E17 and E18, indicative of 
spontaneous abortion.         
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Figure 2.7: Colonization of pregnant rats with E. coli K1 and transmission to neonates. 
Four pregnant rats were inoculated with 10
10
 CFU A192PP and two were inoculated 
with MH broth (control); E. coli K1 was quantified from stool samples. Pregnant rats 
either aborted (▼) or gave birth (▼) to offspring. Neonatal survival was monitored 
post-partum (inset). Error bars represent the SEM of CFU/g of stool from four rats. 
LOD; limit of detection.   
 
2.3.3 Quantification of E. coli K1 by neuS qPCR 
 Culture methods for detecting E. coli K1 in stool and tissue samples are 
laborious and relatively insenstivie; a qPCR assay based on the neuS gene of the K1-
capsule biosynthesis and export kps gene cluster was therefore developed. The neuS 
gene was selected as a single copy gene (neuS copy number equals E. coli K1 cell 
number) of the restricted region II of the kps cluster with no DNA sequence homology 
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to any currently deposited DNA sequences, excluding E. coli K1 sequences, as 
determined by BLAST analysis (http://blast.ncbi.nlm.nih.gov). The primer pair NeuSF3 
and NeuSR3 were determined by Primer-BLAST to be neuS-specific and were designed 
to be relatively long (30 bp) with a high annealing temperature (60 °C) to increase the 
stringency of the PCR and to compensate for any partial homology with unrecorded 
DNA sequences present in the intestinal microbiota.        
 
2.3.3.1 Specificity of the primers 
 The specificity of the NeuSF3/NeuSR3 primer pair was tested in vitro against a 
range of Gram-negative genomic DNA. Genomic DNA was extracted from the strains 
in Table 2.1 and the 332 bp neuS fragment amplified by PCR. Amplicons were resolved 
by agarose gel electrophoresis (Figure 2.8). A single band corresponding to 
approximately 0.3 kbp was produced by all PCR with E. coli K1 strain DNA as a 
template. Amplification was dependent on the presence of E. coli K1 genomic DNA, as 
reactions utilizing DNA from non- E. coli bacterial species and E. coli strains other than 
E. coli K1, including the related group II capsular serotype K5 strains, were uniformly 
negative. Amplification of a band of expected size from the K-12/K1 hybrid strain 
EV36, but not the K-12 wildtype strain CGSC 5073, lent further support in favour of 
amplification specificity towards the K1-biosynthesis/export kps gene cluster. The 
identity of the amplicon as a fragment of the neuS gene was confirmed by cleanup of 
PCR reactions and DNA sequencing.   
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Figure 2.8: Agarose gel electrophoresis of amplicons produced by neuS PCR using 
different gDNA templates. Template DNA from strains A192PP (1), C14 (2), DSM 
10723 (3), CGSC 5073 (4), EV36 (5), LP1674 (6), LP1395 (7), DSM 10797 (8), DSM 
10794 (9), Klspp10 (10), Citro14 (11) and Prmirab42 (12) were used. Lanes containing 
2-log ladder DNA (New England Biosciences) and PCR reactions with no template 
DNA (-ve) are also shown.   
 
2.3.3.2 Validation of the qPCR assay 
 The utility of neuS qPCR for the quantification of E. coli K1 was examined by 
real-time monitoring of PCR using E. coli K1 DNA as a genomic standard and by 
generation of reproducible standard curves. The use of the technique in quantifying E. 
coli K1 from intestinal tissue and stool homogenates was validated by spiking samples 
with known quantities of live E. coli K1 prior to DNA extraction. 
 Total genomic DNA was extracted three times from standardized 
cultures of A192PP; DNA extracts were diluted to 2 x 10
6 
gDNA/µL and serially diluted 
to produce a range of gDNA dilutions for use as qPCR standards. As 5 µL of each 
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dilution was used in each PCR, this range covered genomic DNA corresponding to 10
1
-
10
7
 CFU A192PP. Representative data produced by real-time monitoring of PCR 
reactions utilizing these standards as template DNA is shown in Figure 2.9. 
Amplification of PCR products was detected in all dilutions tested but not in no-
template controls (Figure 2.9 A), demonstrating that this method was extremely 
sensitive and capable of detecting ≤ 10 genome copies. Melt-curve analysis detected a 
single PCR product with an estimated Tm of 78 °C (Figure 2.9 B) which approximates 
the Tm of 77.88 °C calculated for the amplified neuS fragment sequence. The Ct values 
produced by amplification of standard DNA from replicate cultures were highly 
reproducible, allowed the generation of standard curves (Figure 2.9 C) and the 
determination of PCR efficiencies, which ranged from 96-102%. Thus, neuS PCR falls 
within the parameters required for accurate qPCR-based quantification and represents a 
valid method for quantification of E. coli K1.  
Sample spiking was used to determine the capacity of the qPCR assay to 
quantify E. coli K1 DNA from samples containing complex mixtures of bacterial and 
host DNA. DNA was extracted from four adult stools and neonatal tissue homogenates 
containing no E. coli K1 detected by culture and phage typing. PCRs containing these 
DNA extracts were spiked with known quantities of A192PP DNA representing a range 
of 10
1
-10
6
 CFU. E. coli K1 was quantified by neuS qPCR and the results compared to 
spiked CFU values (Figure 2.10). Within the 10
1
-10
5
 CFU spike range, no significant 
differences were observed between spike inoculum CFU values and qPCR results 
derived from analysis of DNA extracted from either stool or tissue homogenates.  
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A
B
C
Cycle threshold (Ct)
Figure 2.9: qPCR of the neuS gene using tenfold serial dilutions of A192PP gDNA. DNA was 
extracted from A192PP. Quantities of DNA corresponding to 10
1
-10
7
 CFU were amplified by 
PCR and reactions monitored in real-time. (A) PCR cycle number against fluorescence. Post-
amplification reactions were subjected to melt-curve analysis (B), comparing temperature and 
Δ(fluorescence). Standard curves (C) were constructed by plotting copy number (CFU) against 
Ct values obtained in A. The cycle threshold is indicated in A and the 95% confidence interval (--
--) in C.    
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Figure 2.10: E. coli K1 detected by qPCR of DNA extracted from adult stool and 
neonatal tissue homogenates spiked with known quantities of A192PP DNA. Error bars 
represent the SEM from four independent experiments. Differences determined by two-
tailed t-test are indicated (*** p<0.001).    
 
However, significantly less E. coli K1 was detected by qPCR in both sample 
types in assays utilizing a 10
6
 CFU spike. Melt-curve analysis of PCRs from spiked 
samples indicated a single amplification product with the same Tm observed previously 
(Figure 2.9 B). No amplification was observed in non-spiked stool and tissue samples. 
These results demonstrate the capacity of the neuS qPCR assay to quantify E. coli K1 
DNA from adult and neonatal intestinal DNA extracts and shows that the upper limit of 
detection of the assay is approximately 10
5
 CFU for each PCR.   
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2.3.3.3 Comparison of culture/phage and qPCR methods in vivo 
 The capacity of the neuS qPCR method to quantify E. coli K1 from animal 
samples was compared to „gold-standard‟ culture and phage typing. DNA was extracted 
from the intestinal tissue homogenates of 24 P2 neonatal pups and stool homogenates 
from twelve A192PP-colonized adult rats and qPCR compared to culture and phage-
typing methods (Figure 2.11). Two sub-populations were resolved. With the majority of 
samples, there was a significant correlation between culture/phage and qPCR data for 
both tissue (n=21) and stool (n=8), with Spearman R
2 
values of 0.87 and 0.95 
respectively. However, a minority of tissue (n=4) and stool (n=4) samples yielded E. 
coli K1 by qPCR but not by culture/phage typing. Melt-curve analysis of DNA 
amplified from these samples indicated a single product with the same Tm as the neuS 
amplification product. Moreover, the CFU/g values determined by qPCR were either 
near or below the LOD for culture and phage typing, as determined previously by 
normalization to mean tissue and stool mass, indicating that qPCR detected E .coli K1 
from samples that were negative by culture/phage typing. Calculation of qPCR LOD 
values for both sample types, based on the dilution steps required for DNA extraction 
and the sensitivity of the qPCR assay, showed that qPCR was 62.5-fold more sensitive 
for quantification of E. coli K1 than culture/phage typing. Taken as a whole, these 
results demonstrate that quantification of E. coli K1 by qPCR assay was more sensitive 
and more reliable than culture and phage typing.           
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Figure 2.11: Comparison of E. coli K1 CFU/g detected by qPCR and culture methods. 
E. coli K1 was quantified from 24 neonatal tissue and twelve adult stool homogenates 
from A192PP-colonized animals. The LODs of culture (solid lines) and qPCR (dotted 
lines) are indicated for stool (blue) and tissue (green) samples. R
2
 =1 (perfect 
correlation; ----). 
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2.4 Discussion 
 
 The neonatal rat model of E. coli K1 infection has been used for almost forty 
years to investigate the pathogenic mechanisms which drive the infectious process (Kim 
et al., 1992; Sukumaran et al., 2003; Zelmer et al., 2008) and to examine the efficacy of 
novel biotherapeutic measures to promote clearance of the pathogen from the neonatal 
circulation (Mushtaq et al., 2005; Zelmer et al., 2010). Here, I have further 
characterized the model in relation to the age dependency of systemic infection and 
mortality in neonatal rats colonized with a highly virulent E. coli K1 strain.  
In our version of the model, the majority of neonates become refractive to 
systemic disease at approximately P7, with no mortality observed in any P9 animals. 
The only other publication to analyse the survival of neonates dosed at different time-
points post-partum (Glode et al., 1977) examined the survival of rats inoculated at P3, 
P5, P15 and P30 and found a relatively low mortality rate (6-8%) in all age groups apart 
from P30. Although this study indicates age dependency of systemic infection and 
mortality it differs from that reported here; these differences may be method-dependent. 
The challenge inoculum of Glode et al. was substantially higher at 10
8
-10
10
 CFU 
compared to 10
7 
CFU in the present study. Furthermore, the strain utilized by Glode et 
al. (C94) did not appear to colonize the GI tract of the rat particularly well, with 
colonization reported to be as low as 19% five days after inoculation, whereas the 
A192PP strain used in this study had colonized all members of all age groups by 72 h. 
Although a relatively high proportion of P3 and P5 C94-colonized neonates developed 
bacteraemia, only a small fraction of these animals developed lethal meningitis, in 
contrast to the present study with A192PP. These differences make a comparison of the 
two studies difficult. However, the use of a fixed inoculum size and a strain with a high 
colonization rate and strong bacteraemia/mortality relationship minimized these 
potential sources of variation and clarified temporal issues relating to development of 
resistance to infection.  
The strong correlation between bacteraemia and mortality in susceptible 
neonates but not in older resistant cohorts provided further evidence that the capacity of 
the pathogen to translocate from the intestines into the bloodstream is a primary factor 
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in the determination of the host‟s susceptibility to systemic infection. Resistance to 
systemic infection began to emerge during the P4-P6 period, as evidenced by the 
intermediate susceptiblity to systemic disease of animals within this age group. 
Examination of phage-mediated clearance of E. coli K1 from the intestines of P2-
colonized neonates provided evidence that the pathogen enters the systemic circulation 
within 24-72 h of colonization and may account for the partial susceptibility to infection 
of the intermediate-susceptible group. Thus, P2 and P9 neonates represent E. coli K1-
susceptible and refractive phenotypes and pups of these age groups will be used for 
further investigations of age dependency. 
The attempt to develop an infection model of maternal-neonatal pathogen 
transmission showed that orally-induced, stable intestinal colonization of the pregnant 
adult rat was feasible but had some drawbacks. Intestinal colonization of the pregnant 
rat by E. coli K1 had a severely detrimental effect on both the gestation process of the 
foetus, as evidenced by spontaneous abortion and small litter size of colonized animals 
and the poor survival prospects of neonates. The most likely explanation for these 
effects is that the genital tract of colonized pregnant rats was contaminated with 
A192PP shed from the intestines; these bacteria may have ascended to the uterus and 
infected the developing foetus. In utero infections in the rat have been shown previously 
to result in loss of the foetus and/or poor survival rates (Payne, 1960) and could account 
for the effects observed in this study. Whilst vertical transmission of the pathogen was 
replicated in this model, the paucity in the number of offspring and the rapidity with 
which they are lost limit the use of this procedure with respect to E .coli K1 
pathogenesis. However, the model could prove useful in future investigations of E. coli 
K1 prophylaxis by clearance of the pathogen from maternal reservoirs of infection, or in 
the investigation of E. coli K1 in utero infections.     
The development of a qPCR-based assay for quantification of E. coli K1 from 
GI samples by determination of neuS gene copy number is reported here. The primers 
utilized to target the gene were specific and capable of amplifying the gene from mixed 
GI-extracted DNA samples in both DNA spike assays and samples from the colonized 
rat. The use of qPCR to quantify different bacterial groups and species, including E. 
coli, from heavily contaminated environments is not novel. E. coli has been quantified 
from GI mucosal (Huijsdens et al., 2002) and environmental samples (Khan et al., 
2007). These authors utilized a set of targets that included the 16S and 23S rRNA 
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subunit genes and the internal transcribed spacer (ITS) region which sits between these 
structural RNA genes. The conserved and variable regions of bacterial rRNA genes 
make them useful targets for these assays; however they are not suitable for 
differentiating E. coli pathovars that do not possess a useful degree of ribosomal genetic 
diversity. Thus, the targeting of pathovar-specific genes such as neuS represents a more 
viable alternative. Although the use of neuS PCR to detect K1 antigen has been 
previously investigated (Tsukamoto, 1997) it has not been used as a means of 
quantification prior to this report. A drawback to utilizing qPCR to quantify bacteria is 
that the method makes no distinction between DNA extracted from live cells and DNA 
fragments expelled during lytic cell death. However, studies indicate that the survival of 
intact naked DNA in the GI tract of both rats and humans is extremely transient, most 
likely due to the high expression of secreted DNase by intestinal tissues and hydrolysis 
by intestinal microbiota (Lacks, 1981; Maturin & Curtis, 1977; Netherwood et al., 
2004; Schubbert et al., 1994). The strong correlation between qPCR and culture/phage-
typing is supportive of this assertion and validates the qPCR method; however, it should 
be noted that extra-intestinal sites may lack this degradative capacity and may not be 
suitable for use in conjunction with this technique.  
 
 
 
 
 
 
 
 
 
 
 
105 
 
 
 
 
 
 
 
CHAPTER 3 
THE INTESTINAL MICROBIOTA 
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3.1 Introduction 
  
 The intestinal microbiota plays an essential role in both the stimulation of 
intestinal development and the provision of an enhanced metabolic capacity to the host 
(Stappenbeck et al., 2002; Cebra, 1999; Round & Mazmanian, 2009; Flint et al., 2007; 
Bäckhed et al., 2004; Resta, 2009). The protective function of the microbiota is also of 
significant importance in preventing infection by opportunistic pathogens. This 
protective function is a component of a mechanism designated colonization resistance 
(CR), defined as the growth restriction and/or clearance of exogenous or indigenous 
pathogens from the GI tract. The other component of CR is the host tissues (reviewed 
by Vollaard & Clasener, 1994; Stecher & Hardt, 2010). It is useful to separate CR into 
microbiota-mediated CR (mCR) and host-mediated CR (hCR) mechanisms. hCR is 
mediated by the physiology of the GI tract (for example, gastric acid, bile salts and 
intestinal motility) and by innate and adaptive elements of the intestinal immune system 
characterized by AMP and secretory IgA (sIgA) production respectively. mCR is based 
on at least three different mechanisms: direct inhibition, competitive inhibition and the 
stimulation of hCR mechanisms. 
 Direct inhibition of colonization is mediated by the production of molecules 
which are toxic to the incoming pathogen. These molecules include metabolites such as 
acetate and short-chain fatty acids like butyrate which have an inhibitory effect on the 
growth of some pathogenic bacteria (Hopkins & Macfarlane, 2003). Many bacteria also 
secrete a range of narrow spectrum antibiotics, the bacteriocins, which predominantly 
target closely-related bacteria (Rea et al., 2010) but can also have broader spectrum 
activities (McAuliffe et al., 1998; Rea et al., 2007). Competitive inhibition is based on 
the denial of vital nutrients and mucus receptor binding sites to the pathogen by the 
endogenous flora. The high bacterial load in the intestines (~10
12
 microbes/mL) means 
that space available for pathogen binding, preventing removal from the lumen by 
flushing mechanisms, is severely limited. Nutrients are relatively scarce in the enteric 
environment, as most are absorbed by intestinal enterocytes and the commensal 
microbiota has evolved to efficiently utilize the remainder. This leaves very little for the 
incoming pathogens to exploit as a metabolic basis for growth (reviewed by Stecher & 
Hardt, 2008).  
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 The microbiota is also vital in mediating clearance of pathogens from the 
intestinal lumen and preventing colonization. Pathogenic members of the 
Enterobacteriaceae, such as Salmonella spp, can disrupt the ecology of the microbiota 
by provoking host inflammatory responses in the intestine (Lupp et al., 2007; Stecher et 
al., 2007). Such inflammatory responses cause alterations in the composition of the 
microbiota, which reduces the efficacy of mCR mechanisms. Restoration of the 
„normal‟ microbiota induces clearance of the pathogen from the GI tract in a process 
which appears to be independent of any known hCR mechanism (Endt et al., 2010).   
The microbiota stimulates both innate and adaptive elements of hCR 
mechanisms. Many hCR mechanisms are constitutively expressed and do not require 
stimulation by the microbiota, as demonstrated by comparison of germ-free and 
conventionally reared animals (Putsep et al., 2000; Karlsson et al., 2008). However, 
elements of the microbiota are required to stimulate production and secretion of 
components of the innate intestinal defences, including REG3 C-type lectins and 
angiogenins (Hooper et al., 2003; Vaishnava et al., 2011). The microbiota is sampled by 
intestinal dendritic cells, which then induce the production of sIgA in intestinal B-cells 
(Macpherson & Uhr, 2004), an event which does not occur in germ-free animals 
(Bevenis et al., 1971). sIgA functions as both a neutralizing agent and immunological 
activator (reviewed by Corthesy, 2007) and the diversity of the sIgA repertoire of the 
intestine increases substantially with age (Lindner et al., 2012). Neonates are therefore 
deficient in this adaptive element of intestinal defences but ingestion of sIgA, acquired 
as a component of maternal breast milk (Hanson, 1999), compensates for this 
deficiency. 
 The relationship between E. coli K1 and the intestinal microbiota is not well 
characterized. However, probiotic species of Lactobacillus reduce E. coli K1 binding to, 
and translocation across, epithelial cells in vitro and they can prevent haematogenous 
dissemination of the pathogen from the rat intestine (Huang et al., 2009; Lee et al., 
2000). Lactobacilli are prevalent in the maternal vaginal microbiota and as such are one 
of the first microbes encountered by the neonate, forming a consistent component of the 
neonatal pioneer GI microbiota (Karlsson et al., 2011). The exact mechanism by which 
this Gram-positive genus provides protection against E. coli K1 remains unclear, 
although there is evidence that it induces mucin expression in colonic epithelial cells 
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(Dykstra et al., 2011) that can prevent binding of EPEC and EHEC strains to the 
epithelial cell surface (Mack et al., 1998).  
 mCR is important for the maintainance of host intestinal tissue defences. It can 
be hypothesised that the dynamic state of the neonatal intestinal microbiota immediately 
post-partum (Palmer et al., 2007) influences the capacity of E. coli K1 to translocate 
from the intestinal tract. The landmark study by Palmer et al. established that the 
neonatal microbiota is dominated by Gammaproteobacteria and certain classes of the 
phylum Firmicutes. The phylum Bacteroidetes is initially absent or transiently present 
but their number increases over the first year of life as the microbiota matures towards 
the adult phenotype. This study also demonstrated that the bacterial load in the human 
intestines varies substantially in the first week post-partum, starting from a relatively 
low point and increasing and stabilizing between P5-P10. If the microbiota is a key 
factor in determining susceptibility to E. coli K1, then the quantitative and qualitative 
dynamism of the neonatal microbiota could play a role in the determination of systemic 
infection (Figure 3.1).  
Analysis of complex microbial communities has benefitted from the advent of 
modern molecular methods. A common basis of such analyses is the gene coding for the 
16S rRNA, which forms the structural scaffold of the 30S (small) subunit of the 
prokaryotic ribosome. This gene is designated as small-subunit ribosomal DNA (SSU 
rDNA) and is a component of the multi-copy rrn operon. The SSU rDNA sequence is a 
mosaic of highly conserved and hypervariable regions (Figure 3.2). These features have 
made SSU rDNA the target of choice for examination of the phylogenetic relationships 
between prokaryotic lineages (O‟Neill et al., 1992). Multiple metagenomic techniques 
have evolved to enable the characterization of complex microbial communities based on 
the quantification of specific SSU rDNA sequences. These include quantitative 
microarray-based analysis and direct sequencing methods. The advent of high-
throughput DNA sequencing technologies means that sequencing is now considered the 
method of choice for microbial community analysis (Gill et al., 2006), but the use of 
this technology is still restricted by the high cost of the sequencing platforms. DNA 
microarrays consisting of probes which target the hypervariable regions of the SSU 
rDNA sequence present a viable alternative to direct sequencing and use pre- 
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Figure 3.1: The potential role of the quantitative (A) or qualitative (B) dynamism of the 
neonatal microbiota in determining susceptibility to E. coli K1 infection.  
 
    
Figure 3.2: The 1.5 kb SSU rDNA sequence. Highly conserved (C; blue) and 
hypervariable (V; green) regions are highlighted.                    
110 
 
existing microarray processing infrastructure. One such array was designed by Palmer et 
al. (2008) and employs probes corresponding to SSU rDNA sequences of 649 of the 
950 taxonomic groups in the prokaryotic multiple sequence alignment (prokMSA) 
database (http://greengenes.lbl.gov/cgi-bin/nph-index.cgi). The microarray incorporates 
species-specific probes for 1,590 bacterial and 39 archeal species, ensuring that 94% of 
the ~16,000 operational taxonomic units (OTUs) in prokMSA are represented at least 
once at some taxonomic level. 
 Another useful tool to study the impact of the microbiota is the axenic or „germ-
free‟ (GF) animal model. GF animals are born and raised in sterile conditions, do not 
possess any element of the normal microbiota and thus function as microbiota knockout 
models. GF animals consistently exhibit increased susceptibility to infection mediated 
by a variety of pathogens in enteric infection models (Inagaki et al., 1996; Nardi et al., 
1989; Tazume et al., 1990). However, data from GF infection models must be 
interpreted with caution, for two reasons. Firstly, they do not allow differentiation 
between different mCR mechanisms. Secondly, colonization by the microbiota triggers 
host developmental pathways beyond the stimulation of hCR mechanisms and as a 
consequence, the environment encountered by the pathogen in GF infection models may 
not be representative of the natural setting of disease (reviewed by Sekirov et al., 2010). 
A means of circumventing these disadvantages is by suppression of the microbiota in 
conventionally reared animals. This provides an experimental host which has received 
the normal developmental stimuli provided by enteric colonization, but which has a 
reduced intestinal microbiota. Such suppression can be achieved experimentally by the 
use of combined antibiotic treatment (Membrez et al., 2008; Croswell et al., 2009). 
 This chapter describes experiments designed to clarify the role of the intestinal 
microbiota in the determination of susceptibility to E. coli K1 infection in the neonatal 
rat. I have therefore undertaken analysis of the colonization kinetics of E. coli K1 in 
susceptible and refractive neonates, quantitative and qualitative profiling of the neonatal 
microbiota of neonates of the different susceptibility groups and an assessment of the 
impact of antibiotic-mediated suppression of the microbiota on susceptibility to E. coli 
K1. 
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3.2 Methods & Materials 
 
Unless otherwise indicated, growth media were purchased from Oxoid Ltd and 
chemicals, reagents and enzymes from Sigma-Aldrich. Oligonucleotides were 
synthesised by, and purchased from, Eurofins MWG Operon. All reagents used in 
microarray sample preparation and hybridizations described in sections 3.2.5 and 3.2.6 
were purchased from Agilent Technologies. SSU rDNA analytical methods are broadly 
based on methods described by Palmer et al. (2008). This section describes methods 
which are specific to the results described in this chapter; however, some methods used 
in Chapter 2 were also employed. 
 
3.2.1 SSU rDNA PCR primers 
 A number of primers were used; primer sequences, target regions on the SSU 
rDNA sequence and original source references are shown in Table 3.1. 
 
Primer Sequence (5'-3') Target Reference 
 
8FB AGGGTTCGATTCTGGCTCAG C1 Palmer et al., 2008 
 
Bact515R TTACCGCGGCKGCTGGCAC C3 Lane et al., 1985 
 
8FM AGAGTTTGATCCTGGCTCAG C1 Lane et al., 1985 
 
1391R GACGGGCGGTGTGTRCA C8 Lane et al., 1985 
  
Table 3.1: Sequences, conserved SSU rDNA target regions and source references of 
primers used in SSU rDNA PCR experiments. 
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3.2.2 SSU rDNA qPCR 
 SSU rDNA copy numbers in tissue and stool samples were quantified by qPCR.. 
DNA was extracted from E. coli K-12 strain CGSC 5073 (see section 2.2.8). Genomic 
standards with known SSU rDNA copies/µL values were prepared by tenfold serial 
dilution. Standards used in qPCR typically ranged from 2-2000 SSU rDNA copies/µL. 
qPCR reactions were performed using Brilliant III Ultra-Fast SYBR Green QPCR 
Master Mix kits (Agilent Technologies) according to manufacturer‟s instructions. 
Universal forward primer 8FM (900 nM), Bifidobacterium longum forward primer 8FB 
(90 nM), universal reverse primer Bact515R (900 nM) and ROX reference dye (30 nM) 
were added to each qPCR. Reactions were prepared in light-protected tubes and in a 
C2BSC to reduce the risk of DNA contamination. qPCR mixes (15 µL/reaction) were 
dispensed into 96-well PCR plates. Genomic standard DNA, experimental sample 
DNA, or nuclease-free ddH2O (acting as a no-template control) were added to each 
qPCR mix to give a final volume of 20 µL per reaction. Wells were sealed using 
optically clear strip caps. qPCRs were run on an Mx3000P system (v.2 software; 
Stratagene) set to detect SYBR1 and ROX fluorescence, utilizing a thermal cycling 
program comprising 95 °C for 3 min, 40 cycles of 95 °C for 20 s, 55 °C for 20 s, 60 °C 
for 35 s, 65 °C for 15 s and 72 °C for 15 s. Fluorescence was measured at the 72 °C step 
of each amplification cycle and amplification curves recorded. DNA melt curves were 
generated by cooling reactions to 55 °C and increasing the temperature to 95 °C over 30 
min with fluorescence measured every 20 s. SYBR1 fluorescence was normalized to 
ROX fluorescence and the SYBR1 amplification curves were used by the software to 
generate Ct values utilizing adaptive baseline and amplification-based threshold 
algorithm enhancements. Genomic standard Ct values were used to generate standard 
curves for the calculation of sample SSU rDNA copies/µL and these values were 
normalised to original sample (tissue/stool) mass. Each qPCR reaction plate utilized 
standard DNA extracted from three separate CGSC 5073 cultures and each standard, 
sample and control reaction was duplicated on each plate. Each plate was replicated and 
data for each sample averaged across the four replicate values.  
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3.2.3 Whole SSU rDNA amplification and cleanup 
 Purified whole SSU rDNA was prepared by PCR amplification and cleanup 
prior to microarray analysis. DNA was extracted and quantified from tissue and stool 
samples as previously described (section 2.2.9). PCR reactions were performed using 
GoTaq Green Master Mix (Promega) according to manufacturer‟s instructions. 
Universal forward primer 8FM (0.4 µM), universal reverse primer 1391R (0.4 µM) and 
sample DNA (1 µg) were added to each PCR. PCRs were performed in a Techne 
Thermocycler (Bibby Scientific). The thermocycling programme comprised 95 °C for 5 
min and 40 cycles of 95 °C for 30 s, 55 °C for 30 s and 72 °C for 30 s, with a final 
extension at 72 °C for 8 min. Reactions were cleaned using a Wizard SV Gel and PCR 
Clean-up kit (Promega) according to manufacturer‟s instructions (section 2.2.11). DNA 
concentration and purity was assessed using a NanoDrop spectrophotometer (Thermo 
Scientific). Samples were stored at -20 °C. The presence of a single 1400 bp DNA 
product was checked by agarose electrophoretic resolution by mixing 10 µL of DNA 
with 2 µL of 6 x Gel Loading Buffer, loading the mixture onto a 1% (w/v) agarose gel 
containing 0.5 µg/mL ethidium bromide and performing electrophoresis at 80 V in Tris-
acetate-EDTA buffer (TAE; 40 mM Tris-acetate, 1mM EDTA, pH8) for 30 min or until 
the dye front reached the end of the gel. DNA was visualized by scanning the gel with a 
Molecular Imager FX system (Bio-Rad) set to detect UV fluorescence.   
  
3.2.4 Microarray reference pool 
 A reference pool of SSU rDNA amplicons was constructed for use in subsequent 
microarray co-hybridizations with experimental sample amplicons according to the 
Palmer et al. (2008). This served as a common reference to allow data normalization 
between microarrays and served to increase the stringency of the microarray 
hybridizations by competing with experimental sample amplicons for binding to 
microarray probes. The reference pool comprised an equimolar mixture of cleaned SSU 
rDNA amplicons from all experimental (108 tissue and 80 stool sample) DNA 
extractions.      
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3.2.5 SSU rDNA amplicon labelling and purification  
 Reference pool and experimental SSU rDNA amplicons were fluorescently 
labelled with, respectively, Cy3 or Cy5 dye-conjugated nucleotides using Genomic 
DNA Labelling Kit Plus reagents according to manufacturer‟s instructions. The 
compositions of buffers utilized in the labelling process were proprietary information 
unless otherwise indicated. All labelling steps employed light-protected tubes to prevent 
Cy3 and Cy5 photobleaching. SSU rDNA amplicons were diluted to 19.23 ng/µL in 
nuclease-free ddH2O, mixed with 5 µL of random primers, heated to 95 °C for 3 min 
and incubated on ice for 5 min. Batches of Cy3 and Cy5 labelling master mix were 
prepared (containing Cy3/Cy5-dUTP; 60µM) and mixed with amplicons to a final 
volume of 50 µL for each labelling reaction. Mixtures were incubated at 37 °C for 2 h 
and 65 °C for 10 min. Individual Cy5-labelled experimental SSU rDNA amplicons were 
mixed with an equal volume (50 µL) of Cy3-labelled reference pool SSU rDNA 
amplicons. Labelled amplicon mixtures were purified using MinElute DNA Cleanup 
Kits (Qiagen) according to manufacturer‟s instructions. Reactions were mixed with 500 
µL of Buffer PB and applied to spin-column membranes. Columns were centrifuged at 
13000 x g for 1 min and the filtrate discarded. Columns were washed twice with Buffer 
PE (500/250 µL) and centrifuged at 13000 x g for 1 min after each wash. Amplicons 
were eluted in 20 µL of nuclease-free water and 2 µL used to confirm dye-incorporation 
with a NanoDrop spectrophotometer (Thermo Scientific). The remaining 18 µL were 
used for hybridization to microarray slides.      
 
3.2.6 Microarray hybridization and washing  
 Labelled SSU rDNA amplicons were hybridised to SSU rDNA Custom cGH 
microarray slides, using the basic format of Palmer et al. (2008), in 4 x 2 array per slide 
format and were washed prior to scanning. Array hybridizations utilized Oligo 
aCGH/ChIP-Chip Hybridization Kit reagents. The composition of buffers for 
hybridization and washing were proprietary information unless otherwise indicated. 
Blocking Agent and Hybridization Buffer were mixed with labelled SSU rDNA 
amplicons to a final volume of 45 µL; hybridization mixtures were heated to 95 °C for 3 
min and incubated at 37 °C for 30 min. Hybridization chambers were assembled by 
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dispensing mixtures into 8 x 2 slide gaskets, aligning array slides on top of each gasket 
slide and clamping the two slides tightly together. Chambers were placed in a rotating 
hybridization oven (20 rpm) and incubated at 65 °C for 24 h. Hybridization chambers 
were disassembled in troughs containing Oligo aCGH Wash Buffer 1. Microarray slides 
were transferred to fresh Oligo aCGH Wash Buffer 1 and incubated at room 
temperature for 5 min with stirring. Slides were washed in Oligo aCGH Wash Buffer 2 
for 1 min at 37 °C with stirring and transferred to acetonitrile for 10 s. Slides were 
submerged in Stabilization & Drying Solution for 30 s and briefly air dried. Washed 
array slides were stored in light-protected containers prior to scanning.  
 
3.2.7 Microarray scanning and data normalization 
Microarrays were scanned in an Agilent High Resolution C Scanner at a 5 µm 
resolution with the extended dynamic range setting at 100 & 10. Cy3 and Cy5 dyes 
were detected using, respectively, 532 nm and 640 nm lasers. Microarray images were 
processed using Feature Extraction software v. 9.5.1.1 with linear normalization, rank 
consistent probe dye normalization methods and background signal was corrected by 
averaging across all negative control array features. Data was processed using 
GeneSpring GX (v. 7.3.1) to combine data from replicate spots on each array and merge 
data from replicate arrays by normalization to standard Agilent array control probes and 
SSU rDNA array-specific positive and negative control probes. Probes were filtered to 
remove any reporters with normalized Cy5 + Cy3 fluorescence values of <1000. 
Combined and normalized Cy5:Cy3 ratios were computed for individual filtered 
reporters, allowing relative quantification of SSU rDNA sequences between different 
experimental samples. 
 
3.2.8 Preparation of competent A192PP cells 
 Competent cells of E. coli K1 strain A192PP were prepared prior to 
transformation with pUC19 plasmid. Single MH agar cultured colonies were used to 
inoculate 10 mL of LB broth and the tubes incubated overnight at 37°C in an orbital 
incubator. The overnight culture was used to inoculate 50 mL of sterile LB broth at a 
116 
 
dilution of 1:100 and incubated at 37°C in an orbital incubator until an OD600 0.5 was 
reached. Bacterial cells were sedimented by centrifugation at 5000 x g for 10 min at 4 
°C and the supernatant discarded. Cell pellets were suspended in 25 mL of 0.1 M MgCl2 
chilled to 4 °C and cell suspensions incubated on ice for 1 h. Bacterial cells were 
sedimented by centrifugation at 5000 x g for 10 min at 4 °C and the supernatant 
discarded. The cell pellet was suspended in 5 mL of 0.1 M CaCl2 chilled to 4°C and the 
cell suspension incubated on ice for 30 min. Competent cells were assayed for viability 
by plating onto MH agar and incubated at 37 °C to check for growth. Cells were mixed 
with an equal volume of sterile 20% (v/v) glycerol and stored at -80 °C prior to 
transformation. 
 
3.2.9 Transformation of competent A192PP with pUC19 
 Competent A192PP cells were transformed with plasmid pUC19. Competent 
A192PP cells were mixed with 100 ng of pUC19 (New England Bioscience) and 
incubated on ice for 15 min. Cells were subjected to heat shock at 42 °C for 40 s and 
returned to ice for 1 min. Cell were mixed with 500 µL of sterile LB broth and 
incubated at 37 °C for 45 min. Cell suspensions were concentrated by centrifugation at 
5000 x g for 10 min and suspended in 100 µL of PBS. The suspension was serially 
diluted tenfold to a factor of 10
-3
, each dilution plated onto selective agar (ampicillin 
[100 µg/mL] in MH agar) and incubated overnight at 37 °C. Single transformed 
colonies were inoculated into 10 mL of sterile MH broth containing ampicillin (100 
µg/mL) and grown to OD600 0.5. Transformants were checked for K1 capsule 
expression by sensitivity to the K1E bacteriophage (section 2.2.7). Transformant 
cultures were mixed with an equal volume of sterile 20% (v/v) glycerol and stored at -
80 °C. A single K1E-sensitive transformant colony was isolated and designated 
A192PPR.  
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3.2.10 Minimum inhibitory concentration 
 The minimum inhibitory concentration (MIC) at which antibiotics prevented 
growth of E. coli K1 strains A192PP and A192PPR was determined in order to assess 
their sensitivity to ampicillin, streptomycin, metronidazole and vancomycin. MIC 
assays were performed in 96-well format according to the standard microdilution 
method of the Clinical and Laboratory Standards Institute (CLSI; http://www.clsi.org). 
Stock solutions of each antibiotic were prepared by dissolving ampicillin sodium salt, 
streptomycin sulphate, vancomycin HCl hydrate or metronidazole in sterile MH broth to 
a concentration of 2.56 mg/mL. Antibiotic solutions were sterilized by filtration with 
0.22 µm MILLEX GP filters (Millipore) and the filtrate stored at 4 °C. Single MH agar 
colonies were used to inoculate 10 mL of MH broth and the tubes incubated overnight 
at 37 °C in an orbital incubator. The overnight culture was used to inoculate 10 mL of 
MH broth at a dilution of 1:100 and incubated at 37°C until OD600 0.13 (McFarland 
Standard 0.5) was reached. MIC plates were prepared by twofold serial dilution of 
antibiotic stock solutions in MH broth in U-shaped 96-well plates (Corning) with 100 
µL antibiotic solution per well. Bacterial cultures were diluted to 10
6
 CFU/mL in MH 
broth and 100 µL of bacteria were dispensed to each well containing antibiotic to 
produce final antibiotic concentrations over the range 1.25-1280 µg/mL. Control wells 
containing bacteria or antibiotic alone were prepared for each plate; each test or control 
was prepared in triplicate on each plate. Plates were sealed, incubated at 37 °C for 24 h 
and assessed visually for bacterial growth. The lowest antibiotic concentration at which 
no bacterial growth was observed was recorded as the MIC.   
 
3.2.11 Antibiotic treatment of neonatal rats 
 Combinations of ampicillin, streptomycin, vancomycin and metronidazole were 
administered orally to neonatal rats. These antibiotics have been used by previous 
investigators, either individually or in combination, to suppress the intestinal microbiota 
(Croswell et al., 2009; Barthel et al., 2003; Rakoff-Nahoum et al., 2004); they represent 
a broad range of antibiotic classes and antibacterial activity spectra (Table 3.2). 
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Antibiotic Class Mechanism of action Activity-Spectrum 
        
ampicillin β-lactam Cell wall synthesis inhibitor Broad-spectrum 
streptomycin Aminoglycoside Protein synthesis inhibitor Broad-spectrum 
vancomycin Glycopeptide Cell wall synthesis inhibitor Gram-positive 
bacteria 
metronidazole Nitroimidazole Reduced to genotoxic 
intermediary* 
Anaerobic bacteria 
 
Table 3.2: Antibiotics used for suppression of the intestinal microbiota. * The 
mechanism of metronidazole activity is poorly characterized. 
 
Antibiotic solutions were prepared by dissolving each antibiotic in water; 
ampicillin and vancomycin were prepared at 400 mg/mL, streptomycin at 120 mg/mL 
and metronidazole at 10 mg/mL. The solutions were sterilized using 0.22 µm MILLEX 
GP filters (Millipore) and filtrates stored at 4 °C. Antibiotics were administered to 
neonatal rats by the oral route using a micropipette. Antibiotics were administered in the 
same order (ampicillin, streptomycin, vancomycin, metronidazole) on each day of 
treatment. Dosing volumes were 25 µL for ampicillin, streptomycin and vancomycin 
and 30 µL for metronidazole, representing a total dose of 10 mg for ampicillin and 
vancomycin, 3 mg for streptomycin and 0.3 mg for metronidazole. Although there are 
no known antagonistic interactions between these antibiotics, they were administered 
individually to neonates, with 1 h between each individual dose. Neonates undergoing 
antibiotic treatment and concurrent inoculation with E. coli K1 strains were inoculated 
with bacteria 4 h after the last antibiotic dose. Oral inoculation with E. coli K1 was 
performed as described in section 2.2.4.  
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3.3 Results 
 
3.3.1 E. coli K1 intestinal colonization 
 Temporal aspects of E. coli K1 colonization of the neonatal intestine were 
investigated to shed light on the role of CR and pathogen clearance in the modulation of 
susceptibility to systemic E. coli K1 infection. P2, P5 and P9 neonates were selected as 
representatives of the three different susceptibility phenotypes (susceptible, intermediate 
susceptible and refractive) identified in Chapter 2. Three litters of fourteen neonates 
from each age group were inoculated with mid-exponential phase A192PP and one litter 
of fourteen neonates from each age-group inoculated with sterile MH broth as negative 
control. At time-points ranging from 0 h (pre-dose controls) to 120 h after inoculation, 
two neonates were culled from each litter (six E. coli K1-colonized and two controls for 
each age group and time point. A large proportion of pups in two litters colonized at P2 
died and further litters were employed to ensure  sufficient live neonates at 96 and 120 h 
were available.  
Intestinal tissues (duodenum to rectum) were removed from culled neonates and 
the E. coli K1 burden determined over a 120 h period by neuS qPCR (Figure 3.2). There 
were no significant differences, at any time point, in the number of E. coli K1 between 
the groups of P2, P5 and P9 neonates (p >0.32; Kruskal-Wallis). The E. coli K1 burden 
was lower (p <0.05; two-tailed Mann-Whitney) at 6 h after colonization than at 24 h. No 
differences were found between groups at 24 h; the number of E. coli K1 reached a 
maximum (mean 8.75 x 10
7 
CFU/g tissue) at this time point and this level of 
colonization persisted over the remaining period of study. No E. coli K1 was detected in 
animals before colonization or in those receiving broth. In summary, E. coli K1 reached 
climax population 24 h after administration of the bacteria in all neonates; these levels 
persisted in P2, P5 and P9 animals over the duration of the study (120 h) and do not 
lend support to a role for CR and pathogen clearance in the modulation of susceptibility 
to E. coli K1.      
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Figure 3.3: E. coli K1 intestinal colonization. P2, P5 and P9 neonatal rats were 
inoculated with strain A192PP and culled at various time points after colonization. 
DNA was extracted from the whole intestine and E. coli K1 CFU/g tissue determined by 
neuS-qPCR. LOD; limit of detection.   
 
3.3.2 P2-P9 neonatal intestinal microbiota 
 The following sections describe the analysis of the neonatal intestinal microbiota 
at P2, P5 and P9 in order to determine if  quantitative and/or qualitative differences in 
the composition of the microbiota influence neonatal susceptibility to E. coli K1 
infection.  
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3.3.2.1 Quantitative analysis of the microbiota 
 The total bacterial load in the intestines of P2, P5 and P9 neonatal rats and adult 
rats was determined by qPCR of SSU rDNA. Four pregnant and four non-pregnant adult 
rats were individually caged and DNA extracted from two stool samples from each 
animal. Three neonates were culled post-partum from each litter at P2, P5 and P9 (n=12 
per age-group), whole intestines (duodenum to rectum) excised and DNA extracted. 
qPCR was used to determine SSU rDNA copy number and results normalized to tissue 
or stool mass (Figure 3.4). 
 There were no significant differences in bacterial load between the age groups 
examined (p >0.52; Kruskal-Wallis). Similarly, no significant differences were found 
between the bacterial load of stools collected from pregnant and non-pregnant adults (p 
>0.38; two-tailed Mann Whitney). Comparison of the overall bacterial load of combined 
neonatal samples and combined adult samples indicated that there was a significant 
difference between these groups (p <0.01; two-tailed Kruskal-Wallis) with an average 
of 8.8-fold more SSU rDNA copies detected per gram of adult stool than per gram of 
neonatal intestinal tissue. Although this indicated that the bacterial load was higher in 
the adult compared to the neonatal intestine, the nature of the samples was different and 
this makes such comparisons difficult. Most importantly, no significant quantitative 
differences in the microbiota were detected over the P2-P9 period.  
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Figure 3.4: Bacterial load in neonatal P2, P5 and P9 intestinal tissues and pregnant 
(Pr) and non-pregnant (N-Pr) adult stool samples. DNA was extracted from neonatal 
tissues, adult stool and SSU rDNA quantified by qPCR and copy number normalized to 
tissue/stool mass. Horizontal bars represent the mean of each group. Kruskal-Wallis 
test * p<0.05, ** p<0.01, *** p<0.001. 
 
 
 
 
**
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3.3.2.2 Qualitative analysis of the microbiota 
 The composition of the intestinal microbiota was determined in P2, P5 and P9 
neonates using the SSU rDNA microarray of Palmer et al. (2008). The array 
incorporated probes with homologies to over 16000 OTU sequences in the prokMSA 
(http://greengenes.lbl.gov) SSU rDNA database. An OTU is defined as a group of 
sequences with >95% homology (DeSantis et al., 2003). The array also incorporates 
probes for the detection of sequences conserved by related OTUs at different taxonomic 
levels between phylum and genus, based on the SSU rDNA region amplified by the 
8FM and 1391R universal primers. Probes were labelled numerically according to their 
prokMSA taxonomy in phylum-species order in 1.2.3.4.5.6.7 format (Table 3.2).   
 
prokMSA Taxonomic Level Taxonomic Designation 
  
1 Superkingdom 
2 Phylum 
3 Class 
4 Order 
5 Family 
6 Genus 
7 Species 
 
Table 3.3: prokMSA database taxonomic levels and equivalent traditional taxonomic 
designations.  
 
For example, E. coli is designated 2.28.3.27.2.007 by virtue of its species-
specific probe, that is, it belongs to the Bacterial superkingdom (2), Proteobacteria 
phylum (2.28), Gammaproteobacteria class (2.28.3), Enterobacteriales order (2.28.3.27) 
and the Escherichia genus (2.28.3.27.2). Thus, any E. coli SSU rDNA will have 
sequence homology to not only its cognate level 7 (species) probe but also to the higher 
level taxonomic probes designed to detect broader groups of OTUs.   
The DNA extracts used for these experiments were those that were employed for 
quantitative analysis of the neonatal and adult intestinal microbiota. Labelled SSU 
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rDNA amplicons from stools of individual pregnant adult rats were pooled and each 
pool used to hybridise a single array. In similar fashion, labelled SSU rDNA amplicons 
from intestinal tissues of three neonates of the same age and litter were pooled and used 
for hybridisation to single arrays (four single arrays for adult, P2, P5 and P9 groups). 
Data from neonatal array probes was filtered to remove low signals and normalized to 
adult array probe data to produce relative (to adult) abundance estimates for individual 
SSU rDNA probes.        
 
3.3.2.2.1 Relative intestinal population overview 
 Processing of the neonatal array data by removal of low probe signals 
identified signals against 137 species level and 122 levels 2-6 taxonomic level probes 
and these were analysed further. The mean relative abundance of different bacterial 
species defined by SSU rDNA sequences from the P2, P5 and P9 neonatal microbiota 
and a comparison of this data with adult samples for taxonomic level 2-6  are shown in 
Figure 3.5. The filtered probe-set was dominated by reporters with specificity to three 
primary bacterial lineages, namely the Bacteriodetes, Proteobacteria and Gram-positive 
bacteria. In addition, the neonatal and adult microbiotas were significantly different.  
The relative abundance of SSU rDNA amplicons belonging to these three phyla 
followed a consistent pattern in all neonatal groups. The Bacteriodetes, represented for 
the most part by the Bacteroides & Cytophaga level 3 taxonomic probes, were much 
less prevalent in neonates compared to adults. Analysis at the species level showed that 
several Bacteroides spp. that were prevalent in the adult stool microbiota were present 
in substantially reduced numbers in P2, P5 and P9 neonates. These species included 
Bacteroides merdae, Bacteroides acidofaciens, Bacteroides fragilis, Bacteroides 
caccae, Bacteroides vulgatus and Bacteroides thetaiotaomicron. At the phylum level, 
the Proteobacteria were significantly enriched in neonatal compared to adult samples. 
Some differences in the sub-phylum composition of Proteobacteria were evident; 
neonatal samples were comparatively enriched for Alpha-, Beta- and 
Gammaproteobacteria and Delta- and Epsilonproteobacteria were present in reduced 
numbers in neonatal compared to adult samples. Analysis at the species level indicated
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Figure 3.5: Mean relative abundance of bacterial taxa detected in P2, P5 and P9 
neonatal intestines. Cy5/Cy3-labelled SSU rDNA amplicons were analysed by SSU 
rDNA-microarrays. Filtered and normalized pooled neonatal array data was 
normalized to pooled adult array data to give relative (to adult) abundance of SSU 
rDNA species in neonatal samples (right panel). Differences between neonatal and 
adult probe data were determined by two-tailed Student’s t-test (left panel). Columns 
represent data from P2, P5 and P9 neonates and rows (n=122) represent individual 
taxonomic probes, ranging from level 2 (phylum) to level 6 (genus) taxa. Taxonomic 
probes belonging to the Bacteroidetes, Proteobacteria and Gram-positive bacteria 
phyla (----) and the location of the level 2 probe (◄) for each of these groups are 
indicated. Taxonomic probes belonging to the level 3 (class) taxonomic groups 
Bacteroides & Cytophaga (B/C), Alpha-Epsilon (α-ε) Proteobacteria, High G/C 
bacteria (H-G/C), Eubacteria (Eub.), Bacillus/Lactobacillus/Streptococcus (B/L/S) and 
Clostridia (Clos.) are also shown (brackets).    
 
that the relative enrichment of the Proteobacteria was due in the main to the 
Gammaproteobacteria Pasteurella and Pseudomonas spp. and E. coli, with lower 
numbers of the Delta- and Epsilonproteobacteria Desulfovibrio and Helicobacter spp. 
Similarly, although the overall presence of Gram-positive bacteria was enriched 
inneonatal samples, there was substantial variation in the relative presence of different 
sub-phylum taxonomic groups. High G/C Gram-positive bacteria were generally 
enriched in the neonatal samples, with Corynebacterium, Rhodococcus, Arthrobacter 
and Bifidobacterium spp. Prominent. Bacteria of the Bacillus/Lactobacillus/ 
Streptococcus level 3 taxonomic group were also present in increased numbers in the 
neonate compared to the adult, with Leuconostoc fallax, Lactobacillus spp. and 
Streptococcus gallolyticus contributing to the substantial presence of this group. 
Conversely, the Eubacteria and Clostridial taxa, represented by species such as 
Butyrivibrio fibrisolvens and Clostridium bifermentans, were present in only low 
numbers in the neonatal microbiota . Although over 92% of the 259 reporters analysed 
were probes belonging to these three primary lineages these were not the only phylum 
level probes which produced signals above the filter cut-off value. Probes for 
Fusobacteria, Nitrospina and Acidobacteria phyla accounted for the remainder of these 
reporters, with Fusobacteria and Nitrospina present in relatively large numbers in 
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neonatal samples. The relative abundance of all bacteria detected by phylum level 
probes is shown in Figure 3.6. No significant differences were detected between these 
phyla, with respect to relative abundance, in the P2, P5 and P9 datasets. 
 
Figure 3.6: Relative abundance of bacterial phyla detected in the P2, P5 and P9 
neonatal intestinal microbiota. Data from analysis of neonatal SSU rDNA amplicons by 
microarray was normalized to data from adult stool samples (represented by the dashed 
line at x=1). Phyla are ranked according to mean Cy3/Cy5 fluorescence with the 
highest at the top of the figure. Error bars represent the SEM from four arrays. Numeric 
codes represent the prokMSA database designation for each phylum.   
  
Comparison of data from the three neonatal groups with adult data indicated that 
the neonatal intestinal microbiota was significantly different from the adult stool 
microbiota. Analysis of all species and higher taxonomic level probe data from P2, P5 
and P9 neonatal arrays with matched probe data from adult arrays by two-tailed 
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Student‟s t-test showed that, of 777 comparisons, only 247 (31.79%) generated p-values 
>0.05, a  clear indication that the neonatal microbiota at P2, P5 and P9 was distinct from 
the adult microbiota.   
 
3.3.2.2.2 Comparison of P2, P5 and P9 intestinal microbiota 
 The microarray data was probed further to determine differences and similarities 
between the neonatal groups at sub-phylum taxonomic levels. The relationship between 
the neonatal datasets was assessed by Pearson correlation of mean relative SSU rDNA 
abundances (Figure 3.7A, B and C). The correlation between all three groups was 
highly significant (p <0.0001), although the strength of the correlation was variable, 
with the strongest between the P2 and P5 and weakest between the P2 and P9 
microbiota. Analysis of individual probes by two-way ANOVA showed that two level 5 
and five level 6 probes revealed significant differences in relative SSU rDNA 
abundance between the groups (Figure 3.7D). Over the P2-P9 period, the abundance of 
the Clostridium polysaccharolyticum and Clostridium subterminale subgroups increased 
four- and two-fold respectively. At the species level, an unclassified Desulfovibrio spp. 
increased tenfold and Clostridium aminovalericum and Mycobacterium tuberculosis 
increased twofold. Significant decreases of 2.5-fold were observed for Helicobacter 
pylori and Blastochloris viridis over the same period. A fourfold increase in 
Lactobacillus casei SSU rDNA abundance was also observed; however, this 
observation was not significant due to the high standard deviation at P9 (4.4-fold) for 
species-specific reporter probes. Overall, these results show that the P2, P5 and P9 
microbiota were highly comparable, with the exception of a restricted number of species 
and genera which varied significantly over this period. Data generated from all probes 
are presented in Appendix A. 
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Figure 3.7: Comparison of the P2, P5 and P9 intestinal microbiota. Mean SSU rDNA 
abundance detected by all probes compared between P2/P5 (A), P5/P9 (B) and P2/P9 
(C) data with Pearson correlation coefficients (R
2
) indicated. (D) Significant differences 
between P2, P5 and P9 data (two-way ANOVA). Probes ranked according to mean 
Cy3/Cy5 fluorescence (highest at the top of the figure). The line at x=1 represents 
normalized adult data. Error bars represent the SEM from four arrays. Numeric codes 
represent the prokMSA database designation for each taxonomic group.  
A B C
D
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3.3.3 Antibiotic-mediated suppression of the microbiota and 
susceptibility to E. coli K1 infection 
 The following work assesses the impact of the microbiota on susceptibility to 
systemic E. coli K1 infection by use of antibiotic-mediated suppression of endogenous 
neonatal intestinal bacteria.  
 
3.3.3.1 Antibiotic-mediated suppression of the neonatal microbiota 
 To optimise suppression of the intestinal microbiota, combinations of ampicillin, 
streptomycin, vancomycin and metronidazole were administered to groups of P7 
neonatal rats. Five litters of twelve neonates each were used, with one control litter 
receiving water; three neonates from each of the remaining litters received either 
ampicillin/streptomycin (AS), ampicillin/streptomycin/vancomycin (ASV), ampicillin/ 
streptomycin/vancomycin/metronidazole (ASVM) or streptomycin/vancomycin/ 
metronidazole (SVM). All neonates were culled 24 h after antibiotic administration and 
DNA extracted from intestinal tissues. SSU rDNA was quantified from DNA extracts 
and normalized to tissue mass. The impacts of these procedures on SSU rDNA/g levels 
are shown in Figure 3.8; all produced a significant reduction in SSU rDNA compared to 
controls. However, the degree of reduction in bacterial numbers produced by each 
treatment was variable. Mean reductions after administration of AS, ASV, ASMV and 
SVM combinations were ~78%, ~86%, ~95% and ~57% respectively. Metronidazole 
and ampicillin contributed significantly to reductions in the bacterial population 
whereas vancomycin contributed little to the overall effect. The largest reduction in the 
size of the bacterial population was induced by ASVM treatment and this antibiotic 
combination was used for further study.  
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Figure 3.8: Suppression of the microbiota by orally administered antibiotic 
combinations. Ampicillin (A; 10 mg), streptomycin (S; 3 mg), vancomycin (V; 10 mg) 
and metronidazole (M; 0.3 mg) were dissolved in water and administered to neonatal 
rats. Intestines were removed 24 h later and the microbiota quantified by SSU rDNA 
qPCR of DNA extracted from tissues. Error bars represent the SEM of twelve animals. 
Significant differences were determined by two-tailed Mann Whitney (* p<0.05, ** 
p<0.01, *** p<0.001).  
   
3.3.3.2 Colonization of microbiota-suppressed neonates with E. coli K1 
 The MIC of A192PP was determined against ampicillin (highly susceptible), 
streptomycin (320 µg/mL MIC), vancomycin (1280 µg/mL) and metronidazole (1280 
µg/mL). An ampicillin-resistant derivative of A192PP was constructed to enable in vivo 
use of the ASVM combination by transformation of competent A192PP with an 
unmodified pUC19 cloning vector encoding TEM1 β-lactamase. The transformant was 
***
*
***
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designated A192PPR and resistance to ampicillin confirmed by MIC determination 
(Figure 3.9). Aquisition of pUC19 increased the MIC of A192PP to ampicillin from 2.5 
µg/mL to >1280 µg/mL; resistance to the other three antibiotics was not compromised 
comfirmed by replicate plating. 
 
 
Figure 3.9: MIC of ampicillin (A), streptomycin (S), vancomycin (V) and metronidazole 
(M) for strains A192PP and A192PPR. Antibiotic concentrations from 1.25-1280 µg/mL 
were tested along with negative (Neg.) and positive (Pos.) controls. Bacterial growth 
(blue; +) or lack of growth (red; -) after 24 h incubation is indicated.   
 
Neonatal rats undergoing ASVM treatment for suppression of the endogenous 
microbiota were colonized by A192PPR; four litters of twelve neonates each were used. 
Prior to the administration of the first dose of antibiotics four P7 neonates (1 from each 
litter) were culled and DNA extracted from intestinal tissues (pre-dose controls). The 
remaining neonates were dosed orally with each antibiotic and doses were repeated on a 
daily basis. Four neonates were culled on each day and DNA extracted from intestinal 
tissues. At P8, neonates were inoculated with 10
7
 CFU of strain A192PPR. DNA 
extracts were analysed by SSU rDNA qPCR to determine total SSU rDNA copy 
number/g of tissue and by neuS qPCR to determine E. coli K1 CFU/g of tissue. E. coli 
K1 qPCR data was converted to SSU rDNA/g of tissue based on the assumption of 7 
Antibiotic concentration (µg/mL)
Antibiotic Neg. Pos. 1.25 2.5 5 10 20 40 80 160 320 640 1280
A - + + - - - - - - - - - -
S - + + + + + + + + + - - -
V - + + + + + + + + + + + -
M - + + + + + + + + + + + -
A - + + + + + + + + + + + +
S - + + + + + + + + + - - -
V - + + + + + + + + + + + -
M - + + + + + + + + + + + -
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SSU rDNA copies per CFU. The mean E. coli K1 SSU rDNA value for each sample 
was subtracted from the total SSU rDNA copy number in order to determine the 
quantity of SSU rDNA which could not be attributed to E. coli K1. This remainder was 
assigned to the endogenous microbiota. The analysis is shown in Figure 3.10.  
ASVM administration reduced the number of bacteria of the microbiota by 
79.4% over the P8-P12 period; this contrasted with the 94.8% reduction determined 
during optimiszation of the antibiotic dosing regimen (Figure 3.9). The proportion of E. 
coli K1 within the bacterial population varied substantially over this period, from 25% 
immediately after colonization to less than 1% at P9-P10. By P13, the gut population 
predominated. This collapse in the endogenous bacterial population was found in all 
four experimental litters, occurring at P12 in one litter and P13 in the other three litters. 
From P13-P18, only E. coli K1 could be detected in the intestinal samples. These results 
indicated that administration of the ASVM combination of antibiotics completely 
suppressed the intestinal microbiota from P12/13 onwards.       
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Figure 3.10: Colonization of microbiota-suppressed neonates with E. coli K1. Neonates 
given daily AVSM antibiotic treatment from P7 onwards were inoculated with strain 
A192PPR. DNA was extracted from intestinal tissues at P7 (pre-dose control) and after 
colonization as indicated. Total SSU rDNA/g  and E. coli K1 CFU/g were determined 
by qPCR. E. coli K1 SSU rDNA (7 copies/CFU) was used to determine remainder 
(Other Bacteria). Pie charts represent the proportion of total SSU rDNA belonging to 
each group from P8-P13 and %’s represent the E. coli K1 fraction. Error bars 
represent the SEM of four neonates.      
  
 
P8             P9            P10           P11           P12           P13                                      
25.1%      0.71%       0.25%      10.15%      15.98%      100%
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3.3.3.3 Impact on susceptibility to E. coli K1 
 The survival of microbiota-suppressed neonates colonized at P2 and P8 was 
determined. The virulence of A192PPR and the impact of ASVM treatment on survival 
were also assessed in susceptible neonates. Two litters of twelve neonates were used for 
each of these experiments; animals were colonized at P2 or P8 and survival monitored 
for two weeks after colonization (Figure 3.11).  
 
Figure 3.11: Impact of suppression of the microbiota by antibiotic combination on 
survival of normally refractive neonates. Neonates given ASVM antibiotic treatment and 
untreated control neonates were colonized with 10
7
CFU of strain A192PP at P2 or P8; 
survival was monitored for two weeks following colonization. Two litters of twelve were 
used for each condition; error bars represent the SEM. Data for untreated neonates 
colonized at P2 and P8 with strain A192PP are also shown.  
 
A192PPR was less virulent than the parent strain A192PP. However, 
colonization with A192PPR resulted in a substantial degree of mortality, with a mean of 
>66% in P2 colonized animals. ASVM administration did not influence survival, 
indicating that death was due to infection with A192PPR and not to antibiotic treatment. 
Age inoculated: P2 P2 P2 P8 P8 P8
E. coli K1 strain: A192PP A192PPR A192PPR A192PP A192PPR A192PPR
ASVM treatment: No No Yes No No Yes
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Neonates colonized with A192PPR at P8 were refractive to systemic infection and 
suffered no mortality during the monitoring period. Survival of all littered neonates rate 
was evident in ASVM-treated and untreated experimental groups, indicating that 
suppression of the microbiota had no effect on susceptibility to E. coli K1 infection. 
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3.4 Discussion:  
 
 There is a sizable body of evidence that the microbiota plays an important role in 
the inhibition of opportunistic pathogens in the intestines. Inhibition is due to mCR 
mechanisms and stimulation of certain hCR mechanisms. In this chapter, I examined the 
relationship between the microbial population of the neonatal rat GI tract and the 
susceptibility of the neonatal rat to E. coli K1 infection. Initially, temporal aspects of E. 
coli K1 intestinal colonization in neonates differing in their age susceptibility to 
infection but not to GI colonization were investigated. 
 E. coli K1 may colonize the GI tract of hosts that are naturally refractive to 
systemic E. coli K1 infection, illustrated by the high rate of commensular E. coli K1 
carriage in the human adult population (Sarff et al., 1975) and from studies in animals 
(Glode et al., 1977; Bortolussi et al., 1978; Pluschke & Pelkonen, 1988). As reported in 
Chapter 2, E. coli K1 intestinal colonization can be induced in P9 neonatal and adult 
rats, although quantitative aspects of intestinal colonization of susceptible and refractive 
neonates were not assessed and no conclusions could therefore be drawn regarding 
differences in colonization rates between these two groups . No differences in the E. coli 
K1 burden after colonization at P2, P5 or P9 could be demonstrated at any time point 
and the temporal development of the K1 population was very similar in these age 
groups. This suggests that CR mechanisms do not affect E. coli K1 colonization and 
survival within the GI tract and the pathogen is not cleared from the intestines of 
susceptible or refractive neonates by the endogenous microbiota. The stabilization of the 
E. coli K1 intestinal load at 24 h after colonization suggests that there is an upper limit 
to the size or growth of the bacterium in the neonatal intestine. The E. coli K1 
population climaxed immediately prior to the bacterial translocation window (24-72 h 
after colonization) reported in the previous chapter. Translocation across the BBB 
requires a threshold bacterial load of around 10
3
 CFU/mL in the bloodstream (Dietzman 
et al., 1974) and it is possible that there is also a threshold of similar dimension for 
translocation from the gut lumen to the bloodstream.  
  The lack of CR or pathogen clearance does not preclude a role for the microbiota 
in the prevention of dissemination of the pathogen from the intestinal tissues. For 
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example, some microbiota-pathogen interactions can modulate the virulence of the 
pathogen without preventing its growth in the intestine: commensal E. coli strain Nissle 
1917 inhibits the invasive mechanisms of EIEC strains and Listeria monocytogenes 
(Altenhoefer et al., 2004). Bifidobacterium and Lactobacillus spp, are able to inhibit the 
function of VFs expressed by pathogenic Salmonella spp. (Bernet et al., 1993; 
Coconnier et al., 2000). In similar fashion, species closely related to some pathogens 
can determine susceptibility to that pathogen (Stecher et al., 2010). Susceptible neonates 
may lack species such as B. thetaiotaomicron and segmented filamentous bacteria that 
induce the secretion of AMPs and maintain luminal bacteria at a distance from the 
intestinal epithelium (Keilbaugh et al., 2005). These studies informed the quantitative 
and qualitative assessment of the P2, P5 and P9 intestinal microbiota that were 
undertaken and described in this chapter.  
The intestinal microbiota of the three neonatal age groups employed in this study 
were quantitatively and qualitatively different to the adult microbiota. Facultative 
anaerobes, including Gammaproteobacteria and taxonomic groups within the Firmicutes 
and High G/C (Actinobacteria) phyla, were prominent members of the neonatal GI 
microbiota and were complemented by a concomitant paucity of strict anaerobes of the 
phyla Firmicutes and the Bacteroidetes. Similar profiles have been found by other 
investigators (Favier et al., 2002; Palmer et al., 2008), supporting the validity of the 
microarray and data analysis methods employed in the current study and indicating that 
the neonatal rat microbiota was broadly comparable to its human equivalent at the 
higher taxonomic levels. Lactobacillus spp, Bifidobacterium spp. and endogenous E. 
coli were prominent members of the neonatal microbiota. Furthermore, the neonatal 
microbiota was deficient in AMP-inducing B. thetaiotaomicron in comparison to the 
adult microbiota. These bacteria are unlikely to have played a role in determination of 
neonatal susceptibility to E. coli K1 over the P2-P9 period. In similar fashion, the lack 
of absolute quantitative differences between the neonatal cohorts indicated that the 
number of endogenous bacteria did not influence susceptibility to E. coli K1. 
Some taxa (including several Clostridial groups) were found to vary, in 
quantitiative terms, over the P2-P9 period. The C. polysaccharolyticum subgroup is a 
poorly characterized genus comprising fifty known OTUs. None of the OTU-specific 
probes for this subgroup passed the probe filter, indicating that the relative increase in 
numbers of members of this group was due to an unidentified component(s) of this 
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genus. The group archetype is a butyrate producing fermenter of cellulose and starch 
originally isolated from ruminant animals (Van Glyswyk, 1980). Butyrate inhibits the 
growth of some pathogens (Hopkins & Macfarlane, 2003) and reduces E. coli 
translocation of enterocytes in vitro (Lewis et al., 2010). Numbers of the C. 
subterminale subgroup (24 OTUs) and C. aminovalericum also increased over P2-P9. 
Both are common constituents of the mammalian intestinal microbiota (Lee et al., 
1991), but any specific mechanism by which they might affect susceptibility to E. coli 
K1 is not immediately apparent. However, an investigation by Itoh & Freter (1989) 
indicated that Clostridial species can control colonic E. coli populations and there is a 
possibility that these organisms have the potential to modulate susceptibility to E. coli 
K1.    
A  Desulfovibrio species increased in numbers substantially over the P2-P9 
period. These bacteria are common constituents of the intestinal microbiota (Gibson et 
al., 1993) and are characterized by the metabolism of sulphate to toxic hydrogen 
sulphide. There is, however, no evidence that they confer any protective effects on the 
host. Surprisingly, another species which increased significantly during the period of 
observation was Mycobacterium tuberculosis, a pathogen associated with chronic 
pulmonary infections but which can survive and cause disease in the intestinal tract 
(reviewed by Donoghue & Holton, 2009). Two species of bacteria, H. pylori and B. 
viridis, showed a significant decline over P2-P9. The relevance and accuracy of the B. 
viridis result is suspect as the relevant probe only fractionally escaped the filtering 
method and the species is not associated with enteric environments. H. pylori is a 
common constituent of the upper GI tract and can be vertically acquired by the neonate 
following vertical transmission from the mother (Solnick et al., 2003). Again, there is 
no known mechanistic basis by which an alteration in this bacterial population could 
influence susceptibility of the neonate to E. coli K1 infection.  
Suppression of the neonatal microbiota by daily oral administration of 
antibiotics produced data that was broadly comparable to results published by other 
investigators (Croswell et al., 2009). The substantial decrease in the microboita after 
several days of treatment has also been previously reported (Croswell et al., 2009; 
Rakoff-Nahoum et al., 2004; Fagarasan et al., 2002). The variable degree of microbiota 
suppression observed for the different antibiotic combinations may be attributable to the 
antibacterial spectra of the individual antibiotics employed. Both ampicillin and 
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streptomycin are broad spectrum and have a significant impact on the microbiota. The 
statistically insignificant impact of vancomycin may be due to the fact that its mode of 
action restricts its activity against Gram-negative bacteria. The antibacterial spectrum of 
metranidazole is limited to anaerobic bacteria; however, this would be unlikely to 
constrain its activity in the anaerobic environment of the GI lumen.  
The resistance of A192PPR to the antibiotics used in this study may have 
provided the strain with an advantage over drug-susceptible members of the GI 
microbiota under the experimental conditions employed and this may have contributed 
to the degree of suppression of the microbiota. This model circumvents the potential 
pitfalls of a GF model, as the neonates have been exposed to the normal microbiota 
prior to P7 and would have received the developmental cues prompted by acquisition of 
commensular intestinal bacteria. The conditions used allowed analysis of the effects 
induced by the absence of the microbiota on susceptibility to E. coli K1 infection. The 
lack of mortality observed in naturally refractive (i.e. P8 or older) neonates is evidence 
that the loss of the microbiota does not affect susceptibility to E. coli K1. However, the 
decrease in A192PPR virulence represents a potential cause for concern, as it implies 
that the transformation process compromised the virulence of the strain. A192PPR may, 
therefore, be less able to survive in extra-intestinal niches of refractive neonates.        
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4.1 Introduction 
 
 The post-natal development of the neonatal intestinal tissues contributes to the 
dynamic nature of the enteric environment. This developmental flux represents a 
variable which could modulate the capacity of E. coli K1 to translocate from the 
intestinal lumen into the systemic circulation. The K1 capsule provides the pathogen 
with a defensive mechanism which inhibits activation of the adaptive arm of the 
intestinal immune system. Therefore, development of the innate intestinal defences is 
likely to be a factor that impacts on the determination of the susceptibility of the host to 
E. coli K1 infection. 
The post-partum increase in Paneth cell differentiation and AMP secretion 
(Mallow et al., 1996; Bry et al., 1994) represents a key element in the development of 
innate intestinal defences. The classic AMP family are the α-defensins, a group of 
small, structurally conserved peptides with strong antibacterial activity against a broad 
spectrum of bacterial species. The enteric members of this family are especially potent 
in terms of their bactericidal activity (Ericksen et al., 2005). Mature α-defensin peptides 
are 29-39 amino acids in length and possess several features which are vital to their 
function. They have an overall cationic charge, conferred by multiple arginine residues, 
are amphiphilic and also possess six conserved cysteine residues mediating the 
formation of three disulphide bridges. The polar properties of the mature peptide 
facilitate interaction and insertion into negatively charged bacterial membranes. The 
tertiary structure of these peptides mediates the formation of a pore-like structure which 
depolarizes the target membrane, induces the leakage of ions and ATP and inhibits 
bacterial respiration (reviewed by White et al., 1995). Enteric α-defensins can also act 
as paracrine regulators of the inflammatory response by stimulation of IL-8 secretion 
(Lin et al., 2004) and inhibition of IL-1β release from activated monocytes (Shi et al., 
2007).    
 The mucus layer is another essential aspect of innate enteric defence and 
functions to maintain luminal bacteria at a safe distance from the intestinal epithelia. 
Gel forming mucins, such as Muc2, are vital in realizing this function; however, the 
exact mechanism by which bacterial/epithelial separation is achieved in the different 
intestinal compartments is variable. In the small intestine, the mucus layer acts to 
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maintain Paneth cell-secreted AMPs in close proximity to the intestinal enterocytes 
(Vaishnava et al., 2011; reviewed by Johansson & Hansson, 2011). In this manner, the 
small intestinal mucus layer maintains bacterial separation using a bactericidal gradient, 
with the highest concentration of AMP closest to the epithelium. The colon lacks Paneth 
cells and the colonic mucus layer thus relies on an alternate mechanism of bacterial 
separation. This mechanism comprises a stratified physical exclusion barrier that the 
majority of intestinal bacteria are unable to penetrate (Johansson et al., 2008). The 
barrier is primarily composed of Muc2 arranged in layered sheets of hexagonal 1 µm 
diameter rings, with each ring composed of twelve Muc2 monomers (Ambort et al., 
2012). The developmental regulation of AMP secretion implies that the barrier function 
provided by the small intestinal mucus layer is developmentally regulated post-partum. 
Conversely, nothing is known of the developmental state of the colonic mucus layer at 
birth and therefore it too may be developmentally immature in the immediate post-natal 
period. Muc2 is expressed in the foetal colon (Chambers et al., 1994); however, there 
are other factors which may be vital to the formation of the stratified exclusion barrier. 
These include two other major goblet cell-secreted proteins; trefoil factor 3 (Tff3) and 
Fc-gamma binding protein (Fcgbp). 
 The trefoil family peptides (Tff1-3) are so named due to their characteristic 
trefoil domain. This consists of a triple loop „clover-leaf‟ structure which is maintained 
by three cysteine-cysteine disulphide bonds. Tff2 has two trefoil domains whereas Tff1 
and Tff3 have one each (Thim, 1989; 1997). Trefoil peptides are the second most 
abundant protein found in mucin-secreting cells and several studies have indicated that 
they play key protective roles in the GI tract. These include a motogenic function, which 
is required to stimulate epithelial healing after damage, and regulation of the 
inflammatory response (Playford et al., 1995; Tran et al., 1999; Kurt-Jones et al., 2007). 
Furthermore, all trefoil peptides bind to Paneth cells and Tff2-KO mice differentially 
express enteric α-defensins and proteins involved in the presentation of antigens to 
immune cells (Poulsen et al., 2003; Baus-Loncar et al., 2005). Trefoil peptides alter the 
viscoelastic properties of the mucus layer by complexing with mucins (Figure 4.1) and 
have a synergistic protective effect on the intestinal epithelium (Thim et al., 2004; 
Kjellev et al., 2006; Playford et al., 2006). Trefoil peptides interact non-covalently with 
mucins through the cysteine-rich von Willebrand Factor C (vWFC) domain of the 
mucin molecule (Tomasetto et al., 2000) and also form disulphide bonds with Fcgbp 
144 
 
(Albert et al., 2010). Fcgbp contains multiple vWFD domains and covalently binds to 
Muc2 (Johansson et al., 2011). The Muc2/Tff3/Fcgbp complex can be purified by co-
immunoprecipitation and visualized in the stratified colonic mucous layer (Yu et al., 
2011). The interactions of mucin, trefoil factors and Fcgbp are thus likely to contribute 
to the stratified colonic mucous barrier. Tff3 is expressed relatively late in gestation and 
expression increases substantially post-partum. This may indicate that the early neonatal 
barrier may not be as robust as that of the older neonate or adult (Lin et al., 1999, 
Mashimo et al., 1995).          
 
Figure 4.1: Trefoil factor 2 complexed with mucins. Images are of mucin (A), trefoil 
factor 2 plus mucin (B) and a magnified image of the long chain Tff2/mucin complex 
(C). Images adapted from Thim et al. (2004). 
The neonate is distinctly susceptible to a range of inflammatory conditions such 
as pneumonia, meningitis and NEC. The implication of this susceptibility is that 
regulation of the neonatal inflammatory response and/or the effector leukocytes 
summoned to the site of inflammation are immature. This would result in either an 
overly prolonged or incapacitated response to inflammatory stimuli. The neonatal innate 
immune response is demonstrably distinct from that of the adult (reviewed by Levy, 
2007); however, whether the neonate is hyper- or hypo-responsive to inflammatory 
A B
C
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stimuli remains a source of controversy. Much of the research in this arena has focused 
on the ex-vivo secretion of pro-inflammatory cytokines by circulatory leukocytes. Some 
investigators have reported a significant deficiency in IL-1β, IL-6 and TNF-α secretion, 
as well as the reduced presence of LPS responsive CD14 and TLR4 receptors in 
neonatal compared to adult leukocytes (Peters et al., 1993; Levy et al., 2006; Qing et 
al., 1995; Förster-Waldl et al., 2005). However, other investigators have reported 
enhanced production of these cytokines and receptors under similar experimental 
conditions (Berner et al., 2002; Yerkovich et al., 2007; Tatad et al., 2007).  
There is ex-vivo evidence that the pre-term and very young neonatal intestine 
tissue is hyper-responsive to inflammatory stimuli (Nanthakumar et al., 2000; Lotz et 
al., 2006; Okogbule-Wonodi et al., 2012). In-vivo data tends to support the hyper-
responsive neonatal phenotype (Cusumano et al., 1997; Zhao et al., 2008). Furthermore, 
the neutrophil population of the neonate is qualitatively distinct from that of the adult 
and shows reduced production of key molecular armaments against microbial 
pathogens. These include the capacity to produce reactive oxygen species, lactoferrin, 
lysozyme and BPI (Ambruso et al., 1984; Levy et al., 1999). It is possible that the 
hyper-inflammatory response of the neonate may be required in order to overcome these 
neutrophil deficiencies. However, this carries the potential cost that inflammation may 
damage host tissues.           
 The transcriptome is defined as the total mRNA produced by individual cells or 
whole multicellular tissues and varies substantially in response to differential stimuli. 
As the functional template for protein synthesis, the transcriptome can be taken as an 
indirect measure of the proteome. This assumption has been validated in-vivo but has 
several caveats, including the inability to detect post-translational regulation or to 
distinguish mRNA associated with active polysomal from inactive monosomal 
ribosomes (Scherl et al., 2005; Kislinger et al., 2006; reviewed by Hegde et al., 2003). 
Comparative analysis of the transcriptome provides a powerful tool for the assessment 
of the reactions of cells or tissues to stimuli, such as microbial infection. This approach 
can also be used to evaluate developmental gene regulation. This chapter describes 
experiments designed to assess the development of the neonatal intestinal tissues over 
the period that resistance to systemic E. coli K1 infection increases. In addition, the 
response of intestinal tissues to colonization by the pathogen was also characterized.  
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4.2 Materials & Methods 
 
Unless otherwise indicated, in the following sections all growth media were 
purchased from Oxoid Ltd, all chemicals, reagents and enzymes were from Sigma-
Aldrich and all oligonucleotides were synthesised by and purchased from Eurofins 
MWG Operon. This section describes methods which are specific to the results 
described in this chapter; some methods used in Chapter 2 were also employed. 
 
4.2.1 Oligonucleotides 
 Multiple oligonucleotides were used in experiments described here. Probe and 
competitor sequences used in NFκB electrophoretic mobility shift assays (EMSA) are 
detailed in Table 4.1. Primer pairs used to amplify fragments of genes analysed by RT-
PCR are detailed in Table 4.2. 
 
Name Strand Sequence (5'-3') 
      
   
NFκB wt Cy5 sense CY5-AGTTGAGGGGACTTTCCCAGGC 
  antisense CY5-GCCTGGGAAAGTCCCCTCAACT 
   
NFκB wt sense AGTTGAGGGGACTTTCCCAGGC 
  antisense GCCTGGGAAAGTCCCCTCAACT 
   
NFκB mut sense AGTTGAGGCGACTTTCCCAGGC 
  antisense GCCTGGGAAAGTCCGCTCAACT 
   
 
Table 4.1: Sense and antisense strand sequences of the NFκB wild-type (wt) Cy5-
conjugated probe with wild-type and mutant (mut) competitors. The NFκB binding site 
is underlined on the wild-type sequences and the mutated base pair is underlined on the 
mutant sequences.   
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Table 4.2: Primers used to amplify gene fragments in RT-PCR. Target genes and 
forward (F) and reverse (R) primer sequences are detailed.    
 
Target Primer Sequence (5'-3') 
     
   
Rps23 F TGTGTCAGGGTGCAGCTCATTAAGAACG 
  R CTTTGCGACCAAATCCAGCAACCAGAAC 
Defa-rs1 F GACCAGGATGTGTCTGTCTCCTTTG 
  R TGTGGACCTTGATAGCCGAATGC 
Pdcd4 F AGAAGTGGAGTAGCTGTGCCCACCAGTC 
  R CCCTTGCCTCCTGCACCACCTTTCTTTG 
Clic4 F AAAGGCATGACGGGCATCTGGAGATACC 
  R GTCACTGTACGCGATTTCCACCTCCTTG 
Cav F GCAAGTGTACGACGCGCACACCAAGGAG 
  R CCAGATGAGCGCCATAGGGATGCCGAAG 
Afp F GTGAGGGACTGGCCGACATTTACATTGG 
  R GTGATGCAGAGCCTCCTGTTGGAATACG 
Amy2 F CAGAAATTGTCGTCTGTCTGGCCTTCTG 
  R CAAGTCTGAACCCTGCTACACCAATGTC 
RT1-Aw2 F GGTCAGGGTGATGTCAGCAGGGTAGAAG 
  R GCTCAGCAGATACCTGGAGCAAGGGAAG 
Btg2 F ACTGCTCCTGCCCAGCATCATCTGGTTC 
  R ATCCAAGGGCTCCGGCTATCGCTGTATC 
Cald1 F CTTGCTTCTGCCGCAGCCTTTCCTGTCG 
  R CCAGGCGCATCTTGCTCAGCGCATTTCG 
Tff2 F GGCATCACCAGTGACCAGTGCTTTAATC 
  R GCAGTGCCCTTCAGTAGTGACAATCATC 
Ins2 F AAGTGACCAGCTACAGTCGGAAACCATC 
  R AGCTTCCACCAAGTGAGAACCACAAAGG 
Defa24 F TGATGAGCAGCCAGGGAAAGAG 
  R TCAGCGGCAACAGAGTATGAGC 
NFκB F CAAGAACAGCAAGGCAGCACTCC 
  R TGTAGAGGTGTCGTCCCATCGTAGG 
Cebp/β F GCCGCCTTTAGACCCATGGAAGTG 
  R AACCGTAGTCGGACGGCTTCTTGC 
Muc2 F CCTCAACGGCATCCATTCC 
 R AGGTGGGTAGCGAGTATCC 
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RT-PCR primer pairs were designed using Clone Manager Suite (v.9) software 
(Scientific & Educational Software). Rattus norvegicus gene-specific mRNA sequences 
were obtained from the NCBI Nucleotide database (http://www.ncbi.nlm.nih. 
gov/nuccore) and used as design templates. Primer pairs spanning known exon-exon 
boundaries were preferentially selected. Primer specificity was examined by testing 
primer pairs using Primer-BLAST (www.ncbi.nlm.nih.gov /tools/primer-blast) with 
primer pair specificity checking parameters set to all deposited bacterial and Rattus 
norvegicus sequences in all DNA sequence repository databases. 
 
4.2.2 RNA extraction 
 Tissue RNA was stabilized by submerging excised tissues in five volumes of 
RNAlater tissue storage reagent (Ambion) and stored at 4 °C for at least 24 h prior to 
nucleic acid extraction. Total RNA was extracted from RNA-stabilized intestinal tissues 
using RNeasy Midi-Kits (Qiagen) according to the manufacturer‟s instructions. The 
compositions of buffers utilized in the extraction process were proprietary information 
unless otherwise detailed. The flow-through produced by centrifugation steps was 
discarded unless otherwise indicated. Tissues were transferred from RNAlater solution 
to 7.5 mL of lysis Buffer RLT containing 1% (v/v) β-mercaptoethanol. Tissues were 
disrupted and homogenized in lysis buffer using an Ultra-Turrax T-10 rotor-stator 
homogenizer. The homogenizer blade was washed once in 70% (v/v) ethanol and three 
times in sterile PBS between samples. Homogenates were centrifuged at 5000 x g for 20 
min. Centrifugation resulted in a pellet and a fatty upper layer, both of which were 
selectively removed using a pipette. The supernatant was mixed with 7.5 mL of 70% 
(v/v) ethanol, applied to spin-columns and centrifuged at 5000 x g for 10 min. Columns 
were washed with Buffer RW1 and centrifuged at 5000 x g for 5 min. Contaminating 
DNA was degraded by on-column DNase digestion using RNase-free DNase Set kits 
(Qiagen) according to the manufacturer‟s instructions. DNase I (375 U/mL) was applied 
to each column and incubated at room temperature for 15 min. Columns were washed 
once with Buffer RW1 and twice with Buffer RPE. RNA was eluted from the columns 
in 150 µL of RNase-free H2O, transferred to RNase-free microcentrifuge tubes 
(Ambion) and stored at -80 °C. RNA concentration and purity were determined using a 
NanoDrop spectrophotometer (Thermo Scientific). RNA (1 µg) was mixed with an 
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appropriate volume of 6 x Gel Loading Buffer (0.05% [w/v] bromophenol blue, 40% 
[w/v] sucrose, 0.1 M pH 8 EDTA, 0.5% [w/v] SDS) and resolved by agarose gel 
electrophoresis as described in section 2.2.10. Gels were visualized using a Molecular 
Imager FX system (Bio-Rad) set to detect UV fluorescence. Images were used to assess 
RNA integrity and the presence of contaminating genomic DNA (Figure 4.2). 
       
 
Figure 4.2: Assessment of RNA integrity and genomic DNA contamination by agarose 
gel electrophoresis. 1 µg of RNA extractions was loaded onto 1% (w/v) agarose gels 
and resolved by electrophoresis. Intact 28S and 18S rRNA bands (indicated) were used 
to assess integrity. No large genomic DNA fragments were detected in these samples.   
 
4.2.3 Protein extraction  
 Protein was extracted from intestinal tissue samples under denaturing conditions. 
Freshly excised tissues were transferred to 4 mL of ice-cold protein extraction buffer 
(1% [v/v] NP-40, 1% [v/v] Tween-20, 10 mM pH 7.4 Tris-HCl, 1mM EDTA in PBS) 
supplemented with 1 x Complete Mini Protease Inhibitor Cocktail (Roche). Samples 
were weighed and homogenized on ice using an Ultra-Turrax T-10 homogenizer (IKA-
Werke). The homogenizer blade was washed once in 70% (v/v) ethanol and three times 
in sterile PBS between samples. Tissue homogenate (0.96 mL) was mixed with 3 mL of 
10 M urea (7.5 M final concentration) and 40 µL of 1 M dithiothreitol (DTT; final 
concentration 100 mM). Samples were incubated for 24 h on a slowly rotating orbital 
shaker at 4 °C. Denatured tissue homogenates were centrifuged at 1500 x g for 10 min 
at 4 °C and the supernatant aspirated and retained. The protein content of the extract 
was measured according to Bradford (1976). Concentrated Protein Assay Dye (Bio-
Rad) was diluted 1:5 with H2O to make a working solution of Bradford reagent. A series 
28S
18S
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of twofold dilutions of bovine serum albumin (BSA; 1 mg/mL) was prepared over the 
range 62.5-1000 µg/mL. Aliquots (20 µL) of these standard solutions or protein extracts 
were added to 1 mL of Bradford working solution and thoroughly mixed. The OD595 of 
the mixture was measured with a Lambda 25 spectrophotometer (Perkin-Elmer). 
Standard OD595 values were used to construct a standard curve and in order to determine 
sample protein concentration. 
 
4.2.4 Preparation of single cell suspensions from tissue 
 Freshly excised intestinal tissues were washed in 2 mL of ice-cold PBS. Washed 
tissues were transferred to 4.7 mL of HEPES buffer (10 mM HEPES, 150 mM NaCl, 5 
mM KCl, 1 mM MgCl2, 1.8 mM CaCl2 in ddH2O) supplemented with DNase I (80 
U/mL) and collagenase (2 mg/mL). Tissues were briefly (~10 s) homogenized on ice 
using an Ultra-Turrax T-10 homogenizer (IKA-Werke). The homogenizer blade was 
washed once in 70% (v/v) ethanol and three times in sterile PBS between samples. 
Homogenates were incubated at 37 °C in an orbiting incubator rotating at 100 rpm for 
30 min followed by another brief homogenization. BD Falcon Cell Strainers (100 µm; 
BD Biosciences) were placed in 50 mL collection tubes and the tissue homogenate 
applied directly to the cell strainer filter. Filters were washed with 3 mL of HEPES 
buffer. Single cell suspensions (the filtrate) were centrifuged at 500 x g for 10 min at 4 
°C to pellet cells. All samples were kept on ice at all times unless otherwise specified. 
All buffers were filter-sterilized using 0.22 µm MILLEX GP filters (Millipore).     
 
4.2.5 Nuclear protein extraction 
 Tissue cell pellets were suspended in 5 mL nuclear extraction buffer (0.32 M 
Sucrose, 10 mM pH 7.4 Tris-HCl, 3mM CaCl2, 2 mM MgOAc, 0.1 mM EDTA, 1 mM 
DTT) supplemented with 0.5% (v/v) NP-40 and 1 x Complete Mini Protease Inhibitor 
Cocktail (Roche) and mixed well to allow lysis of cell membranes. The suspension was 
centrifuged at 500 x g for 5 min at 4 °C to pellet cell nuclei. The cytoplasmic fraction 
(supernatant) was aspirated and stored at -80 °C. Nuclei pellets were washed three times 
in nuclear extraction buffer. Protein was extracted from washed cell nuclei by 
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suspending pellets in 1.5 mL hypotonic buffer (20 mM HEPES, 1.5 mM MgCl2, 20 mM 
KCl, 0.2 mM EDTA, 25% [v/v] glycerol, 0.5 mM DTT) followed by the drop-wise 
addition of an equal volume of hypertonic buffer (20 mM HEPES, 1.5 mM MgCl2, 800 
mM KCl, 0.2 mM EDTA, 25% [v/v] glycerol, 0.5 mM DTT, 1% [v/v] NP-40) with 
constant mixing. Both hypotonic and hypertonic buffers were supplemented with 1 x 
Complete Mini Protease Inhibitor Cocktail (Roche). Samples were incubated at 4 °C for 
45 min on a slowly rotating orbital shaker. Nuclei were collected by centrifugation at 
14000 x g for 15 min at 4 °C and the nuclear protein fraction (supernatant) aspirated and 
stored at -80 °C. Protein concentrations of both cytoplasmic and nuclear protein were 
determined using the Bradford method described in section 4.2.3.       
 
4.2.6 GeneChip target preparation and array hybridization 
 RNA extractions were used to prepare labelled targets to be used for 
hybridization to Affymetrix GeneChip expression microarrays. All equipment and kit 
reagents used in this process were purchased from Affymetrix and used according to the 
manufacturer‟s instructions. The composition of all buffers was proprietary information 
and samples/reagents were retained on ice unless otherwise indicated.  
Double-stranded (ds)cDNA was prepared from total RNA extracts. RNA 
samples (5 µg) were spiked with poly-A RNA controls (1:50000 dilution of stock) using 
the GeneChip Eukaryotic Poly-A RNA Control Kit. cDNA was synthesised from RNA 
extracts using a One-Cycle cDNA Synthesis Kit. RNA was mixed with T7-Oligo(dT) 
Primer (8.3 µM) and incubated for 10 min at 70 °C and for 2 min at 4 °C to allow 
primer binding. RNA was mixed with 1
st
-strand synthesis master mix (1
st
 Strand 
Reaction Mix, 100 mM DTT, 0.5 mM dNTP) and incubated at 42 °C for 2 min. 
Reactions were mixed with 1 µL SuperScript II, incubated at 42 °C for 1 h and cooled 
to 4 °C for 2 min. Reactions were mixed with 2
nd
-strand synthesis master mix (2
nd
 
Strand Reaction Mix, 0.23 mM dNTP, DNA ligase, DNA polymerase I, RNase H) and 
incubated at 16 °C for 2 h. Reactions were mixed with 2 µL T4 DNA polymerase, 
incubated for 5 min at 16 °C and mixed with EDTA (33 mM). Double-stranded cDNA 
was cleaned using a GeneChip Sample Cleanup Module kit. cDNA Binding Buffer was 
mixed with cDNA synthesis reactions, applied to Cleanup Spin Columns and 
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centrifuged at 8000 x g for 1 min. Columns were washed with cDNA Wash Buffer. The 
column membranes were dried by centrifugation at 25000 x g for 5 min with the column 
caps left open. cDNA was eluted in 14 µL of cDNA Elution Buffer.  
Single-stranded biotinylated cRNA was synthesised from cDNA by in vitro 
transcription (IVT) using a GeneChip IVT Labeling Kit. cDNA was mixed with IVT 
labelling master mix (IVT labelling buffer, IVT labelling NTP mix, IVT labelling 
enzyme mix) and incubated at 37 °C for 16 h. Labelled cRNA was cleaned using a 
GeneChip Sample Cleanup Module kit. IVT reactions were mixed with cRNA Binding 
Buffer and 35% (v/v) ethanol, applied to cRNA Cleanup Spin Columns and centrifuged 
at 8000 x g for 15 s. Columns were washed with IVT cRNA Wash Buffer and 80% (v/v) 
ethanol. The column membranes were dried by centrifugation at 25000 x g for 5 min 
with the column caps left open and labelled cRNA eluted in 11 µL RNase-free H2O. 
IVT cRNA yields were quantified using a NanoDrop spectrophotometer (Thermo 
Scientific). Labelled cRNA (20 µg) was mixed with Fragmentation Buffer and 
incubated at 94 °C for 35 min.  
Fragmented, labelled cRNA was hybridized to Rat Expression Set 230 (2.0) 
GeneChip arrays using Hybridization, Wash & Stain Kits. cRNA (15 µg) was mixed 
with hybridization master mix (3 nM Control Oligonucleotide B2, Eukaryotic 
Hybridization Controls, Hybridization Mix, DMSO) and incubated at 99 °C for 5 min 
and 45 °C for 5 min. GeneChip arrays were incubated with Pre-Hybridization Mix at 45 
°C for 10 min. Hybridization mix was applied to individual GeneChip arrays and 
incubated at 45 °C for 16 h. GeneChip incubations were carried out in an Affymetrix 
Hybridization Oven 645. 
      
4.2.7 GeneChip washing, staining, scanning & analysis 
 GeneChip washing and staining were performed using an Affymetrix Fluidics 
Station 450 in conjunction with Hybribization, Wash & Stain Kit reagents. Scanning 
was performed using an Affymetrix Gene Array Scanner 3000. All of these procedures 
were set up and controlled using GeneChip Operating Software (GCOS v. 1.4). 
Hybridized arrays were removed from the hybridization oven and hybridization 
mixtures replaced with Wash Buffer A. Staining reagents were prepared by transferring 
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1.2 mL of Stain Cocktail 1 (containing streptavidin-phycoerythrin; SAPE) into a light-
protected 1.5 mL tube and 600 µL of Stain Cocktail 2 (containing biotinylated goat anti-
streptavidin IgG) and 800 µL of Array Holding Buffer into clear 1.5 mL tubes. Arrays 
and staining reagents were inserted into the appropriate fluidics station modules. Arrays 
were washed sequentially with Wash Buffer A (10 cycles of 2 mixes/cycle) at 30 °C and 
with Wash Buffer B (6 cycles of 15 mixes/cycle) at 50 °C. Arrays were stained for 5 
min with Stain Cocktail 1 at 35 °C and washed with Wash Buffer A (10 cycles of 4 
mixes/cycle) at 30 °C. Arrays were stained sequentially with Stain Cocktail 2 and with 
Stain Cocktail 1 (both at 35 °C for 5 min) and washed with Wash Buffer A (15 cycles of 
4 mixes/cycle) at 35 °C. Arrays were filled with Array Holding Buffer and transferred 
to the array scanner. Arrays were scanned using a solid-state 532 nm laser to detect 
SAPE fluorescence and generate raw fluorescence DAT files. Fluorescence data from 
control oligonucleotide B2 probes were used to align grids for array image analysis and 
generate average probe fluorescence CEL files. Spiked labeling and hybridization 
control probe data were used for array quality control. CEL files were exported using 
the Data Transfer Tool (v 1.1.1) and were imported into GeneSpring GX (v. 7.3.1) 
software (Agilent Technologies) for analysis. GeneChip-Robust Multiarray (GC-RMA) 
normalization was used to determine relative fold-change differences in gene expression 
between different arrays.          
 
4.2.8 Semi-quantitative RT-PCR 
 cDNA was amplified from RNA extracts by one-step RT-PCR and amplicons 
resolved by agarose gel electrophoresis. RT-PCR reactions were prepared in a C2BSC 
to reduce the risk of contamination. RNA (50 ng) was mixed with Brilliant II RT-PCR 
master mix (Agilent Technologies), gene-specific forward and reverse primer pairs (0.5 
µM each) and AffinityScript RT/RNase block enzyme mixture (Agilent Technologies) 
to a final reaction volume of 25 µL. Control reactions without RNA template or 
RT/RNase block enzyme were also prepared. RT-PCR was performed using a Techne 
Thermocycler (Bibby Scientific) running a thermocycling program consisting of 30 min 
at 50 °C and 10 min at 95 °C, followed by 35 cycles of 30s at 95 °C, 1 minute at 60 °C 
and 30 s at 72 °C. Reactions were then mixed with 5 µL of 6 x Gel Loading Buffer 
(0.05% w/v bromophenol blue, 40% w/v sucrose, 0.1 M pH 8 EDTA, 0.5% w/v SDS) 
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and resolved by agarose gel electrophoresis as described in section 2.2.10. Gels were 
visualized using a Molecular Imager FX system (Bio-Rad) set to detect UV 
fluorescence. 
 
4.2.9 qRT-PCR 
 qRT-PCR was performed using Brilliant III Ultra-Fast SYBR Green qRT-PCR 
Master Mix kits (Agilent Technologies) according to the manufacturer‟s instructions. 
Reactions were prepared in a C2BSC to reduce the risk of contamination. RNA (25 ng) 
was mixed with SYBR Green qRT-PCR master mix, gene-specific forward and reverse 
primers (using previously optimized primer concentrations; see next section), 1 mM 
DTT, 30 nM ROX reference dye and RT/RNase block enzyme mixture to a final 
reaction volume of 25 µL. Reactions were performed in 96-well plate format using an 
Mx3000P system and associated v.2 software (Stratagene) set to detect SYBR1 and 
ROX fluorescence. The qRT-PCR thermal cycling program comprised 10 min at 50 °C, 
3 min at 95 °C and 40 cycles of 95 °C for 20 s and 60 °C for 20 s. Fluorescence was 
measured at the 60 °C step of each amplification cycle and amplification curves 
recorded. DNA melt curves were generated by cooling reactions to 55 °C and increasing 
the temperature to 95 °C over 30 min with fluorescence measured every 20 s. SYBR1 
fluorescence was normalized to ROX fluorescence and the SYBR1 amplification curves 
were used by the software to generate Ct values utilizing adaptive baseline and 
amplification-based threshold algorithm enhancements. Ct values were used to calculate 
relative fold-changes in gene expression between control and experimental samples by 
the 2
-ΔΔCt
 method (described by Livak & Schmittgen, 2001). Briefly, all sample Ct 
values obtained from relevant genes were normalized to Ct values produced by the 
normaliser gene rps23 (coding for a component of the 40S ribosomal subunit) for each 
individual sample. Normalized Ct values were used to determine relative fold-changes 
in gene expression. Each qRT-PCR reaction plate included no-template and no-reverse 
transcriptase controls for each gene-specific master mix employed. Each sample was 
analysed in duplicate on each plate, and each experimental plate was duplicated.       
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4.2.10 qRT-PCR optimization and validation 
 Accurate calculation of specific gene expression by qRT-PCR and the 2
-ΔΔCt 
method requires that the amplification efficiency of the normaliser gene (rps23) must be 
comparable to that of the gene under analysis. Optimal primer concentration of each 
gene-specific primer pair was determined by RT-PCR using the reagents, equipment 
and thermocycling conditions described in the previous section. Primer concentrations 
of 100, 200, 500 and 900 nM were tested for each individual forward and reverse 
primer. Ct and dRN Last (final fluorescence) values were recorded for the amplification 
curves produced by each primer pair tested and primer concentrations producing the 
lowest Ct and highest dRN Last values chosen for further use. An optimal concentration 
of 500 nM was determined for all primers tested, with the exception of the Defa24 
reverse primer, which had an optimal concentration of 900 nM. Amplification 
efficiencies of RT-PCR reactions were determined by qRT-PCR using different 
quantities of template reference RNA ranging from 100-0.01 ng. Reference RNA was 
obtained by mixing equimolar volumes of all experimental and control RNA extractions 
(n=288). Ct values of reactions using different initial template quantities were used to 
construct standard curves and calculate amplification efficiencies (Figure 4.3). The 
average amplification efficiency of rps23 was ~103%. Amplification efficiency between 
90-110% was deemed acceptable for valid quantification of relative gene expression by 
qRT-PCR. Reaction specificity was validated by DNA melt-curve analysis and by 
amplicon cleanup and sequencing, as described in section 2.2.11. 
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Figure 4.3: Standard curves utilized to calculate RT-PCR amplification efficiency. 
Representative plots of normalized Ct values (y-axis) and initial template reference 
RNA quantity (ng; x-axis) from RT-PCR of rps23 (red) and Tff2 (blue) are illustrated. 
Pearson correlation coefficients (R
2
) and amplification efficiencies (Eff.) are indicated.  
 
4.2.11 Primary antibody biotinylation 
 Primary antibodies were biotinylated for use in protein immunodetection 
methods. Biotinylation of individual IgG antibodies was performed using EZ-Link 
Sulfo-NHS-LC-Biotinylation Kit reagents (Thermo Scientific) according to the 
manufacturer‟s instructions. Antibody solutions were desalted and exchanged into 
sterile PBS using Zeba Desalt Spin Columns. Columns were equilibrated by three 
washes of PBS and centrifugation at 1000 x g for 2 min. IgG (1 mg) was applied to the 
column resin and left until fully absorbed. Desalted IgG was eluted by another 
centrifugation using identical parameters. IgG was mixed with a 20-fold molar excess of 
Sulfo-NHS-LC-Biotin and incubated on ice for 2 h. Non-conjugated biotin was removed 
using the Zeba Desalt Spin Column procedure and biotin-conjugated IgG exchanged 
into fresh PBS. Biotin incorporation was assessed using a 4'-hydroxyazobenzene-2-
carboxylic acid (HABA) assay in cuvette format. The OD500 of HABA/avidin solution 
Rps23
R2= 0.994
Eff.= 103.9%
Tff2
R2= 0.989
Eff.= 108.7%
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was determined using a Lambda 25 spectrophotometer (Perkin-Elmer). Biotinylated IgG 
was added, mixed with the HABA/avidin solution and OD500 measured. The decrease in 
OD500 observed after addition of biotinylated IgG was used to calculate moles of 
incorporated biotin per mole of protein using a HABA assay calculator 
(http://www.piercenet .com/haba/). Calculated values typically ranged from 5-9 moles 
biotin/mole IgG.     
 
4.2.12 Tff2 competitive-ELISA 
 Competitive ELISA was used to quantify Tff2 protein in denatured tissue 
protein extractions. Goat polyclonal anti-Tff2 primary antibody (sc-23558; Santa Cruz 
Biotechnology) was biotinylated and diluted 1:100 in filter-sterilized (0.22 µm 
MILLEX GP; Millipore) blocking buffer (1 % [w/v] molecular grade casein in Tris-
buffered saline [TBS]) and dispensed in 100 µL aliquots to 0.5 mL microcentrifuge 
tubes. Protein samples (10 µg) were added to individual tubes containing anti-Tff2 IgG. 
Recombinant human Tff2 (rhTff2; Sigma Aldrich) was diluted to 15 ng/mL in PBS. 
This stock was serially diluted twofold and 100 µL of each dilution was added to 
individual tubes to give a final standard range of 1500-23.4 pg rhTff2. Control tubes 
containing only anti-Tff2 IgG were also prepared. Standard/antibody, sample/antibody 
and control tubes were incubated for 6 h at room temperature on a rotating orbital 
shaker.  
rhTff2 solution was diluted to 1 µg/mL in bicarbonate/carbonate coating buffer 
(100 mM Na2CO3, 100 mM NaHCO3 pH 9.6) and 100 µL aliquots transferred into each 
well of a 96-well Maxisorp Immunoplate (Nunc). Control wells containing only coating 
buffer were also prepared. Plates were incubated at room temperature with rotation on 
an orbital shaker for 2 h. Coating solutions were aspirated and wells washed twice with 
wash buffer (0.05% [v/v] Tween20 in PBS). Wells were blocked with 350 µL of 
blocking buffer and plates incubated for 2 h under the same conditions. Blocking buffer 
was aspirated and wells washed twice with wash buffer. Standard/antibody, 
sample/antibody and control solutions were applied to individual wells and plates 
incubated for 16 h at room temperature. Antibody solutions were aspirated and wells 
washed four times with wash buffer. HRP-streptavidin conjugate (Vector Labs) was 
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diluted to 5 µg/mL in PBS, 100 µL applied to each well and the plates incubated for 1 h. 
HRP-streptavidin was removed and wells washed four times with wash buffer. Plates 
were developed by addition of 100 µL of 3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid 
Substrate and incubated in the dark for ~5 min. Colour development was terminated by 
the addition of 100 µL of 0.4 M sulphuric acid. OD450 of individual wells was measured 
using a SPECTROstar Omega plate-reader (BMG Labtech) with wavelength correction 
set at 570 nm. OD450 measurements from standard wells were used to construct standard 
curves (Figure 4.4) which allowed the quantification of Tff2 from experimental protein 
samples. All standard, sample and control wells were run in triplicate on each plate, and 
each plate was duplicated.   
 
 
Figure 4.4: Representative standard curve generated by rhTff2 standards in a 
competitive ELISA system. Data are mean OD450 plotted against the amount of rhTff2 
incubated with anti-Tff2 IgG. Line of best fit is illustrated (----). 
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4.2.13 Serum cytokine ELISA 
 IL-6 and IL-1β were quantified from serum samples by sandwich ELISA. All 
buffers were filter-sterilized using 0.22 µm MILLEX GP filters (Millipore). Blood 
samples (~200 µL) were obtained from culled neonatal rats and mixed with 200 µL 
PBS. Serum was obtained by centrifugation of blood at 1500 x g for 10 min. Total 
serum protein was quantified using the Bradford assay and serum stored at -80 °C. IL-6 
and IL-1β were quantified using Rat IL-6 or IL-1β ELISA Development kit 
(PeproTech) reagents according to the manufacturer‟s instructions. ELISA plates were 
prepared by coating the wells of 96-well Maxisorp Immunoplates with goat anti-Rat IL-
6 (100 ng) and rabbit anti-Rat IL-1β (200 ng) capture antibodies for 16 h. Control wells 
containing only PBS were also prepared. Wells were washed four times with wash 
buffer (0.05% v/v Tween20 in PBS), blocked with 350 µL blocking buffer (1% w/v 
BSA in PBS) for 1 h and washed four times. Standards were prepared by dilution of 
recombinant rat IL-6 and IL-1β to concentrations of 5 ng/mL and 3 ng/mL respectively 
in diluent buffer (0.05% v/v Tween20, 0.1% w/v BSA in PBS). Standards were serially 
diluted twofold and 100 µL of each dilution wells. Serum was diluted in diluent buffer 
and 100 µg serum protein applied to ELISA plate wells. Control wells containing 
diluent buffer only were also prepared. Plates were incubated for 2 h and washed four 
times with wash buffer. Biotinylated goat anti-Rat IL-6 (25 ng) and rabbit anti-Rat IL-
1β (50 ng) detection antibodies were applied to wells, incubated for 2 h and wells were 
washed four times with wash buffer. ELISA plates were developed and OD450 measured 
as described in the previous section. 
 
4.2.14 NFκB electrophoretic mobility shift assay 
 An electrophoretic mobility shift assay (EMSA; Garner & Revzin, 1981) was 
used to determine the presence of active (DNA-binding) NFκB transcription factor in 
nuclear protein extracts. Double-stranded wild-type 5‟ Cy5-labelled probe and double-
stranded wild-type and mutant competitor probe oligonucleotides were prepared by 
mixing equimolar volumes of complimentary sense and antisense single-stranded 
oligonucleotides. Mixtures were incubated at room temperature for 10 min to allow 
strand annealing. Binding reactions were prepared by combining, in order and on ice, 10 
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µL ddH2O, 1 µL of poly-deoxyinosinic deoxycytidylic acid (poly-dIdC; 1 mg/mL), 3 
µL of 5 x binding buffer (50 mM Tris-HCl, 750 mM KCl, 2.5 mM EDTA, 0.5% [v/v] 
Triton X-100, 62.5% [v/v] glycerol, 1 mM DTT), 5 µL of nuclear protein extract (5 µg 
total protein) and 1 µL of labelled probe (10 ng/mL). For competitor reactions, 1 µL of 
non-labelled wild-type or mutant competitor oligonucleotides (1 µg/mL) was added to 
binding reactions immediately prior to Cy5-labelled probe. Reactions were incubated 
for 30 min. Non-denaturing 5% (w/v) polyacrylamide gels (1 mm thick) were prepared 
using 30% (w/v) acrylamide/bis-acrylamide solution (Bio-Rad), Tris-Borate-EDTA 
buffer (TBE; 0.89 M Tris-borate, 20 mM EDTA pH 8.3), ddH2O, 10 % (w/v) 
ammonium persulphate (APS) and tetramethylethylenediamine (TEMED). Gel mixes 
were cast using Bio-Rad mini gel-casting apparatus. Set gels were loaded into mini-
Protean gel electrophoresis modules (Bio-Rad) and the apparatus filled with 0.5 x TBE 
buffer. Binding reactions were loaded onto polyacrylamide gels and resolved by 
polyacrylamide gel electrophoresis (PAGE) at a constant 10 mA current. EMSA PAGE 
was conducted at an ambient temperature of 4 °C. EMSA gels were scanned using a 
Molecular Imager FX system (Bio-Rad) set to detect Cy5 fluorescence.   
 
4.2.15 SDS-PAGE 
Sodium dodecyl sulphate (SDS)-PAGE was used to resolve both nuclear protein 
extracts and denatured protein extracts. PAGE was performed using 10% or 5% (w/v) 
polyacrylamide resolving gels. Protein extracts were diluted to desired concentrations in 
10 µL PBS and combined with an equal volume of 2 x Laemmli Sample Buffer (4% 
w/v SDS, 20% w/v glycerol, 10% v/v β-mercaptoethanol, 0.004% v/v bromophenol 
blue, 125 mM Tris-HCl pH 7). Proteins were denatured by heating to 95°C for 5 min. 
Resolving gels were overlaid with a 4% (w/v) polyacrylamide stacking gel, whole gels 
loaded into mini-Protean gel electrophoresis modules (Bio-Rad) and the apparatus filled 
with electrode buffer (25 mM Tris, 192 mM glycine, 0.1% w/v SDS). Protein samples 
were loaded into stacking gels and separated by electrophoresis at 120 V until the 
bromophenol blue dye-front reached the bottom of the gel. PAGE gels were washed in 
ddH2O and used in Western blots or stained for total protein using Coomassie stain 
(0.25% [w/v] Coomassie Blue, 10% [v/v] acetic acid, 40% [v/v] methanol). Non-protein 
bound Coomassie stain was removed using destaining solution (10 % [v/v] acetic acid, 
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40 % [v/v] methanol) and stained proteins visualised by scanning the gels with a 
Molecular Imager FX system (Bio-Rad) set to detect Coomassie Blue. 
 
4.2.16 Western blots  
 Western blots were used to detect Muc2 in denatured protein extracts and α-
Tubulin in nuclear protein extracts. Protein was transferred from SDS-PAGE gels to 
Immobilon-P PVDF membranes (0.45 µm pore size; Millipore) using a Mini Trans-Blot 
Cell (Bio-Rad). Transfers were performed at a constant voltage of 100 V for 1 h in 
transfer buffer (25 mM Tris, 192 mM glycine). Membranes were blocked using filter-
sterilized (0.22 µm MILLEX GP; Millipore) 1% (w/v) BSA in TBS for 1 h and rinsed 
twice in wash solution (0.05% Tween20 in TBS). Primary antibody was diluted in 
diluent solution (0.1% w/v BSA in TBS) and applied to membranes. The primary 
antibody used to detect α-Tubulin was rabbit polyclonal anti-α-Tubulin IgG (ab4074; 
Abcam) at a dilution of 1:500. Muc2 was detected using rabbit polyclonal anti-Muc2 
IgG (sc-15334; Santa Cruz Biotechnology) at a dilution of 1:500. Muc2 antibody was 
biotinylated before use as described in section 4.2.11. Membranes were incubated with 
primary antibody for 16 h at 4 °C. Primary antibody solutions were removed, 
membranes rinsed and washed four times for 2 min in wash solution. Secondary 
detection reagents were diluted in diluent solution and applied to membranes. Anti-α-
Tubulin IgG was detected using goat anti-rabbit IgG conjugated to AlexaFluor 546 
fluorophore (Invitrogen) at a dilution of 1:1000 and anti-Muc2 IgG was detected using 
HRP-streptavidin conjugate (Vector Labs) diluted to 5 µg/mL. Membranes were 
incubated with secondary detection reagents for 1 h, rinsed and washed four times in 
wash solution. Membranes stained to detect α-Tubulin were scanned using a Molecular 
Imager FX system (Bio-Rad) set to detect AlexaFluor 546. Membranes stained to detect 
Muc2 were developed by application of TMB Liquid Substrate and photographed.            
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4.3 Results 
 
4.3.1 Development of P2-P9 gastrointestinal tract tissues 
 The growth of neonatal rat intestinal tissue was observed over the P2-P9 period, 
during which susceptibility to systemic E. coli K1 infection was lost. Two litters were 
used. Whole intestinal and gastric tissues were removed each day from two neonates 
and the length of the small intestine (duodenum-caecum) and colon (caecum-rectum) 
recorded (Figure 4.5). Representative whole tissues (stomach-colon) were aligned and 
photographed (Figure 4.6).  
 
 
Figure 4.5: Metrics of neonatal intestinal development. Whole intestinal tissues were 
removed from P2-P9 neonates and the small intestine and colon measured. Data points 
are average length of two samples.
163 
 
 
St. Small Intestine Co.
Figure 4.6: Development of the neonatal rat intestine. Whole intestinal tract tissues were removed from P2-P9 neonatal rats and
photographed. Regions comprising the stomach (St.), small intestine and colon (Co.) are indicated.
P2
P3
P4
P5
P6
P7
P8
P9
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The neonatal intestine increased in length by almost 80%; this increase was due 
predominantly to expansion of the small intestinal tissues. The small intestine increased 
in length on average by 2.6 cm/day and the colon by 0.25 cm/day. The proportion of the 
intestine comprised by each element remained approximately constant (90% small 
intestine, 10% colon) over this period. The caecum was larger in older neonates 
compared to younger animals. Thus, there was a substantial degree of macroscopic 
tissue development over the P2-P9 period.   
 
4.3.2 Intestinal tissue transcriptomics  
 The transcriptome of the neonatal intestine was examined to identify 
developmentally regulated genes and differential gene expression in response to E. coli 
K1 colonization. RNA was extracted from P2 and P9 intestinal tissues 12 h after 
colonization with A192PP. RNA was also extracted from non-colonized P2 and P9 
intestinal tissues. Five neonates were used in each group. Equimolar volumes of each 
RNA extract from each group were pooled and each pool hybridized to GeneChip 
expression microarray. Pooled rather than individual samples were employed due to the 
limited number of microarrays available. Relative mRNA fold-changes between 
experimental groups were compared. Differentially expressed genes were assigned to 
functional categories in a similar fashion to previous investigators (Moen et al., 2008; 
Zelmer et al., 2010). Gene functions were determined using the DAVID Bioinformatics 
Resource (v. 6.7; http://david.abcc.ncifcrf.gov/) developed by Huang et al. (2009). 
Genes were assigned to functional groups based on the primary function of their 
product. Gene products which regulate transcription of functionally diverse genes were 
assigned to the „transcriptional regulation‟ group. Similarly, intracellular signal 
transducers that mediate diverse signals were assigned to the „signal transduction‟ 
group. Gene products with unknown functions were assigned to the „unknown‟ group or 
„integral membrane proteins‟ group where appropriate. All differentially regulated 
genes are shown in Appendix B. 
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4.3.2.1 P2-P9 developmental gene expression 
 Developmental gene expression over the P2-P9 period was assessed by 
normalization of non-colonized P9 to non-colonized P2 data. Thus, up-regulated genes 
were those with increased expression at P9 and down-regulated genes were those with 
increased expression at P2 (Figure 4.7). Substantially more genes showed increased 
expression at P9 (255 genes) compared to P2 (44 genes).  
   
 
Figure 4.7: Genes developmentally regulated over the P2-P9 period. Relative gene 
expression was determined by GeneChip (Affymetrix) microarray analysis of P2 and P9 
RNA extracts. Differentially expressed genes were categorized using the DAVID 
Bioinformatics Resource (v. 6.7; http://david.abcc.ncifcrf.gov/).  
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The largest group of differentially regulated genes at P9 were those involved in 
growth and cellular differentiation. These included genes coding for products involved 
in epithelial development and the establishment of cellular polarity (Nr2f2, Fzd3), as 
well as genes that stimulate the differentiation of immune cells (Lrrc8a, Sox4, Bcl112). 
Expression of the pro-inflammatory cytokine gene Il18 was increased in P2 neonates. 
The expression of several AMP genes was increased in P9 neonates. These included the 
α-defensin genes Defa24 and Defa-rs1, as well as phospholipase A2 (Pla2) and the 
putative AMP gene Dmbt1. The gene with the highest fold-increase in expression over 
the P2-P9 period was RT1-AW2 (21-fold), which encodes a class Ib major 
histocompatibility complex (MHC Ib). The expression of genes encoding the gel-
forming mucins (e.g. Muc2), Tff3 or Fcgbp did not alter over this period. However, 
expression of Tff2, which encodes another member of the trefoil family, was 
substantially increased (23-fold) in P2 compared to P9 neonates. The decrease in Tff2 
expression over P2-P9 represented the largest decrease observed. Thus, a large number 
of genes are developmentally regulated in the neonatal intestine over the P2-P9 period, 
some encoding products that play a role in the defence of host tissues.            
 
4.3.2.2 Response to E. coli K1 colonization 
 The transcriptomic response of neonatal intestinal tissues to E. coli K1 
colonization was assessed by normalization of colonized P2 and P9 data to equivalent 
non-colonized data. A substantial number of genes were differentially regulated in both 
P2 (267 genes; Figure 4.8A) and P9 (617 genes; Figure 4.8B) tissues in response to 
colonization. However, only thirty of these genes were shared between the P2 and P9 
responses (Figure 4.8C). The functional group with the most shared genes was the 
immune and stress response group. In terms of up-regulated genes, these included RT1-
Aw2 and the C-type lectin AMP Reg3B. Down-regulated genes from this group included 
MHC class I and II genes (RT1-A3 and RT1-Db) and the mast-cell protease gene Mcpt3. 
Other similarities included an up-regulation of Sox4 and other putative cellular 
differentiation regulators.  
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Figure 4.8: Transcriptomic response of P2 and P9 intestinal tissues to E. coli K1 
colonization. Relative gene expression was determined by GeneChip (Affymetrix) 
microarray analysis of P2 (A) and P9 (B) RNA extracted from neonates colonized by 
A192PP for 12 h. A subset of genes was shared between the P2 and P9 responses (C). 
Data from colonized neonates were normalized to data from non-colonized equivalents. 
Differentially expressed genes were categorized using the DAVID Bioinformatics 
Resource (v. 6.7; http://david.abcc.ncifcrf.gov/).  
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In both neonatal groups, a large number of different genes were up-regulated 
that were involved in diverse transcriptional regulation, signal transduction, 
RNA/Protein processing pathways and the regulation of cytoskeletal functions. 
However, a substantial number of genes belonging to these groups were down-regulated 
in P9 but not P2 neonates. Genes involved in the expression of several apoptotic 
initiators and effectors, including Pdcd4, Bid, Rtn4, Dffb and the caspase genes Casp2, 
Casp3 and Casp8, were up-regulated in P9 but not P2 neonates. This was accompanied 
by down-regulation of anti-apoptotic factors, such as Tgfb2 and Hspa5. Pro-apoptotic 
factor expression was not mirrored in P2 neonates which, conversely, up-regulated the 
anti-apoptotic mediators Btg2 and Iap3. A number of RT1 genes, which encode the 
various MHC classes, were differentially regulated in both P2 and P9 neonates (Table 
4.3); these include representatives of the MHC I, MHC II and MHC Ib classes. 
Expression of RT1-Aw2 increased 17.7-fold in P2 neonates, the largest observed for this 
cohort. Similarly, RT1-Bb expression increased 11.8-fold in P9 neonates. Colonization 
induced differential expression in several genes encoding components of innate GI 
defence. In P2 neonates, trefoil factor gene Tff2 was down-regulated 24.6-fold and in P9 
neonates the α-defensin genes Defa24 and Defa-rs1 were both up-regulated 3.1- and 
5.4-fold respectively, indicating that P2 and P9 neonatal intestinal tissues respond 
differently to colonization by E. coli K1. These differences may influence the capacity 
of the pathogen to cause systemic disease.   
    
Expression P2 P9 Shared 
    
Up-regulated RT1-CE12 RT1-Bb, RT1-CE15 RT1-AW2 
    
Down-regulated RT1-CE15 RT1-A, RT1-Ba RT1-Db1, RT1-A3 
    
 
Table 4.3: MHC-coding RT1 genes differentially regulated in P2 and P9 neonates in 
response to E. coli K1 colonization. MHC I (red), MHC II (blue) and MHC Ib (green) 
classes are indicated. 
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4.3.2.3 Microarray validation 
 Microarray results were validated by qRT-PCR analysis of eleven genes that 
were differentially regulated in microarray. Genes from both the P2 (RT1-Aw2, Btg2, 
Cald1, Tff2 and Ins2) and P9 (Defa-rs1, Pdcd4, Clic4, Cav, Afp and Amy2) datasets 
were selected for analysis. qRT-PCR data were compared to microarray data and the 
relationship between the two sets analysed using Pearson correlation (Figure 4.9). The 
correlation was highly significant (p <0.0001) and demonstrated a good association 
between microarray and qRT-PCR data. 
 
Figure 4.9: Validation of microarray data using qRT-PCR. The relative expression of 
11 genes in E. coli K1-colonized neonates was determined by qRT-PCR of tissue RNA 
extracts. Mean fold-change in expression detected by qRT-PCR (four replicates) was 
plotted against equivalent microarray data. The Pearson correlation coefficient (R
2
) is 
indicated.     
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4.3.3 Modulation of innate defences by E. coli K1 
 The differential expression of the GI innate defence genes Tff2, Defa24 and 
Defa-rs1 in response to E. coli K1 colonization was examined using semi-quantitative 
and quantitative RT-PCR. The purpose of these experiments was to assess the impact of 
colonization on expression of these genes over a broader time period in comparison to 
that examined by microarray. Nine P2 and nine P9 litters (four colonized, four non-
colonized [broth-fed] and one control; twelve neonates per litter) were used. RNA was 
extracted from intestinal tissues of twelve neonates from each colonized and non-
colonized group at 6, 12, 24 and 48 h following colonization by strain A192PP. RNA 
was obtained from the intestinal tissues of three non-inoculated control neonates at these 
time points.    
 
4.3.3.1 Semi-quantitative analysis 
  Equimolar volumes of individual RNA samples from each A192PP-colonized 
and non-colonized group (twelve per group) were pooled and used as templates for RT-
PCR. Amplicons were resolved by agarose gel electrophoresis for comparison of non-
colonized and colonized groups (Figure 4.10). There was a decrease in Tff2 expression 
at 24 and 48 h after colonization in P2 but not P9 neonates. Defa24 expression was 
increased at 6 and 12 h after colonization in P9 but not P2 neonates. Defa-rs1 
expression increased in P9 neonates 48 h after colonization. Expression in P2 neonates 
also increased 24 and 48 h after colonization. Comparison of non-colonized P2 and P9 
data indicated that Tff2 expression decreased and Defa-rs1 expression increased over 
the P2-P9 period. No significant difference in expression of the control gene rps23 was 
detected between samples. These results did not fully concord with microarray data with 
respect to the timing of differential gene regulation, possibly due to the fact that they 
were based on a larger sample size. However, they did indicate that differential 
regulation of these genes varied over the first 48 h after E. coli K1 colonization.   
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Figure 4.10: Semi-quantitative RT-PCR analysis of Tff2, Defa24 and Defa-rs1 
expression. RNA extracts from A192PP-colonized and non-colonized P2 and P9 
neonates were used as templates for RT-PCR amplification of target genes. Amplicons 
were resolved on 1% (w/v) agarose gels. Rps23 was amplified to serve as a control.  
 
4.3.3.2 Quantitative analysis 
 RNA extracts from each experimental group were analysed by qRT-PCR in 
order to quantify the relative expression of these genes after colonization by E. coli K1 
(Figure 4.11). Data from colonized and non-colonized neonates were compared by the 
two-tailed Mann-Whitney test. Tff2 expression was significantly (p <0.0001) decreased 
(4.6-fold) in P2 animals at 24 and 48 h after colonization with A192PP. No significant 
differences in expression of this gene were observed in P9-colonized neonates at any 
time point examined. Defa-rs1 expression was increased threefold in P9 neonates (p 
<0.05) at 6-24 h and 28.5-fold (p <0.0001) 48 h after colonization. Similarly, Defa24 
expression was increased 5.1-fold in P9 neonates at 6 and 12 h after colonization (p 
<0.001) but not at subsequent time points. No significant differences in either Defa-rs1 
or Defa24 expression were detected in P2-colonized neonates at any time point 
examined. 
 
 
P2 P9
Non-colonized             Colonized
6    12   24  48 6    12   24  48 6    12   24  48 6    12   24  48
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Figure 4.11: Quantitative analysis of Tff2 (top), Defa-rs1 (middle) and Defa24 (bottom) 
expression in P2 and P9 neonates colonized with E. coli K1. RNA was extracted from 
A192PP-colonized and non-colonized intestinal tissues at the indicated times after 
colonization and served as a template for qRT-PCR. Data was normalized to mean non-
colonized data at each time point. Error bars represent SEM of twelve replicates. 
Differences between non-colonized and colonized data are indicated; Mann-Whitney (* 
p<0.05, ** p<0.01, *** p <0.001).    
Tff2 protein was quantified from the intestinal tissues of A192PP-colonized and 
non-colonized P2 neonates. Protein was extracted from tissues under denaturing 
conditions at the time points after colonization previously examined. Tff2 protein was 
quantified by competitive ELISA (Figure 4.12). Results showed a significant (Mann-
Whitney; p <0.001) decrease in Tff2 protein at 24 and 48 h after colonization with 
A192PP. A mean decrease in total Tff2 protein of 3.9- and 2.6-fold was observed at 24 
h and 48 h respectively. 
 
Figure 4.12: Quantification of Tff2 protein from E. coli K1-colonized and non-
colonized P2 intestinal tissues. Protein was extracted from A192PP-colonized and non-
colonized P2 neonates at the indicated time points following colonization and 
concentration determined by competitive ELISA. Data was normalized to total protein 
concentration. Significant differences between non-colonized and colonized data are 
indicated; Mann-Whitney (* p<0.05, ** p<0.01, *** p <0.001).     
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4.3.3.3 Effect on developmental expression 
 Transcriptomic analysis indicated that expression of Tff2, Defa-rs1 and Defa24 
was developmentally modulated over the P2-P9 neonatal period. The „normal‟ 
developmental regulation of these genes was assessed in order to better understand the 
impact of E. coli K1 colonization on their expression. RNA extracts from all non-
colonized (broth-fed) neonates were used in this experiment. Intestinal RNA was 
extracted from non-colonized P1 neonates to serve as a reference. Data from broth-fed 
neonates was compared to data from control intestinal RNA extracts in order to ensure 
that feeding of bacteria did not induce changes in gene expression. All samples were 
analysed by qRT-PCR with data normalized to P1 samples. Data obtained in the 
previous section were combined with normal expression data in order to demonstrate 
the effect of A192PP colonization on normal developmental gene expression (Figure 
4.13).  
 Expression of the three genes varied significantly over the P1-P11 
developmental period; however, the pattern of regulation differed between Tff2 and the 
α-defensin genes. Tff2 expression increased by 4.5-fold (Mann-Whitney; p <0.001) over 
P1-P4. The level of Tff2 expression detected at P4 was maintained until P9, after which 
expression decreased (p <0.001) to a level fourfold lower than at P1. Colonization with 
A192PP at P2 reduced expression of Tff2 to a level similar to that observed at P1. The 
expression of both α-defensin genes increased substantially from P1-P11. Defa24 
expression increased by 5.8-fold and Defa-rs1 by 29.2-fold (p <0.001). The increased 
developmental expression of α-defensin genes amplified the overall up-regulation 
induced by colonization with A192PP at P9. For example, Defa-rs1 expression in P9 
neonates 48 h after colonization was 704.5-fold greater than expression of this gene at 
P1.  
This data demonstrated that refractive neonates not only increase expression of 
α-defensins in response to E. coli K1 colonization but also express more of these AMPs 
than susceptible neonates at the time of colonization. Furthermore, the expression of the 
trefoil factor gene Tff2 is developmentally regulated in the intestine and E. coli K1 
colonization disrupts this process in susceptible neonates.    
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Figure 4.13: Normal expression of Tff2 (top), Defa-rs1 (middle) and Defa24 (bottom) 
genes and differential expression induced by E. coli K1 colonization at P2 and P9. 
Expression was quantified by qRT-PCR of intestinal RNA extracts from non-colonized 
and A192PP-colonized neonates on the days post-partum indicated. Data normalized to 
expression of each gene at P1. Error bars represent SEM from at least twelve animals.    
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4.3.4 Repression of Tff2 expression 
 Trefoil factor expression is modulated by numerous regulatory mechanisms 
(reviewed by Baus-Loncar & Giraud, 2005). Expression of Tff2 is negatively modulated 
by the acute-phase transcriptional regulators nuclear factor kappa B (NFκB) and 
CCAAT/enhancer-binding protein β (C/EBPβ; Dossinger et al., 2002). These 
transcriptional repressors are activated by, respectively, IL-1β and IL-6 pro-
inflammatory cytokines. Therefore, either of these regulatory mechanisms may be 
responsible for the decrease in Tff2 expression observed in susceptible neonates after 
colonization with E. coli K1.  
 
4.3.4.1 IL-6 and IL-1β serum cytokine levels 
 The release of IL-6 and IL-1β cytokines in response to E. coli K1 colonization 
was assessed by quantification of serum levels. Serum was obtained from P2 and P9 
neonates 6, 12, 24 and 48 h after colonization with A192PP. Six animals were used for 
sampling at each time point and serum was collected from an equal number of age-
equivalent non-colonized animals. IL-6 and IL-1β were quantified by ELISA and values 
obtained from non-colonized and colonized animals compared by Mann-Whitney test 
(Figure 4.14). Both cytokines were detected in serum of neonates colonized with 
A192PP at P9; however, no significant differences were detected between non-
colonized and colonized neonates at any time point examined. Conversely, only IL-1β 
was detected in the serum of P2 neonates and significantly (p <0.001) higher levels 
were detected in animals colonized with A192PP compared to their non-colonized 
counterparts. Serum IL-1β concentration more than doubled from 6-24 h after 
colonization in these animals, but returned to non-colonized levels 48 h after 
colonization. These results show that IL-1β secretion was significantly increased in 
susceptible neonates in response to E. coli K1 colonization.  
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Figure 4.14: Quantification of IL-6 (A) and IL-1β (B) from neonatal serum. Serum was 
obtained at the times after colonization indicated from P2 and P9 A192PP-colonized 
neonates and from age-equivalent non-colonized animals. Error bars represent SEM of 
six animals. Differences between non-colonized and colonized data are indicated; 
Mann-Whitney (* p<0.05, ** p<0.01, *** p <0.001). 
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4.3.4.2 NFκB and C/EBPβ expression and activity 
 Expression of the genes encoding NFκB and C/EBPβ was examined to 
determine if colonization by E. coli K1 influenced the production of these transcription 
factors. The intestinal RNA extracts used in previous gene expression analyses were 
employed. RNA was examined by qRT-PCR and data from A192PP-colonized animals 
normalized to data from non-colonized animals (Figure 4.15). Colonization by E. coli 
K1 had no impact on the expression of Cebpb at any time point examined. Expression 
of Nfkb1 was increased to a small (1.3-fold) but significant (Mann-Whitney; p <0.01) 
degree 48 h after colonization, providing further evidence that the IL-1β/NFκB pathway 
was the most likely source of Tff2 repression. The activity of NFκB was therefore 
assessed in neonatal intestinal tissues. 
 
Figure 4.15: NFκB (A) and C/EBPβ (B) expression in E. coli K1 colonized intestinal 
tissue. Expression was quantified by qRT-PCR of intestinal RNA from non-colonized 
and A192PP-colonized P2 neonates at the times indicated. Differences between non-
colonized and colonized data are indicated; Mann-Whitney (* p<0.05, ** p<0.01, *** 
p <0.001). 
 
 NFκB activity was assessed by EMSA of nuclear protein extracts, allowing 
semi-quantitative assessment of NFκB activity. Single cells were prepared from the 
intestinal tissues of neonates colonized with A192PP at P2. Tissues were obtained 6, 12, 
24 and 48 h after colonization. Nuclear proteins were recovered and examined for 
cytoplasmic contamination by SDS-PAGE and Western blotting (Figure 4.16). 
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Comparison of cytoplasmic and nuclear protein fractions by SDS-PAGE showed that 
nuclear fractions contained intensely-staining low molecular weight (~12-15 kD) 
protein bands that were largely absent from cytoplasmic fractions. The size of these 
proteins corresponds to the known molecular weight of several nucleus-associated 
histone proteins. Furthermore, Western blots detected α-tubulin in cytoplasmic, but not 
nuclear, protein fractions, demonstrating that nuclear protein was successfully isolated 
and available for use in downstream EMSA. 
 
 
Figure 4.16: Isolation of nuclear proteins from intestinal tissues. Cytoplasmic (C) and 
nuclear (N) protein fractions were resolved by SDS-PAGE (left panel) and stained for 
α-tubulin by Western blot (right panel). Precision-Plus Protein Marker (M; Bio-Rad) 
was used to determine protein molecular weight.   
 
 Nuclear proteins were obtained from six colonized and non-colonized neonates 
for each time point examined. Equal amounts of protein extract from individual 
experimental groups were pooled and analysed by EMSA (Figure 4.17). Assay 
specificity was checked by competition EMSA analysis of combined pooled nuclear 
protein extracts. Band shift was detected in all non-colonized and colonized samples at 
all time points examined. However, the intensity of the band shift was much greater in 
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colonized samples compared to their non-colonized equivalents. Competitor EMSA 
showed that the observed band shift was specific to the sequence of the NFκB probe. 
These results clearly indicated that colonization by E. coli K1 significantly increased the 
amount of active NFκB localized to the nuclei of intestinal tissue cells.  
 
Figure 4.17: Activation of NFκB by E. coli K1 intestinal colonization. Nuclear protein 
extracts were obtained from A192PP-colonized and non-colonized P2 neonates at the 
time points indicated after colonization. Extracts were analysed by EMSA using a Cy5-
conjugated dsDNA probe containing the wild-type NFκB binding site (left panel). 
Competitor EMSA (right panel) was performed using unlabelled wild-type (wt) or 
mutant (mut) competitor dsDNA. The position of free Cy5-conjugated probe is indicated 
(►).     
 
4.3.5 Muc2 expression 
 Expression of the gel-forming mucin Muc2 was assessed in the intestines of 
neonates colonized with E. coli K1 at P2. Expression was analysed at the mRNA and 
protein level by qRT-PCR and Western blot. Muc2 expression was quantified from 
RNA and reduced protein extracts used in previous experiments (Figure 4.18). 
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Figure 4.18: Intestinal Muc2 expression in neonates colonized with E. coli K1 at P2. 
(A) Expression at the mRNA level was analysed by qRT-PCR of RNA extracts. Error 
bars represent SEM of twelve replicates. (B) The presence of Muc2 protein was 
analysed by Western blot of SDS-PAGE resolved reduced protein extracts (n=6; 
pooled). Samples were obtained from A192PP-colonized and non-colonized neonates at 
the time points indicated after colonization. Protein band molecular weight was 
determined using HiMark Protein Standards (Invitrogen).   
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No significant differences in muc2 gene expression between colonized and non-
colonized samples were found at any time point between 6-48 h. Western blot analysis 
detected three immunoreactive protein bands. No bands were detected in control blots 
using secondary detection reagents only; the reactivity of the bands was therefore anti-
Muc2 primary antibody-specific. The approximate molecular weights of these bands 
were 300, 117 and 90 kD. The 300 kD band represented Muc2 monomer whilst the 
smaller bands are probably Muc2 degradation products generated during protein 
extraction. Comparison between A192PP-colonized samples and their non-colonized 
equivalents showed no significant differences from 6-24 h after colonization. However, 
after 48 h, both the 300 and 117 kD band were significantly diminished in comparison 
to the equivalent non-colonized sample. Less Muc2 monomer was detected at the 6 h 
time point compared to all subsequent time points in both colonized and non-colonized 
samples. Overall, these results demonstrate that Muc2 protein was reduced by E. coli 
K1 colonization of the neonatal intestine. Furthermore, this reduction was not regulated 
by the host at the mRNA transcriptional level.          
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4.4 Discussion 
 
 The data presented in this chapter demonstrate that a significant degree of 
intestinal tissue development occurs at the anatomical and molecular levels over the P2-
P9 developmental period. Tissue development occurs over the period during which E. 
coli K1 loses its capacity to translocate from the intestinal lumen to the systemic 
circulation. It is therefore possible that loss of translocational capacity is related to 
maturation of the GI tissues.  
Comparison of the P2 and P9 transcriptomes indicate that several genes 
encoding products of the host innate immune system are expressed to a greater degree in 
the more mature P9 tissues. These include several Paneth cell-secreted AMPs such as 
phospholipase A2, the enteric α-defensin Defa24, the α-defensin related Defa-rs1 and 
the putative AMP Dmbt1. Phospholipase A2 is bactericidal to E. coli strains and has a 
similar minimum bactericidal concentration as the human myeloid α-defensin HNP-1 
(Harwig et al., 1995). The antimicrobial spectra of Defa24 and Defa-rs1 are currently 
unknown; however, they are closely related to the murine Defcr (defensin-related 
cryptidin) and CRS (cryptidin related sequence) enteric α-defensin groups (Patil et al., 
2004). The murine α-defensins are well characterized, possess broad antimicrobial 
activity and are active against E. coli (Hornef et al., 2004; reviewed by Ouellette & 
Selsted, 1996). Dmbt1 is an agglutinin secreted by several cell types including Paneth 
cells. It is not bactericidal, but binds to and agglutinates many bacterial species, 
including E. coli (Bikker et al., 2002). Dmbt1 inhibits the intracellular invasion of 
intestinal epithelial cells by Salmonella enterica (Rosenstiel et al., 2007). It is therefore 
possible that some or all of the developmentally regulated AMPs modulate the capacity 
of E. coli K1 to access the intestinal epithelium and cause systemic disease. 
The gene with the largest increase in expression in P9 compared to P2 intestinal 
tissues also encodes an immune-related protein: RT1-Aw2 (also known as RT1-EC2) is 
an MHC Ib molecule. MHC Ib molecules are very similar to classical MHC Ia 
molecules in that they are used by nucleated cells to present intracellular material at the 
cell surface. This material is generally derived from the processing of cytoplasmic 
proteins by the cytosolic proteasomes and usually consists of normal host peptide 
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fragments. Presentation of foreign peptides (i.e. during intracellular viral or bacterial 
infection) or defective host peptides results in activation of cytotoxic T-cells which 
induce apoptotic pathways in the infected/defective cell. MHC Ia expression is 
ubiquitous and MHC Ia peptide binding sites are highly polymorphic which allows 
them to bind a huge range of peptide ligands. Conversely, MHC Ib expression is tissue-
specific and their peptide binding sites are oligomorphic and thus bind only a restricted 
range of ligands. These ligands include specific prokaryotic molecules such as the 
Hsp60 orthologue GroEL and N-formylmethionine, a modified form of methionine 
which bacteria use to initiate protein synthesis (Colmone & Wang, 2006; reviewed by 
Rodgers & Cook, 2005). This suggests that one function of MHC Ib molecules is to act 
as intracellular PRRs that can rapidly present conserved bacterial peptides at the surface 
of infected cells. This MHC Ib function may be relevant to intracellular E. coli K1 
infection. Unfortunately, the rat RT1 complex is relatively poorly characterized 
compared to its human and murine equivalents. It is also very difficult to draw 
orthologous relationships between MHC molecules based on sequence homology. As 
such, the ligand specificity and function of RT1-Aw2 remain unknown. 
It is clear that substantial development occurs in the intestine over P2-P9. 
However, it is not clear if any of these alterations are directly responsible for the 
modulation of susceptibility to E. coli K1 infection. The differential responses of P2 and 
P9 tissues to E. coli K1 colonization were assessed in an attempt to shed light on this 
question. One potentially significant difference was the up-regulation of the 
developmentally regulated AMPs Defa24 and Defa-rs1. This occurred in P9 but not P2 
neonates. Up-regulation of Defa24 and Defa-rs1 at the transcriptional level was 
unexpected as enteric defensin genes are thought to be constitutively expressed. 
Bacterial PAMPs can induce increased defensin secretion but not a concomitant up-
regulation of defensin mRNA transcription (reviewed by Selsted & Ouellette, 2005). 
Defa24 expression was up-regulated in response to E. coli K1 colonization of P9 
neonates; however, this up-regulation was transient and was not detected >24 h after 
colonization. Conversely, the extent of Defa-rs1 up-regulation increased significantly 
from 6-48 h after colonization. The regulation of defensin-related peptides has not yet 
been specifically characterized and the data presented here strongly indicate that 
expression of this AMP class is inducible. The fact that both Defa24 and Defa-rs1 were 
up-regulated in response to E. coli K1 colonization of P9 but not P2 neonates is 
185 
 
indicative that these two AMPs play a role in modulating susceptibility to the pathogen. 
A further AMP which was up-regulated in response to colonization was Reg3b. This 
protein has recently been implicated in the control of Gram-negative bacteria in the 
intestine (van Ampting et al., 2012). However, this AMP was up-regulated in both P2 
and P9 neonates, suggesting that it is unlikely to be of significance in terms of E. coli 
K1 infection. 
Colonization with E. coli K1 induced differential regulation of multiple MHC 
genes in P2 and P9 neonates. In both groups, the MHC Ib gene RT1-Aw2 was strongly 
up- and RT1-Db1 (MHC II) and RT1-A3 (MHC I) down-regulated. RT1-Bb (MHC II) 
and RT1-CE15 (MHC I) were up-regulated and RT1-Ba (MHC II) and RT1-A (MHC I) 
were down-regulatde in P9 intestinal tissues. Conversely, RT1-CE15 was down-
regulated and RT1-CE12 (MHC I) was up-regulated in P2 intesintal tissues. MHC I 
genes are regulated by multiple factors including NFκB and cAMP response element-
binding (Creb) transcription factors, whereas MHC II gene expression is modulated by 
pathways initiated by interferon gamma (Ifnγ), TNF-α and TGF-β (reviewed by Ting & 
Baldwin, 1993). E. coli K1 colonization has a marked effect on the transcription of 
these important molecules; however, it is difficult to discern a meaningful pattern in the 
differential regulation observed in this study and their significance remains uncertain.    
 Transcriptomic data showed that E. coli K1 colonization resulted in the 
differential regulation of several factors involved in apoptotic pathways. Apoptosis is 
relevant to the intracellular phase of E. coli K1 infection as the pathogen has the 
capacity to prevent apoptotic initiation. This is achieved by the up-regulation of anti-
apoptotic BclXL which inhibits mitochondrial cytochrome c release (Sukumaran et al., 
2004). Therefore, it is interesting that P9 intestinal tissues up-regulated the expression 
of BH3 interacting-domain death agonist (Bid) and reticulon four (Rtn4). Bid promotes 
mitochondrial cytochrome c release (Zhao et al., 2003) and Rtn4 inhibits the activity of 
BclXL (Tagami et al., 2000). In addition, several caspase genes and DNA fragmentation 
factor beta (Dffb), a nuclease which targets cellular DNA during apoptosis (Liu et al., 
1997), were also up-regulated. This pattern of pro-apoptotic gene regulation was absent 
from the transcriptome of neonates colonized at P2. No changes in BclXL expression 
were detected in this group; however, a fourfold up-regulation of apoptosis inhibitor 3 
(Iap3) was detected. Iap3 is a potent inhibitor of caspase-mediated apoptotic pathways 
(reviewed by Deveraux & Reed, 1999). The prevention of apoptosis is essential for the 
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intracellular survival of E. coli K1. This data indicates that neonates that are refractive 
to systemic disease can increase expression of factors which are antagonistic to the anti-
apoptotic mechanism used by E. coli K1.  
There was no evidence that E. coli K1 intestinal colonization affected expression 
of genes encoding Tff3, Fcgbp or any of the gel-forming intestinal mucins. However, 
the trefoil factor Tff2 was significantly down-regulated in the intestines of P2 neonates 
24 h after colonization. In adults, Tff2 is primarily found in the stomach and is not 
conventionally associated with the lower GI tract (reviewed by Thim, 1997). The 
regulation of intestinal Tff3 expression in the foetus and neonate has been described 
previously (Lin et al., 1999; Mashimo et al., 1995) and Tff2 expression has been shown 
in foetal intestinal tissues (Samson et al., 2011); however, the post-natal expression of 
this peptide has not been examined in the neonatal rat. The data presented here 
demonstrate that Tff2 is transiently up-regulated in the neonatal intestine and that this 
increased expression is maintained over the P3-P9 period; however, expression declined 
substantially after P9. It is interesting to note that the period of increased Tff2 
expression exactly matches the period in which the neonatal rat develops resistance to 
systemic E. coli K1 infection. Whilst one cannot assume a causal relationship between 
these observations, the fact that E. coli K1 colonization abolishes the normal pattern of 
Tff2 expression demonstrates that a link does exist. The observation that IL-1β secretion 
and NFκB activation are increased immediately prior to the down-regulation of Tff2 
provides a mechanistic basis for the down-regulation of Tff2 (Dossinger et al., 2002). 
Trefoil peptides have multiple functions, which include regulation of healing, 
inflammation and the immune response (Playford et al., 1995; Tran et al., 1999; Kurt-
Jones et al., 2007) as well as a structural role in the cytoprotective mucus barrier (Thim 
et al., 2004; Kjellev et al., 2006; Playford et al., 2006; Yu et al., 2011). Any of these 
functions could be relevant to E. coli K1 infection. The potential role of Tff2 in the 
intestines can be ascertained from data obtained from Tff2-KO animals (Kurt-Jones et 
al., 2007). A potentially significant observation is that these animals are more 
susceptible to dextran sodium sulphate (DSS)-induced colitis than their wild-type 
counterparts. DSS is commonly used to induce experimental colitis but the mechanism 
of action has only recently been determined. Oral administration of DSS disrupts the 
stability of the inner stratified mucus layer, allowing luminal bacteria to access the 
colonic epithelium (Johansson et al., 2010). One interpretation of these studies is that 
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Tff2 enhances the stability of the mucus layer. Therefore, the developmental increase in 
Tff2 observed in this investigation may form a component of colonic mucus barrier 
development in the neonate. Furthermore, if E. coli K1 colonization disrupts this 
developmental process it would compromise barrier development and allow the 
pathogen to access the colonic epithelium and, potentially, invade the host tissue. The 
reduction in detectable Muc2 protein 48 h after colonization of P2 neonates 
demonstrates that E. coli K1 modulates Muc2 and thus provides preliminary evidence 
supporting this hypothesis.           
 Although the data presented in this chapter do indicate several areas of potential 
interest with regards to E. coli K1 colonization of the intestinal tract there are several 
caveats which must be taken into account. Due to a limited number of GeneChip arrays 
the transcriptomic data was based on a single microarray per experimental group. RNA 
samples from multiple animals were pooled in order to provide data approximating the 
mean transcriptomic response of the tissues analysed; however, it is possible that much 
of the differential regulation indicated by this analysis would not be identified as 
statistically significant by a similar analysis using multiple replicate arrays. Another 
important issue is the fact that all the results described here are based on the analysis of 
whole intestinal tissues. The intestine is a large multi-compartmental structure with each 
compartment comprising distinct tissues. Therefore, treating these tissues as a single 
unit carries inherent risks with respect to the quantification of gene expression. For 
example the up-regulation of a gene in one compartment may be masked by the down-
regulation of the same gene in a different compartment and vice-versa. Furthermore, the 
extraction of RNA and protein from whole intestinal tissues means that these samples 
would have primarily represented the ileal and jejunal tissues, as these are by far the 
largest structures within the intestine. This bias could have influenced the results of the 
assays described in this chapter. The intestine is also directly linked to the stomach and 
pancreas. Although great care was taken to avoid contamination of intestinal samples by 
these tissues, the risk of carry-over must be considered. Finally, it is necessary to note 
that whilst the data presented here demonstrate a correlative link between E. coli K1 
colonization and the tissue responses observed they do not establish a causative link 
between those responses and the progression of E. coli K1 infection.                  
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CHAPTER 5 
GENERAL DISCUSSION 
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 The data presented in this thesis represents an attempt to provide a mechanistic 
basis for the age-dependency of systemic E. coli K1 infection in the neonate. The results 
and potential limitations of the experiments described in the preceding chapters have 
been previously discussed. Therefore, this chapter will provide an overview of the data 
and the potential implications for our current understanding of neonatal E. coli K1 
infection. Avenues for future investigations are also suggested and examples of ongoing 
research, based on the results of this investigation, are included.   
The data presented in Chapter 2 provide compelling evidence that the intestine is 
the basis of age-dependency in the neonatal rat model, as indicated by previous 
investigators (Glode et al., 1977; Mushtaq et al., 2005). The intestinal tract is a highly 
complex environment and our current understanding of it is incomplete. Complexity is 
conferred by the tissues, comprising multiple cell types and interwoven with the enteric 
nervous system and GALT, and the trillions of microbes that comprise the microbiota. 
The intestinal tissues require this complexity in order to fulfil their function as an active 
interface between the host and the external environment. In turn, the microbiota is 
complex due to the multiple ecological niches provided by the enteric milieu. These 
factors make understanding the intestinal environment a challenge. The post-partum 
development of both tissue and microbiota which occurs in the neonate adds another 
layer of variability which also had to be taken into account during this investigation. 
 The previous decade has seen multiple studies which have used culture-
independent methods to highlight developmental aspects of the intestinal microbiota 
(for example Favier et al., 2002; Palmer et al., 2007). This research has significantly 
broadened our understanding of the different taxonomic groups which inhabit the 
intestine and the temporal trends which affect the overall composition of the microbial 
population. The mCR function provided by the commensal microbiota is undoubtedly 
of great importance in protecting the host from colonization by obligate and 
opportunistic pathogens (Hooper et al., 2003; Endt et al., 2010; Vaishnava et al., 2011). 
This protective role is complemented by the capacity of the microbiota to modulate the 
virulence of some opportunistic pathogens (Bernet et al., 1993; Coconnier et al., 2000; 
Altenhoefer et al., 2004). These concepts formed the basis of the hypothesis that the 
microbiota is a key factor in modulating susceptibility to E. coli K1 infection.  
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Quantitative and qualitative analysis of the microbiota of both susceptible and 
refractive neonates failed to identify any immediately obvious differences that could 
account for the age dependency of systemic infection. However, the expansion of two 
clostridial genera over the P2-P9 period potentially represents a population shift of 
relevance to E. coli K1 colonization (Itoh & Freter, 1989). The significance of these 
bacteria could be determined by feeding susceptible neonates with Clostridia followed 
by an assessment of the impact on susceptibility to E. coli K1 infection. Such an 
approach has previously been used to demonstrate the protective effects of 
Lactobacillus spp. (Lee et al., 2000). However, the feasibility of this method with 
respect to Clostridia is questionable as the oxygen tension of the P2 neonatal intestine 
may be higher than that of the P9 equivalent and would thus represent a less hospitable 
environment for obligate anaerobic bacteria. 
Antibiotic suppression of the endogenous microbiota was used to assess the 
potential role of direct and competitive mCR mechanisms in modulating susceptibility 
to E. coli K1 infection. Suppression of the microbiota had no discernible impact on 
susceptibility to E. coli K1, providing further evidence that it does not play a direct role 
in modulating the capacity of the pathogen to cause systemic disease. As previously 
stated, the results of the suppression study must be treated with an element of caution as 
the antibiotic-resistant A192PPR transformant was notably less virulent than the parent 
A192PP isolate. A192PPR is capable of causing systemic disease in neonates colonized 
at P2; however, its capacity to cause systemic disease in the extraintestinal environment 
of refractive neonates was not assessed in the current study. Systemic administration of 
A192PPR to P9 neonates would serve as a useful validation of this method and the 
conclusions based on it.  
Colonization by the microbiota stimulates a number of hCR mechanisms, 
including the secretion of inducible AMPs and production of sIgA (Hooper et al., 2003; 
Macpherson & Uhr, 2004; Vaishnava et al., 2011). This aspect of mCR was not 
assessed in the current study and may be of significance. To date, no investigations have 
compared the susceptibility of GF and conventionally reared animals to E. coli K1 
infection. Such a comparison would clarify whether or not neonates require the 
stimulation of hCR mechanisms initiated by bacterial colonization in order to develop 
resistance to E. coli K1. 
191 
 
Overall, the data does not support the hypothesis that the development of the 
neonatal intestinal microbiota modulates susceptibility to E. coli K1 infection. However, 
the methods used in this investigation do not take into account any spatial aspects of the 
microbial population. The individual GI compartments have distinct biochemical and 
physical properties and thus represent different ecological niches. Accordingly, the 
gastric, small intestinal and colonic compartments each play host to a partially distinct 
subset of the GI microbiota (Eckburg et al., 2005; Hayashi et al., 2005; Bik et al., 
2006). It is possible that significant changes to the composition of the microbiota of 
these distinct regions occurs over the P2-P9 neonatal period and that this variation was 
not detected by the methods employed here. The post-partum development of the 
microbiota of the different GI compartments has not been well characterized and is 
worthy of further investigation.   
The intestinal tissues are subject to significant post-partum developmental 
alterations in response to exposure to the extra-uterine environment and initiation of 
enteral feeding. This development includes the proliferation of two secretory epithelial 
cell lineages which play a key role in maintaining intestinal barrier function in the small 
intestinal and colonic compartments. The colonic goblet cell population continues to 
expand post-partum and this expansion is accompanied by increased production of 
Muc2 and trefoil peptides (Chambers et al., 1994; Fanca-Berthon et al., 2009). The 
small intestinal Paneth cell population also grows rapidly in the post-natal period (Bry 
et al., 1994), as does their secretion of AMPs (Mallow et al., 1996). The proteins 
secreted by these cells are vital for maintaining the microbiota at a safe distance from 
the enteric epithelial surface (Johansson et al., 2008; Vaishnava et al., 2011). The fact 
that they are developmentally regulated therefore indicates that the intestinal barrier 
function in younger neonates is immature. This concept partly informed the hypothesis 
that the development of the neonatal intestine over the P2-P9 period modulated 
susceptibility to E. coli K1 infection.  
The neonatal intestinal tract grew substantially from P2-P9. This growth was 
accompanied by a significant degree of developmental gene regulation, including a 
sustained increase in AMP expression and a transient increase in the trefoil peptide 
Tff2. Based on these results, as well as our current state of knowledge regarding the 
developmental regulation of Paneth and goblet cells, we can formulate a speculative 
model of intestinal barrier development over the P2-P9 period (Figure 5.1). 
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Figure 5.1: Development of innate defence barriers in the 
neonatal intestine from P2-P9. The P2 ileum produces less 
defensin peptides than the more mature P9 tissues. The P2 
colon produces less Muc2 and trefoil factor than the P9 
colon, resulting in a less developed stratified inner mucus 
layer (IML) in the P2 compared to P9 colon. These 
deficiencies allow a closer association between the 
intestinal microbiota (which inhabit the outer mucus 
layer; OML) and the intestinal epithelium in P2 compared 
to P9 neonates.   
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 The comparative lack of defensin expression in P2 compared to P9 tissues is a 
strong indication that the AMP-dependent barrier function of the small intestine is 
weaker at P2 compared to P9. The development of the colonic mucus barrier may be 
related to the transient increase in Tff2 expression from P2-P9. It is interesting to note 
that expression of Tff3 in the rat colon does not start to increase towards adult levels 
until P12-P17 (Lin et al., 1999; Fanca-Berthon et al., 2009). Given the apparent role of 
Tff3 as a structural component of the colonic mucus barrier (Yu et al., 2011), this 
pattern of developmental expression seems unusual. We can speculate that Tff2 plays a 
similar role to Tff3 in the early neonatal intestine. The peptide may stabilize the 
developing colonic mucus barrier prior to the developmental increase in Tff3 
expression. However, tissue-specific aspects of developmental gene expression were not 
assessed in this investigation. Therefore, Tff2 may be localized to the small intestine 
rather than the colon. This issue could be easily resolved by analysis of mRNA and 
protein isolated from individual intestinal compartments by methods described in this 
investigation. Furthermore, the role of Tff2 in formation of the mucus barrier could be 
ascertained using a Tff2-KO animal model. The post-partum proliferation of goblet 
cells and developmental regulation of Muc2 and trefoil peptide expression strongly 
indicate that the colonic mucus barrier develops in the postnatal period. This implies 
that the barrier may be weaker in P2 compared to P9 neonates. The mucus barrier has 
previously been characterized using immunohistological methods (Johansson et al., 
2008) and these would also allow qualitative comparison of the P2 and P9 colonic 
mucus barrier.     
The transcriptional responses of P2 and P9 intestinal tissues to colonization by 
E. coli K1 were highly divergent. Several genes encoding products involved in host 
defence mechanisms were differentially expressed, including developmentally regulated 
defensins and Tff2. The fact that comparatively few differentially expressed genes were 
shared between colonized P2 and P9 neonates indicates that the intestinal tissue of the 
refractive neonate responds very differently to that of the susceptible neonate. This 
demonstrates that the capacity of the host to respond to E. coli K1 colonization is likely 
to be a key factor in determining susceptibility to systemic infection. The suppression of 
Tff2 and loss of Muc2 protein in P2-colonized tissues may allow E. coli K1 access to 
the intestinal epithelium. Conversely, the up-regulation of defensin peptides by P9-
colonized tissues may inhibit this interaction (Figure 5.2).     
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Figure 5.2: Colonization of the P2 and P9 intestine by E. coli 
K1. (P2) 1; defensin deficiency allows bacteria to access 
/invade the small intestinal tissues. 2; bacterial colonization 
is detected by intestinal leukocytes. 3; activated leukocytes 
secrete IL-1β which activates NFκB transcription factor. 4; 
activated NFκB suppresses trefoil factor production in goblet 
cells, resulting in breakdown of the inner mucus layer (IML) 
structure. 5; Loss of IML integrity allows bacteria to 
access/invade colonic tissue. (P9) 1; up-regulated defensin 
production prevents bacteria accessing the small intestinal 
tissues. 2; defensins prevent IL-1β secretion by leukocytes. 3; 
IML prevents bacteria accessing the colonic tissue.    
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 E. coli K1 colonization of the P2 intestine invariably results in translocation of 
the pathogen from the intestine into the systemic circulation. However, a key question 
has yet to be resolved: where in the intestine does translocation occur? This specific 
issue was not addressed by this investigation; however, the developmental deficiencies 
that are likely to be present in both the small intestinal and colonic barrier function of 
the P2 intestine indicate that both of these regions represent a potential route of 
invasion. The lack of secreted defensins could allow E. coli K1 to access the small 
intestinal epithelium. Equally, dysregulation of Tff2 expression may provide access to 
the colonic epithelium. Colonization of the P2 intestine induces the secretion of IL-1β. 
This is most likely due to the detection of PAMPs (for example LPS) by the intestinal 
leukocyte population. Adult intestinal macrophages lack the CD14 receptor which 
systemic macrophages use to detect bacterial LPS (Smythies et al., 2005). LPS 
tolerance prevents intestinal macrophages from inducing potentially damaging 
inflammatory reactions in response to the intestinal microbiota. This tolerance does not 
develop until the peri-natal period (Lotz et al., 2006; Maheshwari et al., 2011) and may 
explain why IL-1β secretion is not induced in P9 neonates. Furthermore, α-defensins 
represent another potential inhibitor of IL-1β secretion from macrophages in the P9 
intestine (Shi et al., 2007). Secretion of IL-1β in P2 intestines colonized by E. coli K1 
results in activation of NFκB and transcriptional suppression at the Tff2 promoter. The 
decrease in detectable Muc2 protein, subsequent to the suppression of Tff2, may 
indicate that loss of the trefoil peptide results in a breakdown of the colonic mucus 
barrier. This would allow access to the colonic epithelium and, potentially, result in E. 
coli K1 invasion via this route.  
 The site of E. coli K1 translocation is an important unknown in the pathogenesis 
of this organism. Thorough histological analysis of colonized intestinal tissues would be 
an ideal method of resolving this issue. The importance of α-defensin production could 
also be assessed experimentally. This can be achieved by selective ablation of Paneth 
cells using the zinc-binding dye dithizone (Sherman et al, 2005). The proposed 
mechanism of colonic invasion could also be examined with relative ease. The effects of 
E. coli K1 colonization on the stability of the colonic mucus barrier could be assessed 
using the immunohistological methods described previously (Johansson et al., 2008) 
and Tff2 protein could be simultaneously localized. Flow cytometry could be used to 
compare the number of CD14
+
 macrophages present in P2 and P9 intestinal tissues to 
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determine if the P2 intestine is more susceptible to LPS-induced inflammation that the 
tissues of older animals. Furthermore, the isolation of intestinal macrophage populations 
by fluorescence-activated cell sorting (FACS) could be used to determine if E. coli K1 
uses this large reservoir of leukocytes for systemic growth prior to haematogenous 
dissemination in susceptible neonates.  
 Some preliminary progress has already been made regarding these avenues of 
investigation. Colonization of the small intestine by E. coli K1 is currently under 
investigation in our laboratory at the UCL School of Pharmacy. Preliminary data 
indicate that there are differences in the capacity of E. coli K1 to colonize the non-
colonic GI compartments of P2 and P9 neonates (Figure 5.3). The higher E. coli K1 
load detected in the proximal (and to a lesser extent distal) small intestine of P2 
neonates compared to P9 neonates may indicate that the small intestine is a more likely 
site of bacterial translocation. Furthermore, dithizone treatment has been successfully 
used to significantly reduce Defa24 and Defa-rs1 expression in P9 neonates. This will 
provide a useful model in which to determine the importance of these peptides in 
modulating susceptibility to E. coli K1.  
The neonatal colonic mucus barrier is currently under investigation in 
collaboration with the Mucin Biology Group at the University of Gothenburg. 
Preliminary data shows that the stratified inner mucus layer, which confers the colonic 
barrier function, is almost entirely absent in the P2 colon but is present in the P9 colon 
(Figure 5.4). This supports the developmental model illustrated in Figure 5.1. 
Intriguingly, colonization of P2 animals with E. coli K1 appears to result in a massive 
decrease in Muc2 stored in colonic goblet cells. This effect is not evident in neonates 
colonized at P9. This observation could mean that E. coli K1 colonization either 
suppresses Muc2 synthesis or induces goblet cells to dump their stored Muc2 into the 
intestinal lumen. The latter may represent an attempt by the host to clear the pathogen 
from the intestines, an effect which has been observed during colonization by the rodent 
intestinal pathogen Citrobacter rodentium (Linden et al., 2008; Bergstrom et al., 2010). 
However, the loss of stored Muc2 at such an early stage in the development of the 
colonic mucus barrier would be likely to compromise this developmental process. These 
results indicate that the colon represents a possible route of infection for E. coli K1.                   
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Figure 5.3: Quantification of E. coli K1 from the GI compartments of P2 and P9 
neonates. Statistically significant differences are indicated; Mann-Whitney (* p<0.05, 
** p<0.01, *** p <0.001). Data provided by Fatma Dalgakiran (UCL School of 
Pharmacy).       
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Figure 5.4: The Muc2 colonic mucus barrier in P2 and P9 neonates. Methacarn-fixed 
colonic tissues from P2 (A) and P9 (D) neonates were stained for Muc2. Colonic tissues 
were obtained from P2 (B/C) and P9 (E/F) neonates 48 h after inoculation with E. coli 
K1 (C/F) or sterile broth (B/E). All images were processed in the same way. The 
stratified inner mucus layer is indicated in D, E and F (----). Scale bars represent 100 
µm. Images supplied by Malin Johansson (University of Gothenburg).     
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 The aim of this investigation was to determine the influence of the developing 
intestinal microbiota and maturing intestinal tissues on the capacity of E. coli K1 to 
translocate from the neonatal intestine into the systemic circulation. The results 
presented in this thesis strongly support the hypothesis that maturation of the innate 
defensive mechanisms of the neonatal intestine accounts for the development of 
resistance to systemic E. coli K1 infection. However, they do not preclude a role for the 
microbiota in the stimulation of this developmental process. Although the mechanics of 
susceptibility and resistance to E. coli K1 infection have not been conclusively 
identified by this investigation, it has provided some interesting avenues of future 
research. In addition, depending on the outcome of that research, both Tff2 and α-
defensin AMPs represent potential therapeutic candidates for the prevention of sepsis 
and NBM mediated by E. coli K1.  
AMPs are now recognized as a potential replacement for standard antibiotics 
(reviewed by Hancock & Sahl, 2006). Recombinant α-defensin-like peptides could be 
used to supplement the neonatal GI tract with AMPs and boost the barrier function of 
the small intestine. However, to date, AMPs have only been successfully used in topical 
applications and have suffered from production problems, toxicity and unfavourable 
pharmacokinetics. Conversely, recombinant Tff2 is easily produced in bacterial 
expression vectors (Sun et al., 2010), is highly stable in the GI tract (Kjellev et al., 
2007) and has been successfully used to treat experimental GI injuries (Poulsen et al., 
1999; Tran et al., 1999; Sun et al., 2009). The dysregulation of Tff2 expression by E. 
coli K1 colonization of the neonatal intestine could be compensated by oral 
administration of the recombinant protein. If Tff2 does play a significant role in 
stabilizing the colonic mucus barrier, or modulates infection by an alternate mechanism, 
this could provide a novel therapeutic strategy for combating neonatal mortality.          
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Figure A1: Comparative sub-phylum phylogenetic analysis of the composition of the GI 
tract microbiota of P2, P5 and P9 neonates. Relative abundance of amplified SSU 
rDNA sequences from P2, P5 and P9 samples binding to class (level 3), order/family 
(level 4) and genus (level 5) taxonomic level microarray probes from the Bacteroidetes 
(A), Proteobacteria (B) and Gram-positive (C) phyla. P2, P5 and P9 neonatal data 
were normalized to adult data as indicated by the dashed lines at x=1. Numeric codes 
correspond to prokMSA (http://greengenes.lbl.gov) SSU rDNA database classifications 
for the indicated taxonomic level probes. Probes were ranked according to average Cy5 
and Cy3 fluorescence across the P2, P5, and P9 datasets, with the highest at the top of 
each figure. Error bars are SEM from four arrays.  
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Table A1: Comparative species level analysis of the GI tract microbiota of P2, P5 and 
P9 neonates. Mean relative SSU rDNA abundance (RSA), RSA standard deviation from 
four arrays (Stdev) and statistical comparison to adult data determined by two-tailed t-
test (p-value) are detailed. 
Name 
P2 P5 P9 
RSA StdDev p-value RSA StdDev p-value RSA StdDev p-value 
Euryarchaeote DJ3 8.63 4.90 1.81E-03 7.87 3.47 4.51E-04 5.82 2.31 7.77E-04 
Verrucomicrobium 
DEV179 0.19 0.06 2.76E-04 0.14 0.10 7.61E-03 0.16 0.06 3.30E-03 
Holophaga spp. 0.09 0.03 7.78E-05 0.09 0.03 8.55E-05 0.10 0.04 3.49E-04 
AB113725 clone: OAB38 0.17 0.09 6.50E-04 0.10 0.02 1.62E-05 0.07 0.03 4.72E-05 
Bacteroides merdae    0.02 0.03 2.46E-03 0.02 0.00 5.90E-13 0.02 0.03 8.56E-05 
Bacteroides acidofaciens 0.03 0.06 1.21E-02 0.04 0.07 1.26E-02 0.03 0.09 1.35E-02 
Bacteroides fragilis   0.04 0.10 2.10E-02 0.03 0.05 1.06E-02 0.05 0.21 3.89E-02 
Bacteroides caccae 0.02 0.05 8.56E-03 0.02 0.01 1.62E-04 0.04 0.10 1.52E-02 
Bacteroides vulgatus 0.02 0.04 6.24E-03 0.02 0.03 2.58E-03 0.03 0.09 2.21E-03 
Bacteroides 
thetaiotaomicron 0.51 0.18 3.02E-03 0.65 0.27 5.92E-02 0.30 0.30 1.54E-02 
Microcystis holsatica 1.33 0.18 4.86E-03 1.43 0.23 5.45E-03 1.16 0.73 6.37E-01 
Microcystis elabens 1.68 0.34 1.04E-04 1.61 0.18 2.06E-07 1.18 0.48 4.34E-01 
Leptospira santarosai 0.10 0.06 3.26E-03 0.09 0.03 4.36E-04 0.09 0.05 3.34E-03 
Sphingomonas spp. 0.48 0.07 1.79E-06 0.56 0.16 3.91E-03 0.57 0.16 3.30E-03 
Sphingomonas sp.  1.20 1.75 7.53E-01 3.54 0.97 1.65E-04 1.77 0.96 6.24E-02 
Sinorhizobium meliloti  4.72 2.39 1.65E-03 3.76 2.44 8.39E-03 2.43 1.18 4.34E-03 
Sinorhizobium fredii  0.67 0.16 3.37E-02 0.58 0.24 6.84E-02 0.31 0.07 5.23E-04 
Rhizobium tropici  5.95 1.04 3.34E-05 4.33 0.95 1.76E-04 1.67 0.62 2.78E-02 
Rhizobium mongolense 0.38 0.16 1.00E-02 0.59 0.43 1.97E-01 0.70 0.31 1.33E-01 
Blastochloris sulfoviridis 0.51 0.37 1.31E-01 0.43 0.22 3.07E-02 0.33 0.11 2.58E-05 
Paracoccus sp. 3.04 1.21 1.54E-04 1.98 1.21 4.75E-02 3.09 0.96 7.54E-05 
L35465 clone SAR 122 0.98 0.40 9.03E-01 1.30 0.60 2.71E-01 1.33 0.37 7.03E-02 
Microvirgula 
aerodenitrificans 3.29 7.04 1.62E-01 6.94 2.26 2.49E-04 4.33 1.73 1.11E-04 
Burkholderia sp. 2.90 1.21 1.29E-02 2.79 0.56 1.88E-03 2.25 0.91 2.52E-02 
AJ408960 clone HuCA4 0.07 0.06 1.78E-03 0.07 0.08 3.66E-03 0.05 0.05 4.67E-03 
Zoogloea sp.  0.47 0.23 4.56E-02 0.32 0.13 1.04E-02 0.65 0.33 1.73E-01 
Z93978 clone T35 0.62 0.21 6.28E-02 0.50 0.18 2.96E-02 0.54 0.21 4.77E-02 
Pseudomonas 
fluorescens 2.21 0.45 4.36E-03 2.19 0.12 8.75E-05 2.20 0.76 1.82E-02 
Pseudomonas sp. 1.64 0.91 1.26E-01 1.63 1.22 2.23E-01 1.26 0.97 5.36E-01 
Alteromonas macleodii 0.85 0.63 6.63E-01 1.47 1.17 3.49E-01 1.80 0.49 1.14E-02 
Shewanella 
frigidimarina 4.92 12.46 1.10E-01 16.21 52.87 3.77E-02 7.99 5.93 7.29E-03 
Vibrio aerogenes 1.64 0.70 5.43E-02 1.88 1.48 1.56E-01 1.02 0.79 9.64E-01 
Aeromonas jandaei  0.22 0.13 5.12E-03 0.35 0.12 8.13E-05 0.42 0.13 2.77E-04 
Pasteurella sp.  5.89 10.41 4.73E-02 13.82 14.67 3.96E-03 8.90 15.44 1.92E-02 
Pasteurella sp.  3.99 41.47 2.89E-01 22.93 40.86 1.32E-02 18.75 7.29 8.75E-04 
Yersinia aldovae 0.93 0.37 7.13E-01 0.84 0.17 1.24E-01 0.79 0.25 1.68E-01 
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Yersinia frederiksenii  0.56 0.25 6.36E-02 0.91 0.34 6.31E-01 0.72 0.35 2.17E-01 
Escherichia coli str. 4.01 15.62 1.94E-01 10.32 15.60 1.86E-02 10.12 14.52 1.90E-02 
Escherichia coli str. 4.64 13.61 1.27E-01 9.69 36.32 6.73E-02 7.11 13.55 3.62E-02 
Rhodobacter capsulatus 11.02 42.31 6.09E-02 27.75 85.44 2.09E-02 33.91 22.97 8.82E-06 
Pantoea agglomerans 1.45 0.91 2.64E-01 2.05 1.25 6.33E-02 1.94 1.22 8.29E-02 
Hydrocarbophaga effusa 7.11 18.18 1.39E-01 11.22 32.19 1.07E-01 25.97 9.70 4.08E-03 
Stenotrophomonas sp.  16.37 16.83 3.34E-03 14.59 15.87 4.60E-03 4.45 4.99 3.26E-02 
Desulfovibrio sp. 0.32 0.17 1.68E-02 0.70 0.79 4.88E-01 3.18 2.66 3.97E-02 
Desulfovibrio sp.  0.07 0.05 3.12E-03 0.06 0.04 3.13E-03 0.12 0.17 2.13E-02 
Desulfovibrio sp.  0.10 0.02 9.46E-09 0.11 0.02 3.03E-07 0.12 0.08 1.17E-04 
Desulfovibrio sp. 0.24 0.13 9.93E-03 0.40 0.35 9.15E-02 0.33 0.18 1.12E-02 
Cytophagales QSSC8L-9 0.19 0.09 3.78E-04 0.24 0.14 2.61E-03 0.28 0.16 1.52E-02 
Helicobacter hepaticus 
str. 0.19 0.16 4.84E-03 0.33 0.26 1.14E-02 0.32 0.15 1.01E-03 
Helicobacter hepaticus 
str. 1.16 1.14 7.24E-01 2.42 1.60 1.85E-02 2.23 1.13 1.01E-02 
Helicobacter hepaticus 
str.  0.98 0.35 9.06E-01 1.22 0.44 2.84E-01 1.28 0.32 7.41E-02 
Helicobacter pylori 3.01 0.35 4.46E-05 2.37 0.81 2.80E-03 1.20 0.24 1.36E-01 
Clostridium rectum  4.42 1.99 2.73E-04 4.63 1.68 2.84E-03 1.59 1.22 2.59E-01 
Propionibacterium 
cyclohexanicum 1.42 6.98 7.21E-01 0.61 0.21 1.48E-02 0.60 0.21 2.51E-02 
Kibdelosporangium 
aridum 4.05 1.75 2.95E-03 4.06 2.77 1.47E-02 2.67 1.06 9.19E-04 
Actinopolyspora 
mortivallis 0.20 0.05 5.59E-09 0.19 0.07 1.70E-05 0.25 0.17 8.30E-03 
Kutzneria viridogrisea 0.21 0.08 6.64E-06 0.17 0.07 1.75E-06 0.23 0.27 3.67E-02 
Mycobacterium 
tuberculosis 0.62 0.19 2.91E-02 0.76 0.14 1.40E-02 1.30 0.18 5.56E-03 
Mycobacterium 
fortuitum 1.38 0.60 1.55E-01 1.56 0.92 1.40E-01 1.16 0.49 4.96E-01 
Corynebacterium 
matruchotii 3.66 1.03 8.14E-03 15.39 70.15 2.53E-01 1.36 0.66 4.43E-01 
Turicella sp.  4.62 2.52 2.36E-03 3.96 1.66 3.02E-04 1.64 0.72 4.20E-02 
Corynebacterium 
flavescens 2.35 1.35 4.95E-02 2.20 1.19 5.29E-02 1.50 1.44 4.75E-01 
Rhodococcus sp.  4.84 3.22 8.14E-04 4.10 2.67 1.45E-03 4.48 1.76 4.82E-05 
Rhodococcus sp. 11.94 12.45 6.78E-04 11.33 9.93 5.42E-04 4.78 7.39 3.52E-02 
Eggerthella lenta  0.09 0.04 1.41E-03 0.07 0.05 4.00E-03 0.08 0.03 6.16E-04 
Geodermatophilus 
obscurus  10.02 11.85 1.45E-02 8.54 2.56 3.65E-06 5.25 5.81 2.58E-02 
Streptomyces albus  1.67 0.66 7.43E-02 1.15 0.75 6.63E-01 0.88 0.43 6.20E-01 
Streptomyces 
brasiliensis 3.99 3.15 1.85E-02 3.65 2.78 2.14E-02 4.08 2.69 1.79E-03 
Streptomyces sp.  4.43 1.17 4.52E-07 4.20 1.48 5.35E-05 2.64 0.89 1.41E-03 
Streptomyces salmonis 1.96 1.02 5.08E-02 1.44 0.59 1.33E-01 1.46 0.59 1.51E-01 
Streptomyces sp. 0.72 12.65 8.02E-01 1.70 20.58 6.66E-01 1.71 8.95 5.98E-01 
Streptosporangia spp. 1.56 0.61 5.04E-02 1.51 0.59 6.59E-02 1.00 0.96 9.98E-01 
AF142943 PENDANT-
31  1.50 0.55 1.00E-01 1.28 0.25 7.29E-02 1.80 1.35 1.30E-01 
Arthrobacter QSSC8-13 9.43 1.11 3.88E-05 9.69 1.67 1.18E-04 3.87 1.47 5.15E-03 
Arthrobacter sp. 2.94 1.01 3.62E-04 2.49 1.77 5.21E-02 1.22 0.61 4.27E-01 
Arthrobacter haridrum 4.51 1.75 1.07E-05 4.23 2.02 2.29E-04 1.27 0.93 4.97E-01 
Micrococcus QSSC8-1 0.35 0.16 8.52E-03 0.27 0.09 2.61E-05 0.46 0.16 2.30E-03 
Arthrobacter sp.  0.74 0.34 2.14E-01 0.65 0.41 1.93E-01 1.08 0.53 7.64E-01 
Kocuria varians 12.58 50.84 5.76E-02 9.45 6.79 5.82E-03 4.94 4.92 2.84E-02 
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Rothia amarae 0.52 0.26 6.58E-02 0.30 0.11 4.21E-03 0.65 0.27 6.98E-02 
Actinomyces howellii  23.28 20.38 1.52E-03 22.11 18.36 1.29E-03 13.54 12.07 1.87E-03 
Actinomyces sp.  4.99 2.34 1.24E-03 4.74 2.82 5.07E-03 3.30 2.07 1.25E-02 
Bifidobacterium sp.  140.37 383.35 6.22E-03 152.89 353.87 4.54E-03 96.21 208.48 4.52E-03 
Bifidobacterium 
magnum 0.70 0.48 2.85E-01 0.71 0.59 3.78E-01 0.62 0.44 1.72E-01 
Kineosporia rhizophila 0.65 0.15 4.52E-03 0.64 0.19 2.03E-02 0.59 0.19 9.98E-03 
Desulfotomaculum 
thermobenzoicum 7.08 5.27 3.92E-03 6.00 1.59 7.35E-07 4.47 1.96 9.79E-05 
AF125206 clone I025 0.91 1.32 8.68E-01 0.72 4.30 7.51E-01 0.84 0.49 5.86E-01 
AF068809 VC2.1 3.06 2.26 3.34E-02 2.30 2.18 1.18E-01 1.95 0.87 2.89E-02 
AY192277 candidate 
division 19.08 23.73 8.85E-03 14.91 14.33 6.84E-03 9.74 18.93 3.57E-02 
Phascolarctobacterium 
faecium  0.12 0.29 5.44E-02 0.10 0.26 4.59E-02 0.14 0.73 1.18E-01 
Butyrivibrio fibrisolvens 
str. 0.09 0.02 1.17E-09 0.10 0.05 1.13E-03 0.08 0.20 5.70E-03 
Butyrivibrio fibrisolvens 
str. 0.05 0.02 4.47E-06 0.05 0.04 1.48E-04 0.07 0.04 3.47E-04 
Coprococcus eutactus 0.06 0.03 1.59E-03 0.05 0.03 1.37E-03 0.11 0.04 9.73E-04 
Clostridium 
polysaccharolyticum 0.18 0.06 5.58E-04 0.18 0.08 8.08E-05 0.23 0.18 3.72E-03 
Fusibacter paucivorans 0.13 0.43 8.10E-02 0.14 0.71 1.20E-01 0.26 1.50 3.37E-01 
Fusobacterium alocis 1.38 873.17 8.69E-01 0.61 1.07 5.47E-01 0.25 7.48 3.66E-01 
Clostridium paradoxum 0.14 0.02 9.83E-05 0.18 0.10 6.80E-03 0.44 0.38 1.10E-01 
Clostridium 
bifermentans 0.55 0.40 1.65E-01 0.32 0.16 1.66E-02 0.59 0.56 2.65E-01 
Alicyclobacillus 
acidocaldarius 0.75 0.25 1.48E-01 0.60 0.21 5.07E-02 0.73 0.15 1.62E-02 
Sulfobacillus 
thermosulfidooxidans 0.29 0.16 1.01E-02 0.35 0.27 4.63E-02 0.44 0.18 1.07E-02 
Bacillus spp. 0.91 0.81 8.14E-01 2.78 4.82 1.66E-01 2.55 0.97 9.53E-04 
Bacillus sp. 0.16 0.09 2.73E-04 0.26 0.12 1.69E-03 0.31 0.15 6.50E-03 
Bacillus senegalensis    1.59 1.50 3.30E-01 3.06 2.02 3.38E-02 1.33 0.53 2.40E-01 
L13147 str. B775 0.29 0.37 6.27E-02 0.53 0.70 2.79E-01 0.42 0.21 7.82E-03 
Lactobacillus spp. 0.28 0.17 1.26E-02 0.49 0.31 7.70E-02 0.64 0.20 1.19E-02 
Lactobacillus spp. 0.92 0.59 7.81E-01 1.74 2.34 3.52E-01 4.24 4.44 3.56E-02 
Streptococcus 
gallolyticus 2.76 1.37 7.52E-03 3.50 1.46 1.39E-03 9.45 3.11 6.73E-05 
Acholeplasma oculi 21.05 24.12 6.33E-03 17.51 10.18 1.24E-03 14.46 10.71 3.30E-03 
Clostridium ramosum 0.12 0.19 2.81E-02 0.15 0.24 3.92E-02 0.24 0.21 2.20E-02 
Clostridium sp.  0.18 0.05 4.72E-04 0.18 0.03 1.75E-05 0.30 0.17 5.90E-03 
Clostridium innocuum 0.12 0.09 5.45E-03 0.06 0.12 3.30E-03 1.03 2.88 9.69E-01 
 AY343175 clone 
REC6M 0.11 0.19 3.17E-02 0.10 0.28 5.26E-02 0.14 0.29 1.19E-01 
AF371739 clone p-4177-
6Wa5 0.03 0.02 1.83E-06 0.05 0.36 5.80E-02 0.09 0.06 7.37E-04 
Clostridium putrefaciens 0.54 0.48 2.02E-01 1.25 1.21 6.21E-01 1.25 0.54 3.04E-01 
Clostridium 
cellulovorans 0.37 0.14 1.21E-02 0.42 0.05 8.05E-04 0.70 1.15 5.76E-01 
AY147280 clone THM-
10  0.94 0.67 8.60E-01 0.64 0.19 5.80E-02 1.31 0.64 3.25E-01 
Clostridium 
tetanomorphum 0.58 0.57 2.51E-01 1.02 0.51 9.50E-01 0.96 0.52 8.78E-01 
Thermus spp. 0.10 0.06 7.93E-04 0.08 0.03 1.10E-05 0.09 0.11 9.29E-03 
Thermus spp. 2.14 6.97 4.03E-01 2.02 2.41 2.30E-01 0.14 6.17 3.41E-01 
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Appendix B 
Table B1: Genes up-regulated twofold or greater in the neonatal rat GI tract 12 h after 
feeding E. coli A192PP to P2 pups 
 
Gene symbol Description Function Mean-fold change 
RT1-Aw2 RT1 class Ib, locus Aw2 Antigen presentation 17.71 
Fam13a1 
family with sequence similarity 13, 
member A1 
Regulation of small GTPase mediated signal 
transduction 8.45 
Malat1 
metastasis associated lung 
adenocarcinoma transcript 1  Non-protein coding regulator of cell motility 6.22 
Btg2 BTG family, member 2 Negative regulator of cell proliferation 5.38 
Luc7l3 LUC7-like 3 RNA binding regulator of apoptosis 5.26 
Setd5 SET domain containing 5 Unknown 5.11 
Wdfy1 
WD repeat and FYVE domain 
containing 1 Endosomal trafficking protein 5.08 
Eif2c2 
eukaryotic translation initiation 
factor 2C, 2 Regulator of RNA mediated gene silencing 5.05 
Pdlim5 PDZ and LIM domain 5 Regulator of cytoskeletal organization 5.05 
Cirbp 
cold inducible RNA binding 
protein Positive regulator of cellular stress response 5.04 
Zeb2 
zinc finger E-box binding 
homeobox 2 Negative regulator of cell-cell adhesion 4.89 
Sltm SAFB-like, transcription modulator Transcriptional inhibitor promoting apoptosis 4.86 
Tiparp 
TCDD-inducible poly(ADP-ribose) 
polymerase Protein ADP ribosylation 4.77 
Sv2b synaptic vesicle glycoprotein 2b Endocrine cell transmembrane transporter 4.75 
Hhip hedgehog-interacting protein Negative regulator of angiogenesis 4.64 
Mfap3 microfibrillar-associated protein 3 Component of the elastin-associated microfibrils 4.54 
Pja2 praja 2, RING-H2 motif containing Ubiquitin-protein ligase  4.51 
Swi5 
SWI5 recombination repair 
homolog DNA repair complex component 4.50 
Mllt10 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog) Transcription factor 4.39 
Slc6a6 
solute carrier family 6 
(neurotransmitter transporter, 
taurine) Taurine transporter 4.31 
Evi5 ecotropic viral integration site 5 Regulator of cell cycle and cytokinesis 4.30 
Ednrb endothelin receptor type B Non-specific receptor for endothelin 4.29 
Ddx6 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 RNA degradation in cellular stress response 4.28 
Clec2h 
C-type lectin domain family 2 
member H Regulator of natural killer cell-mediated cytolysis 4.18 
Bcl11b 
B-cell CLL/lymphoma 11B (zinc 
finger protein) Lymphocyte transcription factor 4.05 
Tmed5 
transmembrane emp24 protein 
transport domain Type I membrane protein, unknown function 4.04 
Srrm1 serine/arginine repetitive matrix 1 Spliceosome component 3.96 
Xiap X-linked inhibitor of apoptosis Apoptotic suppressor 3.91 
Cald1 caldesmon 1 Regulator of actin/myosin interactions 3.88 
Lpgat1 
lysophosphatidylglycerol 
acyltransferase 1 
Catalyzes the reacylation of LPG to 
phosphatidylglycerol 3.68 
Smurf2 
SMAD specific E3 ubiquitin 
protein ligase 2 E3 ubiquitin-protein ligase 3.56 
Arid4a 
AT rich interactive domain 4A 
(Rbp1 like) Transcriptional repressor 3.55 
Aff4 AF4/FMR2 family, member 4 Transcription factor 3.47 
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Gpatch8 G patch domain containing 8 RNA binding protein, unknown function 3.44 
Igfbp5 
insulin-like growth factor binding 
protein 5 Regulator of cellular growth factors 3.44 
Sptbn1 spectrin, beta, non-erythrocytic 1 Actin-membrane molecular scaffold protein 3.43 
Nipbl nipped-B homolog DNA repair complex component 3.41 
LOC81816 hypothetical protein LOC81816 Putative ubiquitin conjugating enzyme 3..39 
N4bp1 Nedd4 binding protein 1 Inhibitor of the E3 ubiquitin-protein ligase ITCH 3.37 
Tmem161b transmembrane protein 161B Multipass membrane protein, unknown function 3.37 
Spnb2 spectrin β2 Actin-membrane molecular scaffold protein 3.31 
Atp8b1 
ATPase, Class I, type 8B, member 
1 
Transport of bile acids from intestinal contents to 
mucosa 3.31 
Jarid1a 
jumonji, AT rich interactive 
domain 1A (Rbp2 like) Histone demethylase regulating cell proliferation 3.28 
Pum1 pumilio homolog 1 RNA binding protein regulating cell proliferation 3.28 
Dock4 dedicator of cytokinesis 4 Regulator of cell-cell adhesion 3.27 
Eif2c1 
eukaryotic translation initiation 
factor 2C, 1 Regulator of RNA mediated gene silencing 3.3 
Znf292 zinc finger protein 292 Putative transcriptional regulator 3.26 
Sfrs2ip 
splicing factor, arginine/serine-rich 
2, interacting protein Regulator of spliceosome assembly 3.24 
Eif3c 
eukaryotic translation initiation 
factor 3, subunit C Initiator of protein synthesis 3.18 
Csnk2a1 casein kinase 2, α1 polypeptide 
Serine/threonine protein kinase regulating cell 
proliferation 3.18 
Ptprb 
protein tyrosine phosphatase, 
receptor type, B 
Signalling protein involved in maintenance of 
endothelial integrity 3.15 
LOC100192313 
hypothetical protein 
LOC100192313 Unknown 3.13 
Cmip c-Maf-inducing protein Signalling protein involved in Th2 cell activation 3.11 
LOC687839 hypothetical protein LOC687839 Unknown function 3.09 
Zfp451 zinc finger protein 451 Putative transcriptional regulator 3.05 
Tnrc6b trinucleotide repeat containing 6B Regulator of RNA mediated gene silencing 3.05 
Dek DEK oncogene 
Involved in splice site selection during mRNA 
processing 3.05 
Acbd3 
acyl-Coenzyme A binding domain 
containing 3 Maintenance of Golgi structure 3.04 
Rad26l 
putative repair and recombination 
helicase Putative DNA repair enzyme 3.01 
Srpk2 SFRS protein kinase 2 
Spliceosome assembly and trafficking of splicing 
factors 3.00 
Hspca 
heat shock protein 90α (cytosolic), 
class A member 1 Molecular chaperone induced by cellular stress 2.98 
Slc4a7 
solute carrier family 4, sodium 
bicarbonate co-transporter, member 
7 Regulator of intracellular pH 2.96 
Loxl2 lysyl oxidase-like 2 Putative role in connective tissue biogenesis 2.94 
Laptm4a 
lysosomal protein transmembrane 
4α Lysosomal membrane small molecule trafficking  2.91 
Rc3h2 
ring finger and CCCH-type zinc 
finger domains 2 Membrane associated DNA binding protein 2.91 
Zfp91 zinc finger protein 91 
Atypical E3 ubiquitin-protein ligase involved in 
anti-apoptosis 2.88 
Crebl2 
cAMP responsive element binding 
protein-like 2 Cell cycle regulator 2.88 
Ankrd11 ankyrin repeat domain 11 
Inhibitor of ligand dependent transcriptional 
activation 2.87 
Maf 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
Broad transcriptional regulator, induces T-cell 
apoptosis 2.86 
Igf2r insulin-like growth factor type 2 
Involved in trafficking of lysosomal enzymes and 
T-cell activation 2.85 
Mgll monoglyceride lipase Gut epithelial lipase 2.85 
Tlk1 tousled-like kinase 1 Nuclear signalling kinase 2.83 
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Ubxn4 UBX domain protein 4 
Involved in endoplasmic reticulum-associated 
protein degradation 2.83 
LOC312273 trypsin V-A Putative digestive protease 2.82 
Dhx36 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 36 Involved in mRNA degradation 2.82 
Tpr translocated promoter region Involved in nuclear protein import 2.82 
Xrn2 5'-3' exoribonuclease 2 RNase, unknown function 2.81 
Tns1 tensin1 
Focal adhesion component involved in 
ECM/cytoskeletal interaction 2.80 
Creg1 
cellular repressor of E1A-
stimulated genes 1 Interacts with Igf2r to promote cell growth 2.79 
Mga MAX gene associated Regulator of cell growth and apoptosis 2.79 
Stat3 
signal transducer and activator of 
transcription 3 
Transcription factor mediating cytokine receptor 
signalling pathways 2.77 
Rbm9 RNA binding motif protein 9 Regulates splicing of tissue specific exons 2.74 
Snrp70 small nuclear ribonucleoprotein 70 Regulator of pre-mRNA splicing 2.72 
Slc44a1 solute carrier family 44, member 1 
Choline transporter involved in membrane 
sysnthesis 2.71 
Dag1 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) Extracellular matrix receptor 2.71 
Ubn1 ubinuclein 1 Regulator of cell death 2.69 
Eif4g1 
eukaryotic translation initiation 
factor 4γ 1 Involved in mRNA recruitment to ribosome 2.69 
Gcap14 granule cell antiserum positive 14 Unknown function 2.68 
Mobkl1a 
MOB1, Mps One Binder kinase 
activator-like 1A Regulator of cell growth and apoptosis 2.68 
Arhgef12 
Rho guanine nucleotide exchange 
factor (GEF) 12  Regulator of RhoA GTpase activity 2.68 
Reg3b regenerating islet-derived 3β Antimicrobial peptide with C-type lectin domain 2.63 
Kcnma1 
calcium-activated channel, 
subfamily Mα Calcium ion activated potassium channel 2.63 
Cbl 
Cas-Br-M ecotropic retroviral 
transforming sequence 
Involved in signal transduction in hematopoietic 
cells 2.62 
Rnd3 Rho family GTPase 3 Regulator of actin cytoskeletal organization 2.61 
Sox4 SRY-box 4 Transcriptional activator involved in development 2.61 
Pik3r1 
phosphoinositide-3-kinase, 
regulatory subunit 1α 
Adaptor mediating association of activated kinases 
to the plasma membrane 2.60 
Hoxb6 homeobox B6  Transcriptional regulator 2.58 
Bend7 BEN domain containing 7 Unknown 2.57 
Arhgap5 Rho GTPase activating protein 5 Regulator of actin cytoskeletal organization 2.56 
Eml4 
echinoderm microtubule associated 
protein like 4 Putative role in microtubule assembly dynamics 2.56 
Ralgps2 
Ral GEF with PH domain and SH3 
binding motif 2 Putative role in cytoskeletal organization 2.55 
Falz fetal Alzheimer antigen 
Histone binding component of nucleosome-
remodelling factor 2.55 
Il6st interleukin 6 signal transducer Intracellular transducer of cytokine signalling 2.55 
Otub1 
OTU domain, ubiquitin aldehyde 
binding 1 Ubiquitin hydrolase regulating T-cell anergy 2.54 
Topbp1 
topoisomerase (DNA) II binding 
protein 1 Regulator of DNA damage response 2.54 
Slc4a4 
solute carrier family 4 (anion 
exchanger), member 4 Regulator of intracellular pH 2.54 
Thoc2 THO complex 2 Involved in mRNA export 2.53 
Hsp90ab1 
heat shock protein 90kDa α 
(cytosolic), class B member 1 
Molecular chaperone involved in cellular stress 
response 2.52 
Itgb3 integrin β3 Mediates cellular adhesion to ECM 2.52 
Rps6ka5 
ribosomal protein S6 kinase, 
polypeptide 5 
Kinase required for activation of stress-induced 
transcription factors 2.51 
Thra thyroid hormone receptor α Nuclear hormone receptor 2.51 
Ccar1 
cell division cycle and apoptosis 
regulator 1 Regulator of cellular proliferation 2.51 
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Zdhhc20 
zinc finger, DHHC-type containing 
20 Unknown 2.50 
Clcn5 
chloride channel 5, transcript 
variant 6 Acidification of the endosomal lumen 2.50 
Cisd2 CDGSH iron sulfur domain 2 Regulator of autophagy 2.50 
Lcorl 
ligand dependent nuclear receptor 
co-repressor-like Transcriptional regulator 2.49 
Ccnd2 cyclin D2 Cell cycle regulator 2.48 
LOC100363275 G protein-coupled receptor 124 Unknown 2.48 
Itsn2 intersectin 2 Involved in T-cell receptor endocytosis 2.46 
Samd8 
sterile alpha motif domain 
containing 8 Unknown 2.46 
Ubn2 ubinuclein 2 Regulator of cell death 2.46 
Bmpr2 
bone morphogenetic protein 
receptor, type II (serine/threonine 
kinase) Involved in calcium regulation 2.45 
Sf3b2 splicing factor 3b, subunit 2 Subunit of splicing factor SF3B 2.44 
LOC681371 hypothetical protein LOC681371 Unknown function 2.44 
Narg1 NMDA receptor regulated 1 
Acetyltransferase involved in hematopoeitic and 
neuronal development 2.44 
Strn3 
striatin, calmodulin binding protein 
3 
Signalling or scaffolding protein involved in 
modulating calmodulin activity 2.44 
Pa2g4 proliferation-associated 2G4 Regulator of cell proliferation 2.44 
Srrm2 serine/arginine repetitive matrix 2 Involved in pre-mRNA splicing 2.42 
Fermt2 fermitin family homolog 2 
Participates in actin organization and cytoskeletal-
ECM adhesion 2.41 
Chd1 
chromodomain helicase DNA 
binding protein 1 Chromatin remodelling 2.40 
Tcf4 transcription factor 4 Enhancer of immunoglobulin expression 2.40 
Ankle2 
ankyrin repeat and LEM domain 
containing 2 Unknown function 2.40 
Trio 
triple functional domain (PTPRF 
interacting) Involved in cytoskeletal rearrangement 2.39 
Herc1 
hect (homologous to the E6-AP 
(UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like 
domain (RLD) 1 Regulator of membrane trafficking 2.38 
Vdac1 voltage-dependent anion channel 1 
Mitochondrial membrane channel involved in 
apoptosis 2.38 
LOC286960 preprotrypsinogen IV Trypsin-like serine protease 2.38 
Hectd1 HECT domain containing 1 Ubiquitin-protein ligase  2.38 
Rbm25 RNA binding motif protein 25 Splicing regulator involved in apoptosis 2.37 
Clk1 CDC-like kinase 1 Putative regulator of RNA splicing 2.37 
Nfix 
nuclear factor I/X (CCAAT-
binding transcription factor) Transcriptional activator  2.36 
Wasl Wiskott-Aldrich syndrome-like Regulator of actin polymerization 2.36 
Ash1l 
ash1 (absent, small, or homeotic)-
like Histone methyltransferase 2.36 
Traf6 Tnf receptor-associated factor 6 
Ubiquitin ligase responsible for activating NFκB 
after IL-1 receptor signalling 2.36 
Marcks 
myristoylated alanine rich protein 
kinase C substrate F-actin cross-linker 2.36 
Rps6ka1 
ribosomal protein S6 kinase 
polypeptide 1 
Mediator of stress-induced transcriptional 
activation 2.35 
RT1-CE12 RT1 class I, locus CE12 Antigen presentation 2.35 
Cpd carboxypeptidase D 
Regulatory peptidase involved in NO synthesis 
during inflammation 2.35 
Wbp4 
WW domain binding protein 4 
(formin binding protein 21) Promotes pre-mRNA splicing 2.34 
LOC685707 similar to neuron navigator 1 Similar to protein regulating neuronal development 2.34 
Nktr 
natural killer tumor recognition 
protein NK-cell receptor 2.33 
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U2af1 
U2 small nuclear ribonucleoprotein 
auxiliary factor Involved in mRNA splicing 2.32 
Ptch1 patched 1 Hedgehog gene receptor 2.32 
Pgap2 post-GPI attachment to proteins 2 
Involved in anchoring proteins to the plasma 
membrane 2.31 
Zc3h11a 
zinc finger CCCH-type containing 
11A Unknown function 2.31 
Raph1 
Ras association (RalGDS/AF-6) 
and pleckstrin homology domains 
1 Negatively regulates cell adhesion 2.31 
Mpp6 
membrane protein, palmitoylated 6 
(MAGUK p55 subfamily member 
6) Regulator of membrane receptor clustering 2.30 
Nr2f2 
nuclear receptor subfamily 2, group 
F, member 2 Steroid thyroid hormone receptor 2.29 
Pkp4 plakophilin 4 Regulator of cadherin function 2.29 
Id3 inhibitor of DNA binding 3 Inhibitor of transcription factor DNA binding 2.29 
Zdhhc21 
zinc finger, DHHC domain 
containing 21 Unknown function 2.29 
Ppp1r12a 
protein phosphatase 1, regulatory 
(inhibitor) subunit 12A Regulates myosin phosphatase activity 2.28 
Pafah1b1 
platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 1 
 Required for proper activation of Rho GTPases 
and actin polymerization 2.28 
Rbm5 RNA binding motif protein 5 Component of the spliceosome A complex 2.28 
Lin7 lin-7 homolog C Involved in maintaining cellular polarity 2.28 
Trim39 tripartite motif containing 39 
Inhibits proteosomal degradation of pro-apoptotic 
factors 2.27 
Brd8 bromodomain containing 8 Co-activiator of nuclear hormone receptors 2.27 
Ap4e1 
adapter-related protein complex 4 
subunit ε-1 
Involved in targeting to the endosomal/lysosomal 
system 2.27 
Lrrc8a 
leucine rich repeat containing 8 
family, member A Involved in promoting B-cell maturation 2.27 
Zfp106 zinc finger protein 106 Unknown function 2.27 
Adipor2 adiponectin receptor 2 Involved in lipid metabolic regulation 2.26 
Fam126b 
family with sequence similarity 
126 Unknown function 2.26 
Add3 adducin 3γ 
Calmodulin binding promoter of actin-spectrin 
network assembly  2.26 
Adrbk2 adrenergic receptor kinase β2 Regulator of receptor function 2.26 
Cdh22 cadherin 22 Calcium dependent cell adhesion protein 2.26 
Alox15 arachidonate 15-lipoxygenase 
involved in the production and metabolism of fatty 
acid hydroperoxidases 2.25 
LOC498544 hypothetical protein LOC498544 Unknown function 2.25 
Rcor1 REST corepressor 1 Chromatin remodelling 2.24 
Mef2a myocyte enhancer factor 2a 
Activator of numerous growth factor and stress-
induced genes 2.23 
Dnmt3a 
DNA (cytosine-5-)-
methyltransferase 3α DNA methylation 2.23 
Vezf1 vascular endothelial zinc finger 1 Regulation of IL-3 expression 2.23 
Eif5 
eukaryotic translation initiation 
factor 5 Initiator of protein synthesis 2.22 
Pip5k2a 
phosphatidylinositol-5-phosphate 
4-kinase, type IIα 
Involved in the regulation of secretion, cell 
proliferation, differentiation, and motility 2.22 
Gatad2b 
GATA zinc finger domain 
containing 2B Transcriptional repressor 2.21 
Ctdspl 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide 
A) small phosphatase-like Negative regulator of transcription 2.20 
Rnf6 
ring finger protein (C3H2C3 type) 
6 Ubiquitin-protein ligase  2.20 
Msi2 Musashi homolog 2 
RNA-binding protein regulating cellular 
proliferation 2.20 
Mxd1 MAX dimerization protein 1 Regulator of cellular proliferation and apoptosis 2.19 
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Arl4d ADP-ribosylation factor-like 4D Involved in intracellular membrane trafficking 2.18 
Krt15 keratin 15 
Responsible for the structural integrity of epithelial 
cells 2.18 
Mll5 
myeloid/lymphoid or mixed-
lineage leukemia 5 (trithorax 
homolog) Histone methyltransferase 2.17 
Rbm27 RNA binding motif protein 27 Unknown function 2.17 
Ptprs 
protein tyrosine phosphatase, 
receptor type, S Signalling protein involved in development 2.17 
Entpd5 
ectonucleoside triphosphate 
diphosphohydrolase 5 Regulator of ATP usage 2.16 
Eif4a1 
eukaryotic translation initiation 
factor 4A1 
RNA-helicase allowing mRNA-ribosome 
interaction 2.15 
Phc3 polyhomeotic-like 3 Involved in transcriptional repression 2.15 
Frg1 FSHD region gene 1  Involved in processing pre-rRNA 2.15 
Eif5b 
eukaryotic translation initiation 
factor 5B Promotes binding of methionine-tRNA to ribosome 2.15 
Hmox1 heme oxygenase (decycling) 1 Essential enzyme in heme metabolism 2.14 
Trove2 TROVE domain family, member 2 Regulator of Y-RNAs 2.13 
Sox11 SRY-box containing gene 11 Developmental regulator 2.13 
Arid4b 
AT rich interactive domain 4B 
(Rbp1 like) Transcriptional repressor 2.12 
Mphosph8 M-phase phosphoprotein 8 Involved in cell-cycle 2.12 
LOC688495 hypothetical protein LOC688495 Unknown function 2.11 
Rgs4 regulator of G-protein signalling 4 Negative regulator of G-protein signaling 2.11 
Meg3 maternally expressed 3 Regulator of cell proliferation 2.11 
Rbm39 RNA binding motif protein 39 Involved in mRNA splicing 2.11 
Trak2 
trafficking protein, kinesin binding 
2 Regulator of endosome to lysosome trafficking 2.10 
Ahi1 Abelson helper integration site 1 Involved in neuronal development 2.10 
Akap13 
A kinase (PRKA) anchor protein 
13 Anchors cAMP-dependent kinase 2.10 
Wdr37 WD repeat domain 37 Regulator of signal transduction and apoptosis 2.09 
Lgr4 
leucine-rich repeat containing G 
protein-coupled receptor 4 Orphan receptor 2.09 
C-myb Myb proto-oncogene Regulates differentiation of hematopoeitic cells 2.09 
Sfrs11 
splicing factor, arginine/serine-rich 
11 Involved in pre-mRNA splicing 2.08 
Rdx radixin 
Binds barbed ends of actin filaments to cell 
membrane 2.07 
Stk25 
serine/threonine kinase 25 (STE20 
homolog) 
Stress-activated kinase regulating protein export 
and cell adhesion 2.06 
Rhoj 
ras homolog gene family, member 
J 
Regulates cell morphology via increased F-actin 
formation 2.06 
Rod1 ROD1 regulator of differentiation 1 Regulator of cell differentiation 2.06 
Ppap2b 
phosphatidic acid phosphatase type 
2B Involved in cell adhesion and cell-cell interactions 2.06 
Tsc22d4 TSC22 domain family, member 4 Transcriptional repressor 2.05 
Arglu1 arginine and glutamate rich 1 Unknown function 2.05 
Arid3a 
AT rich interactive domain 3A 
(Bright like) 
Transcription factor involved in B-cell 
differentiation 2.05 
Rad54l2 Rad54 like 2 DNA helicase 2.04 
Ppargc1b 
peroxisome proliferator-activated 
receptor gamma, co-activator 1β 
Involved in fat oxidation and non-oxidative glucose 
metabolism 2.04 
Scn7a 
sodium channel, voltage-gated, 
type VIIα Mediates sodium ion permeability of membranes 2.04 
Brd4 bromodomain containing 4 Chromatin remodelling 2.04 
Fnip2 folliculin interacting protein 2 Signal transducer of pro-apoptotic factors 2.04 
Wbp4 
WW domain binding protein 4 
(formin binding protein 21) Involved in pre-mRNA splicing 2.04 
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Esf1 
ESF1, nucleolar pre-rRNA 
processing protein, homolog Transcriptional regulator 2.04 
Zc3h12c 
zinc finger CCCH type containing 
12C Putative RNase 2.04 
Luc7l2 Luc7-like 2 Unknown function 2.03 
Eef1a1 
eukaryotic translation elongation 
factor 1α 1  Promoter of protein biosynthesis 2.03 
Rock2 
Rho-associated coiled-coil 
containing protein kinase 2 Regulates actin assembly 2.03 
Lsm12 LSM12 homolog Unknown function 2.02 
Nolc1 
nucleolar and coiled-body 
phosphoprotein 1  
Involved in RNA polymerase I catalysed 
transcription 2.02 
Safb scaffold attachment factor B 
Anchor for RNA polymerase II transcriptomal 
complex 2.02 
Chka choline kinase α Involved in phospholipid biosynthesis 2.01 
Polr3k 
polymerase (RNA) III (DNA 
directed) polypeptide K RNA polymerase III component 2.01 
Sms spermine synthase Involved in polyamine metabolism 2.01 
Axin2 axin 2 
Regulates Wnt signalling by interaction with β-
catenin 2.00 
Fatp4 fatty acid transport protein 4 Transport of long chain fatty acids 2.00 
Trps1 
trichorhinophalangeal syndrome I 
homolog 
Transcriptional regulator of columnar cell 
differentiation 2.00 
 
 
Table B2: Genes down-regulated twofold or greater in the neonatal rat GI tract 12 h after 
feeding E. coli A192PP to P2 pups. 
 
Gene symbol Description Function Mean-fold change 
Tff2 trefoil factor 2 Defence of the mucosal barrier -24.63 
Mgam Maltase-glucoamylase, intestinal Brush border hydrolase -5.49 
RGD:727924 rRNA promoter binding protein Regulator of cell proliferation -4.33 
Ins2 insulin 2 
Hormone regulating carbohydrate and fat 
metabolism -3.97 
RT1-A3 RT1 class I, locus A3 Antigen presentation -3.11 
RT1-CE15 RT1 class I, locus CE15 Antigen presentation -2.86 
Wtap Wilms tumor 1 associated protein Transcriptional and post-transcriptional regulator -2.65 
Senp5 
Sumo1/sentrin/SMT3 specific 
peptidase 5 Protease involved in cell division -2.65 
Ins1 insulin 1 
Hormone regulating carbohydrate and fat 
metabolism -2.64 
Mcpt3 mast cell peptidase 3 Serine endopeptidase -2.62 
Ubd ubiquitin D Targeting for proteosomal degradation -2.48 
RT1-Db1 RT1 class II, locus Db1 Antigen presentation -2.46 
Pbx1 
pre-B-cell leukemia transcription 
factor Transcriptional regulator -2.36 
Pim1 pim-1 oncogene Signalling kinase activity -2.35 
Dcaf12 
DDB1 and CUL4 associated factor 
12 Regulation of ligase activity -2.34 
Mcpt4 mast cell protease 4 Serine endopeptidase -2.30 
LOC100362483 H2-GS14-2 antigen Regulation of antigen presentation -2.29 
Birc6 
baculoviral IAP repeat containing 
6 Regulation of apoptosis -2.27 
ABCB10 ATP binding cassette family Membrane transporter -2.26 
Mcpt1 mast cell protease 1 Serine endopeptidase -2.26 
Coro1c coronin, actin binding protein 1C Involved in cytokinesis -2.23 
Itgav integrin αV Extracellular matrix receptor -2.22 
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Actn4 actinin α4 Intracellular actin anchoring -2.20 
Fam100b 
family with sequence similarity 
100, member B Unknown -2.16 
Wwc1 WW and C2 domain containing 1 Transcriptional activator -2.15 
Gnptab 
N-acetylglucosamine-1-phosphate 
transferase Regulator of lysosomal transport -2.13 
Nfkbil1 Ikb family protein NFκB inhibitor relative -2.09 
Slc1a3 solute carrier family 1, member 3 Glutamate transporter -2.05 
Spag9 sperm associated antigen 9 Regulator of MAPK cascade -2.05 
Larp1 
La ribonucleoprotein domain 
family, member 1 RNA degradation -2.05 
Pga5 pepsinogen 5, group I Digestive protease -2.04 
Dusp6 dual specificity phosphatase 6 Regulator of MAPK cascade -2.04 
Coa5 
cytochrome C oxidase assembly 
factor 5 mitochondrial complex IV assembly -2.04 
Amy1 ; Amy2  
amylase α1A (salivary), amylase 2, 
pancreatic Hydrolase -2.03 
Socs2 suppressor of cytokine signalling 2 Regulator of cell signalling -2.02 
Daf1 Cd55 molecule Classical complement pathway activator -2.02 
 
 
Table B3: Genes up-regulated twofold or greater in the neonatal rat GI tract 12 h after feeding 
E. coli A192PP to P9 pups 
 
Gene Symbol Description Function Mean-fold change 
RT1-Bb RT1 class II, locus Bb Antigen presentation 11.77 
Ints7 Integrator complex subunit 7 Involved in mRNA processing 5.53 
Defa-rs1 defensin α-related sequence 1 α-defensin-type antimicrobial peptide 5.44 
Cirbp 
cold inducible RNA binding 
protein Positive regulator of cellular stress response 5.21 
Pdcd4 programmed cell death 4 Inhibitor of protein biosynthesis 5.08 
Cct6a 
chaperonin containing Tcp1, 
subunit 6A ξ1 
Chaperone involved in correct actin and tubulin 
folding 4.89 
Sept2 septin 2 Filament forming cytoskeletal GTPase 4.86 
RT1-CE15 RT1 class I, locus CE15 Antigen presentation 4.45 
St6gal1 
ST6 beta-galactosamide α-2,6-
sialyltranferase 1 
Transfers sialic acid to galactose containing 
receptor substrates 4.41 
Clic4 chloride intracellular channel 4 Membrane associated ion channel 4.36 
Tm9sf3 
transmembrane 9 superfamily 
member 3 Unknown function 4.11 
RT1-Aw2 RT1 class Ib, locus Aw2 Antigen presentation 3.40 
Casp3 caspase 3 Effector caspase mediating apoptosis 3.95 
Caprin1 cell cycle associated protein 1 Regulation of mRNA transport 3.95 
Vsig10l 
V-set and immunoglobulin 
domain containing 10 like Unknown function 3.82 
Hnrnpa2b1 
heterogeneous nuclear 
ribonucleoprotein A2/B1 Involved in mRNA processing 3.67 
Scgb1a1 
secretoglobin, family 1A, member 
1 (uteroglobin) Anti-inflammatory regulator 3.63 
Vcl vinculin 
Actin binding protein involved in cell-cell and cell-
ECM adhesion 3.60 
Nid1 nidogen 1 
Laminin-associated protein involved in cell-ECM 
adhesion 3.59 
Mylk myosin light chain kinase Regulator of actin-myosin interaction 3.55 
Gatad2b 
GATA zinc finger domain 
containing 2B Transcriptional repressor 3.53 
Hnf4a hepatocyte nuclear factor 4α Transcription factor regulating development 3.43 
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Car3 carbonic anhydrase 3 Reversible hydration of carbon dioxide 3.40 
Actr3 
ARP3 actin-related protein 3 
homolog 
ARP2/3 complex component, involved in cell 
motility 3.38 
Prkacb 
protein kinase, cAMP dependent, 
catalytic, β Mediates cAMP-dependent signalling 3.38 
RGD1309534 
Similar to RIKEN cDNA 
4931406C07 Unknown function 3.38 
Foxn3 forkhead box N3 
Transcriptional repressor responding to DNA 
damage 3.36 
Ssr3 signal sequence receptor γ Regulator of protein-ER attachment 3.34 
Pak2 
p21 protein (Cdc42/Rac)-activated 
kinase 2 Apoptotic regulator 3.32 
Cav1 caveolin 1, caveolae protein 
Co-stimulator of T-cell receptor mediated T-cell 
activation 3.30 
Gna11 
guanine nucleotide binding protein 
α11 Transmembrane signalling transducer 3.30 
Mat2a 
methionine adenosyltransferase 
IIα Catalyses the production of S-adenosylmethionine 3.28 
Tgoln1 trans-golgi network protein Unknown function 3.27 
Cav2 caveolin 2 Major component of plasma membrane caveolae 3.17 
Ppm1a 
protein phosphatase 1A, 
magnesium dependent, α isoform Negative regulator of cellular stress response 3.16 
Pigt 
phosphatidylinositol glycan 
anchor biosynthesis, class T 
Involved in GPI cell surface protein anchor 
biosynthesis 3.15 
Golph3 
Golgi phosphoprotein 3 (coat-
protein) Regulator of Golgi trafficking 3.11 
Defa24 defensin 24α α-defensin-type antimicrobial peptide 3.09 
Hsd3b7 
hydroxy-δ-5-steroid 
dehydrogenase, 3β- and steroid δ-
isomerase 7 Involved in hormonal steroid biosynthesis 3.06 
Canx calnexin 
Molecular chaperone ensuring correct glycoprotein 
folding 3.05 
Crk 
v-crk sarcoma virus CT10 
oncogene homolog Involved in phagocytosis of apoptotic cells 3.03 
Il13ra1 interleukin 13 receptor 1α IL-13 and IL-4 receptor 3.01 
Eif1a 
eukaryotic translation initiation 
factor 1A Promotes accurate ribosomal assembly 3.01 
Rab5b 
RAB5B, member RAS oncogene 
family Involved in vesicular trafficking 3.00 
Lin7c lin-7 homolog C Involved in maintenance of cellular polarity 2.98 
Cbfb core-binding factor, β subunit Broad transcriptional regulator 2.95 
Rcc2 
regulator of chromosome 
condensation 2 Involved in cytokinesis 2.94 
Tmem47 transmembrane protein 47 Unknown function 2.94 
Rnf114 ring finger protein 114 Unknown function 2.93 
Cd36 
CD36 molecule (thrombospondin 
receptor) Involved in cell adhesion and fatty acid transport 2.93 
App amyloid β (A4) precursor protein Involved in neuronal growth 2.91 
Zfp68 zinc finger protein 68 Unknown function 2.91 
LOC683399 
region containing similar to NGF-
binding Ig light chain Unknown function 2.90 
Gpbp1 
GC-rich promoter binding protein 
1 Transcriptional regulator 2.89 
Mcam melanoma cell adhesion molecule Involved in cell adhesion 2.88 
LOC683788 
similar to Fascin (Singed-like 
protein) Unknown function 2.86 
Gga2 
Golgi associated, γ adaptin ear 
containing, ARF binding protein 2 Regulator of endosomal-lysosomal trafficking 2.86 
Rod1 
ROD1 regulator of differentiation 
1 Involved in cellular differentiation 2.85 
Stat5b 
signal transducer and activator of 
transcription 5B IL-2 and IL-4 signal transducer 2.78 
Prcp 
prolylcarboxypeptidase 
(angiotensinase C) Lysosomal prolylcarboxypeptidase 2.78 
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Prkci protein kinase Cί Involved in formation of epithelial tight junctions 2.78 
Lbr lamin B receptor 
Anchors laminin and heterochromatin to the 
nuclear membrane 2.77 
Pik3r1 
phosphoinositide-3-kinase, 
regulatory subunit 1α 
Adaptor mediating protein-tyr kinase membrane 
binding 2.74 
Tmem45b transmembrane protein 45b Unknown function 2.73 
Txnrd1 thioredoxin reductase 1 Involved in protection from oxidative stress 2.72 
Atp1a1 
ATPase, Na+/K+ transporting, α1 
polypeptide Regulator of membrane electrochemical gradients 2.72 
Lasp1 LIM and SH3 protein 1 Regulator of dynamic actin formation 2.72 
Ankle2 
ankyrin repeat and LEM domain 
containing 2 Unknown function 2.70 
Gnai3 
guanine nucleotide binding protein 
(G protein), α inhibiting 3 Modulator of trans-membrane signalling systems 2.70 
Rtn4 reticulon 4 Inhibitor of Bcl-xl and Bcl-2 anti-apoptotic activity 2.70 
Col6a3 procollagen, type VIα 3 Cell binding protein 2.68 
Krt15 keratin 15 Epithelial structural integrity  2.66 
RGD1306148 similar to KIAA0368 Unknown function 2.65 
Picalm 
phosphatidylinositol binding 
clathrin assembly protein Involved in clatherin coated pit formation 2.65 
Cxcl12 
chemokine (C-X-C motif) ligand 
12 (stromal cell-derived factor 1) T-cell and monocyte chemoattractant 2.65 
Pank3 pantothenate kinase 3 Regulator of CoA biosynthesis 2.65 
Myh11 
myosin, heavy chain 11, smooth 
muscle Involved in smooth muscle contraction 2.64 
Ocln occludin 
Involved in formation and regulation of epithelial 
tight junctions 2.64 
Galnt1 
N-acetylgalactosaminyltransferase 
1 (GalNAc-T1) Catalyses O-linked oligosaccharide formation 2.64 
Akirin2 akirin 2 Downstream effector of cytokine signalling 2.63 
Fnbp1l formin binding protein 1-like Involved in actin reorganization during endocytosis 2.62 
Stard5 
StAR-related lipid transfer 
(START) domain containing 5 
Involved in intracellular transport of sterols and 
other lipids 2.62 
Far1 fatty acyl CoA reductase 1 Catalyzes the reduction of saturated fatty acyl-CoA 2.62 
S100a6 S100 calcium binding protein A6 Calcium sensor involved in cellular differentiation 2.62 
Ptprs 
protein tyrosine phosphatase, 
receptor type, S Transmembrane signalling transducer 2.61 
Zyg11b zyg-ll homolog B E3 ubiquitin-ligase complex component 2.61 
Hspa2 heat shock protein 2α Stress-induced molecular chaperone 2.61 
Slc5a1 
solute carrier family 5 
(sodium/glucose cotransporter), 
member 1 
Mediates glucose/galactose uptake from intestinal 
lumen 2.61 
Rbpj 
recombination signal binding 
protein for immunoglobulin κ J 
region 
Transcriptional regulator of NOTCH (cell-cell) 
signalling 2.59 
Rab31 
RAB31, member RAS oncogene 
family Involved in vesicle and granule targeting 2.58 
Eif3s6ip 
eukaryotic translation initiation 
factor 3, subunit 6 interacting 
protein Initiator of protein synthesis 2.58 
Smtn smoothelin Stress fibre cytoskeletal component 2.58 
Arl2bp 
ADP-ribosylation factor-like 2 
binding protein Regulator of STAT activity 2.57 
Ireb2 
iron responsive element binding 
protein 2 Regulator of ferretin/transferrin expression 2.57 
Nov 
nephroblastoma over-expressed 
gene Regulator of cell growth 2.55 
Stk17b serine/threonine kinase 17b Positive regulator of apoptosis 2.55 
Ppp2r4 
protein phosphatase 2A activator, 
regulatory subunit 4 
Involved in apoptosis and negative regulation of 
cell growth 2.55 
Cap1 CD40 associated protein 1 Inhibitor of NFκB activation 2.55 
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Tmed2 
transmembrane emp24 domain 
trafficking protein 2 Involved in vesicular trafficking 2.55 
Calm3 calmodulin 3 
Calcium binding regulator of inflammation, 
apoptosis and muscle contraction 2.54 
Fstl1 follistatin-like 1 Involved in cellular differentiation 2.53 
Hoxb13 homeo box B13 Transcription factor regulating development 2.53 
Actr2 
ARP2 actin-related protein 2 
homolog Involved in actin polymerization 2.53 
Id3 inhibitor of DNA binding 3 Regulator of transcription factor function 2.53 
Xiap X-linked inhibitor of apoptosis Apoptotic suppressor 2.52 
Efna1 ephrin A1 Regulator of angiogenesis 2.52 
Scamp2 
secretory carrier membrane 
protein 2 
Involved in post-Golgi trafficking to the surface 
membrane 2.52 
Ctnnb1 
catenin (cadherin associated 
protein) 1β 
Structural component of adherent junctions, and 
regulator of Wnt responsive genes 2.51 
Casp2 caspase 2 Initiator caspase mediating apoptosis 2.51 
Jak2 Janus kinase 2 Cytokine receptor signal transducer 2.51 
Myh9 
myosin, heavy chain 9, non-
muscle Involved in cytokinesis 2.50 
Gng2 
guanine nucleotide binding protein 
(G protein) 2γ Modulator of trans-membrane signalling systems 2.50 
Cdx1 caudal type homeo box 1 Regulator of enterocyte differentiation 2.50 
Plekhb2 
pleckstrin homology domain 
containing, family B (evectins) 
member 2 Unknown function 2.50 
Ddx3x 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked Helicase involved in interferon response 2.49 
Rnf6 
ring finger protein (C3H2C3 type) 
6 Ubiquitin-protein ligase 2.49 
Ap3d1 
adaptor-related protein complex 3 
1Δ subunit Involved in intracellular granule trafficking 2.47 
Elovl5 
ELOVL family member 5, 
elongation of long chain fatty 
acids Involved in elongation of long-chain fatty acids 2.47 
Rab5a 
RAB5A, member RAS oncogene 
family Promotes membrane-endosomal fusion 2.47 
Asah1 
N-acylsphingosine 
amidohydrolase (acid ceramidase) 
1 
Hydrolyzes the sphingolipid ceramide to 
sphingosine (signalling lipid) and fatty acid 2.46 
Kitlg KIT ligand Stimulates proliferation of Mast cells 2.46 
Arpc2 
actin related protein 2/3 complex, 
subunit 2 Actin binding component of Arp2/3 complex 2.46 
Hsph1 
heat shock 105kDa/110kDa 
protein 1 
Prevents aggregation of denatured proteins during 
cellular stress 2.46 
Tle4 
transducin-like enhancer of split 4 
(E(sp1) homolog Transcriptional co-repressor 2.46 
Cdc42se2 CDC42 small effector 2 Involved in actin organization during phagocytosis 2.46 
Eif2s3x 
eukaryotic translation initiation 
factor 2, subunit 3, structural gene 
X-linked Involved in protein biosynthesis 2.46 
Pfkm phosphofructokinase, muscle Regulator of glycolysis 2.45 
Dck deoxycytidine kinase Phosphorylates deoxynucleotides 2.45 
Csnk1a1 casein kinase 1 1α Participates in Wnt signalling 2.44 
Nedd4 
neural precursor cell expressed, 
developmentally down-regulated 4 Ubiquitin-protein ligase  2.44 
Slco2b1 
solute carrier organic anion 
transporter family, member 2b1 Organic ion uptake 2.44 
Prss35 Protease, serine, 35 Unknown function 2.43 
Slc31a1 
solute carrier family 31 (copper 
transporters), member 1 Copper uptake 2.43 
Adam10 
ADAM metallopeptidase domain 
10 
Cleaves membrane bound TNF-alpha precursor to 
its mature form 2.43 
Cdkn2b 
cyclin-dependent kinase inhibitor 
2B (p15, inhibits CDK4) Effector of TGF-beta induced cell-cycle arrest 2.42 
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Sptlc1 
serine palmitoyltransferase, long 
chain base subunit 1 Key enzyme in sphingolipid synthesis 2.42 
Rnf4 ring finger protein 4 Ubiquitin-protein ligase 2.42 
Cacybp calcyclin binding protein Involved in calcium-dependent ubiquitination 2.42 
Tmprss8 
transmembrane protease, serine 8 
(intestinal) Unknown function 2.41 
Patl1 
protein associated with 
topoisomerase II homolog 1 Involved in RNA degradation 2.41 
Sesn3 sestrin 3 Involved in cellular stress response 2.41 
Cfh complement factor H 
Regulator of complement activation and microbial 
specificity 2.40 
Tpm1 tropomyosin 1α Regulator of actin mechanics 2.40 
Tspan2 tetraspanin 2 Mediator of trans-membrane signalling systems 2.40 
Ahcyl1 adenosylhomocysteinase-like 1 Unknown function 2.40 
Tgfbr2 
transforming growth factor β 
receptor II 
Receptor inducing apoptosis and negatively 
regulating phagocyte activation 2.40 
Scarf2 
scavenger receptor class F, 
member 2 Involved in cell adhesion 2.39 
Ipo5 importin 5 Involved in nuclear protein import 2.39 
Sept7 septin 7 Involved in actin cytoskeletal organization 2.39 
LOC100363366 
amyloid β (A4) precursor-like 
protein 2-like 
Unknown function, interacts with MHC class I 
molecules 2.38 
Dazap2 DAZ associated protein 2 
Involved in TGF-beta signalling and stress granule 
formation 2.38 
Rbm9 RNA binding motif protein 9 Regulator of alternative exon splicing 2.38 
Drg1 
developmentally regulated GTP 
binding protein 1 
May play a role in cell proliferation, differentiation 
and death 2.38 
Slc30a9 
solute carrier family 30 (zinc 
transporter), member 9 Involved in activation of Wnt responsive genes 2.38 
Pfn2 profilin 2 Regulator of actin polymerization 2.38 
Cebpa 
CCAAT/enhancer binding protein 
(C/EBP), alpha Transcriptional regulator 2.38 
Cd44 Cd44 molecule 
Hyaluronic acid (ECM) receptor, involved in 
lymphocyte activation 2.37 
Efnb1 ephrin B1 Involved in cell adhesion 2.37 
Klc1 kinesin light chain 1 Involved in organelle transport 2.36 
Kctd12 
potassium channel tetramerisation 
domain containing 12 GABA-B receptor subunit 2.36 
Nolc1 
nucleolar and coiled-body 
phosphoprotein 1 Involved in RNA polymerase I transcription 2.36 
Pgrmc2 
progesterone receptor membrane 
component 2 Putative steroid receptor 2.36 
Vezf1 vascular endothelial zinc finger 1 Transcription factor regulating cell differentiation 2.36 
Reep6 receptor accessory protein 6 Unknown function 2.35 
Atp2b4 
ATPase, Ca++ transporting, 
plasma membrane 4 Regulator of intracellular calcium homeostatis 2.35 
Lgr4 
leucine-rich repeat-containing G 
protein-coupled receptor 4 Orphan receptor 2.35 
Pdlim7 PDZ and LIM domain 7 Invovled in actin cytoskeletal organization 2.35 
Bid 
BH3 interacting domain death 
agonist 
Pro-apoptotic mediator inducing cytochrome c 
release and inhibiting Bcl-2 activity 2.34 
Soat1 sterol O-acyltransferase 1 
Involved in lipoprotein assembly and cholesterol 
absorption 2.34 
Gtf2h1 
general transcription factor IIH, 
polypeptide 1 
Involved in nucleotide excision repair during 
transcription 2.34 
Mbnl2 muscleblind-like 2 Mediates pre-mRNA splicing regulation 2.34 
Sesn1 sestrin 1 Involved in the reduction of peroxiredoxins 2.34 
Prkar2a 
protein kinase, cAMP dependent 
regulatory, type IIα Involved in membrane association of MAP2 kinase 2.33 
Atp2a3 
ATPase, Ca++ transporting, 
ubiquitous 
Transports calcium from the cytosol to the 
endoplasmic reticulum 2.32 
Nfyc nuclear transcription factor-Yγ Regulator of transcription at CCAAT enhancer  2.31 
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Pkn2 protein kinase N2 Inhibits Akt induced anti-apoptotic activity 2.31 
Pi4k2b 
phosphatidylinositol 4-kinase type 
2β Regulator of vesicular trafficking 2.31 
Gdi2 GDP dissociation inhibitor 2 Involved in vesicular trafficking 2.31 
Larp4 
La ribonucleoprotein domain 
family, member 4 Unknown function 2.30 
Prim1 DNA primase, p49 subunit 
Component of DNA polymerase which synthesizes 
small Okazaki fragment primers 2.30 
Tpm4 tropomyosin 4 Regulator of myosin-actin interactions 2.29 
Cdc26 cell division cycle 26 Ubiquitin-ligase involved in cell cycle 2.29 
LOC501268 nidogen 2 
Basement membrane component involved in 
adhesion and apoptosis 2.29 
Tm9sf4 
transmembrane 9 superfamily 
protein member 4 Unknown function 2.28 
Tfrc transferrin receptor Mediator of iron uptake 2.27 
Bhlhe40 
basic helix-loop-helix family, 
member e40 Involved in control of cell differentiation 2.27 
Reg3b regenerating islet-derived 3β Antimicrobial peptide with C-type lectin domain 2.27 
Tollip toll interacting protein 
Negative regulator of NFκB activation by IL-1 
pathway 2.26 
Cd3e 
CD3 molecule, epsilon 
polypeptide 
Involved in coupling antigen recognition to 
intracellular signalling pathways 2.26 
Rfc1 replication factor C (activator 1) 1 Involved in DNA replication and repair 2.26 
Arl8b ADP-ribosylation factor-like 8B Involved in lysosomal motility 2.26 
Oaz2 
ornithine decarboxylase antizyme 
2 Regulator of polyamine synthesis 2.26 
LOC690372 
similar to U2 (RNU2) small 
nuclear RNA auxiliary factor 2 
isoform b Unknown function 2.26 
Slc9a3r1 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1 
Involved in regulating interactions between 
cytoskeleton and membrane proteins 2.25 
Leprot 
leptin receptor overlapping 
transcript Decreases cellular response to leptin hormone 2.25 
Med14 mediator complex subunit 14 
Involved in regulation of RNA polymerase II 
transcription 2.24 
Toe1 
target of EGR1, member 1 
(nuclear) Positive regulator of TGF-beta expression 2.24 
Cd55 Cd55 molecule Negative regulator of the complement cascade 2.24 
Mgea5 
Meningioma expressed antigen 5 
(hyaluronidase) 
Glycosidase that removes O-GlcNAc from 
glycoproteins 2.24 
Fyttd1 
forty-two-three domain containing 
1 Involved in mRNA export 2.24 
Pla2g10 phospholipase A2, group X Regulator of cellular lipid content 2.24 
Cebpg 
CCAAT/enhancer binding protein 
(C/EBP), gamma Positive regulator of IL-4 expression 2.23 
Parva parvin α Regulator of cellular adhesion 2.23 
Pmm2 phosphomannomutase 2 Involved in glycoprotein biosynthesis 2.23 
Cdkn2aipnl 
CDKN2A interacting protein N-
terminal like Unknown function 2.22 
Ndrg1 
N-myc downstream regulated gene 
1 Involved in stress response and cell differentiation 2.22 
Angptl2 angiopoietin-like 2 Induces sprouting in endothelial cells 2.22 
Sox4 
SRY (sex determining region Y)-
box 4 
Transcriptional activator that binds to T-cell 
enhancer motifs 2.22 
Arfip1 
ADP-ribosylation factor 
interacting protein 1 Arf1 target protein 2.22 
Dlg3 discs, large homolog 3 Regulator of synaptic plasticity 2.22 
Rfk riboflavin kinase Involved in utilization of vitamin B2 2.22 
Ppp3r1 
protein phosphatase 3, regulatory 
subunit B, α isoform 
Regulator of calmodulin stimulated protein 
phosphatase  2.21 
Vps4a vacuolar protein sorting 4  Involved in intracellular protein trafficking 2.21 
RT1-A2 RT1 class Ia, locus A2 Antigen presentation 2.21 
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Map4k5 mitogen-activated protein kinase 5 Involved in transducing cell stress signals 2.21 
Ppp4c 
protein phosphatase 4, catalytic 
subunit Phospatase regulating several cellular processes 2.21 
Tra2a transformer 2α homolog Regulator of pre-mRNA splicing 2.211 
Galnt4 
N-acetylgalactosaminyltransferase 
4  
Catalyses initial reaction in O-linked 
oligosaccharide biosynthesis 2.21 
Arl6ip5 
ADP-ribosylation-like factor 6 
interacting protein 5 
Regulates intracellular concentrations of taurine 
and glutamate 2.21 
Casp8 caspase 8 Initiator caspase mediating apoptosis 2.20 
Pcsk5 
Pro-protein convertase 
subtilisin/kexin type 5 
Involved processing multiple pro-proteins to their 
mature forms 2.20 
Dcn1 
defective in cullin neddylation 1, 
domain containing 1 Ubiquitin-protein ligase 2.20 
Lyn 
v-yes-1 Yamaguchi sarcoma viral 
related oncogene homolog Regulator of cytokinesis and adhesion 2.20 
Hdac1 histone deacetylase 1 Regulator of cell-cycle and development 2.20 
Dnajc5 
DnaJ (Hsp40) homolog, subfamily 
C, member 5 
Involved in membrane trafficking and protein 
folding 2.20 
Ghr growth hormone receptor Involved in post-natal tissue development 2.20 
Pkia 
protein kinase (cAMP-dependent, 
catalytic) inhibitor α Regulator of intracellular signalling 2.20 
Epas1 endothelial PAS domain protein 1 
Involved in the induction of oxygen regulated 
genes 2.20 
Elmod2 
ELMO/CED-12 domain 
containing 2 Positive regulator of interferon response 2.19 
Hpcal1 hippocalcin-like 1 
Involved in calcium-dependent regulation of 
rhodopsin phosphorylation 2.19 
Ppp2r5e 
protein phosphatase 2, regulatory 
subunit B', epsilon isoform Negative regulator of cell growth 2.19 
LOC363060 
similar to RIKEN cDNA 
1600029D21 Unknown function 2.19 
Kcne3 
potassium voltage-gated channel, 
Isk-related subfamily, gene 3 Involved in epithelial electrolyte transport 2.19 
Gsr glutathione reductase Involved in cellular antioxidant defence 2.19 
Csnk1d casein kinase 1Δ Participates in Wnt signalling 2.19 
Arpp19 
cAMP-regulated phosphoprotein 
19 Regulator of mitosis 2.18 
Tubb4 tubulin 4β Major microtubule component 2.18 
Smad4 SMAD family member 4 Mediator of signal transduction by TGF-beta 2.18 
Eif4g2 
eukaryotic translation initiation 
factor 4 2γ General repressor of translation 2.18 
Ebag9 
estrogen receptor binding site 
associated, antigen, 9 Caspase 3 activator involved in apoptosis 2.18 
Aktip AKT interacting protein Regulator of apoptosis via interactions with Akt1 2.17 
Snx11 sorting nexin 11 Involved in intracellular trafficking 2.17 
Nsf N-ethylmaleimide-sensitive factor Involved in ER-Golgi transport 2.16 
Ssbp3 
single stranded DNA binding 
protein 3 Regulator of collagen expression 2.16 
Mapk1 mitogen activated protein kinase 1 Extracellular signal regulated kinase 2.16 
Arl5a ADP-ribosylation factor-like 5A GTP-binding protein involved in development 2.16 
Heg1 HEG homolog 1 Unknown function 2.16 
Shfm1 
split hand/foot malformation 
(ectrodactyly) type 1 Involved in ubiquitin dependent proteolysis 2.16 
Hsd17b6 
hydroxysteroid (17-β) 
dehydrogenase 6 
NAD-dependent oxidoreductase with broad 
substrate range 2.16 
Ankrd12 ankyrin repeat domain 12 Inhibitor of nuclear receptor transcriptional activity 2.15 
Rhoa 
ras homolog gene family, member 
A 
Regulator of membrane-actin stress fibre signal 
transduction 2.15 
Gpd1 
glycerol-3-phosphate 
dehydrogenase 1 Involved in lipid biosynthesis 2.15 
Wdr33 WD repeat domain 33 Involved in cellular differentiation 2.15 
Ldlr low density lipoprotein receptor Mediator of LDL endocytosis 2.15 
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Cdc16 cell division cycle 16 homolog Regulator of cell-cycle 2.15 
Psen1 presenilin 1 
Increases cytoplasmic B-catenenin concentration 
during apoptosis 2.15 
Lamc1 Laminin 1γ Mediator of cellular adhesion and migration 2.15 
Spink4 
serine peptidase inhibitor, Kazal 
type 4 Gastrointestinal protease inhibitor 2.15 
Isoc1 
isochorismatase domain 
containing 1 Unknown function 2.14 
Frem2 
Fras1 related extracellular matrix 
protein 2 
ECM protein involved in maintenance of epithelial 
integrity 2.14 
Map3k3 
mitogen activated protein kinase 
kinase kinase 3 Component of protein kinase signal cascade 2.14 
Ifnar1 interferon (α, β and ω) receptor 1 Mediator of type I interferon signalling 2.14 
Ube2h 
ubiquitin-conjugating enzyme 
E2H 
Catalyses covalent attachment of ubiquitin to other 
proteins 2.14 
Rnf4 ring finger protein 4 Ubiquitin-protein ligase 2.14 
Pld1 phospholipase D1 
Involved in signal transduction and membrane 
trafficking 2.14 
Add1 adducin 1α 
Calmodulin binding promoter of actin-spectrin 
network assembly 2.13 
Tsnax translin-associated factor X Nuclear targeting protein 2.13 
Pmp22 peripheral myelin protein 22 
Major component of myelin in the peripheral 
nervous system 2.13 
Rab6a 
RAB6A, member RAS oncogene 
family 
Regulator of membrane traffic from the Golgi 
apparatus 2.13 
Ddx21 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 21 
RNA helicase involved in ribosome synthesis and 
innate immunity 2.13 
Csnk1g3 casein kinase 1 3γ Participates in Wnt signalling 2.13 
Pnrc2 
proline-rich nuclear receptor co-
activator 2 Involved in mRNA processing 2.13 
Eif3a 
eukaryotic translation initiation 
factor 3, subunit A Involved in protein biosynthesis 2.12 
Slc30a1 
solute carrier family 30 (zinc 
transporter), member 1 Involved in zinc export 2.12 
Ddx17 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 17 RNA helicase 2.12 
LOC685179 
similar to SWI/SNF-related  
regulator of chromatin c2 Unknown function 2.12 
Epb41l3 erythrocyte protein band 4.1-like 3 Unknown function 2.11 
Fam46a 
family with sequence similarity 
46, member A Unknown function 2.11 
Dlg1 discs, large homolog 1 
Involved in maintenance of cellular polarity and 
lymphocyte activation 2.11 
Pdha1 
pyruvate dehydrogenase 
(lipoamide) 1α Involved in linking glycolysis and the TCA cycle 2.11 
Hnf4 hepatocyte nuclear factor 4 
Regulator of liver, kidney and intestinal 
development 2.11 
Ensa endosulfine α Modulator of insulin secretion 2.11 
Ifnar1 interferon (α, β and ω) receptor 1 Mediator of interferons alpha and beta signalling 2.11 
Pafah1b1 
platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 1 
Involved in several dynein and microtubule-
dependent processes   2.11 
Mtpn myotrophin Involved in neuronal differentiation 2.10 
Galnt2 
N-acetylgalactosaminyltransferase 
2 (GalNAc-T2) 
Catalyzes initial reaction in O-linked glycosylation 
of mucins  2.10 
Eif4h 
eukaryotic translation initiation 
factor 4H Involved in protein biosynthesis 2.10 
Rbp4 retinol binding protein 4, plasma Mediator of vitamin A (retinol) transport 2.01 
Tcrb T-cell receptor beta chain 
Recognizes MHC bound antigens on antigen 
presenting cells 2.09 
Rab27a 
RAB27A, member RAS oncogene 
family 
Mediates cytotoxic granule exocytosis in 
lymphocytes 2.09 
Nrp2 neuropilin 2, transcript variant 4 Involved in transmembrane signalling 2.09 
Klra17 
killer cell lectin-like receptor, 
subfamily A, member 17 NK-cell pathogen recognition receptor 2.09 
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Tnks2 
tankyrase, TRF1-interacting 
ankyrin-related ADP-ribose 
polymerase 2 Inhibitor of Wnt signalling 2.09 
Dnajb14 
DnaJ (Hsp40) homolog, subfamily 
B, member 14 
Involved in membrane trafficking and protein 
folding 2.09 
Grinl1a 
glutamate receptor, ionotropic, N-
methyl D-aspartate-like 1A Regulator of transcriptional activation 2.09 
Mafg 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog 
G Transcriptional regulator 2.09 
Snx18 sorting nexin 18 Involved in several stages of endocytosis 2.08 
Sdccag3 
serologically defined colon cancer 
antigen 3 
May be involved in modulation of the TNF 
response 2.08 
Glipr2 GLI pathogenesis-related 2 
Involved in apoptosis and macrophage 
differentiation 2.08 
Sec61a1 Sec61 1α subunit 
Involved in assembly of membrane and secretory 
proteins 2.08 
Slc16a1 
solute carrier family 16, member 1 
(monocarboxylic acid transporter 
1) Lactate and pyruvate transporter 2.08 
Ak2 adenylate kinase 2 
Involved in energy metabolism and nucleotide 
synthesis 2.08 
Tcea1 
transcription elongation factor A 
(SII) 1 Involved in RNA polymerase II transcription 2.07 
Eprs glutamyl-prolyl-tRNA synthetase 
Catalyzes the attachment of the cognate amino acid 
to the corresponding tRNA 2.07 
Hyal3 hyaluronoglucosaminidase 3 ECM regulator 2.07 
Senp5 
Sumo1/sentrin/SMT3 specific 
peptidase 5 
Component of the SUMO post-translational 
modification pathway 2.07 
Arf6 ADP-ribosylation factor 6 
Involved in vesicular trafficking and actin 
remodelling 2.07 
Ubl3 ubiquitin-like 3 Unknown function 2.07 
Dsta dystonin transcript variant a Component of adhesion junctions 2.06 
Rab5b 
RAB5B, member RAS oncogene 
family GTPase modulating endosomal trafficking 2.06 
Akt1s1 AKT1 substrate 1 (proline-rich) Regulator of cell growth 2.06 
LOC686428 similar to Emu2 Unknown function 2.06 
Usf1 upstream transcription factor 1 Transcriptional regulator 2.06 
Mki67ip 
Mki67 (FHA domain) interacting 
nucleolar phosphoprotein Involved in the cell-cycle 2.06 
Vdac1 voltage-dependent anion channel 1 Mediator of cytochrome-c release during apoptosis 2.06 
Akt2 
v-akt murine thymoma viral 
oncogene homolog 2 General protein kinase 2.05 
Ccl2 chemokine (C-C motif) ligand 2 
Recruits monocytes, T(mem)-cells and dendritic 
cells to site of infection 2.05 
Zdhhc3 
zinc finger, DHHC-type 
containing 3 Regulator of cell surface stability 2.05 
Gtpbp4 GTP binding protein 4 Involved in ribosomal synthesis 2.05 
Zdhhc17 
zinc finger, DHHC domain 
containing 17 Involved in endocytosis 2.05 
LOC363060 
similar to RIKEN cDNA 
1600029D21 Unknown function 2.05 
LOC366300 hypothetical LOC366300 Unknown function 2.04 
Selt selenoprotein T Involved in redox regulation and cell adhesion 2.04 
Rab11b 
RAB11B, member RAS oncogene 
family Regulator of exo/endocytosis 2.04 
Arf1 ADP-ribosylation factor 1 
Involved in vesicular trafficking and actin 
remodelling 2.04 
Sf3b5 splicing factor 3b, subunit 5 Spliceosome component 2.03 
Cul4b cullin 4B Ubiquitin-protein ligase 2.03 
Nkx2-3 NK2 transcription factor related,  Possible role in cell differentiation 2.03 
LOC681825 similar to Prefoldin subunit 3  Unknown function 2.02 
Gna12 
guanine nucleotide binding protein 
12α Membrane signal transducer 2.02 
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Siah1a seven in absentia 1A Ubiquitin-protein ligase 2.02 
Camk2d 
calcium/calmodulin-dependent 
protein kinase II delta Transducer of calcium/calmodulin signalling 2.02 
Cobl cordon-bleu homolog May be involved in actin modulation 2.02 
Cd3d CD3 molecule delta polypeptide 
T-cell TCR/CD3 complex component mediating 
signal transduction 2.02 
Cops4 
COP9 constitutive 
photomorphogenic homolog 
subunit 4 (Arabidopsis) Regulator of several signalling pathways 2.02 
LOC288913 
Similar to Leydig cell tumor 10 
kD protein Unknown function 2.02 
Rcc2 
regulator of chromosome 
condensation 2 Involved in mitosis and cytokinesis 2.02 
Mrpl52 
mitochondrial ribosomal protein 
L52 Mito-ribosomal protein component 2.01 
Prlr prolactin receptor  Hormone receptor 2.01 
Jam2 junctional adhesion molecule 2 
Tight junction component involved in lymphocyte 
homing  2.01 
Smek2 
SMEK homolog 2, suppressor of 
mek1 Regulator of microtubule organization 2.01 
Prpf38b 
PRP38 pre-mRNA processing 
factor 38 domain containing B May be required for pre-mRNA splicing 2.01 
Dusp1 dual specificity phosphatase 1 
Negatively regulates mitogen-associated protein 
kinases (MAPK's) 2.01 
Marveld2 
membrane-associating domain 
containing 2 Integral tight junction component 2.01 
Tmem20 transmembrane protein 20 Unknown function 2.01 
Tbc1d1 TBC1 domain family, member 1 May regulate cell growth and differentiation 2.01 
Gpkow G patch domain and KOW motifs Unknown function 2.01 
Phf11 PHD finger protein 11 Regulator of Th1-type cytokine expression 2.01 
Sema4g 
sema domain, Ig, transmembrane 
and short cytoplasmic domain 4G Axon guidance ligand 2.01 
Foxa2 forkhead box A2 Transcription factor involved in development 2.00 
Dffb 
DNA fragmentation factor, β 
polypeptide  Pro-apoptotic caspase activated Dnase 2.00 
Arih1 
ariadne ubiquitin-conjugating 
enzyme E2 binding protein 
homolog 1 Ubiquitin-protein ligase 2.00 
Cdc42bpb 
CDC42 binding protein kinase 
beta (DMPK-like) 
CDC42 effector involved in cytoskeletal 
organization 2.00 
Itga6 integrin 6α 
Involved in cell adhesion and cell-surface 
signalling 2.00 
 
 
Table B4: Genes down-regulated twofold or greater in the neonatal rat GI tract 12 h 
after feeding E. coli A192PP to P9 pups 
 
Gene Symbol Description Function Mean-fold change 
Nucks1 
nuclear casein kinase and cyclin-
dependent kinase substrate 1 May be involved in cell proliferation -11.81 
Afp α-fetoprotein Major plasma protein -11.71 
Tmsb10 thymosin 10β Inhibitor of actin polymerization -8.62 
RT1-Db1 RT1 class II, locus Db1 Antigen presentation -7.46 
Adfp 
Adipose differentiation related 
protein Involved in sequestering lipids -6.33 
RT1-A RT1 class I, locus A Antigen presentation -5.85 
Cav2 caveolin 2 Involved in signal transduction -5.00 
Epsti1 epithelial stromal interaction 1 Unknown function -5.00 
Pacsin1 
protein kinase C and casein kinase 
substrate in neurons 1 May be involved in vesicle transport -4.95 
LOC100362483 H2-GS14-2 antigen RT1 homologue -4.67 
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Tbc1d20 TBC1 domain family, member 20 GTPase-activator for Rab family proteins -4.61 
LOC688090 similar to RT1 class II, locus Bb Antigen presentation -4.42 
Mfsd2 
major facilitator superfamily 
domain containing 2 May regulate cell proliferation -4.35 
Amy2 amylase 2, pancreatic Involved in starch hydrolysis -4.33 
Lox lysyl oxidase Initiator of collagen-elastin cross-linking -4.22 
Krit1 KRIT1, ankyrin repeat containing 
Involved in microtubule formation and 
maintenance of endothelial integrity -3.97 
RGD1308772 similar to KIAA0564 protein Unknown function -3.89 
Ptpn3 
protein tyrosine phosphatase, non-
receptor type 3 Regulator of cell adhesion -3.88 
Smarce1 
SWI/SNF related regulator of 
chromatin e1 
Regulator of transcription via chromatin 
remodelling -3.66 
Rsu1 Ras suppressor protein 1 Suppressor of Ras mediated signalling -3.61 
Galnt1 
N-acetylgalactosaminyltransferase 
1 (Galnt1), transcript variant 2 
Catalyzes initial reaction in O-linked glycosylation 
of mucins  -3.52 
Tgfb2 transforming growth factor 2β Suppressor of IL-2 mediated T-cell growth -3.51 
8430427H17Rik  RIKEN cDNA 8430427H17 gene Unknown function -3.47 
Ints7 integrator complex subunit 7 Involved in processing small nuclear RNA's -3.42 
Mtmr1 myotubularin related protein 1 May be involved in signalling -3.41 
Tlk2 tousled-like kinase 2 Involved in cell cycle regulation -3.41 
Phlda3 
pleckstrin homology-like domain, 
family A, member 3 Repressor of Akt signalling  -3.40 
Nr3c1 
nuclear receptor subfamily 3, 
group C, member 1 Regulator of trans-nuclear membrane signalling -3.25 
Srp54a signal recognition particle 54a May mediate targeting to the ER -3.25 
Zfp191 zinc finger protein 191 Transcriptional repressor involved in development -3.17 
Wwc1 WW and C2 domain containing 1 Regulator of proliferation and apoptosis -3.16 
Pim1 proviral integration site 1 Involved in cell proliferation -3.14 
Ass1 argininosuccinate synthetase 1 Involved in arginine biosynthesis -3.13 
Ahi1 Abelson helper integration site 1 Involved in neuronal development -3.11 
Ttc21b 
tetratricopeptide repeat domain 
21B 
Negative modulator of sonic hedgehog signal 
transduction -3.09 
Zfp422 zinc finger protein 422 Transcriptional regulator -3.09 
Stox2 storkhead box 2 Involved in development -3.07 
CP-2 Cyclic Protein-2 Involved in iron transport -3.06 
Tcf712 
transcription factor 7-like 2, T-cell 
specific, HMG-box Transcription factor involved in Wnt signalling -3.05 
Eml4 
echinoderm microtubule 
associated protein like 4 May modify assembly dynamics of microtubules -3.04 
Znf503 zinc finger protein 503 Transcriptional repressor -3.03 
Stard3 
StAR-related lipid transfer 
(START) domain containing 3 Cholesterol transporter -2.99 
Dlst 
dihydrolipoamide S-
succinyltransferase (E2 
component of 2-oxo-glutarate 
complex) Involved in fatty acid metabolism -2.96 
Id4 Inhibitor of DNA binding 4 Regulator of DNA binding -2.95 
Pafah1b1 
platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 1 Involved in cytoskeletal organization -2.95 
Cyfip1 
cytoplasmic FMR1 interacting 
protein 1 Mediator of translational repression -2.94 
Mrp194 
mitochondrial ribosomal protein 
L49 Component of the mitochondrial ribosome -2.94 
Plcxd2 
phosphatidylinositol-specific 
phospholipase C, X domain 
containing 2 Involved in signal transduction -2.93 
Dpep1 dipeptidase 1 Hydrolysis of dipeptides -2.91 
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Crim1 
Cysteine-rich transmembrane 
BMP regulator 1 (chordin like) May play a role in angiogenesis -2.89 
Acd adrenocortical dysplasia homolog Telosome component -2.87 
Tmem38b transmembrane protein 38B Mediator of rapid intracellular calcium release -2.87 
Gnas Gs α subunit Involved in signal transduction -2.86 
Vash1 vasohibin 1 Angiogenesis inhibitor -2.85 
RT1-Ba RT1 class II, locus Ba Antigen presentation -2.83 
Adam33 
a disintegrin and metallopeptidase 
domain 33 (predicted)-like May be involved in cell adhesion -2.82 
Mocs2 molybdenum cofactor synthesis 2 Involved in molybdopterin biosynthesis -2.82 
Tsc22d2 TSC22 domain family, member 2 Unknown function -2.82 
Tmem131 transmembrane protein 131 May be involved in immune response -2.80 
Hnrnpa1 
heterogeneous nuclear 
ribonucleoprotein A1 Involved in pre-mRNA processing -2.78 
Ptprb 
protein tyrosine phosphatase, 
receptor type, B Regulator of angiogenesis -2.78 
Tmem14a transmembrane protein 14A Unknown function -2.78 
Thbs2 thrombospondin 2 
Adhesive glycoprotein mediating cell adhesion to 
ECM -2.75 
Senp7 
SUMO1/sentrin specific peptidase 
7 Catalyses the removal of SUMO protein markers -2.73 
Slc30a2 
solute carrier family 30 (zinc 
transporter), member 2 Zinc transporter -2.71 
Neu1 sialidase 1 (lysosomal sialidase) Catalyzes the removal of sialic acids from proteins -2.70 
Rab30 
RAB30, member RAS oncogene 
family Golgi-associated signalling protein -2.69 
Tiparp 
TCDD-inducible poly(ADP-
ribose) polymerase 
May play a role in adaptive response to chemical 
exposure -2.69 
Capn7 calpain 7 Ubiquitous calcium regulated protease -2.68 
Pik3r2 
phosphoinositide-3-kinase, 
regulatory subunit 2β 
Adaptor mediating association of activated kinases 
to the plasma membrane -2.67 
Ube2cbp 
ubiquitin-conjugating enzyme 
E2C binding protein Ubiquitin-protein ligase -2.67 
Sgcb 
sarcoglycan, beta (dystrophin-
associated glycoprotein) Involved in anchoring F-actin to the ECM -2.67 
Mcpt3 mast cell peptidase 3 Serine endopeptidase -2.65 
Dcaf10 
DDB1 and CUL4 associated factor 
10 Involved in ubiquitin-protein ligation -2.65 
Slc30a7 solute carrier family 30 Regulator of zinc homeostatis -2.65 
Slc20a1 
solute carrier family 20 (phosphate 
transporter), member 1 Regulator of phosphate homeostatis -2.64 
Itgal integrin Lα 
Intercellular adhesion molecule receptor involved 
in immune cell interactions -2.62 
Ppp1r8 
protein phosphatase 1, regulatory 
(inhibitor) subunit 8 Involved in pre-mRNA processing -2.61 
Hspa5 heat shock protein 5 Involved in regulating protein folding in the ER -2.60 
Tmem33 transmembrane protein 33 Unknown function -2.59 
Eif1b 
eukaryotic translation initiation 
factor 1B May be involved in translation -2.58 
Greb1 
gene regulated by estrogen in 
breast cancer  Hormone-dependent growth regulator -2.58 
Mreg melanoregulin Involved in membrane fusion -2.58 
Anxa7 annexin A7 Membrane fusion promoter involved in exocytosis -2.57 
Slc34a3 
solute carrier family 34 (sodium 
phosphate), member 3 Active phosphate importer -2.56 
Stk24 serine/threonine kinase 24 Involved in signal transduction -2.56 
Gjb3 gap junction protein, beta 3 Mediator of intercellular connexin transport -2.55 
Rnf2 ring finger protein 2 Ubiquitin-protein ligase -2.54 
Itih3 
inter-α-trypsin inhibitor, heavy 
chain 3 
Involved in binding hyaluronan to other ECM 
proteins -2.53 
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Tmem178 transmembrane protein 178 Unknown function -2.53 
Icmt 
isoprenylcysteine carboxyl 
methyltransferase Involved in targeting proteins to the membrane -2.51 
Jag1 jagged 1 
Notch receptor ligand and mediator of Notch 
signaling -2.49 
Mmp15 matrix metallopeptidase 15 Peptidase that degrades ECM components -2.48 
RGD1359529 
similar to chromosome 1 open 
reading frame 63 Unknown function -2.48 
Romo1 
reactive oxygen species modulator 
1 
Induces ROS production to stimulate cell 
proliferation -2.46 
Spsb4 
splA/ryanodine receptor domain 
and SOCS box containing 4 Involved in ubiquitin-protein ligation -2.46 
Lpin2 lipin 2 Regulator of fatty acid metabolism -2.44 
Mcoln1 mucolipin 1 Regulator of endo/exocytosis -2.44 
Kif26a kinesin family member 26A Modulator of enteric neuronal development -2.43 
Dedd death effector domain-containing Modulator of Caspase 3 activity -2.43 
Tcirg1 
T-cell, immune regulator 1, 
ATPase, H+ transporting, 
lysosomal V0 subunit A3 Proton channel involved in T-cell activation -2.43 
Idh2 
isocitrate dehydrogenase 2 
(NADP+), mitochondrial Involved in energy production and metabolism  -2.42 
Arhgef10 
Rho guanine nucleotide exchange 
factor 10 Involved in development -2.42 
Med13 mediator complex subunit 13 Co-activator of RNA polymerase II transcription -2.41 
Pign 
phosphatidylinositol glycan 
anchor biosynthesis, class N  Involved in GPI-anchor biosynthesis -2.41 
Smad5 SMAD family member 5 Transcriptional modulator -2.41 
Procr protein C receptor, endothelial Involved in protein C-mediated blood coagulation -2.40 
Znf618 zinc finger protein 618 May be involved in transcriptional regulation -2.40 
Acot2 Acyl-CoA thioesterase 2 Regulator of intracellular fatty acid levels -2.39 
Tcf4 
transcription factor 4, transcript 
variant 1 Involved in cellular differentiation -2.39 
Hsdl2 
hydroxysteroid dehydrogenase 
like 2 Unknown function -2.39 
Ankrd28 ankyrin repeat domain 28 
Involved in regulating TNF-alpha induced NFκB 
activation -2.38 
LOC687609 
similar to ras homolog gene 
family, member f Unknown function -2.38 
Ndufa5 
NADH dehydrogenase 
(ubiquinone) 1α subcomplex 5 Involved in respiratory chain -2.38 
Park7 
Parkinson disease (autosomal 
recessive, early onset) 7 Redox sensitive chaperone -2.38 
Smc2 
structural maintenance of 
chromosomes 2 Involved in DNA repair -2.37 
Malat1 
metastasis associated lung 
adenocarcinoma transcript 1 Non-protein coding regulator of cell motility -2.36 
LOC100364467 rCG36634-like Unknown function -2.34 
LOC682058 
similar to nucleolar protein with 
MIF4G domain 1 Unknown function -2.33 
Fam64a 
family with sequence similarity 
64, member A Unknown function -2.33 
Mnt max binding protein Regulator of cell growth -2.33 
Pbx1 
pre B-cell leukemia transcription 
factor 1 Transcriptional regulator -2.33 
Wfdc3 WAP four-disulfide core domain 3 Protease inhibitor -2.32 
Mllt10 myeloid (trithorax) homolog 10 Involved in tanscriptional regulation -2.31 
Thsd4 
thrombospondin, type I, domain 
containing 4 Promotes ECM assembly -2.31 
Adar 
adenosine deaminase, RNA-
specific Positive regulator of IL-2 expression in T-cells -2.30 
Cdk7 cyclin-dependent kinase 7 Regulator of cell cycle progression -2.30 
RGD1305457 
similar to RIKEN cDNA 
1700023M03 Unknown function -2.30 
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RGD1565983 
similar to apurinic/apyrimidinic 
endonuclease 2 Unknown function -2.30 
Spon2 
spondin 2, extracellular matrix 
protein 
Bacterial LPS binding ECM component that 
functions as opsonin for macrophages -2.30 
Tulp4 tubby like protein 4 Ubiquitin-protein ligase component -2.30 
Zbtb4 
zinc finger and BTB domain 
containing 4 May be involved in transcriptional regulation -2.30 
Zfp347 zinc finger protein 347 Unknown function -2.29 
Klf5 Kruppel-like factor 5 Transcriptional regulator -2.28 
Cyp17a1 
cytochrome P450, family 17, 
subfamily a, polypeptide 1 Involved in lipid biosynthesis -2.28 
Foxn3 forkhead box N3 
Transcriptional repressor responding to DNA 
damage -2.28 
Hgd homogentisate 1, 2-dioxygenase Involved in amino acid catabolism -2.28 
Dapk3 death-associated protein kinase 3 Regulator of apoptosis -2.27 
Terf2 telomeric repeat binding factor 2 Regulator of telomeric stability -2.27 
Neurl1a neuralized homolog 1A Unknown function -2.26 
Kctd5 
potassium channel tetramerisation 
domain containing 5 Ubiquitin ligase substrate adapter -2.25 
Tcfe3 transcription factor E3 Activator of T-cell CD40L expression -2.25 
Eif2b3 
eukaryotic translation initiation 
factor 2B, subunit 3γ Involved in protein biosynthesis -2.25 
Ada adenosine deaminase Positive regulator of T-cell co-activaton  -2.24 
Slu7 SLU7 splicing factor homolog Involved in pre-mRNA splicing -2.24 
Timp2 
tissue inhibitor of 
metalloproteinase 2  ECM Protease inhibitor -2.24 
Tubgcp2 
tubulin, gamma complex 
associated protein 2 Involved in tubulin assembly -2.24 
Cubn 
cubilin (intrinsic factor-cobalamin 
receptor) Co-transporter involved in iron metabolism -2.23 
Asxl1 additional sex combs like 1  Involved in development -2.23 
Abcc2 
ATP-binding cassette, sub-family 
C (CFTR/MRP), member 2 Mediator of bile secretion -2.22 
Hsf1 heat shock transcription factor 1 Activates heat shock responsive genes -2.21 
Nubp1 nucleotide binding protein 1 Involved in cytosolic Fe/S protein assembly -2.21 
Pnpla6 
patatin-like phospholipase domain 
containing 6 Regulator of neuronal differentiation -2.21 
F8 
coagulation factor VIII, 
procoagulant component Involved in blood coagulation -2.21 
Pigy 
phosphatidylinositol glycan 
anchor biosynthesis, class Y Initiator of GPI anchor biosynthesis -2.20 
Atad2 
ATPase family, AAA domain 
containing 2 Involved in cell proliferation -2.19 
Osbpl3 oxysterol binding protein-like 3 Intracellular lipid receptor -2.19 
Vtl1a 
vesicle transport through 
interaction with t-SNAREs 1B-
like Mediator of vesicle transport pathways -2.19 
Ccdc109a 
coiled-coil domain containing 
109A Unknown function -2.18 
Rnf216 ring finger protein 216 Co-activator of Il-1 induced NFB activation -2.18 
Smap1 
stromal membrane-associated 
protein 1 Involved in clathrin-dependent endocytosis  -2.18 
Npas2 neuronal PAS domain protein 2 Transcriptional regulator -2.17 
Smg7 
Smg-7 homolog, nonsense 
mediated mRNA decay factor Involved in nonsense-mediated mRNA decay -2.17 
Ard1a 
ARD1 homolog A, N-
acetyltransferase Mediator of n-α acetylation of proteins -2.17 
Timp1 TIMP metallopeptidase inhibitor 1 ECM Protease inhibitor -2.17 
Clta clathrin, light chain (Lca) Mediator of endocytosis -2.16 
Mudeng 
MU-2/AP1M2 domain containing, 
death-inducing May be involved in apoptosis -2.16 
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Pls3 plastin 3 (T-isoform) Actin bundling protein in microvilli -2.16 
Smurf1 
SMAD specific E3 ubiquitin 
protein ligase 1 Ubiquitin-protein ligase -2.16 
LOC680155 hypothetical protein LOC680155 Unknown function -2.16 
Dnajb5 
DnaJ (Hsp40) homolog, subfamily 
B, member 5 May be involved in protein folding and transport -2.15 
Ptpn12 
protein tyrosine phosphatase, non-
receptor type 12 Signalling molecule involved in cell motility -2.15 
Mall 
mal, T-cell differentiation protein-
like Involved in raft-mediated membrane trafficking -2.15 
Ubxn2b UBX domain protein 2B Involved in maintenance of ER and Golgi  -2.15 
Nudt11 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 11 May play a role in signal transduction -2.14 
C8g 
complement component 8, γ 
polypeptide Component of the membrane attack complex -2.14 
Slc38a7 solute carrier family 38, member 7 Amino acid transporter -2.14 
Atxn2 ataxin 2 Unknown function -2.13 
Tgfb1i1 
transforming growth factor 1β 
induced transcript 1 Regulator of Tgfb and Wnt signalling pathways -2.13 
Slc5a12 solute carrier family 5, member 12 
Mediator of transport of monocarboxylates from 
intestinal lumen -2.12 
Bat5 HLA-B associated transcript 5 May be involved in immune response -2.12 
Acot1 acyl-CoA thioesterase 1 Regulator of intracellular acyl-CoA's -2.11 
LOC681665 
similar to integrator complex 
subunit 6 isoform a Unknown function -2.11 
Ipo11 importin 11 Receptor for nuclear localization signals -2.11 
Rnf114 ring finger protein 114 Involved in chromatin remodelling -2.11 
Ncapd2 
non-SMC condensin I complex, 
subunit D2 Involved in protein degradation -2.11 
Psmc6 
proteasome (prosome, macropain) 
26S subunit, ATPase, 6 Steroid hormone receptor -2.10 
Paqr8 
progestin and adipoQ receptor 
family member VIII Regulator of microtubule interactions -2.09 
Ppp4r2 
protein phosphatase 4, regulatory 
subunit 2 Unknown function -2.09 
Zfp445 zinc finger protein 445 Receptor for various ECM components -2.08 
Itgb3 integrin beta 3 Ubiquitin-protein ligase -2.08 
Ube2q1 
ubiquitin-conjugating enzyme 
E2Q (putative) 1 Involved in microtubule-dependent cell motility -2.08 
Hdac6 histone deacetylase 6 Unknown function -2.07 
Fam82a1 
family with sequence similarity 
82, member A1 May be involved in mRNA splicing -2.07 
Luc7l LUC7-like 
Involved in T-cell receptor and leptin receptor 
signaling -2.07 
Khdrbs1 
KH domain containing, RNA 
binding, signal transduction 
associated 1 Stabilizes actin cytoskeleton -2.07 
Tpm3 tropomyosin 3γ Regulates stabilization of actin filaments -2.07 
Fam24a 
family with sequence similarity 
24, member A Unknown function -2.06 
Inppl1 
inositol polyphosphate 
phosphatase-like 1 Regulator of actin cytoskeleton remodelling -2.06 
Ptprc 
protein tyrosine phosphatase, 
receptor type, C Positive regulator of T-cell co-activaton  -2.06 
Terf1 
telomeric repeat binding factor 
(NIMA-interacting) 1 Involved in telomeric regulation -2.06 
Mrpl51 
mitochondrial ribosomal protein 
L51 Component of the mitochondrial ribosome -2.05 
Sfrs14 
splicing factor, arginine/serine-
rich 14 May play a role in mRNA splicing -2.05 
Psd3 pleckstrin and Sec7 domain  Unknown function -2.05 
Slc30a3 
solute carrier family 30 (zinc 
transporter), member 3 Zinc transporter -2.05 
Speg SPEG complex locus Regulator of cytoskeletal development -2.05 
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Abhd12 abhydrolase domain containing 12 Unknown function -2.04 
Acbd3 
acyl-Coenzyme A binding domain 
containing 3 Involved in maintenance of Golgi -2.04 
Adarb1 
adenosine deaminase, RNA-
specific, B1 Involved in RNA editing -2.04 
Cela2a 
chymotrypsin-like elastase family, 
member 2A Elastin (ECM component) specific protease -2.04 
Ints1 integrator complex subunit 1 Involved in small nuclear RNA processing -2.04 
Itpkc 
inositol 1,4,5-trisphosphate 3-
kinase C Involved in nuclear export/import -2.04 
Rcn1 
Reticulocalbin 1, EF-hand calcium 
binding domain Regulator of Ca-dependent activities in the ER -2.04 
Clcn5 chloride channel 5 Mediator of acidification of endosomal lumen -2.04 
Abo ABO blood group  Blood group antigen protein -2.03 
Ankrd16 ankyrin repeat domain 16 Unknown function -2.03 
Mt2A metallothionein 2A Heavy metal responsive protein -2.03 
Retsat 
retinol saturase (all trans retinol 
13,14 reductase) May be involved in vitamin A metabolism -2.03 
Slc4a10 
solute carrier family 4, sodium 
bicarbonate co-transporter-like, 
member 10 Regulator of intracellular pH -2.03 
Luc7l3 LUC7-like 3 Involved in mRNA splicing -2.02 
Mfsd7b 
major facilitator superfamily 
domain containing 7B Heme transporter -2.02 
Cox4i1 
cytochrome c oxidase subunit IV 
isoform 1 Involved in mitochondrial respiratory chain -2.02 
Hunk 
hormonally up-regulated neu 
tumor-associated kinase Unknown function -2.02 
Mbnl1 muscleblind-like 1 Mediator of pre-mRNA splicing -2.02 
Scaper 
S-phase cyclin A-associated 
protein in the ER Regulator of cell cycle progression -2.02 
Serf2 small EDRK-rich factor 2 Unknown function -2.02 
Chst3 
carbohydrate (chondroitin 
6/keratan) sulfotransferase 3 May play a role in maintenance of T-cells -2.02 
Eftud2 
elongation factor Tu GTP binding 
domain containing 2 Involved in pre-mRNA splicing -2.02 
Maf v-maf AS42 oncogene homolog Developmental regulator -2.02 
Brd1 bromodomain containing 1 Unknown function -2.01 
Cdc45l CDC45 cell division cycle 45-like Involved in DNA replication -2.01 
Rbbp5 retinoblastoma binding protein 5 Regulator of cell proliferation -2.01 
Traf6 Tnf receptor-associated factor 6 NFκB signal transducer -2.01 
Gnb1 
guanine nucleotide binding protein 
(G protein), beta polypeptide 1 Modulator of transmembrane signalling systems -2.01 
Mtmr12 myotubularin related protein 12 Unknown function -2.00 
Slbp stem-loop binding protein May be involved in cell cycle -2.00 
A2ld1 AIG2-like domain 1 Involved in protein degradation -2.00 
Aqp7 aquaporin 7 Water/glycerol channel -2.00 
Mfap3 microfibrillar-associated protein 3 Unknown function -2.00 
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Table B5: Up- and down-regulated genes shared between P2 and P9 data sets 
 
Gene Symbol Description Function 
Mean-fold 
change1 
RT1-Aw2 RT1 class Ib, locus Aw2 Antigen presentation 17.7/4.00 
Cirbp 
cold inducible RNA binding 
protein Positive regulator of cellular stress response 5.04 
Iap3 Inhibitor of apoptosis 3 Apoptotic suppressor 3.91/2.52 
LOC81816 hypothetical protein LOC81816 Putative ubiquitin conjugating enzyme 3.39 
Rbm9 RNA binding motif protein 9 Regulates splicing of tissue specific exons 2.74 
Reg3b regenerating islet-derived 3β Antimicrobial peptide with C-type lectin domain 2.63 
Sox4 
SRY (sex determining region Y)-
box 4 
Transcriptional activator that binds to T-cell 
enhancer motifs 2.61/2.22 
Pik3r1 
phosphoinositide-3-kinase, 
regulatory subunit 1α 
Adaptor mediating association of activated kinases 
with plasma membrane 2.60/2.74 
Hoxb6 homeobox B6  Transcriptional regulator 2.58 
Ankle2 
ankyrin repeat and LEM domain 
containing 2 Unknown function 2.40 
Vdac1 voltage-dependent anion channel 1 
Mitochondrial membrane channel involved in 
apoptosis 2.38 
Id3 inhibitor of DNA binding 3 Inhibitor of transcription factor DNA binding 2.29 
Pafah1b1 
platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 1 
 Required for proper activation of Rho GTPases 
and actin polymerization 2.28 
Vezf1 vascular endothelial zinc finger 1 Regulation of IL-3 expression 2.23/2.36 
Gatad2b 
GATA zinc finger domain 
containing 2B Transcriptional repressor 2.21 
Rnf6 
ring finger protein (C3H2C3 type) 
6 Ubiquitin-protein ligase  2.20 
Krt15 keratin 15 
Responsible for the structural integrity of epithelial 
cells 2.18 
Ptprs 
protein tyrosine phosphatase, 
receptor type, S Signalling protein involved in development 2.17 
Lgr4 
leucine-rich repeat containing G 
protein-coupled receptor 4 Orphan receptor 2.09/2.35 
Rod1 
ROD1 regulator of differentiation 
1 Regulator of cell differentiation 2.06 
Eef1a1 
eukaryotic translation elongation 
factor 1α 1  Prompter of protein biosynthesis 2.03 
Nolc1 
nucleolar and coiled-body 
phosphoprotein 1  
Involved in RNA polymerase I catalysed 
transcription 2.02/2.4 
RT1-A3 RT1 class I, locus A3 Antigen presentation -3.11 
                          
Mcpt3 mast cell peptidase 3 Serine endopeptidase -2.62 
RT1-Db1 RT1 class II, locus Db1 Antigen presentation -2.46 
Pbx1 
pre-B-cell leukemia transcription 
factor Transcriptional regulator -2.36 
Pim1 pim-1 oncogene Signalling kinase activity -2.35 
LOC100362483 H2-GS14-2 antigen Regulation of antigen presentation -2.29 
Wwc1 WW and C2 domain containing 1 Transcriptional activator -2.15 
Amy1 ; Amy2  
amylase, alpha 1A (salivary), 
amylase 2, pancreatic Hydrolase -2.03 
 
1
In most cases there was complete concordance between the extent of gene modulation 
at P2 and P9; two values are shown when there were quantitative differences between 
values from the two sets of animals (P2 ranked and shown first). 
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